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Abstract  
 
The study used in-depth interviews to explore how prescribing practice, and hence patient 
outcomes, could be improved by a range of stakeholders; namely GPs, pharmacists, 
psychiatrists, representatives from the pharmaceutical industry and service users.  
 
The author, as Chief Pharmacist for Dudley and Walsall Mental Health Partnership Trust 
(DWMHT), is responsible for the strategic leadership in medicines optimisation across the 
organisation.  In the role of Chief Pharmacist, the author has identified that there are disparate 
prescribing patterns across the trust, in addition to a distinct lack of clarity on prescribing 
responsibility with the local health economy.   
 
There is a paucity of research which incorporates the views of a variety of healthcare 
professionals and service users on prescribing practice in a mental health setting; furthermore, 
the author is unaware of any study that has incorporated the views of the pharmaceutical 
industry on joint working with the NHS in a mental health context.  
 
Fifteen healthcare professional interviews were conducted, which included pharmacists, 
psychiatrists and GPs. In addition, 5 expert by experience service users were interviewed 
about their experiences of shared decision-making whilst managed under the care of mental 
health services. The study also explored with representatives from the pharmaceutical 
industry, the scope for collaborative working with the NHS to optimise the use of medicines. 
Semi-structured interviews were conducted and the data was analysed using Framework 
analysis. 
 
This study revealed that four core tensions exist in the delivery of prescribing in mental health. 
These are:  
1. The notion of guideline driven care versus the individual needs of patients  
2. The need for holistic, patient-centred care versus the constraints on healthcare professional 
to deliver this  
3. The rhetoric about patient choices versus the realities of shared decision-making in a 
resource-limited system  
4. The acknowledgement of the need for joint working with the pharmaceutical industry, which 
is based on the current NHS financial climate, versus the inherent mistrust by healthcare 
professionals of the industries’ motives. 
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Further to the identified tensions the study also identified three areas of concord across the 
stakeholder groups which are: 
1. The importance of communication with service users 
2. The role of prescribing guidelines  
3. The meaning of wellbeing for the recipients of care 
 
The complexity of decision-making in prescribing practice was highlighted by the study. The 
success of patient centred care is reliant on healthcare professional attitudes, patient 
empowerment, and resources such as electronic prescribing to support evidenced-based 
prescribing practice. Scarcity of resources impacts heavily upon the decisions that are made 
which can have a substantial impact upon variability in treatment decisions and on the ability 
to facilitate patient choice in a meaningful way.  
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Chapter 1: Introduction  
1.0 Overview 
The author, as the current Chief Pharmacist for DWMHT, has responsibility for the strategic 
oversight of medicines optimisation across the organisation. This involves the review of 
evidence and the production of formularies, clinical guidelines and treatment policies/protocols 
which are designed to facilitate standards of prescribing which are uniform, high quality and 
cost-effective. The author often receives communication from prescribers within the Trust 
detailing poor prescribing practice from primary care colleagues, who would, in some 
circumstances, refuse to prescribe psychiatric medicines for patients with enduring mental 
health illness. The author has also received numerous reports from GPs, detailing poor 
communication from mental health prescribers in terms of the rationale for prescribing and 
clarity regarding the need for continual patient monitoring. 
 
This thesis is grounded in the author’s ongoing interest and experience of working in mental 
health. The study is situated in a time of the greatest organisational change in the NHS since 
its inception. The thesis is based on the author’s observations and discussions with service 
users, prescribers, pharmacy colleagues and representatives from the pharmaceutical 
industry. The author considered the question of what could be done to improve prescribing 
practice across the local health economy and how the service user experience could be 
improved.  
  
1.1 Current Context 
Financial drivers & mechanisms for cost control 
The costs associated with specialist led prescribing in mental health across Dudley and 
Walsall was approximately £1.4 million during the 2015/16 financial year. As part of the 
initiative to deliver cost savings, there is an expectation of a year on year cost improvement 
programme to deliver savings, which includes the allocated drug budget for the trust.  The 
need to deliver efficiency savings has to take into consideration the potential for reduction in 
costs due to generic availability of previously branded medicines, annual inflationary increases 
in drug costs, and the entry of new drugs to market for the treatment of mental health 
conditions which are significantly more expensive than generic alternatives.  
 
The pharmaceutical industry has a potential role to play in optimising the use of medicines 
through transparent and value for money partnerships with the NHS that help secure better 
outcomes for service users. At present, representatives from the pharmaceutical industry 
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market their drugs to healthcare professionals across the trust and their major focus is with 
consultant psychiatrists, who are the drivers for the uptake of new medicines.   
 
Demographics 
Dudley and Walsall boroughs are in the top third of the most deprived councils in England, 
however they have lower than the national average for people who are recorded by their GP 
as suffering with severe mental illness.  
 
There is an anticipated growth in the populations of Walsall and Dudley over the next decade. 
The population in Walsall is expected to increase by 5.1% from 270,900 to 284,700 in 2026. 
In addition to this, Walsall’s older adult population (those aged 65 and above) is also predicted 
to increase by 13.8%, with the number of people 85 years and older increasing from 47,200 
in 2016 to 53,700 in 2026. Similarly, the population in Dudley is projected to increase by 6.4% 
(20,000 people) to 334,000 between 2016 and 2026. The most significant feature is the 
anticipated growth of older age groups, with the 60-74 population projected to increase by 
11.5% and the 75+ age group by 67.9%. These age groups alone equate to 26,000 more 
people. The anticipated growth in population will have implications for healthcare resources, 
increasing demand at a period of limited funding.   
 
1.2 Background 
The mechanism for the entry of new drugs for use across DWMHT involves approval via the 
Trust Medicines Management Committee, which includes representation from across the local 
health economy. Once approval is granted at a trust level, a further application is made to the 
respective Clinical Commissioning Groups (CCGs) in Dudley and Walsall. The outcome of the 
approval by the CCGs determines whether the drug is made available for GPs to prescribe 
across the local health economy. The decision regarding the approval of a drug has clear 
implications for service users because if a drug is approved at a trust level, but not at a local 
health economy level, it means that the provision of pharmaceutical care for that individual will 
be restricted to DWMHT.  The approval of drugs is further complicated by a lack of robust 
clinical trial data when compared with agents used in the treatment of physical health 
conditions. Typically, mental health clinical trials are characterised by smaller participant 
numbers and shorter duration than is experienced in a clinical practice.  
 
Pharmacists across the health economy are instrumental in developing tools for reducing the 
range of drugs prescribed and assisting in implementing these in practice.  
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The three main tools which pharmacists routinely use for improving prescribing are:  
• formularies, which recommend specific drugs and exclude others; 
• clinical guidelines (e.g. the management of depression), which help to ensure that 
treatment of patients is based on evidence of best practice; and  
• prescribing policies (e.g. the guidelines for prescribing on FP10 prescriptions) 
/treatment protocols (e.g.  clozapine treatment guidelines), which assist prescribers in 
using the drugs in a formulary or implementing clinical guidelines. 
 
At the outset of the research project in 2013 there were disparate prescribing patterns across 
DWMHT and limited formulary control, in addition to a distinct lack of clarity for prescribing 
responsibility with the then local primary care trusts in Dudley and Walsall.  
 
One way to improve prescribing within the trust and to ensure clarity of prescribing 
responsibilities between primary and secondary care was the development of joint prescribing 
guidelines (Grant, 2006, p. 32). This approach was designed to establish prescribing practice 
that is consistent with the available  evidence and which could lead to potentially improved 
use of drug therapy (Fleury, Imboua, Aubé, Farand, & Lambert, 2012, p. 11) detailing issues 
such as: 
• Agreeing suitable endpoints for prescribing.  
• Physical monitoring associated with psychotropic prescribing. 
• Agreement on the cost burden for prescribing across primary and secondary care. 
• Managing the entry of new drugs and the exit of old ones across the healthcare 
economy.  
 
At present, an educational outreach approach is adopted across the trust to support the 
implementation of prescribing guidelines. Prescribers receive face-to-face updates at post-
graduate educational meetings, senior clinical forums and as part of a rolling programme of 
feedback to consultant teams which is led by the pharmacy team. In additional to face-to-face 
meetings, newsletters are also used to convey prescribing information across the trust and 
updated policies are communicated to the trust Quality and Safety Committee which includes 
senior medical and nursing staff. 
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1.3 Gap in knowledge 
Prescribing in mental health and monitoring of treatment has been found to be deficient in 
previous research  and it is important to understand the influences on prescribing practice in 
this area (Chapman, Rough, Garnett, Longley, & Wilson, 2014, p. 28). Mental health clinical 
practice guidelines have proliferated, in recent years but there is little evidence regarding the 
degree to which they are implemented in clinical practice (Bauer, 2002, p. 139). This research 
will explore the perceptions of key stakeholders on optimising prescribing practice in mental 
health across a local health economy.  
 
At present, there is minimal evidence to suggest that guideline dissemination alone affects the 
behaviour of mental health clinicians or GPs (Forsner et al., 2010a, p. 2).  Prescribing guideline 
studies are further complicated by the fact that implementation can take several years to 
achieve in many organisations (Forsner et al., 2010b, p. 10).  
 
Service Users 
The views of service users were sought to explore decision-making and prescribing practice. 
The findings from the service users will be used to inform guideline development and service 
delivery.  
 
There is evidence to suggest that mental health patients feel disempowered with respect to 
their involvement in their drug treatment (Rethink 2006, p. 9) and so this study sought to 
explore the service user perspective on how they should be engaged in the prescribing 
process and what recommendations they would give to healthcare professionals to improve 
pharmaceutical care. 
 
Representatives from the Pharmaceutical Industry 
To date no study has attempted to explore the views of representatives from the 
pharmaceutical industry on prescribing practice in a mental health setting and the wider 
engagement with mental health services across the UK.  
 
With the NHS facing the prospect of making efficiency savings of £22 billion by 2020/21, and 
the state of the economy set to increase pressure on public services, access to commercial 
skills and resources will be more important than ever for the foreseeable future. Collaborative 
working with the pharmaceutical industry is one way of optimising existing resources to benefit 
patient care. The views of senior personnel within the pharmaceutical industry were sought to 
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determine how working in collaboration could promote initiatives leading to improved health 
for patients across the local health economy.   
 
Consultant Psychiatrists and GPs /GP commissioners 
There is a lack of studies that compare the attitudes of different groups of doctors to 
prescribing guidelines (Carlsen & Bringedal., 2011, p.158). By comparing the attitudes of GPs 
/ GP commissioners and consultant psychiatrists within the same health economy it is 
anticipated that this will lead to greater clarity in determining the key issues which are barriers 
to guideline implementation. The current study will consider the economic drivers for cost 
effective prescribing and will seek the perspectives of GPs/ GP commissioners and consultant 
psychiatrists on prescribing guidance.  
 
Pharmacists 
Pharmacists are integral to prescribing guidance development (Grant., 2006, p.30) and are 
often responsible for: 
• Reviewing the evidence for medicines. 
• Producing prescribing guidance. 
• Monitoring compliance with guidance.  
• Highlighting cost effective options.  
 
At present, no studies have evaluated the perspectives of pharmacists on the development 
and implementation of psychiatric prescribing guidelines. This study will seek the opinions of 
those actively engaged in prescribing guideline development across the local healthcare 
economy.   
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1.4 Aims and Objectives  
 
Aims 
This study sought to explore different perspectives on prescribing practice and the potential 
for optimising patient care. The study therefore explored the views of service users, healthcare 
professionals and representatives from the pharmaceutical industry. 
 
Objectives 
1. To explore the extent to which service users perceive they were involved in making 
treatment decisions about their prescribed medication and the factors that influence the 
service user’s involvement in treatment decision making. 
 
2. To explore the perceived factors that influence prescribing from the perspective of 
healthcare professionals (consultant psychiatrists, pharmacists involved in formulary/ 
guideline development across the local health economy and GP/GP commissioners) and 
representatives from the pharmaceutical industry with a national or international remit.  
 
3.  To develop an understanding of the perceived factors that influence the implementation of 
prescribing guidelines in a mental health setting from the perspective of consultant 
psychiatrists, pharmacists involved in formulary/ guideline development across the local health 
economy, GP/GP commissioners and senior representatives from the pharmaceutical 
industry.  
 
4. To provide a framework of recommendations for optimising the use of medicines across the 
health economy. 
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1.5 The importance of the research  
 
In the current era of economic, demographic and technological challenge it is critical that 
service users achieve the best possible quality outcomes from medicines. However, there is 
a growing body of evidence which indicates that service users are not achieving this, and for 
service users with enduring mental illness adherence rates have been shown to be as low as 
24% (n=1493) (Lieberman & Stroup, 2011, p. 770). The evidence suggests that service users 
with serious mental illness desire greater involvement in their care and the decision making 
process within the consultation with a healthcare professional (Lester, Tait, England, & Tritter, 
2006, p. 415).  
 
Treatment guidelines are designed to improve quality of care by articulating evidence-based 
best-practice models and by making explicit the rationale for the guidance and the steps 
needed to implement optimal treatment (Bauer, 2002, p.138; Charani et al., 2013, p. 193). The 
successful implementation of prescribing guidelines is dependent on a multiplicity of factors. 
These include the judicious use of evidence in the context of the individual and the need for 
respecting the importance of choice to the service user.  In recent years, there has been a 
move towards treating service users in the community and, where appropriate, under the care 
of a GP. The treatment of patients in primary care  is linked to the wider government agenda 
of achieving parity of esteem between mental health and physical health as well as reducing 
the cost of treatment (BMA, 2014, p. 34). However, despite this ideal, in 2014/15 a national 
review saw the removal of the requirement for GPs to undertake annual monitoring of weight, 
cholesterol and glycaemic levels in patients with severe mental illness. This is particularly 
problematic as there is evidence that physical health monitoring of patients with mental illness 
is inadequate (Patel et al., 2014, p. 507; Barnes & Paton, 2011, p. 330).  
 
A transition of patients from specialist services to primary care necessitates clear 
communication across the local health economy between healthcare professionals as there is 
some evidence to suggest that some GPs lack sufficient knowledge to treat mental health 
patients effectively (Phelan, Stradins, & Morrison, 2001, p. 444; Fleury, Imboua, Aubé, Farand, 
& Lambert, 2012, p. 2). Furthermore, there is evidence to suggest that some GPs are reluctant 
to treat mental health patients in primary care (Crawford, Carr, Knight, Chambers, & Nolan, 
2001, p. 218) which can, in addition to a lack of knowledge, be linked to case-load capacity 
(Fleury, Bamvita, & Tremblay, 2009, p. 4).  One way in which GPs may be supported to care 
for patients with enduring mental illness is with the use of shared-care agreements with the 
mental health trust which would outline monitoring requirements, referral information and 
specific prescribing details (Smith, Allwright, & O’Dowd, 2007, p. 15). 
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A review of the existing mechanisms for the development and implementation of prescribing 
guidelines, which takes into consideration the perspectives of service users and healthcare 
professionals, is key to optimising the use of medicines for people with enduring mental illness. 
The study seeks to identify a series of recommendations for improving prescribing practice 
across the local health economy. 
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Chapter 2: Literature review 
2.1 Overview  
This chapter provides a review of the literature for the 2013 transformational changes to the 
NHS and the relationship between the pharmaceutical industry and the NHS. The review also 
includes the development of service user engagement with mental health services and finally 
details the emerging evidence associated with guideline development and implementation.  
 
First, the literature review provides an overview of the new NHS in light of the reforms of the 
Health and Social Care Act of 2012, which came into effect on April 1st 2013. The review will 
focus on the impact of CCGs and the Department of Health (DoH) policy drivers for service 
user engagement with health care. The review links the transformation in the NHS with the 
economic imperative to achieve cost–effective prescribing as part of a wider medicines 
optimisation agenda.   Following on from the transformation of the NHS the review will consider 
its relationship with the pharmaceutical industry, the implications for innovations in mental 
health and the industry influence on research findings. The review will then consider the 
implications for joint working between the pharmaceutical industry and the NHS and the 
implications for risk sharing initiatives between them.   
   
This chapter will then provide a review of the literature of service user engagement in mental 
health service development and will focus on policy directives and the historical context and 
evolution of service user engagement.  The final part of the review discusses the evidence for 
translating prescribing guidelines into clinical practice and identifies the current gaps in 
knowledge associated with implementation. 
 
2.1.1 Literature search strategy 
Certain topics within the literature review were conceptual in nature, such as the NHS 
transformation and the relationship between the NHS and the pharmaceutical industry.  As 
such, the literature review in this regard did not lend itself to a formal systematic review, but 
the principles of the approach, as outline by the Critical Appraisal Skills Programme (CASP), 
were adhered to. To supplement the search, expert opinions from the pharmaceutical industry, 
key contacts within NHS England and the Department of Health were sought for additional 
information which was relevant to the study aims and objectives.  Further sources were 
identified by following up internal citations and references within the documents retrieved from 
the searches. 
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The overall literature search was kept deliberately broad to incorporate the complexities of the 
literature relevant to the following aspects of the study: 
 
• The impact of the Health and Social Care Act and subsequent NHS reforms 
• The relationship between the pharmaceutical industry and the NHS 
• Service user engagement within the NHS 
• Prescribing guidance in mental health 
 
Any publication with a focus on these subjects was considered relevant to the literature review 
and an initial search was started in 2014 using the following databases:  
 
• MEDLINE 
• PsycINFO 
• EMBASE 
• The Cochrane Library 
• Department of Health Database 
• Health Management Information Consortium 
• Health Business Elite 
 
Following initial searches, an auto-alert was set up to ensure the identification of new and 
relevant publications.  A final search of the above databases was undertaken in February 
2016. The final reference manager database (Mendeley) contained 777 records and included 
papers from a variety of sources. Detailed records of the exact number from each search were 
not recorded, as many papers were picked up by multiple methods, and because the nature 
of the searches was iterative, rather than being conducted all at a single point in time. 
 
Other relevant sources of information were identified by sourcing related publications, 
reports, research studies or relevant policy documents: 
 
• Department of Health database 
• The Office of National Statistics websites 
• ABPI website 
• Conference proceedings 
• Press releases 
• Reference lists of retrieved articles 
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• Search of relevant journals online via the University of Portsmouth Library services 
and NHS Athens  
• Recommendations from experts in the field 
 
The search was conducted using a mix of subject headings (see examples below) and freetext 
terms. Relevant terms were combined for different chapters. 
 
Table 2.1: Literature search terms 
Main headings & subheading  Key search terms 
Shared-decision making  Choice behaviour 
Choice* 
Decision* 
Decision-making 
Informed decision* choice* 
Patient/service user choice 
Preference* 
Shared decision* 
Mental health Anxiety 
Bipolar 
Depression 
Mental* disorder 
Mental* ill* 
Mental-health 
Psychiatr* 
Psychos* 
 
2.2 NHS transformation overview 
The review focuses on the impact of financial drivers for change and the role of the clinical 
commissioning groups (CCGs) against the background of reduced expenditure on public 
services. Furthermore, the review will consider the drive for public engagement with health 
care.  
 
2.2.1 Legislative changes to the NHS 
The 2012, the Health and Social Care Act introduced the most significant change to the NHS 
since its inception in 1948. The changes have been described by the former Chief Executive 
of the NHS as being “so big it could be seen from the moon” (Ramesh & Davis, 2011, para. 
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145). The Act faced substantial criticism when it was first published in draft form and its 
process through parliament proved politically difficult (Timmins, 2012, p. 118).  
 
For some staff working within the NHS the transformation has been a time of uncertainty and 
a shift in focus from patient care to understanding the new NHS landscape and its 
infrastructure.  
 
The integration of health and social care has been on-going for over 40 years (Cameron, Lart, 
Bostock & Coomber, 2012, p. 2) and is viewed as a way to reduce costs and make more 
efficient use of resources, while achieving better patient outcomes. This is of particular 
importance with the increasing demands on health and social care due to an aging population, 
alongside declining investment in the public-sector infrastructure. Thus, the relationship 
between health and social care can prove challenging as both try to deliver services while 
sharing limited resources.   
 
The transfer of responsibility for around £60 billion of NHS spending from PCTs to CCGs is 
one of the most visible aspects of the reforms. CCGs now control much of the budget for 
mental health expenditure and therefore there is greater scrutiny on all aspects of expenditure 
by mental health trusts.  As part of the NHS reform, the existing regulator of NHS foundation 
trusts - Monitor has become the economic regulator for providers of NHS-funded care. The 
push to convert all NHS trusts into quasi-independent foundation trusts, combined with the 
financial pressures being experienced by many providers, means that a significant number of 
mental health trusts may be forced to merge with other provider organisations to achieve 
economic viability. Such mergers are likely to impact negatively on the idea of providing ‘care 
closer to home’ as organisations seek to centralise service delivery. There is also minimal 
evidence to suggest that service users have had meaningful engagement in the NHS service 
reconfigurations.  
 
Figure 2.1 shows the diagrammatic representation of the new NHS structure and the 
interrelationships with care organisations, the relationship between mental health services, 
clinical commissioning groups and local government. 
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Figure 2.1 The Health and Care System (Department of Health, 2013) 
 
 
2.2.2 The economic imperative - NHS 
Following the global economic crisis of 2008, the United Kingdom government has enforced 
a series of measures aimed at reducing expenditure in the public sector. This has led to static 
NHS funding since 2010 (Ford, 2013, p. 1) and the need to reconfigure the NHS infrastructure.   
This comes at a time where the demand for NHS Services is rising at a rate of 4% per annum, 
coupled with an increasingly elderly population, increased costs of treatment, and a rise in 
public expectations of service delivery (NHS England, 2014, p. 3).  The impact of the static 
funding has partly contributed to the financial deficit of £841m across NHS providers during 
2014/15 and which increased to £2.3bn by the third quarter of the 2015/16 financial year 
(Lafond, Charlesworth, & Roberts, 2016, p. 3).   
 
The NHS faces the triple challenge of improving health outcomes while facing increasing 
demand for services and achieving efficiency savings as part of the Quality, Innovation, 
Productivity and Prevention (QIPP) initiative (Faria, Barbieri, Light, Sculpher & Heslington, 
2014, p. 5). QIPP exists in the context of a global drive to improve the  quality of care and 
health outcomes whilst maximising efficiencies in healthcare provision (Ferguson, 2012, p. 
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e93; WHO, 2012, p. 8; Smith, Saunders, Stuckhardt, & McGinnis, 2013, p. 51).  One way in 
which organisations have attempted to reduce expenditure is by reducing staff costs. Critics 
of this approach have highlighted concerns raised by the Francis inquiry which identified a 
focus on savings in staffing costs, while delivering inadequate services (Pollock & Price, 2013, 
p. 2). 
 
In response to the need to achieve improved efficiencies, the NHS commissioned a strategy 
outlining how this might be achieved.   The publication of the ‘5 Year Forward View’ was 
developed by NHS England, Monitor and the NHS Trust Development Authority to propose a 
model of NHS service delivery within the context of the financial constraints facing public 
sector organisations. The strategy includes several themes including the importance of public 
health and ill-health prevention, empowering patients and communities, integrated care and 
making further efficiencies within the health service. As part of the progression of the ‘5 Year 
Forward View’ integrated primary and acute care systems have started to link GP, hospital, 
community and mental health services under what is known as vanguard sites (DoH, 2015, p. 
3). Despite the acknowledgement of the need for greater integration of healthcare providers, 
critics have pointed out that there is limited evidence that previous mergers have achieved 
better value for money or led to meaningful improvements for service users (Audit 
Commission, 2009, p. 50). 
 
The NHS has been challenged to deliver £22 billion of productivity improvements by 2020/21 
(Ham, McKenna and Dunn, 2016, p. 1). This target has been deemed by some as unrealistic 
(Appleby, 2014, p. 1) and has led to an increased scrutiny of prescribing costs, which are 
approximately £15.5 billion per annum; 13.7% of the total NHS expenditure (HSCIC, 2015, p. 
6). The idea of cost-effective prescribing is both a national and international concern and there 
are interventions which are aimed at reducing prescribing costs, including increasing the 
prescribing of  generic drugs where possible (Godman et al., 2010, p. 710). In a move to 
minimise waste and improve adherence the government is set to introduce a scheme to 
display the cost of medicines with a value of over £20 to the NHS on packaging, along with 
the statement “funded by the UK tax payer.”  It is possible that some individuals may feel that 
they are a financial burden to the healthcare system, and the potential impact of displaying 
the costs of medicines on adherence in vulnerable patients is yet to be considered. 
 
The cost of hospital prescribing has risen by 15.4% during 2014/15 compared with a rise of 
2.8% in primary care which is largely due to hospitals prescribing costlier, NICE approved 
medicines (HSCIC, 2015, p. 16).  The recent findings of a cost analysis conducted by health 
  
15 
 
economists at the University of York concluded the NHS is paying too much for new drugs 
(Claxton et al., 2015, p. 98). The National Institute for Health and Care Excellence  (NICE) 
uses a threshold of £20,000–30,000 per quality adjusted life year (QALY) to gauge the benefits 
of new drugs, but the research team concluded that the upper threshold is out of sync with the 
£13,000 per QALY that the NHS spends on other services (Claxton et al., 2015, p. 98). It is 
possible that the upper threshold takes into consideration the contribution of the 
pharmaceutical industry to the UK trade surplus which is approximately 3 billion per annum. 
 
Improving the use of medicines has been demonstrated to improve health outcomes and 
reduce costs. Recent reports indicate that 30–50% of medicines are not being taken as 
intended; resulting in a loss in health gain of billions of pounds (NICE, 2009, p. 1). The rates 
of non-adherence with medication in patients with schizophrenia and related psychotic 
disorders chronic mental health have been shown to be as high as 70-80% (Breen & Thornhill, 
1998, p. 459). The failure to benefit from effective drug treatment has financial implications in 
terms of wasted medicines, poor symptom control, relapse and re-hospitalisation, long-term 
functional disabilities, loss of autonomy, education or employment possibilities, 
homelessness, disengagement with mental health services and ultimately suicide.  
 
2.2.3    Clinical Commissioning Groups 
In the new NHS structure, the responsibility for commissioning mental health services rests 
with the CCGs which came into effect on April 1st, 2013. The CCGs largely superseded PCTs 
as the commissioners of health services for the local health economy. It is acknowledged that 
the commissioning of mental health services is complex and can involve health, social care 
and the third sector.  Critics of the current commissioning of mental health services have 
highlighted the need for improved communication between healthcare providers, better 
technological infrastructure, and greater clarity about responsibility and accountability for 
monitoring physical healthcare (Rodgers et al., 2016, p. 27). Due to the complexity of 
commissioning mental health services,  guidance was made available to CCGs  (Campion & 
Fitch, 2015 p.  5). The Joint Commissioning Panel on Mental Health (JCPMH), a collaboration 
of 17 organisations has produced guidance on commissioning specialist areas of mental 
health including perinatal mental health, rehabilitation services and mental health services for 
young people.  
  
In a survey conducted by Rethink, over half of GPs reported not having the right skills to 
commission mental health services—much higher than other service areas (Rethink, 2010, 
para 3).  The longstanding commissioning of mental health services has been viewed by critics 
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as inadequate, which in part has been attributed to the lack of understanding of mental health 
service provision by PCTs (Turner et al., 2013a, p. 10).  In addition to potentially failing service 
users, a complex care system that is not fully understood by its commissioners can lead to an 
inefficient use of resources and the continuation of clinical services that are of minimal benefit 
(Turner et al., 2013a, p. 10). For CCGs to seek an innovative and responsive service requires 
them to have a clear picture of the service delivery by the provider organisation. It is 
acknowledged that expertise in mental health commissioning is varied, which can be attributed 
in part to the loss of organisational memory in light of  the dissolution  of PCTs and the 
formation of CCGs (Miller & Rees, 2014, p. 150). It is estimated that approximately 70% of 
CCGs have mental health leads in place, although this does not imply that they have 
significant experience in commissioning mental health services (Dent, 2013, p. 1; Gilburt, 
Edwards &  Murray, 2014, p. 33). Many CCGs have opted to continue the existing contracts 
as it is too early for them to be able to challenge the status quo (Dent, 2013, p. 1).  
 
One way in which CCGs work with provider organisations is to implement the nationally driven 
Commissioning for Quality and Innovation (CQUIN) targets. CQUINs are part of a national 
framework that was first established as part of the 2009/10 NHS Operating Framework as an 
incentive scheme which forms part of the contract between a commissioner and a provider 
organisation. CQUIN schemes link successful delivery of specific outcomes and actions with 
a financial incentive for the provider organisation. CQUIN schemes include a measure of the 
quality of medicines optimisation across a provider organisation. The cost associated with, 
and the complexity of a medicines optimisation CQUIN can vary across providers within the 
same health economy. The payment for a CQUIN scheme is withheld by commissioners until 
the target is achieved, thus failure to achieve an agreed target can compound existing cost-
pressures faced by provider organisations.  
 
2.2.4 Payment by results  
Mental health services account for the largest proportion of programmed expenditure in the 
English NHS, at nearly 11% of the healthcare budget (DoH 2011, p. 64).   The introduction of 
payment by results (PbR), is now being rolled out in mental health services and will be the 
single biggest change in the way NHS psychiatric and related services are financed (Jacobs, 
2014, p. 155). 
 
At present, NHS mental health services are primarily funded through block contracts agreed 
between commissioners and providers of care, or based on levels of existing ‘inputs’ such as 
the number of beds (Mason 2011, p. 235). Without a link to quality and activity, this will not 
deliver incentives to improve quality or efficiency. Indeed, research suggests mental health 
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services have significant scope to improve their efficiency, with very large variations in activity 
levels (Naylor & Bell, 2010, p. 18). Critics of the  system have highlighted that there are large 
variations in activity levels between provider organisations which could lead to efficiency 
savings (Naylor & Bell, 2010, p. 36). Despite this view there is an acknowledgement that 
mental health services have experienced approximately 40 per cent reductions in income in 
2013/14 and 2014/15 (Gilburt, 2015, p. 8) and that this has been linked to a reduction in service 
user access as mental health trusts transform service delivery models to achieve efficiency 
savings (Gilburt, 2015, p. 20). The issue of quality is notable in that only two out of seventy-
one (2.8%) of English mental health trusts have achieved a rating of ‘outstanding’ as 
determined by the Care Quality Commission.   
 
A care cluster has been adopted which will involve clinicians assessing the clinical need of 
service users using secondary mental healthcare services. Service users will then be allocated 
into one of 21 clusters depending on their care needs which will correlate with the payments 
received by the provider organisation. 
 
One issue that is yet to be resolved between the commissioners and provider organisations is 
the tariff price for the drug therapy associated with the care clusters. One possibility is that the 
tariff price will include the cost for the pharmacological treatment with the lowest acquisition 
cost. This will lead to increasing scrutiny of prescribing costs and adherence to agreed 
prescribing guidelines.   
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2.3 NHS changes – Summary 
There are several re-organisational factors that have impacted on mental health services in 
recent years. The most significant change has resulted from the Health and Social Care Act 
2012 and the subsequent emergence of CCGs. Coupled with the implementation of CCGs, 
mental health trusts are facing increasing financial pressure with an expectation of delivering 
year on year cost improvement targets (Ham, McKenna and Dunn, 2016, p. 1). During the 
2014/15 financial year, the cost of hospital prescribing has shown an increase of 15.4% which 
is linked to the prescribing of costlier medicines by secondary care. Across the local mental 
health trust, the main drivers for increased drug expenditure are the prescribing of the newer 
long-acting antipsychotic injections that are not currently prescribed in primary care due to 
their high costs. In addition to the expectation of cost containment by the mental health trust, 
there is an increasing scrutiny on the quality of service delivery by external organisations such 
as the CCGs and the Care Quality Commission (CQC). At present, very few mental health 
trusts are achieving demonstrable achievements in high quality services as outlined by the 
CQC and there is evidence to suggest that strong financial performances have been delivered 
at the expense of cuts in staff and risks to patient care.  
 
Against a backdrop of unprecedented financial constraints on the new NHS there is an 
increasing need to ensure the optimal use of allocated resources.  With a current expenditure 
of approximately £1.4 million by the trust per annum; there is a need to ensure that the 
investment in, and use of medicines is fully realised by healthcare professionals and the 
recipients of care.  
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2.4 Pharmaceutical Industry – Overview 
This study seeks to understand from the pharmaceutical industry how prescribing practice can 
be improved in line with current evidence and how the industry perceives the future working 
relationship with the NHS.  This section of the literature review outlines the historical context 
of the pharmaceutical industry’s relationship with the NHS. The review considers the economic 
factors impacting on the pharmaceutical industry and the conflicting findings of the costs 
associated with research and development and the potential implications for the NHS. The 
impact of innovation in mental health therapeutics is reviewed and considered from the 
perspective of the pharmaceutical industry and the NHS. The influence that the 
pharmaceutical industry has on research findings is identified, as well as the influence on 
service users in the UK. The review then considers the context of and drivers for joint working 
between the pharmaceutical industry and the NHS. Finally, the review considers the historical 
context of risk sharing between the pharmaceutical industry and the NHS.   
 
2.4.1   The Industry and the NHS  
Since 1957, drug prices in the United Kingdom have been regulated at company level through 
the Prescription Pricing Regulation Scheme (PPRS). The scheme applies to branded 
medicines (under patent) which comprise around 70% of NHS spending on medicines 
(Raftery, 2013, p. 1). Generic medicines make up the bulk of prescriptions as they cost much 
less than branded equivalents, therefore there is an imperative to optimise their use where 
possible (Godman et al., 2010, p. 707). NHS patients contribute minimally to prescribing costs, 
via prescription charges, which accounts for  less than five per cent of expenditure on 
prescription medicines (Abraham, 2009, p. 947). 
 
The PPRS is renegotiated periodically by the government and the Association of the British 
Pharmaceutical Industry (ABPI), usually every five years. The ABPI aims to secure the 
provision of safe and effective medicines to the NHS at reasonable prices, promote a strong 
and profitable pharmaceutical industry in the UK, and encourage the efficient and competitive 
development and supply of medicines (Raftery, 2013, p. 1). Prior to 2009 there was minimal 
interaction between NICE and the PPRS, however since 2009 revisions to the scheme have 
enabled the negotiation of price reductions for drugs that have been initially refused by NICE. 
The resulting “patient access schemes” have been used by companies to offer price 
reductions for some drugs unlikely to meet NICE’s cost-effectiveness criteria. Following an 
agreement on a revised price, NICE can subsequently approve the drug. The added 
complication is that the UK is a price referencing country and therefore the agreed discounts 
are kept confidential, so that the pharmaceutical industry can maintain their listed prices 
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internationally, thus NICE could be viewed as complicit with the industry in lacking 
transparency.  
 
These elementary features of the relationship between “consumer demand” and the setting of 
prices for NHS drugs, together with the consequential need for a system of pharmaceutical 
price regulation, has been recognised by governments as early as the 1950s. 
 
2.4.2 The economic imperative  
Despite the global recession of 2008, some of the larger pharmaceutical companies have 
managed to maintain healthy profit margins and in 2013, five pharmaceutical companies made 
a profit margin in excess of 20%; Pfizer, Hoffmann-La Roche, AbbVie, GlaxoSmithKline (GSK) 
and Eli Lilly (Anderson, 2014, para 6).  
 
These profit margins have largely gone unnoticed by the general public. This is in contrast to 
the public outcry when the UK energy regulator predicted energy companies' profit margins 
would grow from 4% to 8% during 2014. One key difference is that the general public do not 
pay directly for the true cost of their medication and have minimal awareness of the price of 
medicines (Sukkar, 2015, p. 174). 
 
In the years of low and negative growth in developed economies that have followed the 2008 
global financial crisis, some pharmaceutical companies have been forced to restructure to 
reduce costs; often cutting back in areas that do not have an immediate impact on the 
perceived short or intermediate term financial advantage. 
 
The sustainability of healthy profit margins by the pharmaceutical industry in the long-term is 
questionable and the current challenges facing them have been well documented in the 
literature (Forster, Stegmaier, Spycher, & Seeger, 2014, p. 1; Holmes, 2012, p. 1863; Khanna, 
2012, p. 1101; Bennani, 2012, p. 779). Some of the main challenges facing the pharmaceutical 
industry include: declining research and development budgets, coupled with patent expiries of 
income generating pharmaceuticals, national austerity measures, regulatory bodies such as 
NICE tightening their approval processes and drugs failing in the late stage of development in 
the face of rising research and development costs. In an attempt to overcome some of these 
challenges, pharmaceutical companies have undergone mergers and acquisition.  
 
One expected outcome of reconfiguring organisational structures is an expansion of research 
and development pipelines, this could be viewed as advantageous in marketing and clinical 
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trials. Despite the expectation of expanded research portfolios there is evidence to suggest 
that growth in research and development is negatively impacted by mergers and acquisitions 
(Rafols et al., 2014, p. 25). 
 
2.4.3 Research and development costs 
The costs of research and development associated with the development of a new drug have 
been widely debated (Light & Lexchin, 2012, p. 4; Collier, 2009, p. 279). Industry estimates 
for the cost for developing a new molecular entity is approximately £834m (DiMasi, Hansen, 
& Grabowski, 2003, p. 151). Critics estimate the true cost to be £209m, and have drawn 
attention to the lack of scientific rigor associated with the proposed industry model on which 
costings have been based (Light & Warburton, 2011, p. 44). The projected cost of new drug 
development and the associated research and development is often used by the 
pharmaceutical industry as a way of rationalising the high cost of newer drugs even if the 
newer drugs have no significant therapeutic advantage over cheaper alternatives.  
 
In an attempt to reduce expenditure on medicines, generic substitution is a common practice 
in NHS hospitals (Duerden & Hughes, 2010, p. 335; Ferner, Lenney & Marriott 2010, para, 2) 
including DWMHT.  
 
One commonly pursued strategy by which the pharmaceutical industry attempts to 
compensate for patent loss is to extend the life cycle of existing branded medicines through 
reformulations (Hitchings, Baker, & Khong, 2012, p. 3). For example, in view of Aricept 
(donepezil), an acetylcholinesterase inhibitor used for the treatment of Alzheimer’s-type 
dementia, losing its patent protection in 2010, the manufacturer developed two reformulations: 
a sustained release oral formulation and a once-weekly transdermal patch.  
 
The development of the sustained release preparation of Aricept was set against a backdrop 
in which the drug was the highest income generating therapy in the market for the treatment 
of Alzheimer’s disease, with over $2bn in annual sales in the United States alone (Schwartz 
& Woloshin, 2012, p. 1). Four months before its patent protection expired, the US Food and 
Drug Administration (FDA) approved a new 23mg daily dose. As generic donepezil is available 
only in 5mg and 10mg tablets, a 23mg dose cannot be administered except by using the 
branded product. This preparation is associated with marginal improvement in efficacy, of 
doubtful clinical importance, but with substantially more side-effects (Schwartz & Woloshin, 
2012, p. 2).  
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A further example of a patent extension in psychiatry occurred when Astra Zeneca, the 
manufacturers of Seroquel, in an attempt to extend the patent which expired in March 2012, 
created an extended-release preparation, with a formulation patent that was due to expire in 
May 2017. The patent on the extended release version was ruled unlawful by a UK court judge 
following challenges from multiple generic manufacturers.  
 
2.4.4 A crisis in innovation 
A critical issue to the current NHS is the lack of new drugs entering the market that represents 
a therapeutic advance (Light & Lexchin, 2012, p. 1; Dix, 2015, p. 210). At present, there is a 
disconnection between the NHS perception of innovative treatment and the pharmaceutical 
industry perspective. This is reflected in the below average uptake of new drugs in the UK 
when compared with other developed countries which was reflected in the findings by the 
Department for Business, Innovation & Skills (DBIS) report (2015, p. 35). The NHS views 
innovation in pharmacotherapy as the development of therapeutically superior medicines 
(Abraham, 2010, p. 613).  The pharmaceutical industry however, measure innovation in terms 
of new molecular entities which in most cases have provided only modest benefits over 
existing treatments (Light & Lexchin, 2012, p. 3). The conservative approach to the adoption 
of new drugs in the UK, coupled with industry pressure has led the UK government to publish 
the Accelerated Access Review which plans to speed up to access to new drugs whilst at the 
same time acknowledging the financial pressure the NHS is facing (DBIS, 2015, p. 7).  
 
During the period 1974-94, the pharmaceutical industry’s Barral Report on all internationally 
marketed new medicines concluded that only 12% were therapeutically and pharmacologically 
innovative (Barral, 1995, p. 21). Similarly, a French study (La Revue Prescrire, 2005, p. 73) 
reviewed 3100 new medicines or new indications for existing medicines internationally, from 
1981 to 2004, and concluded that only 10% offered moderate to significant therapeutic 
advance. A more recent study of the Canadian national approval process for new medicines 
between 2004 to 2009 concluded that only 10% of new drugs were innovative which was 
comparable with the findings a French review during the same time period in which 8% of new 
medicines were deemed to be innovative (Lexchin, 2012, p. 223).  
 
Since the mid-1990s, further independent reviews have also concluded that about 85-90% of 
all new medicines provide few or no clinical advantages for patients (Angell, 2005, p. 53; Van 
Luijn, Gribnau, & Leufkens, 2010, p. 446). There are clearly not enough medicines entering 
the market place that represent a therapeutic advance over existing treatments, furthermore 
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there is an increasing pressure to curb prescribing costs and maximise the outcomes for 
service users. 
 
2.4.5 The influence on research findings  
The pharmaceutical industry  has been shown to exercise excessive influence in a number of 
mental health domains including clinical trials, research funding, scientific journals, psychiatric 
conferences, professional organisations, medical education, government policy, clinical 
guidelines, regulatory bodies and prescribing by individual prescribers (Read & Cain, 2013, p. 
431; De Freitas et al., 2014, p. 220; Herxheimer, 2003, p. 1210; Spurgeon, 2008, p. 742; 
Muijrers, Grol, Sijbrandij, Janknegt, & Knottnerus, 2005, p. 627). 
 
Drug company sponsored research is the mainstay of available information on which local 
prescribing committees base their decision to approve a new drug for use in a psychiatric 
setting (Heres et al., 2006, p. 191). Often the use of medicines in psychiatry is not mandated 
by NICE, therefore their use at a health economy level is based on local approval.  There are 
few new medicines in development or approved for depression, bipolar disorder, 
schizophrenia, or anxiety disorders and non-industry funding for clinical trials has, with few 
exceptions, diminished substantially in the past 6 years (Nierenberg, 2009, p.528). 
 
The value of clinical trials has been undermined, fuelled by suspicion that negative results 
have been withheld by pharmaceutical companies and that these same companies have 
emphasised minimal benefits while hiding the risks of their products (Rafols et al., 2014, p. 35; 
Turner, 2013b, p. 457; Das, 2011, p. 17).  
 
A particular example of this was highlighted by Kirsch et al. (2008, p. 262) who reviewed data 
on all clinical trials submitted to the FDA for the licensing of the four new-generation 
antidepressants (fluoxetine, venlafaxine, nefazodone and paroxetine). Most of the studies 
were of six weeks duration, despite the fact that these agents are promoted and prescribed 
for long term use (Kirsch et al., 2008, p. 262). Further studies have also called into question 
the long-term benefits from psychotropic medication (Khan et al., 2001, p. 113; Gitlin et al., 
2004, p. 1839; Mann et al., 2005, p. 2071; Moncrieff 2009, p. 15; Das, 2011, p. 16). The 
randomised controlled studies indicated that placebo was 80% as effective as drugs and that 
clinically significant differences only occurred in patients who were severely depressed (Kirsch 
et al., 2008, p. 266). This has led others to question why so many patients are treated with 
antidepressants in light of the fact that they have minimal benefit over placebo (Jelinek & 
Neate, 2009, p. 218; Lenzer & Brownlee, 2008, p. 533). 
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Eyding et al. (2010, p. 9) in their meta-analysis of reboxetine for treatment of major depression, 
analysed published and unpublished studies and identified that 74% of patient data was 
unpublished at the time of marketing the drug. When all the data were analysed, the perceived 
superiority of reboxetine versus placebo shown in published data was reduced to a non-
significant difference and the non-significant difference between reboxetine and SSRIs 
antidepressants resulted in the demonstrable inferiority of reboxetine (Eyding et al., 2010, p. 
8).  
 
Arguably the most publicised controversy in psychiatry occurred when the manufacturers of 
paroxetine (GlaxoSmithKline) were publicly shamed by the BBC’s Panorama when it aired 
'The Secrets of Seroxat'. Not only was the drug company shamed but to a lesser extent it 
called into question the robustness by which the Medicines and Healthcare Products 
Regulatory Agency (MHRA) had executed its duty to assess the safety, quality and efficacy of 
medicines.  
 
In the United Kingdom, paroxetine was widely prescribed “off label” (outside of its licensed 
indication) for use in children and adolescents and in response to the allegations made by 
Panorama, the MHRA was forced to issue recommendations that paroxetine should be not be 
used in children and adolescents for the treatment of depressive illness because of concerns 
about an increased risk of self-harm and potentially suicidal behaviour (Doshi, 2013, p. 1). In 
2012, GSK agreed to pay $3bn in a fraud settlement with the United States government. In a 
statement connected with the lawsuit, the Department of Justice declared that “the centrepiece 
of GSK’s efforts to market Paxil (the brand name in the US) for childhood depression was the 
GSK funded Study 329.”  The justice department concluded that the “article distorted the study 
results and gave the false impression that the study’s findings were primarily positive, when 
they were, in fact, primarily negative” (Thorpe, 2011, p. 9).  
 
A further example of publication bias is evident with the drug agomelatine which is licensed 
for the treatment of depression. In ten premarketing trials: five were positive and published, 
while the five negative trials remained unpublished (Howland, 2011, p. 11). The limitations in 
trial data for agomelatine have also been noted in a recent review by Taylor, Sparshatt, Varma, 
& Olofinjana  (2014, p. 6). 
 
Such practice by the pharmaceutical industry is inconsistent with the NHS constitution which 
affirms that decisions regarding pharmacological treatment will be made following 
comprehensive consideration of the evidence (DoH, 2009, p. 7), furthermore there are clear 
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public health risks, if trial data is withheld from scrutiny coupled with unjustified hopes of 
potential benefits for patients.  
 
The lack of transparency in clinical trials has implications for service user choice as a 
healthcare professional cannot fully facilitate the process of shared decision-making if they 
are unaware of unpublished studies. 
 
2.4.6 Influence on prescribing 
The impact of the pharmaceutical industry on research findings coupled with their role in 
dissemination of clinical trial data, has caused concerns about their undue influence on 
prescribing practice (Royal College of Physicians, 2009, p. 4). These concerns led to the 
publication in 2005 of the House of Commons Health Select Committee report. The committee 
expressed concerns about the over reliance on medicines which was influenced by the 
pharmaceutical industry. Thus, as identified by other studies the  influence of pharmaceutical 
industry is experienced through the dissemination of largely industry sponsored research 
findings, which in turn, impacts on prescribing practice  (Jelinek & Neate, 2009, p. 220; 
Spurling et al., 2010, p. 22). Furthermore,  psychiatry has been identified as being more prone 
to publication bias than other therapy areas, thus compounding the problem of delivering 
evidenced-based practice  in a clinical setting (Fanelli, 2012, p. 895).  
A more recent study of the impact of  industry sponsored hospitality on prescribing, concluded 
that receipt of industry-sponsored meals was associated with an increased rate of prescribing 
the brand-name medication relative to other agents in the same class (DeJong et al., 2016, p. 
1121). The findings from the study included the impact of advertising which was linked to 
increased prescribing of desvenlafaxine over other Selective Serotonin Reuptake Inhibitors 
(SSRIs) and Serotonin-noradrenaline reuptake inhibitors (SNRIs) despite a lack of evidence 
to demonstrate superior efficacy.  
 
2.4.7 The influence on service users 
At present the pharmaceutical industry is prevented from direct marketing of prescription only 
medicines to patients in the UK. This is supported by general practitioners and hospital doctors 
who have expressed concerns that the practice would be unethical and could have negative 
impacts on patient care (Reast, Palihawadana, & Shabbir, 2015, p. 239). Despite restrictions 
on direct marketing to patients in the UK, the pharmaceutical industry has collaborated with 
patient groups.  A particular example in mental health occurred when NICE recommended 
restrictions on use of cholinesterase inhibitors. The Alzheimer’s Society, which is partly funded 
by  industry, mounted an intense lobbying campaign and joined the manufacturers of 
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donepezil in a legal challenge, despite a very modest evidence-base for patient benefit 
(Mintzes, 2007, p. 935).   
 
Read & Cain (2013, p. 431) in their meta-analysis of pharmaceutical industry sponsored 
mental health websites, concluded that the internet has been used to provide consumer 
marketing internationally, which has also been used to shape public opinion in a manner 
consistent with increasing pharmaceutical sales. One recommendation of their review was to 
inform patients of the bias inherent in industry sponsored websites and to signpost them to 
more balanced websites that incorporate a range of evidence-based information about 
causation and treatment (Read & Cain, 2013, p. 431). At present employees of DWMHT are 
encouraged to signpost service users and carers to the Choice and Medication website which 
has been approved by the College of Mental Health Pharmacy. The site provides unbiased 
information on medicines used to treat mental health conditions and the associated clinical 
conditions. 
 
2.4.8 Joint working with the NHS 
Joint working has been defined as collaboration between the NHS and the pharmaceutical 
industry which requires the pooling of skills, experience and/or resources for the joint 
development and implementation of patient centred projects with a shared commitment to 
successful delivery (ABPI, 2015, p. 7). The concept differs from that of sponsorship in which 
the pharmaceutical companies simply provide funds for a specific event or work programme. 
While the definition of joint working outlines an ideal, the DoH and the ABPI acknowledge that 
it can be made difficult to initiate due to the variety of stakeholders involved and the lack of 
clear shared objectives (DoH, 2010a, p. 17). There are numerous barriers to joint working, 
which can include the disproportionality of the arrangement, which potentially would lead to 
one party undertaking most of the work and receiving limited benefits. Often the failure of joint 
working can be linked to attitudinal issues which are entrenched in a culture of mistrust 
between the NHS and the pharmaceutical industry (Megget, 2015, p. 29). Despite the inherent 
mistrust between the pharmaceutical industry, there are those that advocate that the NHS has 
much to gain in terms of the governance framework for research and development (Nelson, 
2007, p. 117).  
 
NHS organisations are under increasing pressure to achieve improved quality and productivity 
under severe economic pressure, thus they are increasingly having to call on external 
expertise to enable them to meet these challenges and there is a recognition that joint working 
can be beneficial (Ousey & Bielby, 2011, p. 154). Collaborative working with the 
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pharmaceutical industry is one way of optimising existing resources to benefit patient care and 
while there is some evidence that collaboration can lead to improved efficiencies (Angus et 
al., 2012, p. 429);  there is a lack of systematic evidence to determine the impact of joint 
working with the pharmaceutical industry on patient outcomes. At present, there are some 
studies underway to determine patient outcomes as a result of joint working and the wider 
societal and economic impacts such partnerships are yet to be determined. 
 
The DoH and the ABPI publication “Moving beyond sponsorship—joint working between the 
NHS and pharmaceutical industry”, states that the potential benefits for patients and the 
system include better care and improved health (DoH, 2010a, p. 7).  Benefits for companies, 
according to industry documents, are “more and/or better use of medicines, including the 
company’s medicine(s)” (DoH, 2010a, p. 7).  The implied notion a of common agenda between 
the NHS and the pharmaceutical industry has been criticised as the pharmaceutical industry 
aims to maximise profit, while the health system aims to maximise population health at minimal 
cost (Moynihan, 2011, p. 1).  
 
Lockwood, Marinoni, & Ando, (2012, p. A290) in their survey identified a total of 165 of joint 
working projects, involving 37 pharmaceutical companies, of these 129 (78%) involved a 
single company, and 36 (22%) involved multiple partnerships.  Most projects were related to 
respiratory medicine; by comparison 6% of projects were related to mental health. Joint 
working projects encompass a broad range of therapeutic areas, with most companies active 
in areas in which they have pharmacological portfolio. These projects can be classified into 
several different categories, including; service redesign, service appraisals in light of current 
guidelines, and techniques to better manage or educate patients.  
  
Critics of joint working have highlighted the case of Janssen Cilag, the manufacturers of the 
antipsychotic risperidone and paliperidone who have entered into an agreement with the 
mental health network of the NHS Confederation (representatives of the  NHS funded mental 
health and learning disability service providers in England) (Moynihan, 2012, p. 2). Janssen 
have developed a social networking site to help GPs in the commissioning of mental health 
services which has obvious implications for the use of their drugs (McCartney, 2011, p. 343). 
In addition, Janssen have also sponsored the NHS Confederation conference.  
 
Increasingly, the pharmaceutical industry has been encouraged by the DoH to develop care 
pathways with CCGs (DoH, 2010a, p. 6). The move has been welcomed by industry officials 
but less so by GP commissioners who have expressed concerns regarding potential conflicts 
of interest. One of the concerns raised by GPs is the potential for joint working with the industry 
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to identify under-diagnosis or an unmet need. The concerns raised are that such outcomes 
could be determined by the industry who have a vested interest in increasing their market 
share in pharmaceutical sales (ABPI, 2012, para 10). An example was shared by a colleague, 
who recently attended a conference in Canada, where clinicians were informed to consider 
the potential for adult attention deficit disorder (ADHD) in patients diagnosed with 
schizophrenia who were partially responsive to antipsychotic treatment (personal 
communication). There is, at present, no strong evidence to substantiate this claim of a link 
between schizophrenia and ADHD; however, the association could lead to increased 
prescribing of ADHD medication. 
 
A further example of joint working between the pharmaceutical industry and the NHS is 
highlighted by the collaboration between Lundbeck and the Wessex Academic Health Science 
Network. The project aims to engage with local commissioners to develop treatment pathways 
for patients with increasing and higher risk drinking levels, thus facilitating the prescribing of 
their drug.  Lundbeck has received approval from NICE in November 2014 for the use of their 
drug Selincro, which is licensed to treat people with alcohol dependence (NICE, 2014, p. 38). 
This approval was given, despite independent reviews such as the Midlands Therapeutic 
Review and Advisory Committee (MTRAC),  which concluded that the evidence for nalmefene 
was weak (MTRAC, 2013, p. 1).  
 
It has been acknowledged that there is a knowledge gap in diagnosing and treating mental 
health conditions in primary care (Fleury et al., 2009, p. 9).  One way of addressing the 
knowledge gap would be to adopt a model of guided consultation, in which the guidelines 
would incorporate guidance for diagnosis, treatment options and follow-up monitoring. In the 
UK this approach has been used in the treatment of chronic obstructive pulmonary disease 
(COPD) and has led to improved monitoring of patients with increased referrals for smoking 
cessation, oxygen assessment, and pulmonary rehabilitation (Angus et al., 2012, p. 429). This 
typifies an example of the potential for joint working with the pharmaceutical industry that could 
support the development of software, to enable more accurate diagnosis of common mental 
health conditions in primary care, with guidance for appropriate physical health monitoring.  In 
the USA, there have been trials incorporating the use of decision aids in electronic medical 
records which has been successfully implemented  by healthcare professionals (Milner et al., 
2009, p. 1012).  
 
The implications for joint working across the local health economy are that the evidence for a 
drug needs to be fully evaluated, proven to be effective by local appraisal of the evidence and 
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that any joint project should be led by the NHS for the benefit of service users and aligned 
with the unmet needs of the population served by the mental health trust.  
In the current economic climate, joint working should be also be able to demonstrate a cost 
benefit for the health economy.  
 
2.4.9 Risk sharing with the NHS  
As part of the exploration of the factors that impact on prescribing, it is important to consider 
the context for joint working between the NHS, in particular DWMHT. 
 
Risk sharing is an arrangement in which the pharmaceutical industry and the NHS agree a 
rebate for the full cost of a drug if there is a failure to achieve a defined clinical endpoint 
(Barros, 2011, p. 462).  
  
One of the earliest examples of a national risk-sharing agreement between the pharmaceutical 
industry and the NHS occurred with beta interferon. NICE concluded in their review of the drug 
that it should not be funded by the NHS (Sculpher, Drummond, & O’Brien 2001, p. 944). The 
decision by NICE not to approve the drug led to a subsequent appeal by the pharmaceutical 
manufacturers, patient groups, consultant neurologists, and the Royal College of Nursing who 
challenged NICE’s scientific methodology of calculating treatment cost per quality-adjusted 
life year (QALY). Nevertheless, having considered these appeals, NICE concluded that beta 
interferon was not cost-effective enough for use in the NHS (NICE, 2002, p. 10).  
 
The pressure on the government led to the DoH negotiating  a “risk-sharing scheme” with the 
pharmaceutical  manufacturers Biogen, Teva-Aventis, and Serono that would  provide NHS 
funding for beta interferon (Crinson, 2004, p. 40). The government presented the risk-sharing 
scheme as clinical research intended to confirm the cost-effectiveness of the drug via post 
market monitoring. This approach was criticised by some as lacking scientific rigor (Sudlow & 
Counsell, 2003, p. 391). 
 
One of the potential benefits of adopting a risk-sharing agreement across the local health 
economy would be the potential to reinforce the principle of ‘paying for performance’. In 
addition, such an approach would allow the local health economy to determine the confidence 
of the manufacturer in their product as well as post-marketing evaluation of the drug. As 
payment for a drug would be dependent on outcomes, one of the challenges that such an 
approach would pose is that the NHS provider organisations would be likely to require more 
robust outcomes than would be agreeable to the pharmaceutical industry.  The use of risk-
sharing may lead to a more cost-effective use of pharmaceuticals.  
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Nationally there are no risk sharing schemes in place for mental health treatment; however, 
there are on-going discussions with the pharmaceutical industry on a local level to adopt risk-
sharing initiatives. In particular, for the use of newer antipsychotic agents which lack evidence 
for superior efficacy to existing agents, but for whom specific patient groups might benefit.  
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2.5 Pharmaceutical Industry – Summary 
The UK expenditure on pharmaceuticals exceeds £15 billion and consumes around 13% of 
the NHS budget (Andalo, 2015, p. 1). In the current time of static NHS funding, the opportunity 
costs of pharmaceuticals are all too clear. There is evidence to suggest that there are minimal 
innovative drugs entering the UK market which confer a therapeutic advantage over existing 
medicines in mental health, this is coupled with a paucity of robust evidence from clinical trials 
which are largely industry sponsored in mental health (Turner, 2013, p. 459). The limited 
evidence as well as multiple approval processes that exist in the UK, account in part for the 
modest uptake of newer medicines compared with comparator countries (DBIS, 2015, p. 35). 
Despite the limitations of clinical trial data, there is evidence to suggest that the pharmaceutical 
industry has an influence on prescribing practice in mental health which has been identified in 
a recent study which involved antidepressant therapy (DeJong et al., 2016, p. 1121). 
 
Joint working with the industry offers the potential for post-marketing evaluation and greater 
consideration for risk sharing between the NHS and the pharmaceutical industry. Risk sharing 
has the potential to facilitate greater emphasis on the value proposition of newer 
pharmacological agents; while such a collaborative approach has been adopted in other 
therapy areas, it is in its infancy in mental health. 
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2.6 Service user engagement within the NHS – Overview 
This study seeks to understand the service user perspective on their involvement in the 
treatment they receive, and the extent to which they feel that they are involved in the decision-
making process. This section of the literature review explores the historical context and policy 
drivers for service user engagement in mental health. The review considers the importance of 
choice for the service user and the factors that impact on adherence to treatment.  
 
2.6.1 The background and history 
The language used to describe service users is perhaps more varied in mental health than in 
any other sector of health and social care. The term ‘service user’ has been in use for over 25 
years to varying degrees (Beresford, 2005, p. 472). Users are most frequently portrayed as 
patients and defined by their clinical diagnosis (Rogers & Pilgrim, 2014, p. 120). However, 
users can also be consumers, survivors and providers, all of which imply different notions of 
the roles and responsibilities of people with mental health problems and the relationship 
between them and mental health services (Tait & Lester, 2005, p. 168). 
 
Service users are increasingly seen as consumers who can exercise an informed choice about 
the services they receive, and can shop around, which means that if they are not satisfied, 
they can take their ‘business’ elsewhere (Tait & Lester 2005, p.168). Despite the consumeristic 
view of service users, the review by Nilsen, Myrhaug, Johansen, Oliver, & Oxman, (2006, p. 
15) concluded that there was minimal evidence to suggest that consumers of healthcare have 
achieved meaningful strategic engagement in service delivery at a health economy level.  
 
Service user involvement in health care has become increasingly important in many countries. 
In the UK this is driven by various agendas including democracy as tax paying citizens and 
the desire to increase accountability throughout the health service and above all consumerist 
principles which is linked to the patient choice agenda (Lester, Tait, England & Tritter, 2006, 
p. 415). While accountability to service users is considered the ideal (Weinstein,2010, p. 81) 
there is minimal evidence to suggest that service users are empowered to hold healthcare 
providers to account; in fact, the converse was highlighted by the Francis report into failings 
at Mid Staffordshire. The findings of the report revealed that patients often felt prohibited from 
voicing concerns, even when they were extremely concerned about safety or the quality of 
care they are received (Francis, 2013, p. 245). 
 
The origin of service user involvement in statutory health policy and guidance can be traced 
back to the establishment of the Community Health Councils in 1973 (Noorani, 2013, p. 51). 
Service user involvement continued through the proliferation of NHS consumer based 
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principles and the growing importance of satisfaction with healthcare in the 1980s (Tait & 
Lester, 2005, p. 168). 
 
From 1997, the then Labour government, envisioned patient and public involvement as a 
central tenet of their modernisation agenda. The NHS Plan (DoH, 2000, p. 69) was committed 
to creating a patient-centred NHS, with service user needs central to service design and 
delivery. Furthermore, Section 11 of the Health and Social Care Act (2001) required all NHS 
organisations to engage users in planning and evaluating services, as well as in decision-
making on issues of treatment (Tait & Lester, 2005, p.169).  
 
The Expert Patients Programme (2001) was hailed by England’s Chief Medical Officer as 
“ushering in a new era of opportunity for the NHS” (Donaldson, 2003, p. 1279). The 
programme was based on self-management for people living with a chronic (long-term) 
conditions and was designed to promote self-care and to alleviate the burden of care by these 
individuals on the NHS. Despite the rhetoric, Wilson, (2001, p. 141) in her critique of the Expert 
Programme, noted that although  the initiatives focuses on the rights and responsibilities of 
those with chronic illness, there is no corresponding strategy to challenge professionals’ 
assumptions and actions toward those with chronic illness, thereby limiting its implementation. 
 
In 2003, a ‘Patient Tsar’ was appointed to advise on improving the service user experience 
(Tait & Lester, 2005, p. 169), and to publish measures to increase patient choice across the 
NHS (DoH, 2003, p.11). Despite the appointment of a tsar, little is known about the impact this 
has had for service users.  
 
The guidance on the Care Programme Approach (DoH, 2008, p. 3) and the New Horizons 
Strategy (DoH, 2010b, p. 17), further supported service user involvement in all levels of 
decision making. The more recent strategy, written by the Conservative-Liberal Democrat 
coalition government, No Health Without Mental Health (DoH, 2011, p. 34), appears to focus 
on emphasizing ‘choice’, together with a focus on active service user and carer involvement. 
It is possible that this reflects an assumption that market-driven choice is synonymous with 
involvement; however how this concept will evolve, especially with the current financial 
constraints on the NHS, is yet to be fully determined. 
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2.6.2 Consumerism and service user participation 
Consumerism in the NHS has its origins in the Conservative government of the 1980’s (Gabe 
& Monaghan, 2013, p. 203), but is currently set against a backdrop of a consumeristic society  
in which service users have increasing expectations about the standard of care they receive 
(O’Neill, 2002, p. 9). In the age of the internet and 24-hour news coverage, service users are 
more informed and able to make informed decisions. In an early attempt to determine service 
user preference and increasing the focus on individuals exercising choice, managers were 
employed across the NHS infrastructure to champion the preferences of ‘consumers’ of health 
care provision and to integrate this into healthcare decision making. One limitation in the use 
of managers was that their focus was based on the hospitality aspect of care (for example, 
cleanliness and food) rather than their perception of the clinical effectiveness of care (Calnan 
& Gabe, 2001, p. 122). 
 
The 1990s saw the introduction of further policy developments aimed at enhancing consumer 
choice, an example of this was the introduction of the Patients Charter in 1992. This sets out 
the rights and service standards that patients could expect (Stocking, 1991, p. 1148). The 
charter was designed to improve quality and make the NHS more responsive to recipients of 
care. Despite the introduction of the charter, the extent to which service users could exercise 
choice and influence service provision is minimal. Critics note that the notion of consumeristic 
principles is at odds with the potential for individuals to be detained under the Mental Health 
Act (Sayce, 2016, p. 147).  
 
In 1997, the Labour party gained power and the focus was shifted from accountability of the 
NHS to its consumers, to one of engagement with them in decision making (Gabe & 
Monaghan, 2013, p. 204). In the NHS Plan, published in 2000, it became a statutory duty for 
Strategic Health Authorities (responsible for the oversight of trusts), PCTs and NHS trusts in 
England to involve users and the public in the planning and operation of services (DoH 2000, 
p. 68). The extent to which this was achieved is unknown as there are no studies evaluating 
the impact of the NHS plan.  
 
2.6.3 Involvement in mental health services  
During the 1980s, with the shift from institution to community based care, service user groups 
grew in the UK. The growth in the service user groups was, in part due to the deconstruction 
of mental health institutions and a growing confidence on the part of service users to advocate 
on their own behalf.   
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Following the UK community care reforms of the early 1990s, there was an additional drive 
that contributed to official acceptance and encouragement of the role of user organisations.  
 
The UK NHS and Community Care Act 1990 transformed the NHS into an internal market with 
purchasers and providers of healthcare, while reaffirming the principle of healthcare being free 
at the point of use. Provider organisations were incentivised by being given the opportunity of 
becoming self-governing trusts, with the promise of increased financial freedom and 
autonomy. Purchasers GPs were permitted to become fundholders, who could purchase non-
emergency care on behalf of their patients. The rationale for the development of this market 
healthcare was that it would focus attention on the needs of patients and not the providers of 
healthcare. GPs were however, purchasing services on behalf of patients, thus acting as proxy 
consumers, with patients having no rights of their own (Gabe & Monaghan, 2013, p. 204).  
Given that patients lack the necessary knowledge or inclination to shop around in the medical 
marketplace, critics have argued that there is little evidence that this reform markedly 
increased consumer choice (Calnan & Gabe, 2001, p. 121).  
 
The NHS and Community Care Act 1990 also required service providers to consult with users 
of their services and their ‘carers’. With associated funding for local groups becoming more 
available this gave a new impetus to the activities of service users. There was however, 
minimal evidence to suggest that meaningful engagement with service users was achieved 
and critics have highlighted that there was a degree of confusion about the meaning and 
purpose of user engagement (Bowl, 1996, p. 178). 
 
A succession of policy directives has introduced service user involvement into every aspect of 
the planning and provision of mental health services (DoH, 1999, p. 4), the education and 
training of professionals (Postgraduate Medical Education & Training Board 2008, p. 4) and 
people’s own treatment plans through the Care Programme Approach, introduced in 1991. 
 
Service user involvement has been far from an unqualified success but has established the 
legitimacy of service users’ views (Read, 2009, p. 4; Wallcraft, Rose, Read, & Sweeney 2003, 
p. 62; Campbell 2005, p. 77). There has been an associated centralised funding for local 
service user groups which has given a new impetus to the activities of these networks. It has 
been argued that funding has changed the focus of these groups.  Instead of deciding on their 
own priorities and campaigns, service users were being asked to respond to more limited 
agendas set by the DoH (Read, 2009, p. 4). 
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In 2014, a survey of community based service users (n=303) took place across DWMHT, 53% 
responded that they were ‘definitely’ given information about newly prescribed medication in 
a way they could understand (Care Quality Commission, 2014, p. 4). The survey findings 
indicated that 55% of people said that the mental health services had involved their family, or 
someone close to them, as much as they would like. The authors of the report have identified 
family engagement as an area for improvement, which is consistent with the findings of a 
Scottish study in which family support was considered as one of the most important factors 
supporting recovery (Reid, Hinchliffe, & Waterton, 2014, p. 3). Furthermore, the importance of 
a supportive network including family and friends has been well documented (Braunholtz, 
Davidson, Myant, Mori, & O`Connor, 2006, p. 6; Fisher, 2003, p. 3;  Smith-Merry, Sturdy, & 
Freeman, 2010, p. 98). 
 
There is a belief by some, that in the light of national policy drivers, stakeholder projects and 
national campaigns, that it is inevitable that there will be some significant changes in 
relationships between healthcare professionals and service users (Read 2009, p. 7). This 
view, however, is contested by others and there is evidence to suggest that the intentions of 
policy makers can sometimes fail to move beyond rhetoric into reality, particularly for mental 
health service users (Tait & Lester, 2005, p. 169). User representatives on a national group 
convened by the DoH in 1998 to develop the National Service Framework (NSF) for Mental 
Health resigned when it became clear that the government was going to insist that compulsory 
treatment orders were non-negotiable (Donnelly, 1998, p. 4). The final document (DoH, 1999, 
p. 10) stated that “specific arrangements should be in place to ensure service user and carer 
involvement in their care plan”, but there are few other references to user empowerment 
throughout the seven standards of the NSF or directly in the Five Years On review (DoH, 2004, 
p. 53).  
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2.6.4 The rationale for user involvement  
Involving users of health services in healthcare planning may serve a number of related 
functions for healthcare providers. First, public involvement may improve the quality of 
services, by clarifying what the patients want. This has tended to be the motive emphasised 
by UK policy directives. The perspective of user involvement as a goal in itself is reinforced by 
the World Health Organization (WHO) who state that; 
Secondly, service user involvement in the planning of free access health services paid for by 
taxation is a sound democratic principle (Milewa, Valentine, & Calnan, 1999, p. 445). This 
approach emphasises equity and empowerment with participation as a key concept (Lupton, 
Peckham & Taylor, 1998, p. 45).  The principles underpinning the approach is that public 
participation is beneficial to maintaining a healthy democracy and in allowing people to 
become full citizens, and second, that the diversity of interests in society should be a fully 
represented model of care offered by the NHS (Lupton, Peckham & Taylor, 1998, p. 10). A 
third reason for public involvement is that it may be viewed as legitimising unfavourable 
change or rationing of services, allowing politicians to deflect blame  on the basis of a wider 
consensus (Redwood, 2000, p. 13). The tension between public demand and political 
appeasement was highlighted following the NICE rejection of drugs for renal cancer in 2009. 
Following public and healthcare professional lobbying, the government required NICE to apply 
less stringent criteria for “end of life” drugs, reversing the decision of NICE on one of these 
drugs (Raftery, 2013, p. 2). 
 
Although successive UK governments have encouraged healthcare providers to include 
service users as part of service delivery, evidence of changes resulting from service users is 
minimal (Crawford et al., 2003, p. 413). Uncertainty of outcome is exacerbated by uncertainty 
about the process, as policy guidance has offered minimal clarification on the meaning of 
‘involvement’. Terms such as ‘partnership’ and ‘consultation’ are used interchangeably 
(Barnes & Wistow, 1994, p. 348). The consultation is a model in which the professional retains 
control of both the process and outcomes of service users, while partnership implies similar 
status, shared power and some equality of influence over both the agenda and outcomes of 
shared decision-making (Chadderton, 1995, p. 227). 
 
 
 
“The people have the right and duty to participate individually and collectively in the planning 
and implementation of their health care” (WHO, 1978, p. 3).  
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2.6.5 Optimising the use of medicines  
Defining optimal outcomes in individuals with enduring illness is complex and incorporates 
three inter-related, but somewhat independent, dimensions: clinical response, functional 
ability and quality of life (see Figure 2.2).    
 
Clinical improvement is symptom focused and response driven; which can transition into 
remission over time. Symptomatic remission favours improved functional outcome and quality 
of life but guarantees neither. Quality of life can be enhanced by both clinical and functional 
improvement but is not simply the product of these; it is, at least in part, determined 
subjectively by the recipient of care.  Recovery, as currently conceptualised, is a process 
rather than dichotomous, incorporating each of these dimensions on an individualised basis 
(Remington, Foussias, & Agid, 2010, p. 15).  
 
 
 
Figure 2.2 Outcomes in Mental Health 
 
 
 
 
 
 
 
Optimal 
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Service user engagement has wide ranging implications for care. The use of medication is key 
issue for service users and healthcare professionals alike. In the author’s experience, it is 
often a source of conflict between them.  
 
Enabling service users with enduring mental illness to achieve the best outcomes from 
medicines (medicines optimisation) is set against a backdrop of evidence that suggests that  
engagement with healthcare providers is poor and that nonadherence with medication in this 
group remains a challenge (BMA, 2014, p. 25; Farooq & Naeem, 2014, p. 1070; Reilly et al., 
2012, p. 7; Velligan et al., 2009, p. 6).  
 
Optimal prescribing may be affected by poor compliance with best-practice guidelines (Van 
Fenema, Van Der Wee, Bauer, Witte, & Zitman, 2012, p. 76), inappropriate prescribing – under 
or over use of medicines (Lang et al., 2010, p. 379) and prescription errors (Duerden & Payne, 
2013, p. 5). In addition, suboptimal prescribing may occur from misdiagnosis or failing to detect 
that a particular symptom is caused by another medicine (Faria et al., 2014, p. 5). 
 
One of the ways in which service users can gain optimal benefit from medication is if 
healthcare professionals engage with them  to  understand their concerns and involve them 
in the decision making process (RPS, 2013, p. 5). This may include: discontinuation of 
medicines, the use of medicines to treat associated comorbid disease states or the provision 
of non-medical interventions such as psychological therapies, as well as, holistic advice based 
on the individual’s lifestyle (Cole, 2014, p. 342; Pampallona, Bollini, & Tibaldi, 2004, p. 718). 
Furthermore, service users have expressed dissatisfaction with the care provided by 
psychiatrists and the need for them to take a more holistic view beyond the focus on 
symptomatology  (Smith-Merry, Sturdy, & Freeman, 2010, p.130;  Borg & Kristiansen, 2004, 
p. 502). 
 
A meta-analysis of differences in prescribing for physical disorders found that individuals with 
enduring mental illness received lower than expected prescriptions for essential drugs used 
to treat cardiovascular diseases, including ACE inhibitors, beta-blockers, and statins (Mitchell, 
Lord, & Malone, 2012, p. 437). The findings by Mitchell et al, is particularly concerning because 
of the higher incidences of comorbid diseases in this patient group; which include: 
cardiovascular disease and diabetes mellitus (De Hert et al., 2009, p. 413). This is further 
compounded by the side effect profile of some psychotropic medication which can induce 
weight gain or worsen other metabolic cardiovascular risk factors.  
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2.6.6 Choice and medication 
Service user involvement in their treatment and care is one of the most important elements in 
the recovery process. Enabling individuals to have a choice in the treatment they receive in a 
holistic, reliable way with flexible support systems is critical to promoting recovery (Smith-
Merry et al., 2010, p. 120; Picton & Wright, 2013, p. 1). 
 
The issue of how decisions are made regarding pharmacological treatment in mental health 
and the arbiter of the final decision, service user or practitioner is a fundamental one. In the 
United Kingdom all medical treatment, including the administration of medicines, normally 
requires the informed consent of the service user requiring treatment.  To be informed there 
are a set of criteria that must be fulfilled, which includes an understanding of the rational for 
the treatment, what it involves, the intended impact, likely adverse effects, the implications if 
treatment is withheld and the alternatives. Usually, service users are entitled to a second 
opinion prior to giving consent. There are circumstances under which consent is not required. 
These include the immediacy of harm to the service user, or another individual, or if the service 
user is incapacitated or detained under the Mental Health Act 2007.  
 
A lack of capacity can be defined by an inability to understand, retain and evaluate information 
to decide or the inability to communicate their decision-making process. Doctors can be 
required to give treatment in the best interests of the person in accordance with the legal 
framework of the Mental Health Act 2007. If the service user has made an advance decision 
regarding their treatment preference, this decision applies to the treatments the individual does 
not wish to receive and is only taken into consideration if the individual is not admitted for care 
under the Mental Health Act (Nicholson, Cutter, & Hotopf, 2008,  p. 323).  
 
All developed countries have legislation governing the compulsory detention and treatment of 
individuals with metal health illness. However, the power to treat individuals while they are 
living in the community is somewhat controversial and less universal (Read, 2009, p. 31).  
 
There has been a decline in the psychiatric inpatient population in developed countries since 
the 1950s (Torrey, Entsminger, Geller, Stanley, & Jaffe, 2008, p. 2). Compulsory supervision 
in the community setting has been developed internationally for the treatment of mentally ill 
people following widespread deinstitutionalisation (Churchill, 2007, p. 17). Community 
treatment orders (CTOs) for psychiatric patients became available in England and Wales in 
2008 (Burns et al., 2013, p. 1627). CTOs require service users to accept clinical monitoring 
and allow rapid recall for assessment. CTOs do not authorise forcible treatment outside 
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hospital setting but do allow for this within the hospital setting. The focus on 
deinstitutionalisation has led to treating individuals in the community setting and many service 
users, particularly those with a psychotic illness now receiving routine care outside of a 
hospital setting and in some cases in a GP setting by mental healthcare specialists (Lind, 
2015, para 2).  
 
Many individuals are subject to repeated compulsory admissions “the revolving door 
syndrome” (Appelbaum, 2001, p. 348) and the absolute rate of involuntary admissions has 
increased (Priebe et al., 2005, p. 125). Legislation for compulsory outpatient psychiatric 
treatment has been widely introduced in the USA, Australasia, some Canadian provinces, the 
UK, and several other European countries (Churchill, 2007, p. 9). 
 
Critics of CTOs view it as a system that is open to abuse and conclude that this is independent 
of the treatment setting (Lawton-Smith, Dawson, & Burns, 2008, p. 97). The opponents have 
expressed concern that CTOs can be used too extensively, for too protracted a period of time, 
or for the wrong reasons, and it can be implemented in a manner that contravenes human 
rights. However a study of service user views which was conducted in New Zealand found 
that service users were broadly positive about CTOs and expressed a preference for treatment 
under a CTO to treatment in an inpatient setting (Gibbs, Dawson, Ansley, & Mullen, 2005, p. 
366).  
 
The NHS Modernisation agenda focused on the issue of patient choice, however there is a 
degree of scepticism about the rhetoric of choice. This is understandable in view of the 
potential for compulsory treatment or the lack of service user engagement and poor 
prescribing practice which has created a culture of mistrust (Read, 2009, p. 30).  
 
While the number of service users who are detained under the Mental Health Act is small in 
relation to the overall number of mental health service users (Mental Health Network 
Confederation, 2014. p. 3), the stigma of admission to a hospital under compulsion has a 
disproportionate impact on how service users perceive mental health services, and how 
healthcare professionals perceive service users, and how the public perceives mental illness. 
The fact that mental health professionals can detain service users under compulsory detention 
orders is at variance with the conceptual idea of service user choice. For this reason, the 
extension of compulsory powers through the CTOs that were introduced to the Mental Health 
Act 2007 was bitterly resisted by service user groups (Batty, 2007, para 4).  
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The importance of choice is internationally recognised, and national strategies have been 
adapted to include the language of patient empowerment, participation and choice (Sainsbury 
2006, p. 7). The UK government has acknowledged that better healthcare outcomes are 
achieved when both the service user and healthcare professional share the decision-making 
process with regards to treatment and care, however, this has not been entrenched in the 
culture of the NHS. Furthermore, there is evidence to suggest that service users fear the 
consequences of open and transparent engagement with healthcare professionals (Francis, 
2013, p. 245).  
 
Service users from Black and Ethnic Minority backgrounds appear to be confused about the 
meaning of choice and are unclear about the options that were available to them, which is 
coupled with entrenched cultural attitudes held by healthcare professionals about service user 
choice (Sainsbury, 2006, p. 3). There is also an acknowledgement that this is compounded by 
a lack of investment in culturally sensitive and appropriate service provision for minority groups 
(Weinstein, 2010, p. 60; Read, 2009, p. 36)   
 
2.6.6.1 The importance of Service User choice 
There are several reasons for engaging with service users to empower them to have the right 
to determine their own treatment. Primarily, service user autonomy should be respected for its 
own sake and this is in keeping with human rights convention (Hope, 2002, p. 101). 
Furthermore, service user involvement underpins the concepts of citizenship and democracy. 
Another reason for engagement is linked to the idea of optimising the use of medicines for the 
individual and improving outcomes from the investment in pharmacological treatment. The 
implementation of service use choice as part of the healthcare professional-service user 
consultation has been demonstrated to produce improved outcomes (Heisler, Cole, Weir, 
Kerr, & Hayward, 2007, p. 1442) although systematic evidence is still lacking (Duncan, Best, 
& Hagen, 2010, p. 15).  
 
Service user engagement supports the expectations of the individual and explores how 
pharmacological treatment fits within the context of their aspirations and desired outcomes. 
For example, a service user who is treated for bipolar disorder might not find value in the 
complete remission of manic symptoms. The presentation of symptoms albeit attenuated, 
might be important for creativity and so while an individual might have decided that medication 
contributes to their well-being, they might equally decide to be partially adherent to treatment. 
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It is estimated that half of the medicines which are prescribed for long term conditions are not 
taken as directed, representing a failure to translate potentially effective treatment into optimal 
outcomes for service users including the wider societal benefits (NICE, 2009, p. 3; WHO, 
2003, p. 7).  It is also acknowledged that there is a paucity of research on non-adherence in 
psychiatry (Farooq & Naeem, 2014, p.1070). 
 
It is estimated that 50% of individuals with major depression for whom antidepressants are 
prescribed, do not take the medication beyond three months following initiation (Vergouwen, 
Bakker, Katon, Verheij, & Koerselman  2003, p. 1416) and rates of adherence among patients 
with bipolar affective disorder are as low as 20% (Lingam & Scott, 2002, p. 166). These 
findings suggest that service users are exercising some choice regarding whether or not to 
take prescribed medicines and there is also evidence that, when provided with information 
service, users usually make rational choices that are often more conservative than would be 
recommended by their clinician (Stacey et al., 2014, p. 30). 
 
The need for individuals to comprehend the treatment options and probable outcomes is a key 
step in adherence to treatment. As is often the case in psychiatry, a pharmacological agent 
does not usually confer a clear therapeutic advantage over existing alternatives, therefore the 
service user is not faced with the potential option of choosing a therapeutically superior 
medicine but rather an option based individual preferences which can include convenience, 
associated stigma, and an acceptable side effect profile. An example of this can be seen in 
the treatment of schizophrenia. A pivotal meta-analysis of antipsychotics concluded that there 
was a lack of significant differences in effectiveness between most of the first and second-
generation antipsychotic agents (Lieberman & Stroup, 2011, p. 771). One of the implications 
of the findings from this study is that a decision cannot be made for a single antipsychotic as 
a therapeutically superior option, but rather, the likelihood that the service user will experience 
the health outcomes that is acceptable to them which includes tolerability.  
 
The study by Bolster & Manias (2010, p. 163) identified several steps as part of a collaborative 
process which they describe as patient centred. The steps include defining the nature of the 
risk of treatment versus non-treatment, clarifying the goal of communication; describing risk 
perspectives; managing the difference, prioritising risk perspectives; and deciding. Defining 
the nature of risk involves exploring medication use from both the service user and clinician 
perspective. The service user may have concerns about the risk to their lifestyle or well-being 
while the clinician may be concerned about relapse prevention (Perkins, 2001, p. 9).  These 
concerns need to be explored and openly discussed. Clarifying the goal of communication 
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involves making it explicit that the discussion is about coming to a shared decision and not 
one of advice-giving regarding the need to take medication. The overall goal of the 
consultation is to incorporate both scientific evidence and personal feelings about the risks of 
taking long-term medication. Describing risk perspectives involves both patient and clinician 
sharing their perspectives on the treatment options. Managing the difference and prioritising 
risk perspectives involves the clinician and patient clarifying the values of the risks associated 
with treatment. Making a decision should be based on a shared understanding in which the 
patient is better equipped to make a quality decision because both the clinical evidence and 
their own perspective have been incorporated into the information sharing (Collins & Street, 
2009, p 1511). 
 
2.7   Adherence  
 
Adherence has been defined as the “active, voluntary, and collaborative involvement of the 
service user in a mutually acceptable course of behaviour to produce a therapeutic result” 
(NICE, 2009, p. 3; Weiden & Rao, 2005, p. 206). This definition implies that the service user 
has a choice and that both service users and providers mutually establish treatment goals. 
This contrasts with compliance which is the extent to which the service users’ behaviour 
matches the prescribers’ recommendations (Felzmann, 2012, p. 407). 
 
The largest clinical trial comparing atypical antipsychotics found that 74% (n=1493) of patients 
with schizophrenia were non-adherent with their antipsychotic medication over 18 months 
(Lieberman & Stroup, 2011, p. 770). The most common reasons for discontinuation were 
patient choice, lack of effect or intolerability linked to side-effects. 
 
Medication adherence reflects a spectrum ranging from individuals who take no medication, 
despite verbally acceding with the healthcare professional to take prescribed medication, to 
those who take each dose as directed. Between these two extremes are patients who show 
varying degrees of adherence, taking some medication but not consistently as prescribed.  
This practice is termed partial adherence. 
 
2.7.1 Measures of adherence 
The methods for determining adherence can be stratified into direct and indirect methods of 
measurement. Directly observed therapy can include measurement of concentrations of a 
drug or its metabolite in blood or urine. This approach can be useful with certain medicines. 
For instance, the serum concentration of drugs such as phenytoin or valproic acid will probably 
give a useful indication of the extent of adherence to treatment; however, such approaches 
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are potentially costly and burdensome to the health care provider, and susceptible to distortion 
by the individual e.g. compliance with treatment prior to a clinic appointment.  
 
Indirect methods of measurement of adherence include asking the patient about adherence 
to treatment, assessment of clinical response as a surrogate marker of adherence, counting 
unit doses of medication, use of pharmacy databases and patient diaries. Indirect methods 
can be subject to subjective analysis and misinterpretation (Sajatovic & Ross, 2009, p. 23). 
Unit dose assessments are also prone to error as patients can discard medicines intentionally 
or switch between medicine containers to give the appearance of adherence. In the study by 
Byerly et al. (2007) psychiatrists were found to underestimate non-adherence when compared 
with objective electronic measures (electronic detection 57%, 34 of 61 participants vs 7%, 4 
out of 60 for prescriber estimates). The recent review of self-reported adherence by Stirratt et 
al. (2015, p. 477) concluded that this method of ascertaining adherence is imperfect, and that 
adherence is overestimated when compared with other assessment approaches. Despite this 
acknowledgement the authors contend that self-reporting is the most common method for 
assessing adherence behaviour in clinical care, and suggest that the validity of self-report 
adherence measures may be enhanced by using validated scales. In routine clinical practice, 
adherence is reported in variety of ways which makes objective determination of adherence 
difficult to achieve. Stirratt et al, (2015, p. 477) asserts that the use of rating scales in clinical 
practice can be used to determine if further investigation is warranted when an individual 
reports issues related to adherence. 
 
2.7.2 Determinants of poor adherence 
Intentional non-adherence 
Intentional non-adherence is linked with the individual’s rationale for and against taking 
medication and in the review by Mitchell & Selmes, (2007, p. 338 ) was identified as a common 
reason not to start a course of medication, but was minimally associated with missing 
individual doses. This is consistent with the later review of adherence by (Chapman & Horne, 
2013, p. 449). Predictors of intentional non-adherence include: patient perception of whether 
medication works and the general impact on their quality of life (Jimmy & Jose, 2011, p. 157; 
Higashi et al., 2013, p. 210).  In a recent systematic review by Mohammed, Moles, & Chen, 
(2016, p. 12) the authors concluded that medicated related burden experienced by the 
individual was likely to impact on their decision to adhere to treatment. Hence individuals were 
less likely to adhere to medication regimes that impacted negatively on the activities of daily 
living.  This has important implications for clinical practice as it provides an opportunity for 
healthcare professionals to identify how medication might impact on service users and provide 
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individualised care through shared decision-making. As a minimum, such an approach is likely 
to lead to increased service user satisfaction and this finding was identified in the Cochrane 
review of shared decision making in mental health by Duncan et al. (2010, p. 15). Despite the 
acknowledgement by the review that shared decision-making supports the individual’s needs, 
the authors acknowledged that there was minimal evidence linking the approach to improved 
health outcomes.  
 
Intentional non-adherence is predicted by the balance of an individual’s reasons for and 
against taking medication, as suggested by utility theory. This reinforces the need for the 
clinician to engage with the service user in an on-going dialogue to understand the service 
user’s perspective on the prescribed treatment. The need for engagement and information 
was also identified by Coulter, Roberts & Dixon  (2013, p. 14) who, in their report on long-term 
conditions recommended  that patients receive copies of their care plans as part of the 
consultation process.  
 
A further factor that has been identified in support of adherence to treatment is continuity of 
care. Kauppi, Hätönen, Adams, & Välimäki, (2015, p. 782) in their study of factors impacting 
on adherence from healthcare professionals and service users, identified the importance of 
continuity of care and recommended that healthcare providers maintain the same health care 
professionals for treating individuals.  This finding is not surprising and is possibly linked to 
the provision of consistent information, leading to potentially improved medicine-taking 
behaviour.  
 
Understanding and Information 
The review by Mitchell & Selmes, (2007, p. 339) identified that patients’ understanding of their 
condition and the need for treatment is positively related to adherence, and in turn adherence, 
satisfaction and understanding are all related to the amount and type of information given. The 
importance of timely and relevant information has been identified in a number of studies  in 
which services users have felt disempowered (Hill & Laugharne, 2006, p. 86; Olofinjana, 2005, 
p. 371; Smith-Merry et al., 2010, p. 123). While service users have indicated a desire to 
engage in shared decision-making there is minimal evidence to suggest that this is common 
practice; furthermore, this approach to consultation may have implications for legal and 
professional responsibility and accountability (NICE, 2009, p. 20). At present service users 
and healthcare professionals enter decision-making with very different levels of knowledge 
and informational asymmetry. It is possible that shared decision-making will require structural 
changes to health services and the current delivery model. Perhaps, more fundamentally there 
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will be a need for a cultural change in the nature of engagement between healthcare 
professionals and service users. 
 
A lack of insight has also been linked with non-adherence and in the case of individuals with 
schizophrenia or bipolar disorder, the level of insight into their illness, can have implications 
for the perceived need for medication. In a survey involving clinical experts, illness severity 
and poor insight was deemed to be the most important factor contributing to non-adherence 
(Velligan et al., 2009, p. 16). This finding is contrasted in the review by Mitchell, (2007, p. 18) 
in which the individual’s fluctuating clinical need was identified as the key factor in adherence 
to medication regimens; thus, healthcare professional perspectives may be at odds with the 
recipients of care as to the most important factors driving medication taking behaviour and the 
subsequent determination of the impact of medicines on patient outcomes.  
  
Side effects  
The side-effects of medication are  a cause of distress for service users and have been linked 
to non-adherence with treatment (de Boer, Castelein, Wiersma, Schoevers, & Knegtering, 
2015, p. 675;  Mitchell & Selmes, 2007, p. 338; Weiden, Mackell, & McDonnell, 2004, p. 55). 
However, in a review of factors impacting on adherence in  schizophrenia, the authors 
concluded that, experts gave more prominence to side effects as a contributor to adherence 
problems than has been reported in the literature (Higashi et al., 2013, p. 215).  
 
A study by Hudson et al. (2004, p. 213) identified non-adherence associated with side effects 
in approximately 35% (n=153 total) of patients with schizophrenia; similarly, Loffler et al, 
(2003, p. 108) in a study of non-compliance in patients with schizophrenia found that 50% 
(n=307 total) of patients reported side effects as a reason for non-compliance. In the  study  
by Baldessarini, Perry, & Pike, (2008, p. 99) of non-adherence in patients with bipolar disorder, 
adverse effects were associated with discontinuation in 13.1% of individuals (n=432 total).  
Fortney et al, (2011, p. 831) identified discontinuation with antidepressant treatment in 42.9% 
(n=35 total). Thus, non-adherence figures can vary widely; which is understandable in view of 
the different populations, variety of diagnoses, variable follow-up periods, and the different 
definitions and measurement methods used in studies. 
 
 
 
 
 
  
48 
 
2.7.3 Specific adverse effects 
Discrepancies have been identified between psychiatrists and service users in their estimation 
of the degree to which psychotropic medicines exert their adverse effects (Rettenbacher, 
Burns, Kemmler & Fleischhacker, 2004, p. 2871). This has important implications for 
concordance as individuals can often discontinue treatment due to intolerable adverse effects. 
Furthermore, doctors can be reluctant to disclose information on adverse effects due to 
concerns that such disclosures may demotivate patients from engaging with treatment (Seale, 
Chaplin, Lelliott, & Quirk, 2006, p. 2870). Despite the doctors’ concerns, the review by 
Desplenter, Simoens, & Laekeman, (2006, p. 340) which explored the impact of informing 
psychiatric patients about their medication, including potential adverse effects, concluded that 
there was a positive association between educational interventions and adherence to 
treatment.  
  
Weight gain has been linked with non-adherence with treatment and subjective distress in 
individuals (Fakhouri, 1999, p. S285; Oehl, Hummer, & Fleischhacker, 2000, p. 84; Weiden, 
Mackell, & McDonnell, 2004, p. 56; Seale et al., 2006, p. 2866; Read, 2009, p. 138; Sajatovic 
& Ross, 2009, p. 30). In the study by Fakhouri (1999, p. S285), 39% of the 202 respondents 
reported weight gain as an adverse event. For those individuals that reported weight gain 74% 
of respondents described it as ‘extremely distressing,’ this percentage was higher than any 
other reported side effect. Furthermore, obese individuals have been found to be more than 
twice as likely as those with a normal body mass index to omit their medication (Weiden, 
Mackell, & McDonnell, 2004, p. 56). This is of particular concern as some of the second-
generation antipsychotic medicines are noted for their propensity to induce weight gain.  
 
Sexual dysfunction has been identified as a side effect of medication that is particularly 
distressing for service users and is linked with poor adherence (Sajatovic & Ross, 2009, p. 
30).  Olfson, Uttaro, Carson & Tafess, (2005, p. 331) studied sexual dysfunction in 139 out-
patients with a diagnosis of schizophrenia who were treated with antipsychotic medication as 
the only treatments associated with sexual side-effects. Sexual dysfunction occurred in 45.3% 
of the patients and was associated with significantly lower ratings on the quality of life rating 
scale. In a review of the literature evaluating sexual dysfunction in patients with a diagnosis of 
schizophrenia the authors identified that between 16% for quetiapine (n=1446) to 60% for 
thioridazine (n=49) of the patients included in the studies reported sexual dysfunction, possibly 
related to the use of antipsychotics (Serretti & Chiesa, 2011, p. 135). Psychotropic-related 
sexual dysfunction in serotonergic antidepressants when compared with placebo was reported 
in between 25.8% for mirtazapine (n=49) to 80.3% for sertraline (n=970) of treated individuals 
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(Serretti & Chiesa, 2009, p. 261). In a more recent review  Montejo, Montejo & Navarro-
Cremades, (2015, p. 419) acknowledge underreporting of sexual side effects and recommend 
that discussions should be held about the potential impact of psychotropic medicines on 
sexual function with all patients.  
 
Rosenberg, Bleiberg, Koscis, & Gross (2003, p. 293) examined the effects of sexual side-
effects on adherence in 51 severely mentally ill outpatients and found that 62.5% of men and 
38.5% of women felt that their psychotropic medicines were causing sexual side effects; 
furthermore 41.7% of men and 15.4% of women admitted discontinuing their medication as a 
result. An important finding from the study is that 50% of the participants never, or infrequently, 
spoke about sexual functioning with their healthcare provider. Whilst this study has important 
findings it is limited by its small sample size. A recent meta-analysis by Reichenpfader el al, 
(2014, p. 28) identified that under-communication of sexual dysfunction is common and that 
there is a lack of specific research in this subject. 
 
2.7.4 Adherence in mental and physical health  
Despite a search of the literature there are no recent reviews or meta-analyses comparing 
rates of medication adherence between mental and physical health. This is possibly because 
of the variable methods which are used to measure treatment adherence and the inherent 
difficulties in making comparisons between them.   
 
In an earlier systematic review by Cramer and Rosenheck, (1998, p. 199) the mean rate of 
medication adherence in patients with physical disorders was 76% (range 40 to 90%; n=7 to 
n=259), whereas in patients with psychoses the mean rate was 58% (range 24 to 90%; n=20 
to n=591). One of the limitations of the review was that varying methods were used to 
determine compliance and it is possible that these differing approaches could account for the 
differences in adherence rates between physical and mental health. Rates of partial 
adherence have also been reported in asthma (30–70%), diabetes (36-93%, at 6-24 months) 
and hypertension (41-51%, at 6 months) reflecting the wide spread nature of non-adherence 
(Bender, Milgrom, & Rand, 1997, p. 177; Cramer, 2004, p. 1218; Mazzaglia et al., 2009, p. 
1603). 
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2.7.5 Impact of non-adherence  
In a study by Ascher-Svanum, Zhu, Faries, Furiak, & Montgomery (2009, p. 4)  adherent 
patients were significantly less likely to have a psychiatric hospitalisation (17.1%; n=1758) 
compared with partially adherent (30.6%; n=36) and non-adherent patients (29.6%; n=216).  
In  a study of 4325, Medicare patients with a diagnosis of schizophrenia, compliance with 
treatment as measured by no gaps in medication taking was associated with a hospitalisation 
rate of  6.4%, compared with 21.6% in those for whom there was greater than 30 days gap in 
medication taking (Weiden, Kozma, Grogg, & Locklear, 2004, p. 890).  
 
In a one year observational study of over 60,000 patients with schizophrenia, the relationship 
between adherence and hospitalisation demonstrated that patients with sufficient medication 
90% of the time, had on average an admission rate of 8.3%, compared with rates of greater 
than 20% for patients with sufficient medication for 50% of the time (Llorca, 2008, p. 238).  
There are many factors that influence adherence, however a thorough discussion of these is 
beyond the scope of this review; these factors can be seen as falling into four main categories: 
patient, treatment, environment and physician-related. 
 
2.7.6 Illness beliefs and knowledge of medication 
Concepts of health and disease state are important factors in determining adherence in mental 
health. A service users understanding and agreement with a diagnosis are key steps in 
determining the likelihood of adherence. In turn, adherence, satisfaction and understanding 
are related to the quality of information imparted to the individual service user, and where 
appropriate the carer of the individual. Sajatovic, Davies & Hrouda (2004, p. 268) suggest that 
successful strategies aimed at improving adherence, incorporate knowledge of the medicines 
as well as awareness and illness self-management. 
 
One major factor that influences adherence is the patient’s ability to read and understand 
verbal instructions associated with their medication regime (Jimmy & Jose, 2011, p. 156). 
Patients with low literacy may have difficulty understanding instructions; which could ultimately 
results in decreased adherence and poor medication management (Praska, Kripalani, Seright, 
& Jacobson, 2005, p. 1441; Kochevar & Yano, 2006, p. S27). This is particularly relevant for 
this study as the literacy rates in Dudley and Walsall are below the national average (Sedghi, 
2011, para. 2). Another factor that can contribute to non-adherence is the complexity of the 
medication regimen; this can include timing of administration, and amount of medicines.  
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Such complexities should be taken into account by the prescriber as part of the consultation 
process. A failure to address issues related to the complexity of a medication regimen is likely 
to lead to a decreased therapeutic outcome for the service user concerned. 
 
There is often an assumption by healthcare professionals that service users understand a 
reasonable amount about their illness, yet a study conducted over 40 years ago by Joyce et 
al (1969, p. 189) demonstrated that patients were unable to recall half of the information given 
to them by their doctor. A more recent study, in which there was a high report of patient 
dissatisfaction with communication, identified that less than half of the important discharge 
information, including the name of the prescribed medication, dose, frequency, duration of 
administration, signs of improvement or worsening clinical status, was recalled at an exit 
interview (Isaacman, Purvis, Gyuro, Anderson, & Smith 1992, p. 1204). The findings of the 
study identified that the addition of written instructions to standardised verbal instructions did 
not improve recall of discharge information. The findings from the study would suggest the 
need for a communication strategy, which is multi-agency in nature and focused on addressing 
the needs of the intended recipients. Such an approach is consistent with the concept of 
‘Channel Management’ in which bespoke messages are targeted for specific stakeholder 
groups (Mehta, Dubinsky, & Anderson, 2002, p. 430).  
 
Bezreh, Laws, Taubin, Rifkin, & Wilson, (2012, p. 13) in their study of physician-patient 
communication, undertook a content analysis of commentaries to an article that was published 
in the New York Times about low rates of medication adherence. The study identified three 
key themes: mistrust and criticism of health care institutions, patient empowerment secondary 
to independent research, and patients not wanting to discuss adherence with their doctor. The 
study also revealed the impact on individuals paying full prescription costs as a reason for 
non-adherence to treatment. The author recommended that doctors encourage their patients 
to be open and honest about issues related to trust.  
 
A study by Olfson et al. (2000, p. 221) identifying  predictors of noncompliance in patients with 
schizophrenia concluded that substance misuse was the strongest predictor of medication 
noncompliance. Social isolation was also associated with poor adherence. The study 
demonstrated that a significantly higher proportion of patients who were non-adherent had 
relatives who had refused to be involved with their care during hospitalisation (Olfson et al., 
2000, p. 220). 
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2.7.7 Healthcare professional impact 
The importance of good communication between service user and health professional is 
increasingly acknowledged in relation to adherence (Duncan, Best, & Hagen, 2010, p. 15). In 
essence, this means forging a joint therapeutic agreement with full end user engagement. This 
is a two-way process in which willingness to discuss mental health issues with a healthcare  
professional is predicted largely by the perceived helpfulness of, and trust in that individual 
(Laugharne, Priebe, McCabe, Garland, & Clifford, 2012, p. 499).  
 
 A lack of engagement in treatment decisions can lead to adherence which is based on an 
instruction from a healthcare professional. In the study by Gray, Rofail, Allen, & Newey (2005, 
p. 36) service users stated that they took medication only because they were told to. Service 
users typically leave the consultation with a poor understanding of the rationale for therapy 
(Weiden, Mackell, et al., 2004, p. 56).  In one study of 30 patients, 50% claimed that they were 
offered no information on the medicines they were prescribed and 90% reported that they 
were offered no choice in the medicines that they were prescribed (Olofinjana & Taylor,  2005, 
p. 370). Another study identified that two-thirds of psychiatric in-patients did not understand 
why they were taking medication, and the vast majority had not given informed consent to their 
treatment, furthermore only one-tenth knew about the adverse effects of their prescribed 
medication (Brown, Billcliff & McCabe, 2001, p. 133). A more recent study, conducted in an 
elderly inpatient ward, comparing knowledge of psychotropic and non-psychotropic medicines 
identified that only 42% of respondents (n=86 total) demonstrated an understanding of the 
purpose of taking both psychotropic and non-psychotropic medication, 15% understood only 
their psychotropic medication, 16% understood only their non-psychotropic medication and 
27% understood neither medication (Perecherla & Macdonald, 2011, p. 222). The study has 
important implications for adherence which is linked to service user understanding; as older 
adults are prescribed more medicines and therefore have a greater pill burden than their 
younger counterparts. This finding was consistent in both detained and informal in-patients. 
Similarly, many patients misunderstand prescription instructions. Demyttenaere et al. (2001, 
p. 32) in a study of n=272 patients with depression found that 53% believed they did not need 
their antidepressants and discontinued treatment within 6 months of initiation. The main 
reason for discontinuation was “feeling better.” Overall, 24% of the patients did not inform their 
clinician about discontinuation of treatment.  
 
The public campaign Defeat Depression revealed that many people were wary of taking 
antidepressants because they believed that individuals with depression should ‘pull 
themselves together’ and more than three-quarters believed that antidepressants were 
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addictive (Paykel, Hart & Priest, 1998, p. 520). In addition, service users may have limited 
expectations about the benefits of pharmacological treatment (Lang, 2005, p. 584).  
 
2.7.8 Non-adherence  
Traditionally,  non-adherence with medication  has been viewed by healthcare professionals 
as misguided (Kane, Kishimoto, & Correll, 2013, p. 216). This view fails to take into 
consideration the complexity associated with medicine taking behaviour (Deegan & Drake 
2006, p. 1636) and maybe underpinned by professional prejudicial attitudes (Jorm, Reavley, 
& Ross, 2012, p. 1035; Cook & Wang, 2010, p. 9).  Askey, Gamble, & Gray (2007, p. 363) 
also suggest that the impact of coercive treatments and stigma may be important variables to 
examine in relation to medication use in service users with enduring mental illness.   
Service users and prescribers bring pre-existing beliefs about the illness and treatment (Jorm, 
2000, p. 399; Horne & Weinman, 1999, p. 562) which influence the individual’s evaluation of 
the prescribed medication, their adherence and even beneficial or adverse outcomes 
(Felzmann, 2012, p. 408).   A new approach has been developed which acknowledges the 
service users right to discuss and negotiate with prescribers and ultimately, to make their own 
decisions. A NICE clinical guideline, ‘Medicines Adherence: Involving Patients in Decisions 
about Prescribed Medicines and Supporting Adherence’ describes a more equitable 
relationship between clinicians and service users which emphasises the importance of shared 
decision-making (NICE, 2014, p. 18). The guidance draws on expertise from both the medical 
and psychiatric evidence-base and lived experience of service users to contribute to the 
process of decision making.   
 
Interventions which are aimed at improving compliance are often designed to increase service 
users’ behavioural conformity to the clinicians’ view of optimal treatment (Deegan & Drake, 
2006, p. 1636). Interventions which have largely focused on service user compliance with 
recommended treatments have been criticised as being paternalistic (Horne et al, 2005, p. 
117). While a paternalistic approach to medication taking may be justified under certain 
circumstances, for example, during an acute psychiatric emergency, there are a number of 
factors which should be considered, including the significant limitation of a person’s 
competency for decision making and the potential harm, including irreversible harm (Corrigan 
et al., 2012, p. 171).  However the study by Hamann et al, (2006, p. 271) demonstrated the 
potential for achieving   shared decision-making even during the acute phase of schizophrenia. 
The findings from the study indicated that patients who were engaged in shared decision- 
making reported improved knowledge about their disease and treatment.  
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Despite the considerable costs of non-adherence, a recent review concluded that there was a 
lack of evidence evaluating the cost effectiveness of adherence interventions (Oberjé et al., 
2013, p. 1168). In the review by Garcia-Pérez & Serrano-Aguilar, (2011, p. 121) they identified 
four studies which assessed the cost-effectiveness of interventions to enhance medication 
adherence in psychiatric patients. The outcomes on adherence reported by the four studies 
were inconsistent.   
 
2.8 Shared decision-making  
Shared decision-making has been described as a transactional and interpersonal model of 
communication, in which health care providers and patients work collaboratively to select 
treatment and care. These include patients' health experiences and preferences (Curtis et al., 
2010, p. 15; Adams & Drake, 2006, p. 90). In shared decision-making, “the practitioner 
becomes a consultant to the service user, helping to provide information, to discuss options, 
to clarify values and preferences, and to support the user's autonomy” (Deegan & Drake, 2006, 
p 87; Horne et al., 2005, p. 6). This is in keeping with government policy, in particular the DoH 
paper ‘Equity and Excellence: Liberating the NHS’, which reflects the importance of shared 
decision-making by stipulating that it should become the ‘norm’ in clinical practice.  
 
Shared decision-making differs conceptually from compliance because of the inherent 
assumption that there are two professionals (the service user and the practitioner) who are 
engaged to determine the optimal treatment (Corrigan et al., 2012, p.170). Many recipients of 
mental health care do not see themselves as equal partners or feel empowered to make 
decisions about their mental health treatment (Curtis et al., 2010, p. 14). Although there is 
evidence to suggest that service users typically want more involvement in their mental health 
treatment, this is often not often experienced by them (Tait & Lester, 2005, p. 170; Weinstein, 
2010, p. 23; Read, 2009, p. 4). 
 
There is a considerable gap between service users’ preferences for information and their 
actual involvement in shared decision-making (Ford, Schofield, & Hope, 2003, p. 77; Fotaki et 
al., 2008, p. 182; Read, 2009, p. 59; Weinstein, 2010, p. 86).  Furthermore, there is evidence 
to suggest that a substantial proportion of service users are  inadequately informed to be able 
to exercise treatment choice effectively (Entwistle, Sheldon, & Watt, 1998, p. 220) and that for 
individuals with enduring mental illness the desire for autonomy is similar  to that of other 
patient groups (Hill & Laugharne, 2006, p. 82). 
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Trevena & Barratt (2003, p. 267) identified that the suitability of a decision for shared decision- 
making is dependent upon the clinical context, patient preferences, practitioner responsibilities 
and the underpinning evidence. Montori, Gafni, & Charles, (2006, p. 25) further refined the 
shared decision-making concept in relation to long-term conditions to include “on-going 
partnership between the multidisciplinary team and the patient”. 
 
The importance of shared decision-making has been well documented within the medical 
literature (Duncan, Best, & Hagen, 2010, p. 3). In non-psychiatric chronic diseases, shared 
decision-making has been proven successful in improving the therapeutic alliance between 
provider and service user, treatment adherence, self-care and overall treatment outcomes 
(Joosten et al., 2008, p.225; Coulter, 2006, p. 85). The study by Heisler et al. (2007, p. 1439) 
demonstrated that an informed and inclusive communication style of the physician, which 
included a participatory role for the patient in decision making, resulted in significant 
improvement in patient self-care and glycaemic control (glycated haemoglobin [HbA1c] 
improved by as much as 0.7%). In another study (Greenfield et al., 1988 p. 455) the 
improvement in HbA1c was found to be even greater (1.5%) as a result of patient engagement.  
 
The emerging literature in psychiatry indicates that shared decision-making has led to 
improved clinical outcomes and improved concordance (Clever et al., 2006, p. 400; Bunn, 
O’Connor, Tansey, Jones, & Stinson, 1997, p. 244). Shared decision-making has also been 
shown to have an economical benefit by reducing hospitalisation for patients with 
schizophrenia (Hamann et al., 2007, p. 995). However, shared decision-making in psychiatry, 
can be complicated due to a lack of insight into the illness by the service user or predominant 
negative symptomatology; both of which can impact on the perceived need or benefit from 
pharmacological therapy.  
 
Another factor which can influence shared decision-making is the individual psychiatrist and 
the importance of service user trust  (Mather, Baker, & Laugharne, 2012, p. 166). However, 
this is contrasted with the findings of Hall et al., (2001, p. 628) who identified that the desire 
for shared decision-making is independent of the level of trust and based more on a desire for 
autonomy. Furthermore, Bezreh, Laws, Taubin, Rifkin, & Wilson (2012, p. 17) in their review 
concluded that mistrust of doctors was more widespread than was perceived by them. This 
led to them recommending that doctors encourage individuals to express their true feelings 
about prescribed medication.  
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Mitchell & Selmes (2007, p. 347), in  their review of treatment adherence, conluded that a 
positive relationship with the prescriber contributed to improved adherence. The 
importance of continuity of care in which  a positive relationship has been developed over a 
period of time has also been identified as an important factor in patient care (Laugharne, 
Priebe, McCabe, Garland, & Clifford, 2012, p. 499; NICE, 2014, p. 6). Furthermore, the quality 
of the relationship between clinician and service user has been demonstrated to empower and 
influence attitudes to prescribed medicines (Coulter, 2002, p. 669; Laugharne, Priebe, 
McCabe, Garland, & Clifford, 2012, p. 82; Bolster & Manias, 2010,  p. 163).   It has been 
suggested that research is needed to identify the psychiatrist factors that lead to a wide 
variation in engaging with patients (McCabe, Khanom, Bailey, Priebe, 2013, p. 328). Duncan, 
Best, & Hagen, (2010, p. 15) concluded in their review, that there was insufficient evidence to 
suggest that shared decision-making leads to improved health outcomes for patients with 
mental health conditions. They did however acknowledge that shared decision-making may 
increase patient satisfaction, without an increase in consultation times, or use of health 
services resources.  
 
Despite the numerous studies in shared decision-making, there is limited evidence to suggest 
how service users wish to be involved in decisions related to their care (Woltmann & Whitley, 
2010, p. 30). 
 
2.8.1 The service user perspective  
Choice, self-determination and empowerment are fundamental values for service users with 
enduring mental health diagnosis (Deegan & Drake 2006, p 1636). The shared decision model 
upholds these values and aims to bridge the empirical evidenced-base which is based on 
specific population averages with the unique concerns, values and lifestyle of the individual 
(Deegan & Drake 2006, p 1636). In many cases, it is unlikely that the individual will be able to 
assess the evidence for a specific drug; therefore, the contextualisation of the evidence for 
the individual service user remains the responsibility of the healthcare professional. Often the 
question of how the medication will impact on the individual becomes an open experiment for 
the service user and the practitioner (Deegan & Drake 2006, p. 1636). In psychiatry, the 
response rates to psychotropic medication are variable; this further complicates the ability to 
determine the potential impact on individuals. An example of this is highlighted in the study by 
Kirsch et al, (2008, p. 265) who, in their meta-analysis of antidepressant efficacy concluded 
that the overall effect of the new-generation antidepressants did not achieve the threshold for 
clinical significance. 
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There is evidence to suggest that service users are often dissatisfied with the communication 
aspect of a healthcare consultation (Henry, Fuhrel-Forbis, Rogers, & Eggly, 2012, p. 309; 
Mahone et al., 2011, p. 7;  Curtis et al., 2010, p.16; Ford, Schofield, & Hope, 2003, p. 77) and 
further evidence suggests that doctors overestimate the amount of information that they have 
given to patients (Makoul, Arntson, & Schofield, 1995, p. 1252). This has important 
implications for successful outcomes with pharmacotherapy. Some studies have 
demonstrated that the quality of clinical communication is related to positive health outcomes 
(Kirkman, et al., 2015, p. 608; Ha & Longnecker, 2010, p. 42; Hamann et al., 2006, p. 272).  
 
Woltmann & Whitley (2010, p. 33) found that, unless service users felt they had control over 
the decisions that were made for their care, they did not consider the process shared. They 
appeared to regard their own autonomy as central to any decision-making process, and if they 
were unsure about a particular decision, they specifically asked someone else they trusted for 
help with that decision. When service users believed a clinician was making decisions for them 
in a paternalistic fashion, they verbally acceded to the clinician and did not voice their own 
preferences. It is suggested this may be one of the reasons why noncompliance and 
disengagement with services occurs. Service users tended to view the decision-making 
process as one which occurred over time and in the context of the relationship they have with 
their case clinician which is based on trust and compassion (Cleary, Horsfall, & Escott, 2015, 
p. 563 ; Rethink, 2006, p. 10). This is in keeping with the findings of the review  by Joosten et 
al. (2008, p. 224) who concluded that successful shared decision-making  is an ongoing 
process rather that an isolated event.   
 
The dissatisfaction with the quality and extent of information on prescribed medication has 
been expressed on a local level across DWMHT by service user groups. This has contributed 
to the decision to include trust pharmacists in an outreach programme with local service user 
groups to address concerns related to medicines they are prescribed. The programme is 
designed to provide information and to signpost them to the range of services available to 
support their needs.  
 
2.9 Expert Service Users in policy development   
 
In the past decade, there has been a significant increase in the contribution of service users, 
carers and members of the general public in the development of clinical guidelines (Harding, 
Pettinari, Brown, Hayward & Taylor, 2011, p. 352).  
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Recently, NICE has introduced its Patient and Public Involvement Programme (PPIP) to the 
Public Involvement Programme (PIP). The PIP is designed to incorporate a range of 
stakeholders including; patients, carers, service users, advocates, members of particular 
communities, parents or guardians, or other audiences. One of the ways in which NICE 
engages with stakeholders is through the technology appraisal process. This involves the 
submissions from various stakeholders via the NICE website and through the national press 
for service user groups and voluntary organisations. Another way in which NICE targets 
service users is via its Citizens Council. The council is comprised of 30 people who are 
intended to reflect the wider English and Welsh population. The Citizens Council are required 
to give their views on values, such as fairness and need. 
 
Individuals are nominated by groups representing national patient or voluntary organisations 
and are co-opted to work on relevant work streams.  The WHO has reviewed NICE’s 
experience of involving patients and the public in clinical practice guidelines and concluded 
that it is uncertain whether the right stakeholders were involved and whether their input was 
as efficient as it could have been (Légaré et al., 2011, p. 12). 
 
The Guideline International Network Patient and Public Involvement working group (GIN-
public) is an international corporative initiative that aims to support the development, 
implementation and evaluation of service user and public involvement in guidelines (Boivin et 
al 2010, p. 1). In a review of patient and public involvement in clinical guidelines Boivin et al 
(2010, p. 4) concluded that there were several socio-political barriers limiting patient and public 
involvement in clinical practice guidelines development internationally. These barriers 
included professional resistance to service user engagement, the social isolation experienced 
by service users in a professional environment, the service user lack of knowledge of 
evidence-based medicine and the marginalisation of the evidence from patients’ and 
caregivers’ experiences. 
 
In the UK, service users have contributed to the development of National Service Frameworks 
(NSFs) for mental health (as well as NSFs for older people, coronary heart disease patients 
and diabetes patients) which outlined national standards for service provision.  The 
appropriate role of the public and service users is disputed because of the current emphasis 
on evidence-based medicine and technology. There is dissent among professionals in relation 
to the competence of lay people to understand the complexities of present day practice 
(Fudge, Wolfe, & McKevitt, 2008, p. 5). Nevertheless, service users are increasingly 
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represented on clinical governance committees of trusts (Crawford et al., 2003, p. 411). Part 
of the incentive for such involvement may be a more holistic approach to evaluating treatment.  
 
Recently, there have been initiatives to involve the public and service users in practice 
guideline development and implementation; this could improve the consideration of patient 
preferences and values in the formulation of in practice guideline (Harding, Pettinari, Brown, 
Hayward & Taylor, 2011, p. 352). Although prescribing guidelines are designed for  specific 
patient populations, they are in essence a ‘one size fits all’ recommendation and  they cannot 
take into account all the individual differences in patient characteristics and preferences 
(Tambuyzer, Pieters, & Van Audenhove, 2014, p. 139). The development of guidelines which 
incorporate a broader context regarding prescribing practice would be useful to address the 
lack of holistic care that has been expressed by service users. One way which this could be 
approached is the use of multidisciplinary stakeholders including service users to develop 
guidelines which would then be targeted at a wider range of issues relevant to them.     
 
In the study by Van der Weijden et al., (2013, p. 858) which included interviews with 
healthcare professionals and patient representatives, the key recommendations for facilitating 
shared decision-making included the adaptation of clinical guidelines to include a separate 
section for shared decision-making, also the use of encouraging language as well as an 
adapted form of the guidelines for use by patients.    
 
This study seeks to understand from the service user perspective, what are the factors that 
matter to them with respect to the medicines they are prescribed.  The study also seeks to 
explore the extent to which service users feel that they should be involved in guideline 
development and where appropriate, how best to achieve this. It is hoped that the findings of 
the service user interviews will be used to inform the production of future local prescribing 
guidance taking, into consideration key recommendations from this stakeholder group. 
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2.9.1 Service user in medicines priority setting 
 
There is emerging literature on pubic and service user involvement in health care decision- 
making. One aspect of decision-making in the health sector, priority setting and resource 
allocation, also has received much attention in recent years (Mitton, Smith, Peacock, Evoy, & 
Abelson, 2009, p. 220). In their review Mitton et al.  (2009, p. 227) concluded that on-going 
public engagement as part of the priority setting agenda was preferred to an ad hoc approach. 
However, one of the limitations of the studies reviewed was the lack of evidence of any formal 
evaluation of engagement efforts. This is consistent with the findings of Williamson (2014, p. 
7) who also concluded that there was a lack evidence to determine how public views have 
been integrated when allocating resources. 
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2.10 Service User engagement in the NHS - Summary 
 
Service user engagement has established itself as part of a significant feature of mental health 
service delivery. The importance of service user engagement has been reinforced by 
successive policy directives including the National Service Framework for Mental Health, the 
2000 NHS plan, the 2001 Health and Social Care Act and more recently the 2012 Health and 
Social Care Act. While these policy drivers have focused on service user engagement, there 
is minimal information guiding providers of care on the extent to which users should be 
involved and how best to achieve this. 
 
The review has identified that there is a clear desire by service users for a greater choice in 
the pharmacological treatments that they receive, and that non-adherence can be due to a 
multiplicity of factors including: adverse effects, the perceived or actual lack of benefit, regime 
complexity and impact on lifestyle (Crowe, Wilson, & Inder, 2011, p. 900; Mitchell & Selmes, 
2007, p. 339; NICE, 2009, p. 7). The review also highlighted that shared decision-making 
increases service user satisfaction but identified that there is no specific, systematic evidence 
to suggest an improvement in clinical outcome measures for individuals with enduring mental 
health conditions (Duncan et al., 2010, p. 15).  
 
The findings of this literature review are consistent with the Royal Pharmaceutical Society 
(RPS) principles of putting the individual at the centre of care. Figure 2.3 identifies in 
diagrammatical form the underlying principles that support patient-centred pharmaceutical 
care.  
 
 
 
Figure 2.3 Principles of Medicines Optimisation (Royal Pharmaceutical Society, 2013)   
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2.11 Prescribing Guidelines in Mental Health – Overview 
One of the objectives of the study is to understand the perceived factors that influence the 
implementation of prescribing guidelines.  
 
This section of the literature review provides an overview of the context of guidelines in clinical 
practice and the rationale for their use. The review considers the factors that impacts on 
successful implementation of guidelines and makes reference to implementation studies that 
include, but which are not limited to, psychiatry. The review then considers the strategies for 
successful implementation of guidelines and the associated evidence underpinning them.  
 
2.11.1 Evidence Based Medicine  
Evidence based medicine (EBM) is the conscientious, explicit, and judicious use of current 
best evidence in making decisions about the care of individual patients (Sackett, Rosenberg, 
Gray, Haynes, & Richardson, 1996, p. 71).  
 
In many western countries, psychiatric organisations have developed and implemented 
evidence-based guidelines for the pharmacological treatment of psychiatric disorders.  
Prescribing guidelines are based on international or national recommendations and it is 
expected that their implementation will lead to improved effectiveness of pharmacological 
treatments whilst reducing treatment variation (Bauer, 2002, p. 138). There are, however, 
many limitations to the assumption that adherence to guidelines will lead to improved patient 
care, including the robustness of the evidence incorporated into the guidance and the potential 
for the individual to have comorbid disease states.  
 
The WHO refers to the ideal state of prescribing and use of medicines as ‘rational use of drugs’ 
which is defined as:  
The process of achieving evidence-based prescribing comprises of three steps: synthesising 
evidence, translating evidence into recommendations and implementing recommendations 
(Michie, 2008, p. 65). This is set against a backdrop of evidence, which suggests that this is 
not routinely achieved (Bauer, 2002, p. 138; Weinmann, Koesters, & Becker, 2007, p. 432). It 
is estimated that approximately half the patients visiting general medical practitioners receive 
treatment which differs from recommended best practice (Grol, 2001, p. II-50) which can lead 
“The patient receiving medication appropriate to their clinical need, in doses that meet their own 
individual requirements for an adequate period of time, and at the lowest cost to them and their 
community. (WHO conference of experts, Nairobi 1985, p. 299)”. 
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to suboptimal treatment based on outdated evidence. In psychiatry this figure is unknown due 
to a lack of studies (Forsner et al., 2010a, p. 1). The few existing studies that have examined 
barriers and facilitators to implementation have focused on the perspective of psychiatrists 
with very little attention given to other healthcare practitioners (Forsner et al., 2010, p. 2). 
There is also recognition of the importance of involving patients in the implementation (Tait & 
Lester, 2005, p. 170), as evidenced through the production of public versions of guidelines in 
the form of patient information leaflets, audio recordings and online databases (Michie & 
Lester, 2005, p. 367; Woolf, Grol, Hutchinson, Eccles, & Grimshaw, 1999, p. 527).  
 
2.11.2 Guidelines in clinical practice  
There are numerous prescribing guidelines which have been developed for use across 
DWMHT. These guidelines have been developed in conjunction with medical and nursing 
colleagues and involved consultation with expert by experience service users. The guidelines 
take into consideration the best available evidence and details the prescribing standards the 
clinicians are expected to adhere to across DWMHT and primary care. The standards as 
outlined in the guidelines incorporate the need to integrate appropriate physical health 
monitoring with key pharmacological treatments. At present, each guideline has an 
implementation plan associated with its development to ensure that clinicians are aware of its 
existence across the local health economy.  
 
As part of a national mandate to publish a list of approved drugs in use for each provider 
organisation by April 1st, 2013, DWMHT published a formulary of approved drugs which 
included information on NICE technology appraisals. There are clear implications for this 
approach as it is possible for service users to compare the availability of pharmacological 
treatments across different provider organisations. Thus, difficult questions could be asked of 
organisations that, for some reason, have not approved a pharmacological agent when it is 
available at a neighbouring organisation.  
 
2.11.2.1 The rationale for prescribing guidance  
Clinical guidelines are “systematically developed statements to assist practitioners and patient 
decisions about appropriate healthcare for specific clinical circumstances,” they are often used 
for promoting evidence-based practice and have been demonstrated to be particularly 
beneficial with less experienced prescribers (Field & Lohr, 1990, p. 58; Grimshaw et al., 2004, 
p. 47; Pulcini, Williams, Molinari, Davey, & Nathwani, 2011, p. 85). Prescribing guidelines may 
lead to improved quality of care by decreasing inappropriate variation in clinical practice 
(Weinmann et al., 2007, p. 421) and they are often used to promote cost-effective prescribing 
(Grant, 2006, p. 28). The latter point is not without contention, as some psychiatrists have 
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highlighted suspicions that financial motives often lay behind clinical guidelines, and that cost 
control and standardisation of care might threaten the doctor or doctor-patient relationship 
(Forsner et al., 2010a, p. 4). This view is in contrast to that of GPs who are mindful of 
prescribing costs and the management of drug budgets (Horne, Mailey, Frost, & Lea, 2001, p. 
192). 
 
Despite the merits of an evidence-based approach, many prescribing guidelines fail to impact 
on prescribing practice due to poor implementation and the inappropriate variation that exists 
in cost and quality of care (Rashidian et al., 2008, p. 149).  
 
High quality, contextual clinical guidelines are considered to be an expression of evidence-
based medicine, combining a systematic approach to the review of established evidence with 
a multi-professional approach which includes service users, along with robust systems for 
consultation and review (Kendall, Pilling, Glover & Taylor 2011, p. 314). While Kendall et al. 
have expressed the ideal embodiment of clinical guidelines, in practice it is acknowledged that 
there is a significant challenge in the implementation of evidenced-based guidance which is 
both complex and widespread (Weinmann, 2007, p. 423; Bauer, 2002, p. 139).  
 
A further complication of translating evidence-based practice in a psychiatric setting into 
clinical practice is that the evidence-base for pharmacological interventions are often limited 
by small trial size and relatively short durations. The selection criteria that are used in clinical 
trials would often exclude the type of patients that are treated in a clinical setting, thus 
clinicians tend to be cautious when generalising research findings to daily practice 
(Nierenberg, 2009, p. 529).  One further complication in psychiatry, which has previously been 
highlighted in this thesis, is publication bias. A recent review by Fanelli, (2011, p. 895) 
concluded that publication bias occurred to a greater extent in psychiatry than in any other 
field of medicine. A further review by Turner, (2013b, p. 465)  advised clinicians to insist that 
their drug regulatory agencies improve transparency. The recommendation by Turner was 
echoed in an editorial in the British Medical Journal (Lehman & Loder, 2012, p. 2).  
 
2.12 Implementation of guidance  
Factors influencing the effective implementation of guidelines in psychiatry remains poorly 
understood; a more detailed understanding of barriers and facilitators is therefore important 
for effective implementation (Bero, et al., 1998, p. 467). In addition to this, it is recognised that 
many guidelines do not have a clear implementation plan (Graham et al., 2001, p. 159) and 
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that the evidence for effective implementation strategies are modest (Grimshaw et al., 2004, 
p. 68).   
 
A review of quantitative studies focusing on adherence to clinical guidelines in mental health, 
revealed that compliance was found in just 7 of 26 studies (27%) where there were no 
interventions for improvement (Bauer, 2002, p. 149). This was contrasted with six of nine 
controlled trials (67%) which demonstrated positive results indicating compliance with 
guidelines when interventions were made to improve adherence (Bauer, 2002, p. 148). These 
findings are consistent with that of Rashidian et al., (2008, p. 149) who concluded from their 
study that guidelines fail to impact on practice and inappropriate variation exists in the cost 
and quality of care.   
 
2.13 Factors influencing the implementation of guidelines 
The reported barriers to guideline implementation included lack of awareness, lack of 
familiarity, concerns regarding the quality of the guidelines, lack of organisational support, lack 
of outcome expectancy, impracticality of the guidance,  the reluctance to change practice and 
external barriers which including patient characteristics (Cabana et al., 1999, p. 1458; 
Francke, Smit, de Veer, & Mistiaen, 2008, p. 7).  
 
Theories of change suggest that individuals and organisations differ in their receptivity to 
change and perceive different benefits and barriers to change. Requiring others to change 
demands an understanding of the problems they face (Glasgow, Klesges, Dzewaltowski, Bull, 
& Estabrooks, 2004, p. 4).  
 
Guideline implementation often fails because minimal consideration is given to address the 
barriers required to change practice in a healthcare setting (Cabana et al., 1999, p. 1463). 
Two types of barriers to the implementation of guidelines have been identified in the literature: 
those internal to the guideline itself, and the external barriers relating to the clinical 
environment and particular local circumstances, including a knowledge of the guideline 
existence (Ploeg, Davies, Edwards, Gifford, & Miller, 2007, p. 216). 
 
However, even if clinicians are aware of clinical guidelines, there may still be a lack of 
familiarity with the specific content or details of the guideline which, in turn, may lead to non-
adherence (Cabana et al., 2002, p. 36). To facilitate use, clinical guidelines must also be 
readable and readily accessible, however, this has to be balanced against an over simplistic 
approach which can impede clinician uptake (Addington, Kyle, Desai, & Wang, 2010, p. 1328; 
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Milner et al., 2009, p. 1012; Cabana et al., 1999, p. 1461; Kasje, Denig, & Haaijer-Ruskamp, 
2002, p. 514). It is important, therefore, for guideline authors to take into account the 
complexity of the guidelines. This is particularly important when developing prescribing 
guidelines for use across a health economy which is directed at several target groups of 
prescribers, as is the case with DWMHT. 
 
With the advent of non-medical prescribing, there are an increasing number of prescribers 
from a range of professional backgrounds. For medical prescribers, there are a variety of 
specialisms and experience which presents a challenge to produce recommendations which 
are understandable and usable for all stakeholder groups. 
 
There is broad consensus that the production of guidelines should be multidisciplinary in 
nature (Smith, Walker & Gilhooly, 2004, p. 559; Francke, Smit, de Veer, & Mistiaen, 2008, p. 
7; Martens, Winkens, Weijden, De, & Severens, 2006, p. 2; Cabana, Rushton, & Rush, 2002,  
p. 41). In addition, involvement of representatives from the target group may imply that the 
guideline is first tested in practice before large-scale implementation takes place (Tansella & 
Thornicroft, 2009, p. 284). While such a collaborative approach may seem a logical to ensure 
end-user engagement, the study by Davis, Thomson, Oxman & Haynes (1995, p. 704) asserts 
that findings are not always unanimous regarding whether guidelines that are developed by 
end users are more often used. They conclude that future research will be required to provide 
more insight into this issue.  
 
2.13.1 Level of agreement with guideline recommendation 
Implementation studies have demonstrated that some clinicians do not consider clinical 
guidance as relevant, unless it originated from trials in a similar healthcare setting, including 
patients with co-morbid disease states (Cabana et al., 1999, p. 1463).  
 
A lack of contextualisation of guidelines to reflect the clinical setting of the clinician and patient 
profile, has led some to conclude that the evidence is irrelevant or unconvincing (Rashidian et 
al., 2008, p. 153).  Kochevar & Yano (2006, p. S28), in their review, identified that guidelines 
were also more likely to be used when they were made relevant to the local health economy.  
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2.13.2 Credibility of prescribing guidance  
A key factor in the acceptance of prescribing guidance by clinicians is whether the  
information obtained is from reputable bodies with a national remit (Kyle, Wang & Desai, 2010, 
p. 1330). National bodies such as NICE and Scottish Intercollegiate Guidelines Network 
(SIGN) can be perceived as credible. 
 
The high representation of secondary care consultants in guideline development across local 
health economies have been perceived to undermined guideline credibility. Consultants are 
viewed as seeing ‘filtered’ patients and are associated with a lack of appreciation of the   
patient–doctor communication in general practice (Rashidian et al., 2008, p. 149).     
 
2.13.3 Lack of outcome expectancy 
In a study conducted by  Cabana et al.  (2002, p. 37), it was suggested that clinicians may not 
adhere to depression guidelines due to low outcome expectancy and the belief that the 
performance of a behaviour will lead to the desired outcomes. In this case, it is the lack of 
confidence that implementing the guideline recommendations will lead to improved health 
outcomes (Cabana et al., 2002, p. 38).  
 
In the review by Carlsen, Glenton & Pope  (2007, p. 974) they concluded that the guideline 
format was a key determinant of GP attitudes towards guideline adoption. The guideline was 
expected to be clearly written, i.e. in terms of clarity and conciseness. The research provided 
insight into the value of quick reference guidelines and the algorithmic layout of guidelines.  
Connelly et al. (1990, p. 356) found that clinicians accessed guidelines if they felt they would 
achieve a more fruitful outcome from them in a time limit. Grol & Grimshaw (2003, p. 1228) 
found that doctors were more likely to adhere to guidelines when they were written using clear 
descriptive medical terminology over ambiguous language. The study recommended the use 
of ‘professional writers’ to review guideline drafts.  
 
2.13.4 Influences to prescribe  
A study by Lewis & Tully (2011, p. 10), which involved interviews with hospital prescribers, 
concluded that patients exerted an undue influence on prescribing practice which led to ‘non-
scientific prescribing’. A similar influence was reported in the exploratory study of GP 
perceptions by Henriksen & Hansen (2004, p. 53). However, these findings contrast with the 
findings of the study by Rashidian et al. (2008, p. 154) in which the perceived patient pressure 
was not considered a significant factor in deviation from established guidance. Davis & Taylor-
Vaisey (1997, p. 412) in their study identified patients with co-morbid disease states as 
contributory factor to non-compliance of clinicians with clinical guidelines. 
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2.14 Strategies for implementation of guidelines 
Bauer (2002, p. 150) & Weinmann et al. (2007, p. 431), in their meta-reviews of adherence to 
mental health guidelines, concluded that ‘multifaceted and resource intensive’, specific 
interventions were the most effective in successful guideline implementation.  
 
Grimshaw et al. (2004, p. 67), in their systematic review of the effectiveness and costs 
associated with guideline development, dissemination and implementation strategies, 
concluded that there was insufficient evidence to determine the most cost effective approach. 
Furthermore, as mental health services were not included in the review, the authors concluded 
that findings of the review would not be generalisable to a mental health setting (Grimshaw et 
al., 2004, p. 60). The results suggest that educational outreach, (a term which is used to 
describe a personal visit by a trained person, to health professionals in their own settings) may 
result in modest improvements in the delivery of care, but this needs to be offset against both 
the resources required to achieve this change and practical considerations (O’Brien et al., 
2007, p. 2). The use of peer-led championing of guidelines is reflected in the findings of the 
review by Flodgren et al. (2011, p. 14) and has been demonstrated to have a moderate impact 
on prescribing practice. 
 
Grol & Grimshaw (2003, p. 1228) in their review identified that educational input which 
encouraged the clinician to change their behaviour, rather than just suggesting knowledge 
based strategies were not found to be effective long term. The review by Grol & Grimshaw 
(2003, p. 1228) also identified that there was no one specific implementation strategy which 
works in all situations. Their recommendation was that implementation models should be 
devised to meet the clinical needs of the specific service providers, so that they are applicable 
to the audience that will be using them.  
 
Barriers related specifically to the implementation of guidelines in psychiatry, have been 
described and relate to the tradition of prescribing with minimal constraint (Forsner et al., 
2010b, p. 6).  There is a recognised need for further studies to identify the barriers at which 
the implementation of evidence-based practice in mental health can fail, and to systematically 
understand how each can be successfully bridged (Tansella & Thornicroft, 2009, p. 284).  
 
2.15 Shared decision-making – A healthcare professional perspective 
A key issue in shared decision-making in psychiatry is the healthcare professionals’  
willingness to enter into shared decision-making processes with service users (Kemp, 2011, 
p. 146). Curtis et al. (2010, p. 21) in their review noted that service user involvement in shared 
  
69 
 
decision-making about choice of medication was lacking, although such involvement is 
considered critical to the recovery process.   
 
A survey of psychiatrists demonstrated that, although most endorsed shared decision-making, 
they did so up to a point (Hamann et al., 2009, p. 1111). That point was a judgement made by 
psychiatrists on the type of decision under review and the level of insight and compliance they 
believed the service user demonstrated. In particular, this was highlighted when a decision 
was required for the treatment of psychoses in an acute episode.  Psychiatrists endorsed the 
view that, where noncompliance was a problem, shared decision-making could be a tool to 
improve compliance. Psychiatrists expressed concern about the capacity of service users to 
make sound decisions when they were very unwell, however, this concern did diminish when 
service users were stable. The findings of the survey are similar to an earlier qualitative study, 
in which psychiatrists showed a preference for a therapeutic alliance with patients with 
schizophrenia, but they also considered patient competence as a critical obstacle to 
participatory approaches (Seale et al., 2006, p. 2870).  
 
It has been suggested that mental health practitioners, and not just those with prescribing 
powers, need knowledge of the effectiveness of medication and at least a working knowledge 
of psychotropic pharmacology. A more widespread understanding of medication, it is believed, 
would enable discussions amongst the multidisciplinary team members, and the service user 
on the most effective use of medication (Falloon et al., 2004, p.104). 
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2.16 Prescribing guidelines in mental health - Summary 
Mental health practice guidelines have proliferated, but there is little evidence regarding the 
degree to which they are implemented in clinical practice. The lack of robust implementation 
strategies is coupled with a lack of expectancy and availability of guidelines in practice. This 
is of relevance for prescribers working within the mental health trust as there is no supportive 
electronic prescribing reminders which are available to primary care colleagues. Thus, in a 
mental health setting prescribing guidelines are often unavailable at the point of need. 
Furthermore, there is evidence to suggest that while the rationale for prescribing guidance 
may be understood, it does not mean that the guidance will be used (Cabana et al., 1999, p. 
1463). There are at present no detailed studies in mental health which outline a broad 
recommendation for guideline implementation. This is in part due to the unique range of 
barriers that exist in a specific healthcare setting.  
 
A range of implementation strategies need to be adopted and the development of guidelines 
needs to reflect the requirements of the end user as well as the service user. One of the keys 
to successful adaptation of guidelines is the level of engagement in its development and the 
continued education surrounding its use.  
 
2.17 The current gap in knowledge   
The author is unaware of any study that has attempted to explore the views on mental health 
prescribing by comparing specialists and CCG prescribers across a local health economy. 
 
The author is unable to identify any literature in which the views of healthcare professionals 
and service users have been explored in the context of mental health prescribing practice. 
 
To date no study has attempted to explore the views of representatives from the 
pharmaceutical industry on prescribing practice and joint working in a mental health setting.  
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Chapter 3:  Theoretical basis of research method 
3.1 Introduction 
A discussion of the methodological foundations for the thesis will follow. An overview of 
research paradigms and a rationale for the approach adopted in this study will be provided. 
Specific details will be provided about the characteristics of the researcher and approaches 
implemented to enhance methodological quality. Finally, details regarding ethical and 
research governance approval and the identification of study sites will be outlined. 
 
3.2 Research Aims and Objectives  
Aims 
This study sought to explore different perspectives on prescribing practice and the potential 
for optimising patient care. The study therefore explored the views of service users, healthcare 
professionals and representatives from the pharmaceutical industry. 
 
Objectives 
1. To explore the extent to which service users perceive they were involved in making 
treatment decisions about their prescribed medication and the factors that influence the 
service user’s involvement in treatment decision making. 
 
2. To explore the perceived factors that influence prescribing from the perspective of 
healthcare professionals (consultant psychiatrists, pharmacists involved formulary/ guideline 
development across the local health economy and GP/GP commissioners) and 
representatives from the pharmaceutical industry with a national or international remit.  
 
3.  To develop an understanding of the perceived factors that influence the implementation of 
prescribing guidelines in a mental health setting from the perspective of consultant 
psychiatrists, pharmacists involved in formulary/ guideline development across the local health 
economy, GP/GP commissioners and senior representatives from the pharmaceutical 
industry.  
 
4. To provide a framework of recommendations for optimising the use of medicines across the 
health economy. 
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3.3 Theoretical basis 
In choosing an appropriate method, the author was presented with a number of challenges 
and a wide range of fundamentally different strategies to generate new knowledge. One 
approach involves starting from a philosophical perspective and the assumptions that the 
researcher brings to the research (Crotty, 1998, p. 66). Central to this approach are the 
assumptions of epistemology and ontology. Epistemology has been described as ‘the possible 
ways of gaining knowledge of social reality, whatever it is understood to be.’ In short, claims 
about how what is assumed to exist can be known (Blaikie, 2007, p. 18).’ Ontological 
assumptions focus on the ‘philosophy of reality’ (Krauss, 2005, p. 758). 
 
Thus, epistemology is concerned with what it is possible to know, whereas, ontology concerns 
what there is to know in the world.    
 
Research is rooted in philosophical beliefs about values, concepts, and the nature of 
knowledge held by researchers (Killman, 2013, p. 6).  These belief systems were described 
by Kuhn as a paradigm (Kuhn, 1970, p. 16). The term paradigm was later defined as the “basic 
belief system or world view that guides the investigation” (Guba & Lincoln, 2011, p. 33). 
Paradigms have been identified as:  
Historically, research has been influenced by two major paradigms – positivism and 
interpretivism, which in turn influence the methods by which data are collected. This historical 
view has been challenged.  Secker, Wimbush, Watson, & Milburn (1995, p. 85) have 
advocated a ‘horses for courses’ approach to the choice of paradigm, depending upon the 
object of the research. Rather than seeing the choice of methods as dictated by questions of 
ontology and epistemology, they argued that the researcher should choose his or her 
philosophical position on the basis of the task in hand. Such an approach is consistent with 
an emergent third paradigm – pragmatism.  
‘…claims and assumptions that are made about the nature of social reality, claims about what 
exists, what it looks like, what units make it up and how these units interact with each other. Thus 
ontological assumptions are concerned with what we believe constitutes social reality.’ 
(Blaikie, 2007, p. 8). 
‘[establishing] the parameters and [setting] the boundaries for scientific research and, in the 
ordinary course of events, scientific enquiry is carried out strictly in line with it.’ (Crotty, 1998, p. 
35). 
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3.3.1 Positivism  
Positivism is a reality-based belief that the social world can be examined in terms of invariant 
laws like the natural world. Positivism is reality-orientated and posits that everything exists 
independent of consciousness.  
 
These assumptions underpin the positivist perspective which is often regarded as a ‘scientific 
method’ involving knowledge being gathered in ways that are not subjective but are direct 
experiences (Crotty, 1998, p. 22) and which are replicable, involving logically deduced 
hypotheses and confirmed evidence (Charmaz, 2006, p. 5). Reality is said to exist on cause 
and effect principles which is subject to determination. Positivists seek methods that yield 
correspondence with the “real world”; thus this is sometimes referred to as a correspondence 
perspective. It has been argued such an approach fails to capture the complexity of human 
behaviour and social interaction (Jensen, 1989, p. 77). 
 
Post-positivism is an evolution of the original positivistic paradigm and its revision has taken 
into consideration the limitations of rigid positivism and now informs much contemporary social 
science research (Patton, 2002, p. 92).  
 
3.3.2 Interpretivism  
Interpretivism was initially proposed as an alternative to positivism.  Interpretivism is founded 
in the belief that the social world is actively constructed by human beings and that there is 
continuous involvement in making sense of, or interpreting, the social environment (Secker et 
al., 1995, p. 75). Interprevists believe that reality exists and can be measured, but recognise 
that interpretation of information cannot be wholly objective; rather there is a need to control 
or limit the biases present when collecting data (Hanson, 1958, p. 19). It thus proposes that 
there can be multiple realities of phenomena, and that these realities can differ across time 
and place. 
 
Interpretivism aims firstly to understand the context and then to make an interpretation that is 
shaped by experience. Qualitative methods are frequently used when ‘little is known about a 
phenomenon’ (Green & Thorogood, 2013, p. 36) and where the investigator seeks to collect 
‘information rich’ cases (Patton, 2002, p. 46). Qualitative research, broadly defined, means 
‘any kind of research that produces findings not arrived at by means of statistical procedures 
or other means of quantification’ (Strauss & Corbin, 1990, p. 17). Data are collected by 
qualitative means through interviews, focus groups or observations and analysis involves 
examining the words that are recorded during these interactions. Qualitative studies are 
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regarded as being subjective and the researcher’s interpretation of the events recorded is 
paramount to address ‘research questions that require explanation or understanding of social 
phenomena and their contexts’ (Snape & Spencer, 2003, p. 5). 
 
Over the past decades there have been numerous debates regarding the merits of the existing  
paradigms (Grbich, 1999, p. 6). The notion of adopting a single stance was held by many. 
However, a new era of research methods slowly emerged where it was considered by many 
‘that the struggle for primacy of one paradigm over others is irrelevant as each paradigm is an 
alternate offering with its own merits’ (Guba, 1990, p. 27).  
 
3.3.3 The Pragmatism Paradigm  
The pragmatist approach is a theoretical stance that has been widely regarded as the ‘third 
paradigm’ (Patton, 2002, p. 71; Creswell, 2013, p. 10; Denzin, 2011, p. 29). The pragmatism 
paradigm eschews methodological orthodoxy in favour of methodological appropriateness as 
the primary criterion for judging methodological quality (Patton, 2002, p. 70). Studies 
conducted within health services research, where aims reflect the priorities of funders, often 
adopt this viewpoint (Green & Thorogood, 2013, p. 36; Lewis & Nicholls, 2014, p. 67). Patton 
(2002, p. 72) argued that methodological approaches should be flexible and appropriate for a 
specific inquiry situation or interest. In health care research, the choice between qualitative 
and quantitative approaches are likely to be determined by the degree of knowledge of the 
phenomenon to be studied. The more that is known about a programme and its underlying 
theories, the more possible and logical it becomes to use quantitative design. The less that is 
known, the more appropriate it is to understand concepts such as beliefs, experiences, 
motivations and intentions, a more qualitative approach (Murphy et al., 1998, p.  221). 
Pragmatists hold the belief that when making a decision about the method or methods to be 
adopted, the limitations and opportunities of the context in which the research is to be 
conducted are of primary importance (Greene et al., 2001, p. 28; Seale, 1999, p. 475). Patton 
(2002, p. 71) stresses the importance of not getting ‘bogged down’ with the opposing 
differences that different paradigms present but to use a pragmatic approach, responding to 
the context in which the research is conducted. Pragmatism is also associated with research 
using both quantitative and qualitative methods (Creswell & Piano-Clark, 2013, p. 13). 
Pragmatism does not consider that a specific method be adopted although, simultaneously, is 
not an approach where ‘anything goes’ (Denscombe, 2008, p. 274); it is one that is flexible in 
the approach to the collection and emergence of data (Patton, 2002, p. 255). The current study 
aimed to gather knowledge on the experiences of prescribing practice within a mental health 
setting. In achieving this aim, consideration of methodologies and the methods that could be 
used were undertaken by the author.  Morgan (2007, p. 68) stated that while the theoretical 
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underpinnings of a methodology and the methods themselves should be considered of equal 
importance,  
3.4 Research purpose  
The purpose of the research project has important implications for the design, measurement, 
analysis and reporting (Patton, 2002, p. 213). The significance of purpose in the choice of 
methods is evident when considering alternative research purposes along a continuum from 
theory to action:  
• Theoretical research: to contribute to fundamental knowledge and theory.  
• Applied research: to illuminate a societal concern. 
• Action research: to solve a specific problem. 
 
The following section considers the research continuum in the context of theoretical, applied 
and action research and the implications for the research project. The section also considers 
the prevailing debate regarding the distinctions which are made between applied and 
theoretical research.  
 
3.4.1 Applied and theoretical research 
A distinction is often made in the literature between applied and theoretical research. 
Theoretical research is concerned with the aim of testing, generating or enhancing thinking 
within a particular discipline (Ritchie & Ormston, 2014, p.  28). Patton (2002, p. 215) outlines 
the purpose of theoretical research as ‘the contribution to fundamental knowledge and theory.’   
 
Applied research is concerned with the use of acquired knowledge gained through research 
to contribute to the understanding or resolution of a contemporary issue. Applied research is 
the term often used to denote studies that have the objectives of developing, monitoring or 
evaluating policy and its related practice (Silverman, 2013, p. 276).  The aim of this research 
is to obtain knowledge gained through face-to-face interviews to understand current 
prescribing practice across the local health economy. In essence, the research is designed to 
help the author understand the nature of prescribing practice and to facilitate a framework of 
recommendations for improvement which is consistent with applied research (Ritche, 2006, p. 
24). Another characteristic of applied research is that it reflects the concerns experienced by 
‘we need to use our study of methodology to connect issues in epistemology with issues in research 
design rather than separating our thoughts about the nature of knowledge and from our efforts to 
produce it.’ 
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people and articulated by policymakers (Patton, 2002, p. 217). This has particular relevance 
to the research. The author, as Chief Pharmacist for DWMHT has received numerous reports 
from healthcare professionals and service users who have expressed concerns about 
prescribing practice and poor communication across the health economy.   
 
In applied policy research, the questions that need to be addressed can vary depending on 
the research project, but can be broadly divided into four categories (see Table 3.1). The 
objectives are shaped by the specific information requirements, e.g. the need to understand 
how the use of prescribing guidelines can be improved, thus the research is targeted towards 
providing answers to the issues under consideration.  
 
Table 3.1: Applied policy research categories and questions 
Category Goal Sample Questions 
Contextual Identifying the form and nature of what 
exists 
 
What is the nature of people’s experiences? 
 
Diagnostic Examining the reasons for, or causes 
of, what exists 
What factors underlie particular attitudes or 
perceptions? 
  
Why are decisions or actions taken, or not 
taken?  
 
Why do particular needs arise?  
 
Why are services or programs and not been 
used? 
 
Evaluative  Appraising the effectiveness of what 
exists 
 
How are objectives achieved? 
 
What affects the successful delivery of 
program services?  
 
How do experiences affect subsequent 
behaviours?  
 
What barriers exist to systems operating? 
 
Strategic  Identifying new theories, policies 
plans or actions 
What types of services are required to meet 
needs? 
What actions are needed to make programs 
services are more effective? 
 
How can systems be improved? What 
strategies are required to overcome the 
defined the problems? 
Ritchie & Spencer (1994, p. 174). 
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There is some debate about the justification of articulating a distinction between applied and 
theoretical research (Ritchie & Ormston, 2014, p. 28). It is suggested that all research is based 
on theoretical assumptions, concepts or hypotheses. As Silverman states: 
Similarly, it is argued that all forms of social research can contribute to theoretical knowledge 
by providing greater understanding of, and knowledge regarding, the social world (Ritchie & 
Ormston, 2014, p. 28). Meanwhile Denzin & Lincoln (2011, p. 24) have argued that good 
theoretical research should have applied relevance and implications.    
 
3.4.2 Action research 
Action research has been defined as a participatory, democratic process concerned with 
developing practical knowing in the pursuit of worthwhile human purposes, grounded in a 
participatory world-view which is emerging at a given moment (Reason & Bradbury, 2001, p. 
6). It seeks to bring together action and reflection, theory and practice, in participation with 
others, in the pursuit of practical solutions to issues of pressing concern to people, and more 
generally the flourishing of individual persons and their communities (Reason & Bradbury 
2001, p. 84). This definition of action research is particularly relevant to the author’s research 
that seeks to explore potential ways of improving prescribing practice from those persons who 
are engaged in the prescribing process as either clinicians or recipients of care.  
 
Action research is explicitly and purposefully part of a change process and one of the most 
important features of the approach is found in the relationship in those conducting the research 
and those ‘being researched.’  The subjects therefore become partners in the research 
process and share responsibility for identifying specific problems and applying local, action-
oriented strategies (Denzin & Lincoln, 2011, p. 29; Whyte, 1989, p. 381). The idea of 
empowering stakeholders to articulate solutions to identified problems is consistent with the 
approach taken in this research project. Staley (2009, p. 26) takes the notion of stakeholder 
engagement further by recommending that the research population has a direct role in shaping 
the research project. In the context of the research project, the author did not explicitly consult 
with stakeholder groups to shape the research project; however, the author was mindful of the 
concerns expressed by all stakeholder groups and this helped to develop the research aims 
and objectives.   
 ‘even down-to-earth policy orientated research designed to evaluate some social service will…. 
embed itself in theoretical issues as soon as it selects a particular evaluation method’  
(Silverman, 2013, p. 108).  
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Russo (2012, p. 15) argues that as part of action research participants should, as a minimum, 
be provided with their data and the means to comment on and clarify it before the findings of 
the research are developed. In the author’s opinion the purpose of the interviews was to gain 
an honest and open account of experiences. The suggestion of subsequent amendments 
would detract from the research findings that represent specific perspectives at a point in time.  
Therefore, in addition to the lack of access of participants to their interview transcripts, coupled 
with the lack of participation in shaping the study, this project cannot be considered to be 
action research.  
 
3.5 Data collection methods 
This section outlines the data collection methods that were considered for the research. The 
advantages and disadvantages of each method are considered, as well as, the rationale for 
acceptance of the data collection approach. 
 
3.5.1 In-depth interviews 
In-depth interviews were used in this research to provide a detailed investigation of each 
person’s personal perspective. According to Ritchie & Spencer (2003, p. 36) in-depth 
interviews allow “undiluted focus on an individual person” to understand their personal 
perspective in significant depth. The use of in-depth interviews allowed the collection of data 
within the context of a narrative, born of personal history or experience, such as the nature of 
the relationship between service user and clinician. Furthermore, in-depth interviews 
facilitated the exploration of a variety of issues, which were dependent on the individual’s 
circumstances, such as the impact on the service user of the therapeutic relationship with the 
clinician.  
 
The complexity of understanding the service user’s perspective on their involvement in 
treatment decisions is multifaceted and is thus best addressed using in-depth interviews.  The 
use of in-depth interviews for capturing complex and sensitive information is well documented 
(Kumar, 2014, p. 156; Yeo, et al., 2014, p. 177; Patton, 2002, p. 339). In-depth interviews 
facilitated the process of detailed discussion with service users and enabled the author to seek 
clarification and detailed understanding of the topic under consideration.  Similarly, 
understanding the motivations and decisions, or exploring impacts and outcomes, generally 
requires the detailed focus that in-depth interviews allow. The use of in-depth interviews 
facilitated the process of exploring beyond what could be considered the expected norm. Thus, 
in the case of the pharmaceutical industry interviews, there was a focus on exploring the 
thoughts of the participants beyond the official company rhetoric, to understand the personal 
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views of its employees in terms of the historical relationship with the NHS and how the industry 
should engage with the NHS in the future.    
 
3.5.2 Semi-structured interviews 
Semi-structured interviews were used because they allowed the researcher to gain a detailed 
account of the participant’s beliefs or perceptions; this is because the interviewer retains the 
flexibility to follow up on themes that may illuminate a particular subject (Gray, 2004, p. 217).  
An example of following up on themes is shown below and is taken from the interview with 
Service User 1, who when asked about their psychiatric history expressed the following: 
The mention of becoming more vocal over the years led the investigator to probe further to 
understand why the individual had become more vocal. This led to the following response: 
Semi-structured interviews have been used to explore the deep rooted and complicated issue 
of health professionals’ attitudes to prescribing guidelines (Rashidian et al., 2008, p. 151).  
This is exemplified by an extract from the interview with GP 1, which identifies the role of 
guidelines in enabling GPs to keep abreast of change.  
 
 
GP 1. “For us, prescribing guidelines across whatever field are really useful. It acts as a massive 
safety net; it hems things in as to the range of things you can actually do. But once things are in 
guidelines it also gives you some security that somebody else has reviewed, tested, tried these 
things. So they're established, accepted bits of practice.” 
“The other thing is with the amount of change and variation in different fields, psychiatry for one 
for example, there's various things that will progress, but being in general practice you might not 
be the forefront of new introductions to things and new drugs coming out, et cetera. So we also 
are quite dependent on guidance, so usually guidelines as to what we can prescribe, how we 
follow things and what we do” 
Service User 1. “in the early days, I wasn’t really given much choice, just given a prescription, 
and having no idea what the medication was about.  Now I’m more vocal and do have a little bit 
more understanding of medication” 
Service User 1 “I guess, in a lot of ways, there’s nobody else that will actually speak on my behalf, 
so…you have to do it yourself, otherwise…some consultants and doctors you can trust, and some 
health people are very, very good, but if you just sit there and don’t say anything, then you will be 
given any tablets, just loads of tablets, basically.”   
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3.5.3 The limitations of interviews  
The use of in-depth interviews requires significant time and patience and necessitates 
coordinating of schedules with busy stakeholders. In addition to the logistic consideration of 
this method of data collection, there is a vast amount of data to analyse and the task of 
presenting the findings in a coherent manner can be challenging (Lichtman, 2012, p. 27). 
Interview driven research is characterised by an emerging design with data collection, merging 
into data analysis with countless hours devoted to transcription and no definitive clarity on 
what constitutes sufficient data (Mears, 2012, p. 171).   
 
3.5.4 Focus groups  
Initially, focus groups were considered as a means of data collection but they were 
subsequently rejected for a number of reasons which have been outlined for each key 
stakeholder group.  
 
Service Users  
The use of focus group discussion can provide ‘safety in numbers,’ and facilitate the process 
of research for people who might find, for a variety of reasons, a one-to-one encounter 
intimidating or uncomfortable. This was a concern which might have been of particular 
relevance to the service user group. ‘Expert by experience’ service users were chosen to 
participate in this research because they were actively engaged in representing the views of 
other service users and carers across a range of stakeholder groups in the wider community. 
Service users were encouraged to be open and honest about the pharmaceutical care that 
they had received and this required a degree of openness and transparency that is often 
difficult to achieve in a group setting (Oliveira, 2011, p. 3100; Stewart & Shamdasani, 2014, 
p. 101). The interviews with service users included the exploration of personal and sensitive 
information.  It was felt that the use of focus groups would limit the public expression by service 
users of deeply held feelings in a group setting.  
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Pharmaceutical Industry 
Focus groups have the potential to generate ideas through participant interaction and 
influence which is reflective of a ‘real-life situation’, however due to the sensitive nature of the 
enquiry, involving the perspectives of representatives from the pharmaceutical industry, the 
author felt that this would not lend itself to group discussions. Some of the topics covered as 
part of the research were confidential. Representatives from the pharmaceutical industry were 
encouraged to give an open and frank account of their perspectives on joint working, including 
an exploration of the complexity of the relationship between the pharmaceutical industry and 
the NHS. The commercial sensitivities for representatives from the pharmaceutical industry 
would limit the potential for focus group participation.  
 
Healthcare Professionals 
One of the aims of the research project was to explore the perceived factors that influence 
prescribing in mental health from the perspective of individual clinicians. The use of focus 
groups is more time efficient as more participants can be questioned in the same timeframe it 
would take to interview a single participant. 
 
Both GPs and Consultant Psychiatrists are difficult stakeholder groups to arrange interviews 
with, and in one case the researcher had to book an interview with a GP six months in advance 
due to their work schedule. Furthermore, in the case of GPs and psychiatrists it is possible 
that group discussions would have been dominated by those with more senior roles and the 
views of less senior colleagues could have been suppressed. 
  
A further practical limitation of using focus groups would be the need to attend a common 
location for participation in the research project. It is likely that this would have inhibited the 
accessibility of the research to potential participants. There would also be difficulties in trying 
to cluster sufficient numbers of participants across the Dudley and Walsall boroughs.  
 
3.6 Data analysis method that were initially considered    
Several data analysis methods were considered for the research. Many of these approaches 
were associated with specific disciplines and are underpinned by philosophical ideas which 
shape the process of analysis.  
 
There are a number of approaches to qualitative data analysis, including those that pay close 
attention to language and how it is used in social interaction such as discourse analysis 
(Fairclough, 2013, p. 56).  
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The use of discourse analysis was briefly considered but not used because the focus of the 
project was not to analyse language in a social context, but rather to understand meaning in 
relation to current prescribing practice and how this might be improved.  
 
Phenomenology 
A phenomenological approach to data analysis was considered initially as a means of focusing 
on meaning, experience and language. This approach to data analysis is consistent with 
phenomenology (Larkin & Thompson, 2011, p. 102); however, as the author reflected on this 
approach he was mindful that the primary focus of the research was not to understand what a 
given experience was like (phenomenology) and how someone made sense of it 
(interpretation), but rather the use of experience and interpretation to generate potential 
solutions to the identified shortcomings in prescribing practice.  
 
Grounded Theory 
Grounded Theory was considered as a method of data analysis by the investigator, as its 
purpose is to understand how reality is constructed for people, to identify the concepts and 
then develop theory as the research evolves. Grounded theory leads to an exploration of 
emergent relationships between the concepts (Charmaz, 2006, p. 106).  However, the aim of 
the author’s research project was not to develop theory from the concepts which emerge from 
the data, but to identify solutions to problems as articulated by research participants with 
respect to joint working, prescribing, prescribing guidance and shared decision-making, 
therefore grounded theory as a method of data analysis was rejected.  
 
Ethnography 
An ethnographic approach may have been considered as the ideal research method as the 
researcher or ethnographer becomes integrated within the lives of the people being studied, 
enabling an exploration of culture within a group (Richards & Morse, 2012, p. 54-55). However, 
the resources to recruit and follow people through their various day to day activities were 
beyond the scope of this research project.  
 
Framework Analysis 
 Framework analysis was chosen for the following reasons:  
• It provides coherence and structure to otherwise cumbersome, qualitative data (i.e. 
interview transcripts).  
• It facilitates systematic analysis, thus allowing the research process to be explicit and 
replicable.  
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The detailed rationale for the use of Framework analysis is given below. 
3.7 Rationale for using Framework Analysis  
First, the Framework approach is particularly suited to analysing cross-sectional descriptive 
data, thus allowing thematic comparisons between the various stakeholder groups, enabling 
different aspects of the phenomena under investigation to be captured (Spencer, Ritchie, 
Ormston, O’Connor, & Barnard, 2014, p. 282). The Framework method would thus facilitate 
the analysis of divergent and convergent themes across the various stakeholder groups whilst 
maintaining the connection with the individual account.  Second, it is easy to identify relevant 
data extracts and to determine if there is sufficient evidence for a proposed theme; hence the 
researcher’s interpretations of the participant’s experiences are transparent. This ensures 
rigour and transparency as part of the analytical process, which is essential in assessing the 
quality of the research and its confirmability. A third reason for using Framework analysis is 
that the transition from data management to developing the analysis sufficiently to answer 
research questions can be a challenging task for a novice researcher such as is the case for 
the author.  The interconnected stages in the framework approach explicitly describe the 
processes that guide the systematic analysis of data from initial management through to the 
development of descriptive to explanatory accounts. 
 
3.8 Framework Analysis 
The Framework method is not aligned with a particular epistemological, philosophical, or 
theoretical approach. Framework analysis is a flexible tool that can be adapted for use with 
many qualitative approaches that aim to generate themes (Gale, Heath, Cameron, Rashid, & 
Redwood, 2013, p. 3). Framework analysis sits within the wider family of analysis methods 
known as thematic analysis or qualitative content analysis.  These approaches identify 
commonalities and differences in qualitative data, before focusing on relationships between 
different parts of the data, thereby seeking to draw descriptive and/or explanatory conclusions 
clustered around themes.  
 
The Framework method was originally developed  for use in large-scale policy research  
(Spencer et al.,  2014, p. 282) and is now used widely in health research (Jones, 2000, p. 555; 
Rashidian et al., 2008, p. 148; Sheard et al., 2012, p. 339; Ellis et al., 2012, p. 831; Gale & 
Sultan, 2013, p. 1; Ayatollahi, Bath, & Goodacre, 2010, p. 189). The unique feature of the 
Framework method is its matrix output: rows (cases), columns (codes) and ‘cells’ of 
summarised data, providing a structure into which the researcher can systematically reduce 
the data, in order to analyse them by case and by code. Most often a ‘case’ is an individual 
interviewee, but this can be adapted to other units of analysis, including predefined groups 
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such as GPs, service users, specialist pharmacists or representatives from the pharmaceutical 
industry.   While in-depth analyses of key themes can take place across the whole data set, 
the views of each research participant(s) remain connected to other aspects of their account 
within the matrix so that the context of the individual’s views is not lost.  
 
Comparing and contrasting data is vital to qualitative analysis. The ability to compare with 
ease data across cases, as well as within individual cases, is built into the structure and 
process of the Framework method.  
 
The Framework method is most commonly used for the thematic analysis of semi-structured 
interview transcripts and is consistent with the data collection method for this research. 
Reflexivity, rigour and quality are issues that are requisite in the Framework method just as 
they are in other qualitative methods.  
 
3.8.1 Limitations of the Framework Analysis 
The systematic approach and matrix format, is intuitively appealing from a quantitative 
perspective and the ‘spreadsheet’ look perhaps further increases the temptation to attempt to 
quantify qualitative data (e.g. ‘15 out of 30’ participants said prescribing guidelines were 
helpful). In the context of the research project this statement would be meaningless because 
the sampling is not designed to be representative of a wider population, but purposive to 
capture diversity around the stakeholder group of interest. In common with other qualitative 
analysis methods, the framework method is time consuming and resource-intensive.  
 
3.8.2 Sample size  
There is no definition of the ideal sample size for framework analysis (Fugard & Potts, 2015, 
p. 12 ). In the review by Gale et al. (2013, p. 2 ) the number of interview participants ranged 
from 20 to 76 and in one identified study there was a single participant in which a diary entry 
was subject to analysis (Jones, 2000, p. 559).   Charmaz (2006, p. 114) for example, suggests 
that 25 participants are ‘adequate for smaller projects’ while according to Ritchie, Lewis, Elam, 
Tennant & Rahim (2014, p. 118) qualitative samples often ‘lie under 50.’ The results of a study 
which explored data saturation and sample size in qualitative PhDs showed that on average 
the sample size was 31 and in the case of action research the number of participants ranged 
from 3 to 67  (Mason, 2010, p. 8).  
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In this research project a sample size of 5 participants from each stakeholder group was 
decided on (total of 25 participants). There were a number of factors that governed the 
capacity for participant enrolment in the research project. At the time of conducting the 
interviews there were a total of six pharmaceutical companies actively promoting drugs in 
mental health. This was a key consideration for the author as it was unlikely that 
pharmaceutical companies would participate unless they were actively promoting a drug, or 
at least looking to bring a new drug to the UK market at the time of the interviews. A further 
consideration at the time of conducting the interviews was that there were five expert by 
experience service users employed across the trust.  
 
3.8.3 Data Saturation 
The term data saturation is often used in qualitative research, to define the point at which no 
new themes emerge from the data and may be used to determine the point at which no new 
participants are recruited to a study. As described by Ritchie & Spencer (1994, p. 175), applied 
research studies are often bound by constraints of time and resources. Framework analysis 
sits within the context of applied policy research and is an approach suited to facilitating 
systematic analysis of data to generate answers to specific questions, as is the case with this 
research; therefore, data saturation is not a requirement of this method of analysis.   
 
3.8.4 Sampling 
Framework analysis is suited to homogenous data and sampling is usually purposive (Gale et 
al., 2013, p. 3). With Framework analysis the data must cover similar topics or key issues so 
that it is possible to categorise it. Individual interviewees may have very different views or 
experiences in relation to each topic, which can then be compared and contrasted using this 
method. Homogenous samples were chosen to give a detailed picture of a phenomenon, for 
example, individuals who have extensive experience of treatment within mental health 
services. The use of homogenous subgroups allowed for detailed investigation of social 
processes in the context mental health services across DWMHT.  
 
The methodology does not imply that findings can necessarily be generalised to, or held to be 
equally true of, the parent population from which the sample is drawn, nor does the method 
imply that the findings can be related to other settings or contexts beyond the one sampled, 
namely the Dudley and Walsall Mental Health economy.  
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3.9 Ethical issues  
As the research project involved interviewing service users with enduring mental illness, 
ethical approval for the study was sought and granted by the NRES Committee London – City 
& East on October 22nd 2013. This approval letter is enclosed in Appendix 7.  
 
As part of the local trust governance procedure the project was also subject to approval by the 
DWMHT Research Ethics Committee.  
 
Written consent was obtained from all participants prior to interview and ongoing consent was 
used as a supplement to traditional informed consent, to repeatedly give service users the 
opportunity to stop the interview if they felt distressed. Participants were informed that consent 
would be sought to use interview material, and participants would receive routine feedback on 
the excerpts that are to be used in publication unless participants forbid the use of verbatim 
quotations.  
 
3.10 Researcher context  
The author, as the current Chief Pharmacist for DWMHT, has responsibility for delivering 
efficacy savings against the prescribing budget as well as strategic oversight of medicines 
optimisation across the organisation. With a background in mental health and experience of 
delivering cost-effective savings across a local primary care trust, the author understands the 
NHS focus on maximising cost-effective prescribing. The achievement of cost-effective 
prescribing is dependent on engagement with the recipient of care and meeting their needs.  
Thus, there is a recognition of the importance of distributive justice in the context of delivering 
health economy efficiencies while engaging with service users’ individual needs.  
 
In the author’s experience GPs tend to lack expertise in mental health therapeutics and are 
more mindful than their specialist counterparts in managing prescribing expenditure. 
Specialists by contrast, are more focused on the individual patients and complexity of mental 
illness which often leads to less of a focus on wider health economy expenditure. These 
differences can be a potential source of conflict between GPs and psychiatrists.  
 
The author is also keen to explore with the pharmaceutical industry new ways of working which 
will deliver efficiency savings and improve service delivery for service users.   
 
Based on observations and discussions with service users, prescribers, pharmacy colleagues 
and representatives from the pharmaceutical industry, the author considered the question of 
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what could be done to improve prescribing practice across the local health economy and how 
the service user experience could be improved.  
 
3.11 Researcher as data collector 
The researcher was the data collector for this project which was subject to scrutiny by a project 
supervisor and work based supervisor as part of a strategy to ensure rigor as part of the 
research process. The interview schedules were designed to facilitate a free and open 
discussion by participants and were subject to inspection by the project supervisor.    
 
3.12 Issues of quality in Qualitative Research  
Quality in qualitative research remains a ‘complex and emerging area’ (Creswell, 2013, p. 227) 
and it has been argued that such research lacks scientific rigour. There is considerable debate 
as to whether the principles of validity, reliability and generalisability, which many consider to 
be deeply rooted within quantitative research, can be applied effectively to studies adopting a 
qualitative interpretative approach (Stenbacka, 2001, p. 555; Healy & Perry, 2000, p. 125). 
Researchers have argued that alternative criteria are more applicable in qualitative research 
and new terms such as credibility, transferability, and conformability have been argued to 
better reflect the interpretivist outlook (Seale, 1999, p. 466). Others, however, have argued 
that the same principles can be applied but that they need to be modified (Mays & Pope, 2000, 
p. 51) to take account of the differing features and goals of qualitative research. The concepts 
of validity, generalisability (external validity) and reliability within qualitative research will be 
outlined: 
 
3.12.1 Generalisability (External validity)  
Morse (1999, p. 5) stated that ‘if qualitative research is considered not generalisable then it is 
of little use, insignificant and hardly worth doing’. As Lewis, Ritchie, Ormston & Morrell (2014, 
p. 349) highlighted, there are several potential ways that the concept of generalisation can be 
applied. One of these is inferentially by generalising from one particular study context to 
another (representational generalisation). To facilitate this, it is imperative that in reporting the 
research a ‘thick description’ of the original research process and setting is provided (Geertz, 
2002, p. 175). The importance of representational generalisation is also highlighted where 
there is clear demonstration that the sample is a true reflection of the population studied and 
that the conclusions drawn are an accurate reflection of the data provided by the participants 
(Lewis, Ritchie, Ormston & Morrell 2014, p. 350; Murphy et al., 1998, p. 18).  Within the context 
of this study the data collection method was used appropriately to strengthen the interpretation 
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provided.  The use of Framework analysis further facilitated the levels of interpretation and 
transparency.  
 
3.12.2 Validity 
Parahoo (2014, p. 67) described the concept of validity as ‘the accuracy with which the findings 
reflect the phenomenon being studied. There are several methods to ensure that the research 
remains as truthful to reality as possible. Mays & Pope (2000, p. 51) suggest the following 
ways to improve validity: – triangulation of results from different methods of data collection; 
asking participants to validate the researcher’s interpretations; being aware of aspects of the 
research that may have influenced the way in which the data was collected e.g. researcher 
and participant characteristics; clear exposition of the data collection and analytical methods; 
taking into consideration participant data that may contradict other data collected by reporting 
fully and finally, ensuring that the research takes into consideration a wide variety of 
perspectives. For this study, the researcher was aware of the importance of transparency in 
relation to data collection and analysis. The dataset and emergent themes were subject to 
external scrutiny by work-based and project supervisors. Furthermore, the stakeholder groups 
facilitated the collection of a variety of perspectives. 
 
3.12.3 Reliability  
Parahoo (2014, p. 31) described the concept of reliability as: ‘The consistency of a particular 
method in measuring or observing the same phenomena.’ Another way of considering 
reliability is the extent to which results are consistent over time and an accurate representation 
of the total population under study.  Determining reliability within qualitative studies can be 
challenging as the data collected are based often on face-to-face situations where participants 
are providing information on real-life experiences. Such methods are prone to elements of 
misinterpretation or personal biases of the researcher. Demonstrating and enhancing 
reliability in qualitative research is important therefore each step in the process of data 
collection and analysis should be open to external scrutiny.  Several methods have been 
identified to assist with demonstrating the reliability of qualitative research, such as conducting 
and reporting the research in a systematic way, and ensuring that any interpretations provided 
are supported by the data (Lewis, Ritchie, Ormston, Morrell, 2014, p. 355). Throughout the 
research project the concept of reliability was addressed to minimise any possible 
misinterpretation or bias. This involved conducting fieldwork using a consistent approach that 
allowed participants to readily portray their experiences, clarifying any ambiguities with 
participants during the interview, confirming interpretations of interview data by multiple 
reviews with research supervisors and reporting the findings systematically. In order to ensure 
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that quality was maintained throughout the research process, various applications of these 
principles have been applied in context and demonstrated throughout this thesis. 
 
3.13 Summary 
Face-to-face interviews are integral to the research that was conducted and was considered 
to be the most appropriate data collection method for meeting the study aims and objectives. 
Semi-structured interviews were used for an in-depth exploration of the experiences and 
perspectives of a range of stakeholders.  This approach facilitated a flexible way of exploring 
the context of prescribing practice and ‘medication-taking behaviours’; in addition to this, the 
semi-structured nature of the interviews enabled an exploration of particular attitudes and 
perspectives as well as appraising the effectiveness of existing medicines optimisation 
systems.  
The Framework method was used for data analysis because it provides a systematic model 
for managing and mapping interview data. The Framework method is suitable for thematic 
analysis of interview transcripts, where it is important to be able to compare and contrast data 
by themes across numerous stakeholder groups, while also contextualising each perspective 
by retaining the connection to other aspects of each stakeholders account.  
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Chapter 4: Methodology  
4.1 Introduction 
 
This chapter describes the method used to collect and analyse the data provided by the key 
stakeholder groups. The data was used to identify the factors that influence the 
implementation of prescribing guidelines in a mental health setting, the key influences on 
prescribing and the extent to which service users felt involved in making treatment decisions.   
 
4.2 Stakeholder engagement 
Purposive sampling was used in this research. This approach enabled the selection of 
individuals because they have particular characteristics or knowledge which would enable 
detailed exploration and understanding of the central themes which the researcher wished to 
study. In the case of this research, these features related to specific experiences and roles.  
 
Pharmaceutical Industry 
Representatives from the pharmaceutical industry, who were engaged in the promotion of 
drug therapy across the trust, were approached for the contact details of marketing managers 
and product managers with a national portfolio. The idea of interviewing senior personnel 
within the pharmaceutical industry was to identify individuals with a strategic remit at a national 
level to gain a more informed perspective on joint working between the industry and the NHS. 
 
Expert by Experience Service Users 
Expert by experience service users were chosen to participate in this research because they 
were considered central to the impact of prescribing practice as the recipients of care. In 
particular, expert by experience service users are highly active strategically across the trust 
and are able to impact on the development of policies and procedures.  
 
Consultant Psychiatrists  
Consultant psychiatrists, employed by the trust working in a variety of specialities, were invited 
to participate in the research.  Those consultant psychiatrists actively involved in the Medicines 
Management Committee and/or guideline development were approached first to participate in 
this study.  Consultants were chosen because of their seniority within the medical directorate 
and their medicines management remit.  
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GPs /GP Commissioners  
GPs /GP Commissioners with an interest in mental health therapeutics across the local health 
economy were invited to participate in the research project.  GPs actively involved in locality 
prescribing committees and those with a remit for commissioning mental health services were 
also invited to participate.   
 
Pharmacists 
Pharmacists who were involved in mental health prescribing guideline development or those 
with a remit for assuring medicines management standards in the mental health trust on behalf 
of the local commissioners were invited to participate in the research project. In addition, 
senior pharmacists with a strategic role across the local health economy were invited to 
participate.   
 
The inclusion and exclusion criteria for the various stakeholder groups is shown in Table 4.1. 
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Table 4.1: Inclusion and exclusion criteria 
Group  Inclusion criteria Exclusion criteria  Rationale  
Representatives of the 
pharmaceutical industry  
 
Representatives from the 
pharmaceutical industry 
with an active portfolio in 
psychiatric drug therapy 
or with an existing 
portfolio of psychotropic 
agents.  
 
 
 
Representatives from the 
pharmaceutical industry 
without a mental health 
portfolio.  
 
Representatives from the 
pharmaceutical industry 
without a national 
portfolio.  
 
 
Representatives from the 
pharmaceutical industry 
understand the key 
drivers for the delivery of 
mental health services 
and are familiar with a 
range of prescribing 
interface issues across 
health economies.   
 
Expert by Experience 
Service Users 
Service users with a 
diagnosis of psychotic or 
affective related disorder.  
Currently attending 
outpatients or being cared 
for by community mental 
health teams across 
DWMHT.  
Capable of giving 
informed consent to 
participate in the study. 
Anxiety related disorders 
or Personality disorders.  
Relapse in the previous 
18 months.  
History of substance 
misuse in the previous 18 
months.  
Evidence of organic 
impairment. 
Those requiring an 
interpreter. 
Those currently receiving 
care in an in-patient 
setting. 
A face-to-face interview 
can be anxiety provoking 
and therefore participants 
with a primary anxiety 
disorder will not be 
approached to participate 
in the study.  
 
Pharmacological therapy 
is not the recommended 
treatment for personality 
disorder and therefore this 
patient group will be 
excluded.   
Organic impairment is a 
complicating factor in the 
presentation of mental 
disorder and is generally a 
reason for exclusion 
unless the study is 
specifically focussing on 
this as the main issue of 
investigation. As a novice 
researcher, the 
investigator was 
unfamiliar with the   social 
& scientific methods that 
facilitate research in 
patients with cognitive 
impairment.  
Interviews will be 
conducted in English and 
as they will have to be 
transcribed, using an 
interpreter would 
introduce extra complexity 
in the communication that 
cannot be the focus of this 
study. 
Consultant Psychiatrists  Consultant psychiatrists 
working for DWMHT.  
Doctors working for the 
trust at a more junior level 
than consultant 
psychiatrist.   
The researcher sought 
representation from 
consultant psychiatrists 
working in a variety of 
specialisms across the 
trust.   
As consultants assume 
ultimate responsibility for 
the impact of 
pharmacological therapy 
they were approached for 
interviews.  
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Table 4.1: Inclusion and exclusion criteria continued 
Group  Inclusion criteria Exclusion criteria  Rationale  
 
GPs / GP 
Commissioners 
GPs working across the 
local health economy 
with a special interest in 
mental health. 
 
GPs with involvement in 
commissioning local 
mental health services.   
GPs who do not have a 
specialist interest in 
mental health and who 
are not involved in 
commissioning mental 
health services.  
GPs working outside of 
the local healthcare 
economy.  
 
GP commissioners of 
mental health services 
and those with a 
specialist interest in 
mental health are likely 
to be able to contribute 
to the understanding of 
the factors that influence 
prescribing across the 
local healthcare 
economy.   
Pharmacists  Pharmacists working 
across the local health 
economy engaged in 
area prescribing 
committees and or 
involved in the 
development of mental 
health related 
prescribing guidance or 
commissioning of 
psychiatric services.   
Pharmacists not actively 
engaged in the 
commissioning of mental 
health services or 
strategic remit for the 
development of mental 
or physical health 
prescribing guidance.  
Pharmacists actively 
engaged in mental 
health related 
prescribing guidance 
and or commissioning 
are likely to have an 
understanding of the key 
prescribing issues 
across the local health 
economy.   
 
 
4.3 Design of the data collection tool 
Open-ended questions were used to achieve both breadth of coverage across key issues, and 
depth of coverage within each. A combination of content mapping questions and content 
mining questions were used. Content mapping questions were used to open up research 
territory. In the case of service users, an example of this open-ended style of questioning 
included: “tell me about your relationship with your doctor.” To understand the relationship in 
more depth a follow-up question would ask about the specific aspects of the relationship, “what 
characterises a good relationship for you and how does it make you feel?” This allowed a more 
detailed understanding personal perspective on the nature of the relationship and its impact 
on the therapeutic alliance between the service user and doctor.  
 
The initial interview schedule for service users was shared with an acquaintance with a 
longstanding mental health diagnosis to test understanding, language and appropriateness of 
the questions. As a result of this pilot some of the wording was simplified.  Furthermore, all 
interview schedules were subject to scrutiny by a neuro-linguistic programmer at Keele 
University and project supervisors for comments. All schedules were refined and in 
accordance with relevant feedback which was based on the need to change the order of 
questions.  
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The interview schedules (Appendix 2), were designed to explore participant’s belief about 
prescribing and prescribing practice in mental health and how communication could be 
improved. The interview schedules were also informed by a review of the literature in relation 
to prescribing practice in mental health and took into consideration some of the broader 
themes from the review such as shared decision-making, information sources and the impact 
of the therapeutic alliance between clinician and patient.  More specifically the interview 
schedules for healthcare professionals included the broad headers of implementation, choice 
(patient and clinician), cost effectiveness, joint working, interface issues and effectiveness. 
For service users the broad headers included communication, information, shared decision- 
making and wellbeing. Interview schedules were developed for each stakeholder group to 
reflect issues that were specific to that group; e.g. for the pharmaceutical industry, an area of 
exploration related to their ongoing relationship with the new NHS and the factors that might 
impact on this.   
 
4.4 Pilot data collection  
Pilot interviews were conducted with a service user, GP and pharmacist.  Each of the 
interviewees was known to the researcher and contact was established via a telephone call to 
confirm participation. Each participant was provided with an “information for participants” sheet 
(Appendix 3) to ensure their understanding of the research project and consent form for 
completion prior to the interview.  
 
Following the three pilot interviews some of the questions, prompts and order of questions 
were amended. This is consistent with the recommendations of Yeo, Legard, Keegan, Ward, 
Nicholls & Lewis (2014, p. 173) who suggest that pilot studies provide a valuable opportunity 
to see if the proposed interview questions allow the participants to give a full and coherent 
account of the central issues and incorporates factors that are of importance to the subjects. 
Gerrish & Lacey (2010, p. 22) suggest that pilot studies provide a valuable opportunity to 
determine if the proposed interview questions are understandable, relevant and appropriate.  
 
The researcher started the first interview by following the interview schedule, however, it was 
difficult to follow the schedule as talk developed naturally, leading from one set of questions 
to the next. As the pilot interviews continued, the researcher allowed the questions to flow 
from the participant response. By the conclusion of the pilot interviews, the researcher did not 
follow the interview schedule but found that all the areas included in the schedule were at 
some point discussed during the interview. This approach felt comfortable and the pilot 
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interviews provided an invaluable opportunity to practice interview skills in advance of the 
formal interviews.  
 
4.4.1 Feedback 
Following feedback from each of the pilot interviews, some of the questions and prompts were 
amended and this formed the finalised interview schedules. Feedback from the service user 
led to the omission of a question regarding prescription charges as it was felt that this was 
largely irrelevant to the aims and objectives of the research project which sought to understand 
the level of service user engagement in the prescribing process.  
  
For the purposes of this study the pilot interviews were not included for analysis in the research 
project as there was sufficient data emerging from later interviews.  
 
4.5 Face-to-face interviews 
Minor amendments were made to the interview schedule following the pilot interviews. The 
pilot exercise did confirm that a semi-structured interview approach was appropriate as it 
allowed the participants to move from one topic area to another in a natural way, combining 
structure with flexibility and allowing the researcher to control the overall interview. Although 
the interviews across the stakeholder groups were based on interview schedules, the structure 
was sufficiently flexible to permit topics to be covered in the order which naturally flowed from 
the interviewee. This also allowed responses to be fully probed and explored and enabled the 
researcher to be responsive to the relevant issues raised spontaneously by the interviewee.  
The researcher was mindful to allow the interviewee to talk freely when answering questions 
and to use a range of probes to achieve the depth of answers in terms of penetration, 
exploration and explanation. Follow-up questions were used to develop a fuller understanding 
of the participant’s meaning. The researcher was keen to fully explore the factors that 
underpinned a participant’s response including, reasons, feelings, opinions and beliefs. 
   
4.5.1 Requirements of an interviewer 
The researcher was aware of his relative lack of experience in conducting interviews and was 
mindful that part of the success of interviewing would depend on his interpersonal and 
professional qualities.  The use of pilot interviews and subsequent feedback was used to help 
in later interviews. All pilot interviews were recorded and listened to by the interviewer to gain 
a sense of the flow of the interview and the wording of the respondents. Feedback was also 
sought from the participants in terms of the interview flow and timing.  
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4.5.2 The order of interviews 
Interviews were conducted across the various stakeholder groups subject to confirmation of 
availability of the interviewee. This approach enabled the researcher to explore ideas across 
the stakeholder groups e.g. the meaning of wellbeing/efficacy as conceptualised by service 
users compared with healthcare professionals or representatives from the pharmaceutical 
industry. Service users largely articulated efficacy in terms of social functioning. An extract 
from Service User 4 is given below. 
Healthcare professionals and representatives from the pharmaceutical industry defined 
efficacy in more clinical terms. An extract from Industry Representative 4 is given below.  
However, when prompted to consider efficacy from the perspective of a service user, Industry 
Representative 4 responded with the following statement: 
As a result of conducting interviews across the stakeholder groups the researcher was able to 
link ideas from prior interviews and to develop this in future interviews.  
 
4.5.3 Field notes 
Interviews were recorded using a digital voice recorder and field notes were made to 
supplement the information obtained from the recordings. The use of field notes enabled the 
researcher to record what was seen or heard outside of the immediate context of the interview. 
This included references to non-verbal cues, the dynamics of the encounter, ideas for inclusion 
in later fieldwork and issues that might be relevant to the analytical stage. The use of field 
notes was instrumental in linking the ideas from previous interviews.  
 
 
 
 
Industry Representative 4. “Does it do what it should do, is it safe, is it tolerable.” 
Industry Representative 4. “does it help me achieve my treatment goals and the outcomes that I 
want to get. Which then tolerability is an element, safety is another element, interactions with 
other medication is a big element.” 
Service User 4. “Oh, absolutely enormous, I couldn’t…I think two generations ago, I’d probably 
be a long time patient in a psychiatric hospital, it’s set me free, It’s given me back a normal life.” 
  
97 
 
4.5.4 Location 
All interviews were conducted in a time and place of the choosing of the interviewee. Email 
confirmation was sought from participants 24 hours before the scheduled interviews. Potential 
participants were sent a copy of the ‘consent to participate form’ and details of the research 
project. In the case of service users, they were sent a screening questionnaire to determine 
their suitability for participation in the study; in addition to the ‘consent to participate form (see 
Appendix 3, 4 and 6). 
 
4.5.5 Management of data 
The interviews were digitally recorded by the researcher and the audio recordings were 
transcribed (by an independent company) and checked for accuracy, independently of the 
researcher, by the project supervisors and work based supervisor. Electronic copies of 
transcripts and digital recordings were held on a password protected computer and the digital 
recordings have been archived on an encrypted computer to be kept for 5 years after the date 
of publication of this thesis.   
 
4.5.6 Analysis of the data  
 
Transcription 
Transcription of interview data is one of the most common ways to prepare it for analysis 
(Bazeley & Jackson 2013, p. 23). Whilst it was the initial intentions of the researcher to 
transcribe the interviews himself, due to time constraints, and the fact that data collection and 
analysis within the study were being conducted simultaneously, it was necessary to employ a 
transcriber. In order to ensure that the transcriber chosen was rigorous and professional in 
their approach, advice was sought from University of Portsmouth colleagues about suitable 
transcription services.  
 
Following the receipt of the research transcripts, to ensure similarity in transcription style 
across the whole dataset, the researcher, project supervisors and work based supervisor 
examined the interview transcripts to ensure accuracy by listening to the audio-recording and 
reading the transcripts simultaneously. As the Framework analysis is focused on the content, 
rather than the structure of participants’ responses for analysis, long pauses, interruptions and 
nonverbal communication (such as laughter) were noted within the text. All transcripts were 
supplemented with field-notes made during and immediately after the interview, for example 
noting background information and instances where views were given after the digital recorder 
was switched off. 
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Computer assisted qualitative data analysis (CAQDAS) 
In order to manage large amounts of qualitative data in a systematic way and to ensure 
efficient retrieval of that data, a number of computer software packages have been developed. 
Whilst such packages help to assist with the data analysis process, they are not an alternative 
to researchers’ time, effort and skills but have been viewed as a means of enhancing the rigour 
of qualitative studies (Bazeley & Jackson, 2013, p. 4) and can encourage proximity of the 
researcher with the data (Pope, Ziebland & Mays, 2000, p. 115). For these reasons, following 
transcription of interviews into Microsoft Word, data were stored and managed using specialist 
software for qualitative data, NVivo-10 (Bazeley & Jackson, 2013, p. 63). 
 
Familiarisation with the interview 
The researcher thoroughly read and re-read each transcript, and listened back to the audio-
recorded interviews to become familiar with the whole data set. Initial thoughts and 
impressions were noted in the margins of the transcripts; for example, where participants 
expressed exceptionally strong or contrasting views to their counterparts. This included one 
service user who expressed a strong view against the merits of clinicians trying to empathise 
with patients suffering from a psychotic type illness. This view contrasted with other service 
user participants who strongly expressed the need for clinicians to communicate closely with 
their patients. Familiarisation through reading and annotating the interview transcripts also 
enabled ready access to prior thoughts emerging from the reading of the transcripts. 
 
Coding 
The researcher coded all transcripts which were then independently checked by the research 
project supervisors.  All relevant segments of text were extracted and coded using the left-
hand margin to describe the content of each passage with a label or code. This could range 
from only a few words, to parts of sentences or whole paragraphs. The right-hand margin was 
then used to record more detailed notes and ideas. Below, in Table 4.2 an excerpt of open 
coding is presented. The participant, a representative of the pharmaceutical industry, talks 
about the role of prescribing guidelines. 
 
Data analysis 
 
The stakeholder groups were analysed separately to enable the unique themes from each 
group to be identified. This approach to the analysis enabled an understanding of the 
emergent themes from each stakeholder group and facilitated an understanding of the areas 
of concord and divergence between these groups. The analysis of data by stakeholder group 
also allowed for issues specific to the stakeholder group to be explicitly identified as part of 
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the analysis; an example of this is the theme that emerged from interviews with pharmaceutical 
industry representatives in which their relationship with the NHS was identified as a key 
determinant of their future commercial success in the United Kingdom. The approach of 
analysing the stakeholder groups separately  is consistent with other studies  (Lester et al 
.,2006, p. 418; Bolster & Manias, 2010, p. 159)  where the findings from healthcare 
professionals and service users were also analysed separately. 
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Table 4.2: Excerpt of open coding from the Pharmaceutical Industry interviews 
         
Codes Industry 2  Notes and Ideas 
Prescribing 
Guidelines 
Evidence base 
Choice  
 
Para 15, p 2: Prescribing guidelines should inform clinical 
best practice, they should be research-based, evidence-
based guidelines, and they should give the opportunity for 
the patient as well as the clinicians to understand what the 
best treatments may be for their individual circumstances 
 
Industry perspective on the role of 
prescribing guidelines. EBM 
patient as well as clinician 
engagement. Holistic in nature. 
Financial control 
 
 
Para 2, p 3: Standardisation is needed to a degree to help 
control finance 
……the NHS at the moment isn’t an endless pit of money 
 
Financial aspect of prescribing 
guidelines   
Need for patient 
specific care  
Para 2, p 3: It shouldn’t discourage individualised treatment; 
because I think it does at times 
Need to balance guideline driven 
care with the needs of the 
individual 
 
Influence on 
prescribing  
Para 4, p 3: the industry influence that, the industry’s 
marketing attitude influences that 
 
I think other clinical endorsement, key thought leaders, key 
opinion leaders, I think sometimes it’s exciting and new, I 
think it’s…. 
 
I think it’s the this is something different from my standard 
practice – which excites a lot of people – as opposed to is it 
necessarily the best thing to do in the organisation. 
Multifactorial factors that impact 
on prescribing practice. Internal 
and internal in nature. 
  
The researcher labelled this as ‘prescribing guidelines’ with sub codes ‘evidence’ and ‘choice’. 
The researcher’s extracts emphasise interesting parts of the data that he felt were worth 
coding or noting. 
 
Developing a working analytical framework 
The researcher coded all transcripts which were reviewed by the project supervisors. 
Feedback was received regarding the assigned codes and a discussion was held in terms of 
why the codes had been interpreted as meaningful and the relationship to the research aims 
and objectives.  
  
A set of codes was agreed on, each with a brief definition. This formed the analytical 
framework for that stakeholder group.  
 
The example below, in Table 4.3 from the pharmaceutical industry interviews shows one 
category from the analytical framework with codes and subsequent description of codes.  
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Table 4.3: Extract of the Analytical Framework for the Pharmaceutical Industry 
Code Description 
NHS Working Practices 
Relationship 
between primary 
and secondary care 
Barriers, gaps, advantages and drawbacks, working 
relationships 
Knowledge of EBM  
Education, and source of information on prescribing 
practice.  
Primary/Secondary 
care interface 
Instances of working together from two or more different 
disciplines, working across care sectors 
Changes in working 
practices 
Impact / outcome in terms of changes to working practice 
(e.g. Saturday clinics), changes to clinician workload, 
consultant travel 
 
Applying the analytical Framework 
The final analytical framework was applied to each transcript using Microsoft Word. In practice, 
this meant exporting the assigned codes from NVivo ready for indexing. Each meaningful 
passage from the data set was selected and coded with the final analytical framework. The 
analytical framework was subject to scrutiny by the research supervisors. Below is an excerpt 
from ‘Industry 2’ where the text is highlighted that is relevant to the theme ‘NHS working 
practice.’  The interviewee discussed the limitation of GP understanding of mental health 
diagnosis and treatment and the commissioning of mental health services. 
 
“psychiatrists and mental health professionals know the GPs don’t know anything about it, so 
there’s a lack of trust”  
 
 
 “but I don’t think, you know, mental health, the mental health 
arena hasn’t got there yet.”     
 
Charting data into the framework matrix 
Once all the data had been coded using the analytical framework, the data was summarised 
in a matrix for each theme using Microsoft Word. As illustrated below in Table 4.4, the matrix 
comprised of one row per participant and one column per code. A separate sheet was used 
for each category. The data were taken from transcripts for each participant and code, and 
inserted into the corresponding cell in the matrix.  
Knowledge of EBM 
Primary/Secondary 
care 
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NVivo proved to be invaluable at this stage, as it allowed for quick and easy retrieval of indexed 
data for specific codes within each transcript. All charting was subject to scrutiny by the 
research supervisors. The example below is an extract from the ‘NHS Working Practices; 
matrix, with page and paragraph references.  
 
Table 4.4: Pharmaceutical Industry Matrix:  Extract from philosophy of care  
 
 
Role of guidelines Patient-centred care  Evidence 
I2 Para 15, p 2: Prescribing 
guidelines should inform 
clinical best practice, they 
should be research-based, 
evidence-based guidelines, 
and they should give the 
opportunity for the patient as 
well as the clinicians to 
understand what the best 
treatments may be for their 
individual circumstances 
Para 2, p 3: It shouldn’t 
discourage individualised 
treatment; because I think it 
does at times 
Para 5, p.3 I think it’s easier to 
see a harder outcome and a 
clearer outcome in physical-
health settings than it is in 
psychiatry. So that changes 
things. 
I2 Para 2, p 3: Standardisation 
is needed to a degree to 
help control finance  ……the 
NHS at the moment isn’t an 
endless pit of money 
Para 3, p 16: Then as the trained 
clinician you turn back to your 
shelf of choices and you work 
those from a shelf of five or six 
which might be the two or three 
best ones to meet the needs of 
that individual patient; 
Para 1, p.4 I think that also 
makes it easier to decide in a 
physical-health setting what 
won’t go onto a formulary as well 
as what will go onto a formulary. 
I2 Para 7, p.4 I think GPs – in 
certain areas, it depends, it 
varies up and down the 
country – but in certain areas 
GPs welcome the guideline 
and the government’s 
approach around a 
reassurance they’re doing 
the right thing.  
Para 3, p 16: you have a 
discussion about those two or 
three, the benefits, the risks, the 
side effects 
Para 7, p 9: Because it’s not 
about, well, you improve your 
clinical trials, it’s about, well, how 
do we do it together. 
I2 Para 7, p.4 I think specialists 
tend to be more 
experimental, 
understandably, because it’s 
more individualised in their 
care. 
Para 3, p.16: we have to get to 
what is important to you as an 
individual and what your 
treatment goals are 
Para 1, p 14: But have you really 
done this, or has your years of 
experience made you take 
several short cuts which means 
you’ve missed something? 
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Interpreting the data 
Themes were generated from the data set by reviewing the matrix and making connections 
within and between participants and categories. This process was influenced both by the 
original research objectives and by new concepts generated inductively from the data.  
During the interpretation stage, an overview of individual descriptions was developed to 
identify themes which offered possible explanations for what was happening within the 
dataset. This process was repeated several times until themes were developed which 
transcended individual accounts.   Ideas were generated, explored and fleshed out using 
analytical memos and discussion with the project supervisors.  Notes were developed with 
sub-headings, including a definition of the category, specific codes that were directly related 
to it, a summary of the raw data, discussion of any deviant cases, and further points for 
consideration and comparison. 
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Chapter 5: Findings and discussion 
 
5.1 Overview  
The findings and discussion have been combined in this thesis. A brief overview of the findings 
is presented in diagrammatical form at the start of each section. The diagrams indicate the 
major themes and subthemes.  
 
The findings from the study presented in this thesis will be discussed in five interconnected 
sections, each relating to a specific stakeholder group (pharmaceutical industry 
representatives, service users, pharmacists, GPs and psychiatrists). A total of twenty-five 
people were interviewed; five in each stakeholder group. The findings of this study are based 
on the Framework analysis of the interview transcripts. The findings will reflect the main 
themes that emerged from the analysis of the interview transcripts and will incorporate the use 
of verbatim quotes to illustrate those ﬁndings.  
 
A final discussion section in this chapter relates the findings of the study to existing research 
to set them in a wider context.  
5.2 Pharmaceutical Industry representatives 
The interviews with the pharmaceutical industry were conducted over the period of December 
2013 to July 2014. During this period, there was a major reconfiguration in one of the 
pharmaceutical companies with a portfolio in mental health. After initially declining to 
participate in the study, the author approached the company in question for a second time to 
determine if they would be interested in participating. Following the second contact, the 
company agreed to participate. The interviews with the industry representatives ranged from 
46 to 78 minutes in length and were conducted in a variety of settings including NHS, industry, 
and a hotel location.  
 
All interview participants from the pharmaceutical industry had a national or international role 
and included a Chief Executive Officer, Strategic Lead for Europe and Canada, UK CNS 
Business Head, Healthcare Marketing Manager and Head of Market Access for the UK. 
Interviews were conducted with senior industrial representatives to gain a more strategic 
perspective on the working relationship with the NHS and the potential for joint working. 
Industry representatives 1 and 5 had a prior history of working in the NHS. Using Framework 
analysis, three main themes, and several sub-themes were identified. These are presented in 
Figure 5.1 
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Figure 5.1 Pharmaceutical Industry Interviews: Main themes and subthemes 
A discussion of these themes and sub-themes generated from the data will now be presented 
which will include the identification of any relevant interrelationships between these. The 
identified themes are as follows: 
• Philosophy of Care 
• NHS Infrastructure 
• NHS-Industry Relationship   
 
The first theme, ‘Philosophy of Care’, incorporated the idea of tensions between the ideology 
of providing evidence-based care and the practicalities of delivering it in a ‘real world’ setting. 
 
The second theme, ‘NHS infrastructure’, identified the pharmaceutical industry’s response to 
the reform of the NHS in England through the Health and Social Care Act 2012. This theme 
focuses on the implication for commissioning of services and its potential impact on drug 
utilisation. The theme also explores the relationship between primary care and mental health 
services.  
 
The third theme focuses on the ‘NHS-Industry relationship’ and includes the historical context 
to this relationship. Market access is considered in the context of the pharmaceutical industry’s 
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need to understand and integrate with the changing NHS landscape.  Finally, the theme takes 
into consideration new ways of working between the pharmaceutical industry and the NHS.  
 
5.3 Philosophy of care 
The first theme ‘Philosophy of Care’ incorporated the idea of tension between the ideal and 
reality of providing evidence-based care. The theme includes the subthemes of prescribing 
guidelines and their role in clinical practice as well as their implementation and limitations. The 
theme also includes the limitation of pharmacological clinical trial evidence in mental health 
and the potential impact on pharmaceutical sales in the context of the austerity measures 
facing the NHS.  
 
5.3.1 Role of prescribing guidelines  
In this study, as in other studies, representatives from the pharmaceutical industry identified 
the clear rationale for the role of prescribing guidelines in clinical practice (Charani et al., 2013, 
p. 193; Bauer, 2002, p. 139). The role of guidelines was viewed as embodying evidence to 
support medicines optimisation for the individual as illustrated by industry representative 2: 
The notion of guidelines in the role of empowering and informing patients is also articulated in 
the literature. Woolf et al. (1999, p. 527) recommend the use of ‘consumer’ versions of 
guidelines, embracing a range of communication media and technologies. It is argued, that 
such guidelines can empower patients to make more informed healthcare choices and to 
consider their personal needs and preferences in selecting the best treatment option.  
In the response from Industry Representative 5, the use of prescribing guidelines was set in 
the context of expert opinion and clinician freedom, however there was also an 
acknowledgement of the role of guidelines in the promotion of prescribing efficiencies.  
 
Industry Representative 2 Para 15, p 2: “Prescribing guidelines should inform clinical best 
practice, they should be research-based, evidence-based guidelines, and they should give the 
opportunity for the patient as well as the clinicians to understand what the best treatments may be 
for their individual circumstances.” 
 
Industry Representative 5 Para 4, p.24 “I do think that guidelines are important still. I think it’s 
nice to have a unified opinion on what is the right algorithm, where you start because there’s 
efficiency in it.” 
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The role of prescribing guidelines as a mechanism for cost containment was also identified in 
the following response: 
The above comment identifies a potential concern for the wider pharmaceutical industry that 
might be looking to launch new drugs in the UK. In mental health the lack of significant 
developments in innovative drug treatments is likely to lead to fewer drugs being approved for 
use as NHS organisations will be looking to maximise cost-effective prescribing.  
The use of guidelines in terms of organisational expectations was expressed by one industry 
representative. 
This view contrasts with that expressed by consultant colleagues who were interviewed (see 
section 5.25.1), as organisational expectations were not considered of primary importance 
when prescribing for an individual patient.  
 
Prescribing guidelines were identified as a needed resource for junior doctors due to their lack 
of clinical expertise. 
The study by Pulcini et al. (2011, p. 85) demonstrated that the availability of prescribing 
guidelines was judged by junior doctors to be the single biggest intervention to improve 
prescribing practice, closely followed by educational interventions.   
 
 
 
 
 
Industry Representative 2.  Para 2, p 3: “Standardisation is needed to a degree to help control 
finance, the NHS at the moment isn’t an endless pit of money.” 
Industry Representative 5. Para 12, p.24. “So I guess for junior doctors when people build on the 
expertise, that’s probably where guidelines make most value.” 
 
Industry Representative 4. Para 11, p.5. “I think guidelines are very good at, or can be very good 
at saying you know we expect our prescribers to follow the guideline perhaps for eighty ninety 
percent of the time.” 
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5.3.1.1 The limitations of prescribing guidelines   
Representatives from the pharmaceutical industry made a clear distinction between the role 
of prescribing guidelines for GPs and consultant psychiatrists. Consultant psychiatrists were 
perceived as operating outside of the framework of prescribing guidelines, largely based on 
their knowledge and experience. GPs were perceived as being more amenable to the use of 
prescribing guidelines, perhaps because of their wider clinical prescribing remit.  
The limitation of prescribing guidelines in the treatment of the individual patient was further 
highlighted and set in a context of the need for individualised care.  
 
In contrast to the view that GPs are more likely to adhere to prescribing guidelines, there was 
an acknowledgement that they are independent contractors and therefore in one sense freer 
to prescribe outside of organisation constraints.  
One of the identified limitations of prescribing guidelines was the lack of technological 
infrastructure and the implications this had for wider patient physical health monitoring, which 
was considered in the context of prescribing practice.  
This is in keeping with the findings of Mitchell, Lord, & Malone (2012, p. 437) who in their 
meta-analysis concluded that patients were less likely to be prescribed cardiovascular 
medicines than their counterparts without enduring mental illness. Phelan, Stradins, & 
Morrison (2001, p. 444) noted that doctors who were uncomfortable with mental illness were 
reluctant to engage with patients about physical symptoms and unlikely to perform associated 
physical examinations.  
Industry Representative 2.  “I think GPs – in certain areas, it depends, it varies up and down the 
country – but in certain areas GPs welcome the guideline and the government’s approach around 
a reassurance they’re doing the right thing.” 
“I think specialists tend to be more experimental, understandably, because it’s more 
individualised in their care.” 
Industry Representative 4 Para 8, p.10. “Whereas with GPs they you know; they are independent 
contractors who contract with the NHS.” 
Industry Representative 3 Para 2, p.13. “You know erm, because its paper based maybe the 
physical health checks aren’t as regular as they should be.” 
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A further limitation of the use of prescribing guidelines was that there were often assumptions 
that are inherent in their development with which the GPs may be unfamiliar.  
 
5.3.1.2 Implementation of prescribing guidelines  
Industry Representative 4 outlined a proposed approach to marketing guidelines using a 
multidisciplinary educational outreach.  
The representative was formally a prescribing advisor for a PCT and therefore had first-hand 
experience of implementing prescribing guidelines in clinical practice.  
  
Implementation was also considered from a national level in terms of either NICE or the 
Scottish Medicines Consortium (SMC). There was a concern expressed that despite national 
approval, a drug might not necessarily receive approval for use at a local level.  
There are a variety of reasons why local implementation might not necessarily be readily 
adopted, and this can be related to the agreement of funding streams for the new medicine, 
or in some cases where the treatment should be initiated and the subsequent development of 
shared care protocols. Other factors that can impact on the uptake of a new medicine can also 
include the culture of the trust. A trust that is committed to implementing guidance is likely to 
be one that has an infrastructure for managing NICE guidance and governance arrangements 
for ensuring compliance.  
Industry Representative 2. Para 8, p 13: “There’s a whole raft of questions sit behind what will 
get you to where, and there’s the assumption that everyone knows those questions.” 
 
Industry Representative 4. Para 3, p.8. “Why would people buy into it you know, erm quite often if 
it’s a, if it’s a new product or it’s a specialist type of product that requires then transfer of 
responsibility to primary care then you know some degree of if I can use the word selling of the 
guideline by, by the people who are designing the guidelines so the, the GP prescribing lead that 
was involved, the consultant clinician who was involved, the pharmacist who was, so you know it’s 
almost a road show type of thing.” 
Industry Representative 1. Para 6, p.3. “I think one of the biggest issues, so even where you have 
a positive NICE or a positive SMC at a local level, sometimes that recommendation is poorly 
implemented.” 
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One of the challenges from the industry to the wider NHS was set in the context of its methods 
of communication. In the extract below, the limitations of the NHS approach are outlined by 
Industry Representative 2. 
With the changes to the NHS as a result of the Health and Social Care Act 2012, there is a 
need to review communication strategies both within the trust and across the local health 
economy to ensure that messages are delivered to the appropriate stakeholder.  Channel 
management is a term which has its origins in marketing; it refers to the process of analysing, 
planning, organising, and controlling an organisation’s communication/marketing channels. 
Channel management involves the development of a strategy for communicating, agreeing 
the mechanism of communication, identifying the key stakeholders e.g. mental health 
commissioners, identifying the needs of the recipients of the messages (e.g. a simplified 
protocol for lithium management in primary care), coordination of a mechanism of 
communication and assessing performance by determining if the message has reached a 
target audience e.g. GPs in a particular locality and managing any potential conflicts that arise 
(Mehta, Dubinsky, & Anderson, 2002, p. 430).  
 
The concept of channel management is particularly important to enable key messages to be 
targeted across the local health economy.  
 
A limitation in the implementation of prescribing guidelines was linked to a poor technological 
infrastructure within trusts.  
This limits the availability of prompts at the point of prescribing and, at present, an educational 
outreach approach is adopted across the trust to support the implementation of prescribing 
guidelines. 
Industry Representative 2 Para 2, p 12: “So there is an element of how are you communicating 
what information to whom and by which channel, so do you do channel management….” 
 Para 7, p 12: “Which is how the NHS communicates.” 
Para 9, p 12: ”they’ll communicate the message and think it’s landed, and then do no assessment 
of how it landed or what the issue was or what they could change to do something different. So 
they do it once and think it’s done, job done.” 
Industry Representative 3. Para 12, p.12. “I think it’s very hard if you don’t have; its classic 
things like the technology I mean if you look at psychiatrist’s paper based prescribing in the acute 
setting in trusts you don’t have electronic prescribing record.” 
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5.3.2 Patient centred care   
The theme of patient centred care incorporates the subtheme of ‘Patient Understanding’. 
Industry Representative 4 identified the factors that are required from a patient perspective to 
support concordance. In particular, attention is paid to the importance of the medication fitting 
the lifestyle of the recipient.  
The review by  Mitchell & Selmes (2007, p. 337) identified that medication regimens that cause 
disruption to lifestyle, or require special techniques are less welcome by patients and hence 
less likely to lead to compliance with treatment. 
 
The concept of treatment was broadened beyond pharmacological intervention by Industry 
Representative 5 who identified treatment in the context of the patient’s best interest.  
The idea of not limiting treatment of the service user to pharmacological interventions implies 
holistic care. In the interviews with service users, there are clear findings which support the 
need for a more holistic approach to treatment which is discussed in the context of the findings 
from the service user interviews (see section 5.9.4). The need for the holistic care of patients 
has been articulated by the RPS (2013, p. 5) as a partnership between healthcare 
professionals and the recipients of care. The desire to be considered in holistic terms was one 
of the findings of the Scottish Governments report into mental health recovery (Smith-Merry 
et al., 2010, p. 130). The report also identified that service users wished to be provided with a 
range of treatment options extending beyond pharmacological interventions.  
 
 
 
 
 
 
 
Industry Representative 4. Para 6, p.7 “that actually it is helpful, it fits your lifestyle, the patient 
knows that because the medicine is there, working on the chemistry of their brain, and the chances 
of them getting rebound symptoms or anything are minimised and therefore chances for them to go 
downhill.” 
Industry Representative 5. Para 2, p.2 “What based on their needs is the best treatment for them?”  
Para 2, p.2 “And I say treatment, because we know it’s not just a pill.” 
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5.3.2.1 Service User understanding  
The extract below highlights the importance of a service user’s understanding of the treatment 
they are prescribed.   
An important aspect of treatment in mental health is that the service user has an understanding 
of their diagnosis and the need for treatment. Such an understanding has been positively 
linked to adherence and  satisfaction (Mitchell & Selmes, 2007, p. 339). Furthermore, service 
users understanding of the treatment they are prescribed has been related to the amount, type 
and timing of the information received (Ha & Longnecker, 2010, p. 42).  
 
5.3.3 Evidence 
The paucity of robust clinical trial data is widely acknowledged in psychiatry (Turner, 2013b, 
p. 457; Das, 2011, p. 17; Heres et al., 2006, p. 191; Jelinek & Neate, 2009, p. 218; Rafols et 
al., 2014, p. 35; Nierenberg, 2009, p. 529).  Industry Representative 1 identified this issue in 
relation to other therapy areas she had previously worked in.  
There was also an acknowledgement that the pharmaceutical industry has a responsibility to 
produce more meaningful evidence for the NHS.  
 
Industry Representative 1. Para 11, p.17. “It’s up to us as a pharma industry to show the NHS 
that our drugs drive the outcomes that they’re looking for, the efficiency outcomes that they’re 
looking for.” 
Para 3, p.18. “it’s just that we need to show it, we need to stop doing clinical trials that don’t use 
outcomes that the NHS actually care about.” 
Industry Representative 4.  Para 7, p.6. “I’ve been a patient myself at one point, so when I take 
something I want to have belief that it’s going to make a difference to me.” 
Industry Representative 1. Para 2, p.7. “There’s a few things I’ve noticed having worked in other 
therapy areas a lot is, one, is the data is poor in comparison with other clinical areas.” 
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The perspective of industry responsibility for clinical trial data was challenged by Industry 
Representative 2 with the following statement: 
This statement implies that there is a shared responsibility for the clinical trial data which would 
imply the idea of post-marketing evaluation.  
 
While post-marketing evaluation of medicines is key to determine outcomes in a ‘real world 
setting’, it is often problematic to determine the benefits afforded by newer psychotropic 
medicines over above existing ones. 
 
5.4 NHS infrastructure 
One of the key concerns expressed by the pharmaceutical industry representatives was the 
implications for achieving market growth in the changing NHS landscape. There was an 
acknowledgement of the need to fully understand the commissioning infrastructure and key 
drivers at a local health economy level. This was also set in the context of the financial 
constraint facing the NHS and the need to demonstrate the value proposition of a medicine. 
This theme focuses on the commissioning of services, the interface between specialist 
services and primary care and the importance of the existing interrelationships. 
 
5.4.1 Commissioning  
Successive UK governments have promoted commissioning as the process through which the 
health service is planned and overseen (Miller & Rees, 2014, p. 145). Across the local health 
economy CCGs are responsible for the commissioning of the majority of clinical services.  It 
is clear from the interviews that the pharmaceutical industry views the relationship with 
commissioners as key to its continued success. This was especially concerning for those who, 
at the time of the interviews, were looking to gain approval for new drugs. 
Industry Representative 3. Para 9, p.16. “You probably need as a pharma company to understand 
a lot about that local health economy and what goes on with commissioning, what are some of the 
key challenges they face.” 
Industry Representative 2. Para 7, p 9: “Because it’s not about, well, you improve your clinical 
trials, it’s about, well, how do we do it together.” 
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The traditional block commissioning of mental health services was identified as a limiting factor 
in the care pathways that exist for service delivery. Payment by results in mental health is a 
relatively new concept, however, it has existed for at least a decade in acute physical care 
(Jacobs, 2014, p. 157). This was reflected in the comments by Industry Representative 1 
below. 
 
Industry Representative 1 identifies some of the potential reasons why commissioners might 
choose not to invest in mental health which is linked to the concept of investing to save and 
the delivery of the return on investment within the existing financial year.  
The financial pressure on commissioning and provider organisations to achieve demanding 
financial in-year targets makes long-term investments unappealing in the current economic 
environment.  The approach of dealing with the immediacy of the present financial demands 
can potentially lead to failure to achieve longer-term savings.  
Furthermore, the failure to consider longer term investments is not limited to the NHS, but 
includes the pharmaceutical industry; which is reflected in a lack of mental health related 
research and limited psychopharmacological agents in development (Dix, 2015, p. 210).  
 
Another factor  that could contribute to the reticence to invest in mental health therapeutics is 
the paucity of evidence in mental health related clinical trials and outcome data that are 
understood by commissioners. Miller & Rees (2014, p. 152), in their study of mental health 
commissioning, concluded that there was insufficient knowledge and experience  to bring 
about transformative changes in mental health service provision. This was further echoed by 
Gilburt, Edwards &  Murray (2014, p. 33) who identified that there was limited focus and skills 
in the commissioning of mental health services.  
Industry Representative 1. Para 3, p.5. “so for a commissioner, actually, I might be more tempted 
to go and spend on osteoporosis, so that I don’t get that falls rate, or whatever, and I get my in 
year money back, which is what it’s all about at the moment, isn’t it?”  
Industry Representative 1. Para 3, p.5. “It’s tough to make the decisions to invest heavily in 
mental health, I might not see that result for years to come.” 
Industry Representative 1. Para 10, p.3 “I actually think mental health is probably 10 years 
behind even the physical health agenda with commissioning and making sure that there’s a joined 
up approach to commissioning.” 
  
115 
 
5.4.2 Primary/Secondary Care 
The continuity of care for a mental health service user is dependent on a number of factors 
including; accessibility to a range of services across a health economy, the provider of care, 
and the service user. Problems can occur when there are barriers at any of these levels, e.g. 
an appointment system that makes personal continuity difficult, or if the service user is not an 
effective negotiator or is disadvantaged; as is often the case in people with severe and 
enduring mental illness, e.g. patients suffering with bipolar disorder or schizophrenia  (Reilly 
et al., 2012, p. 7). People with severe mental illness value continuity of care but the evidence 
suggests that it is poor for a substantial proportion of service users (Reilly et al., 2012, p. 10; 
BMA, 2014, p. 29).  
 
The statement by Industry Representative 3 embodies the notion that GPs are not fully 
engaged in the treatment of mental health illness.  
There is an acknowledgement that GPs are not always willing to include mental health 
services in a primary care setting (Crawford, Carr, Knight, Chambers, & Nolan, 2001, p. 218). 
The reasons for a lack of engagement may be multifactorial, with studies showing that GPs 
lack expertise in treating service users with personality disorders, mental disorders associated 
with substance abuse, and serious disorders e.g. schizophrenia and bipolar disorder (Fleury, 
Imboua, Aubé, Farand, & Lambert, 2012, p. 2). In addition to a lack of expertise, inter-
professional relationships with specialist services and their clinical caseload can also impact 
on the willingness of GPs to engage with mental health service users (Fleury, Bamvita, & 
Tremblay, 2009, p. 4).   
 
The reluctance of GPs to engage with service users was identified by Industry Representative 
1, who alluded to attitudinal issues underpinning the lack of engagement.  
 
 
Industry Representative 3. Para 4, p. 17. “My view would be that general practitioners in primary 
care have left mental health services alone.” 
Industry Representative 1. Para 4, p.19. “GPs don’t like doing the mental health, so actually 
there’s a, kind of, hands off approach, they don’t want somebody with serious mental illness in 
their surgery, so quite happy to push them back.” 
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Traditionally, Community Psychiatric Nurses (CPNs) have been linked to mental health 
provider organisations and this is reflected in the comment by Industry Representative 1 who 
draws a comparison between the mental health, nursing delivery model and that of other 
therapy areas.  
A recent project in London has led to the deployment of CPNs in GP surgeries for service 
users who wish to receive care in a GP practice setting. The CPNs have been responsible for 
monitoring the physical and mental health of service users who have been assessed as 
clinically stable. The initiative in Newham has demonstrated a 90 % retention of service users 
in primary care (Lind, 2015, para 2).  
 
5.5 NHS – Industry Interface  
The theme of the NHS-interface focuses on the relationship between the pharmaceutical 
industry and the NHS. This theme explores the issues of market access and new ways of 
working that is mutually beneficial to the pharmaceutical industry and the NHS.  
 
5.5.1 Access  
The issue of market access was discussed by industry representatives in the context of the 
changing NHS landscape and the austerity measures impacting on healthcare provision. This 
is set against a government report which identified that uptake of new medicines approved by 
NICE  is just 11% of the average of other developed countries after one year, less than a third 
of the average after two years, and only half the average after four years (DBIS, 2015, p. 
35). Industry Representative 3 identified the differing NHS tiers that have to be overcome by 
the pharmaceutical industry to gain market access.  
A source of frustration as expressed by the pharmaceutical industry was the various hurdles; 
national, regional and local infrastrutures that exist for drug approval. Furthermore, the 
approval process  was considered to be  difficult to circumvent with conflicting opinions based 
on differing healthcare settings.  
Industry Representative 3. Para 8, p.5. “I think when you get below that hurdle to local market 
access. I think the same term becomes very blurred and I think that’s dependent on the 
characteristics of the trust in the area that you are working in.” 
Industry Representative 1. Para 6, p.19. “it is divided, you know, you look at other areas where 
community teams operate from out of the GP practice, you know, CPN teams don’t, why not?” 
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An example is given below of the variable approaches to drug approval by differing NHS 
organisations.  
At present, across the West Midlands Mental Health Trusts, there is no uniformity of new 
psychotropic drug approval, and in effect, a post-code lottery exists which could  justifiably be 
challenged by service user groups. The fact that this variability exists is often due to the 
financial constraints facing mental health trusts, which is often compounded by the need to 
demonstrate year on year efficiency savings on drug budgets.  
 
In some cases, an investment in pharmacy services can often be expected to be ofset by an 
efficiency saving in prescribing, for example an investment in an electronic prescribing system 
might be tied to the expectation of a reduction in some aspect of prescribing costs which might 
impact the uptake of newer medicines.  
 
Industry Representative 3 demonstrated in his response a degree of understanding of the 
drivers of prescribing uptake that was not fully appreciated by fellow Industry Representative 
5.  
There was an acknowlegdement by Industry Representative 5 that there was a need to 
understand in greater detail the role of CCGs and the issues at the local level and this 
prompted  the following statement: 
 
 
Industry Representative 3. Para 5, p.6. “There are certain trusts that adopted paliperidone and said 
it’s an unmet need therefore we recognise that this is a me too atypical   without huge differentiation 
but because all patients respond differently we prefer to have it on our formulary.” 
Industry Representative 3. Para 9, p.6. “While in certain other trusts that’s not gonna get on their 
clinical guidance for love nor money and it is seen as a cynical ploy by pharma.” 
Para 11, p.6. “It’s just beyond NICE large degrees of variance.” 
 
Industry Representative 5. Para 4, p. 12. “It seems a bit ridiculous, because once the medicine 
has been approved… So there is service in place, it’s been approved, it shows the benefit.” 
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5.5.2 New ways of working 
All representatives from the pharmaceutical industry expressed the need for joint working and 
in particular, new ways of working which in part was linked to the financial pressures faced by 
the NHS. The language used in the interviews was focused on demonstrating the value 
proposition of new medicines and targeting the unmet need in psychiatric therapeutics.  
Industry Representative 1 expressed her vision for the restructuring of the existing 
pharmaceutical industry workforce model of regional managers, key account holders  and 
representatives.  
The revised model would work alongside the local health economy as an implementation team 
which would be multidisciplinary in nature.   
 
A variant on the implementation team was outlined by Industry Representative 2 who 
proposed a model based on financial target setting between the industry and the local health 
economy.  
Such an approach is likely to identify the local needs and cost pressures and could adopt tailor 
made solutions for identifying the unmet clinical needs across a local health economy.  
  
The proposal as outlined is consistent with the Department of Health who have recently 
published the ‘Accelerated Access Review’ in response to pressure from the pharmaceutical 
industry (DBIS, 2015, p. 35). The report outlines plans for speeding up the access to new 
drugs in the UK but recognises the financial pressure facing the NHS and proposes a model 
of incentivisation to adopt “new innovations.” Thus, the UK government is balancing the 
Industry Representative 2. Para 5, p 6: “I actually think the way that we should do it is that we 
should come and sit down with the organisation, we should lay out all the evidence, we should talk 
through where we think the medication would fit, and then we would agree together how we would 
market it as an organisation.” 
Para 7, p 6: “So there needs to be a little bit more agreement between the industry and the 
organisation.” 
Industry Representative 1. Para 4, p.20.” I believe that we should move away from 
representatives selling directly to clinicians and actually put in service implementation 
programmes, potentially your pharma industry contribution to a health economy is, you know, a 
small team, probably of a medic, health economist/data capture person and maybe a project 
manager who go into a health economy, they’re in there helping with the implementation of 
nationally approved and locally approved medicines that they provide. So they’ll help you with the 
data capture, with the implementation, helping to put the pathways together so that you can…they 
essentially drive an uptake of nationally approved medicines that they manufacture.” 
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financial constraints of the NHS with the need for income generation from the pharmaceutical 
industry which has, over the past decade, consistently generated a large trade surplus in the 
UK of  £1.1 billion per annum (ABPI websitehttp://www.abpi.org.uk). 
 
Industry Representative 4 was a previous NHS employee with  a background in medicines 
management. His response to the existing mode of pharmaceutical industry sales at a local 
level was balanced with the need for a new  patient-centred approach.  As a former prescribing 
support  pharmacist, Industry Representative 4 demonstrated an understanding of the cost  
pressures and the ease with which a prescribing budget could targeted for delivering financial 
efficiences. 
 
 
  
Industry Representative 4. Para 5, p.15. “I’m happy to sit with your finance director and see what 
his, what his efficiency targets might look like, I’m happy to bring my finance man with me to say 
you know, to be honest for this population in the West Midlands.” 
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5.6 Summary 
The main themes that emerged from the interviews with the pharmaceutical industry 
representatives were philosophy of care, NHS infrastructure and NHS-Industry interface. The 
theme of philosophy of care incorporated the role of guidance in clinical practice and this was 
discussed in the context of its benefits, limitations and implementation and in particular, 
Industry Representative 2 identified poor communication practice within the NHS. 
 
The changing NHS and the implications for commissioning was discussed by all industry 
representatives who considered this a challenge in view of their existing limited workforce.  
 
It was acknowledged that new relationships would need to be developed across health 
economies, to strategically convey value proposition messages about new pharmacological 
treatments. There was a view amongst industry representatives that GPs were reluctant to 
engage in the treatment of service users with enduring mental illness and that communication 
between them and mental health services was poor. 
 
Finally, the NHS-Pharmaceutical industry interface was considered in terms of access,  which 
included market access and the need to engage with the new NHS. There was a concern 
expressed that local uptake of medicines by provider organisations was variable and that 
approval processes for new medicines was inefficient. 
 
The pharmaceutical industry representatives recognised the need for new ways of engaging 
with the NHS which is typified by the quote below: 
  
 Industry 4. Para 9, p. 17. “I’m trying to get us to go into partnership working and that for me, 
that is the way forward.” 
  
121 
 
5.7 Service Users  
Interviews with service users were conducted between  December 2013 and  February 2014. 
Service user 1 was a former NHS professional, Service User 2 was at the time of the 
interviews, a health care professional working in private practice; Service User 3 had 
experience of working as a counselor in mental health services and Service Users 4 and 5 
had no experience of working for the NHS. Service User 5 however, was actively engaged in 
a mental health self-help group.  Interviews with the service users ranged from 39 to 69 
minutes and were conducted at NHS locations with the exception of one interview which 
conducted  at a local charity setting.     
 
Using  Framework analysis, four main themes and several sub-themes were identified (see 
Figure 5.2). 
 
Figure 5.2 Service User Interviews: Main Themes and Subthemes 
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The emergent themes are as follows: 
• Choice and medication 
• Response to medication 
• Patient centred care 
• Communication 
 
The theme of choice and medication explored the extent to which service users felt involved 
in making treatment decisions about prescribed medication. This theme also explored the 
service user’s medication taking behaviour and the factors that influence their decision 
making. 
 
The second theme, response to treatment, explored the impact of medication on the individual 
and the benefits and limitations of treatment. The third theme, patient centred care, related to 
the support systems in place for the individual and the desire for holistic interventions as part 
of mental health treatment. The final theme, communication, explored the relationships 
between healthcare professionals and service users and the impact of the relationship on 
medicines optimisation.  
 
A discussion of the themes and sub-themes generated from the data will  be presented using  
Framework analysis, which will include the identification of any relevant interrelationships 
between them. 
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5.8 Choice and Medication 
Service users had negative perceptions about the choices offered to them. They all recognised 
the difficulties that they faced and the lack of choice that was made available. It was apparent 
that the lack of treatment options was a concern for Service User 1. 
Service User 5 indicated a historical background to prescribing practice which was set against 
a context of not being offered treatment options.  
The lack of choice in prescribed medication was echoed by Service User 1. Despite the lack 
of available treatment options, the service user was the final arbiter of the decision to take the 
medication or not. 
The deliberate decision not to take medicines is often termed ‘intentional non-adherence’ in 
the literature and  is predicted by the balance of an individual’s reasons for and against taking 
medication (Mitchell & Selmes, 2007, p. 338).  Intentional non-adherence is a common reason 
not to start a course of medication and is embodied in the response by Service User 5 below. 
The service user desire for more information is consistent with the findings of numerous 
studies in psychiatry which indicate that in addition to the need for greater information, service 
users want to be involved in decision-making (Gray, Rofail, Allen, & Newey, 2005, p. 36; 
Olofinjana & Taylor, 2005, p. 371; Duncan, Best, & Hagen, 2010, p. 12). 
Service User 1. Para 12, p.19. “You’re not presented with, well, there’s A, B, C.  The side effects 
of A are…the side effects of B are…the side effects of C are.” 
Service User 1. Para 1, p.20. “I mean, in my last lot of meds there wasn’t any discussion; it was 
like, I think you should take these, and that’s it.” 
Service User 5. Para 3, p.2. “I’ve been put on so many different medications for my eating, and I 
guess in the early days I wasn’t really given much choice.” 
Service User 5. Para 2, p.4. “He prescribed this medication, gave me the form, and I knew when I 
was sitting in the room, I’m not taking it so what’s.” 
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Service User 5 was clear in her role as the final arbiter of the decision to take medicines 
throughout the interview, and her responses, indicated that the doctor’s therapeutic goal was 
for her to achieve symptom remission. 
The fear of non-compliance was expressed by Service User 2 and considered in the context 
of compulsory hospitalisation under the Mental Health Act.  
 
5.8.1 Concordance 
The concept of concordance is not synonymous with either compliance or adherence. 
Concordance does not refer to a patient’s medication-taking behaviour, but rather the nature 
of the interaction between healthcare professional and patient. Concordance involves mutual 
respect and understanding in pursuit of an ideal therapeutic alliance. The issue of 
concordance was discussed by all participants and it was clear that there was a challenge to 
achieve a concordant relationship with their healthcare practitioner. Furthermore, there was a 
stigma associated with non-compliance, which was discussed in the context of a response to 
a breakdown or non-existence of a concordant relationship.  
In the following extract, Service User 2 indicated that she had made an informed decision not 
to take medication based on an aversion to the side-effects.  Later in the interview, Service 
User 2 articulated the beneficial impact of medicines on her well-being which was linked to the 
absence of adverse effects (see Section 5.32.12).  
Service User 2. Para 7, p.4. “What I want you to take, because if you don’t take them, they say 
you’re non-compliant and then you get frightened that if you’re non-compliant, they’re going to 
put you in the hospital.” 
Service User 2. Para 5, p.4. “I’ve got to admit, I’ve been known not to take my medication, 
because I start to panic about the side effects, you know, it’s, like, the liver and whatever else, you 
know, and you think, do I need it?” 
Service User 1. Para 1, p.20. “And I started them when I was in hospital, so I didn’t even have the 
patient information leaflets to read.” 
Service User 5. Para 12, p.8. “But that’s only because I will make sure if I take it or not.  They’re 
not going to physically come out and make me take the tablet.” 
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Service user engagement in medication use  has been identified as a way of improving 
outcomes,  as well as minimising waste (RPS, 2013, p. 15). 
 
A concordant approach to medication taking was detailed by service user 3 who led the 
process of exploring treatment options as a series of trials with medicines.  
This notion of trial and error in determining how the medication will impact on the individual is 
in keeping with the view of a concordant relationship as articulated by Deegan and Drake 
(2006, p. 1638). 
 
 
5.8.2 Shared decision making 
A preference for a cooperative relationship involving shared decision-making, choices that 
reflected the service users wishes, negotiated agreements and a sense of partnership, was 
alluded to by Service User 2.  
 
As part of an ongoing discussion with psychiatrists, service users expressed the importance 
of considering alternative therapies which included: prayer, mindfulness, acupuncture and 
reflexology.  
 
Service User 2. Para 7, p.20. “It’s a bit pointless giving me a load of medication that I know I’m 
not going to take, I can sit there and I can agree with you and I’ll say, yeah, I’ll take them.” 
Service User 3 Para 5, p.4.  “..then olanzapine, I tried some olanzapine.  It didn’t stop the 
paranoia and I just put on a lot of weight, I was worried about diabetes, and all that…on 
reflection, I decided the Modecate would be better” 
Para 5, p.4. “Second time I went to Dr xxxxxx and he was very fed up with me in a sense, for 
messing him around, because I changed my mind, but he did after a time, after about three weeks, 
let me go back on the Modecate.” 
Para 5, p.4. “as I say, I’ve been extremely well ever since and able to function.” 
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Service User 5 explained that over the years, she had become more vocal in her treatment 
options and this was typified by the extract below.  
 
The desire for a discussion about the rationale for prescribing and the proposed benefits of 
treatment was discussed in the context of what would be considered the ideal consultation by 
Service User 2.  
 
5.9 Response to medication 
The second of the four themes ‘response to medication’ will be discussed in the context of the 
perceived impact of medication on quality of life and activities of daily living. In particular, this 
theme examines the impact of the adverse effects of medication as well as the benefits in 
terms of well-being.  
 
5.9.1 Adverse effects  
When confronted with a range of possible adverse effects, it can be challenging for a service 
user to retain a sense of proportion about them. They are a reality for the service user that 
has to be confronted and managed, and discrepancies have been found between psychiatrists 
and service users in estimating the degree to which psychotropic medicines exert their 
adverse effects (Rettenbacher, Burns, Kemmler & Fleischhacker, 2004, p. 2871).  At the same 
time, explaining a medication’s full side effect profile can prove difficult to achieve in clinical 
practice and may be regarded by  doctors  as impractical (Seale et al., 2006, p. 2866). The 
findings from a National Service User Survey for inpatients across DWMHT indicated that 33% 
of respondents reported that they had received comprehensive information about the side 
effects of prescribed medication. This figure was higher than the national average and 
indicated the limited information given to service users on the side effects of prescribed 
medication.   
 
Service User 2. Para 7, p.4. “Then a joint talk about why they’re going to suggest that I take this 
medication and why it’s going to be beneficial for me.” 
Service User 5. Para 2, p.3. “But, if you are more vocal and say, right, can we try this and this 
before the tablets, and then if…really tablets should be the last resort…then you can actually work 
with the consultants.” 
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All participants in this study discussed the adverse effects of medication and the impact on 
their quality of life. 
Weight gain was associated with the use of medicines in all interviewees. The potential for 
weight gain with medication was associated with decisions to not take medicines.  
This finding is consistent with that of other studies which have identified  that body mass index 
(BMI) status and distress over weight gain served as indicators for noncompliance with 
treatment (Weiden, Mackell, & McDonnell, 2004, p. 56; Fakhouri, 1999, p. S285; Seale et al., 
2006, p. 2866; Oehl, Hummer, & Fleischhacker, 2000, p. 84). 
Service User 5 discussed the impact of medication on suicidal ideation. In particular, she 
described how her depression was worsened by the prescribed medication. 
The association of antidepressants with suicidal ideation and completed suicides has been 
increasingly documented (Doshi, 2013, p. 1; Lenzer & Brownlee, 2008, p. 533; Eyding et al., 
2010, p. 8). In addition to the reports in the literature, patient information leaflets also outline 
the increased risk of suicidal ideation in young adults with comorbid psychiatric diseases.  
 
Service User 1. Para 12. “I’m not taking quetiapine because that, I know for a fact that put a 
tremendous amount of weight on me.”  
Service User 5. Para 13, p.3. “One psychiatrist wanted me to go on this medication and I didn’t 
because I wasn’t in the right frame of mind to start putting on weight.” 
Service User 5. Para 4, p.2. “In the past, I’ve had medication that has made me have suicidal 
thoughts…. and this medication, all I could think about was killing myself, walking in front of buses, 
jumping out of a window.” 
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The interview extract below identifies the lack of awareness of the service user regarding the 
suicidal ideation associated with the prescribed antidepressant.  
Previously in the interview, it became clear that the service user had become more assertive 
with regards to prescribed medication (see Section 5.8.2) and viewed herself as the expert of 
her wellbeing, with the prescriber acting as her support, helping to provide information, to 
discuss options, to clarify understanding and preferences, and to ultimately support her 
autonomy. This model of consultation is consistent with the model as outlined by Deegan & 
Drake (2006, p. 87).   
 
The physical health impact of prescribing for mental health conditions is outlined by Service 
User 4 who explained in greater detail, the specific physical health complications associated 
with the long-term use of lithium and the lack of focus of the mental health doctor in terms of 
modifying her treatment regime to account for the adverse physical health effects.  
 
The extract from Service User 4 reinforces the notion of clinician-centric decision making with 
the best interest of the service user seen as resident in the healthcare professional.  
Service User 5. Para 4, p.2. “So, I did take an overdose, because I couldn’t cope with it…… 
 So, I did it again.  Because I didn’t realise it was the medication.” 
Para 4, p.2. “A consultant there that actually treated me, and he was on that ward then, and he 
looked at the actual medication I was on, and he says, no wonder, he said, this may be the cause 
why you’re having these suicidal thoughts.” 
Service User 4. Para 14, p.2. “I took lithium for a long time, but I started having some nasty side 
effects from that.” 
 
Service User 4. Para 1, p.5. “Well, I’ve already got an impaired thyroid because of it, but then I 
started getting this psoriasis in lots of places on my body.” 
Para 3, p.5. “I went to see a skin consultant, and he said, well, when he found out that I was 
taking lithium, that I really shouldn’t be taking it, because it was aggravating for the psoriasis.” 
Para 3, p.5. “So, it took a letter from him to the psychiatrist before he started, sort of, taking me 
seriously, and trying to find an alternative.” 
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The best interest of individual should be holistic in nature, taking into consideration potentially 
distressing side effects of their intervention. There is a clear need to ensure that 
pharmacological treatment is tailored to the needs of the service user, taking into consideration 
the individual preference, lifestyle, supporting evidence, tolerability and ease of administration 
as well as cost. The pharmacy profession is key to the delivery of patient centred  care, which 
takes into consideration the optimisation of medicines in the treatment of the physical and 
mental wellbeing of the individual (Jimmy & Jose, 2011, p. 157; RPS, 2013, p. 3).   
 
5.9.2 Medication and wellbeing  
Wellbeing for service users has been linked to choice and autonomy (Read, 2009, p. 156). 
Although service users desire freedom from the debilitating symptoms of mental illness, they 
typically place as much emphasis on a good quality of life (Perkins, 2001, p. 9).  
 
Wellbeing was considered by service users in the context of their individual functioning and 
quality of life. This was described in terms of accessing mainstream facilities, activities and 
gaining a social identity following integration into mainstream leisure and employment 
activities. 
Service user 3  identified wellbeing in terms of symptom remission which is more in keeping 
with the medical model and reflects the goals of healthcare professionals (Sajatovic & Ross, 
2009, p. 28). 
Service User 1. Para 10, p.21. “Being well is being able to function; you know, being able to go 
out, being able to enjoy things.” 
Service User 3. Para 11, p.5. “Basically, the ability to rationalise things and to not have painful 
thoughts.” 
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The interviews explored what wellbeing meant to the individuals and how this was attributed, 
if at all, to the medication they were prescribed. Service User 3 articulated the benefits 
achieved from prescribed medication. 
The impact of medication on wellbeing was linked to compliance for Service User 3, who was 
a healthcare professional. By contrast Service User 1 acknowledged the benefits of 
medication but had decided to discontinue medication through fear of weight gain.  
Some service users discontinue treatment because they perceive treatment to not be as 
effective as they expect or that it is not required in the absence of presenting symptoms (Oehl 
et al., 2000, p. 84). In this particular scenario, the respondent was a former healthcare 
professional and had an understanding of the role of medication in wellbeing. She exercised 
her right to discontinue treatment, fully aware of the potential impact on her mental state. 
 
The impact of bipolar disorder was summarised by Service User 4, who explained during the 
interview that there was a family history of mental illness. Wellbeing was linked to both physical 
and mental health functioning.  
Service User 3 Para 3, p.3. “It acts like an oil, to oil the cogs of my mind and it keeps me thinking 
straight.” 
Para 5, p.4. “As I say, I’ve been extremely well ever since and able to function.” 
Para 3, p.9. “The deliverance has helped me in that way, but the Modecate I still need, because I 
know if I start to, my mind would crash and I would lose confidence and I would basically not be 
able to treat my patients and do my writing and things like that.” 
Service User 1. Para 4, p.9. “Because I’m not taking my medication, my mental health is shot.” 
Para 4, p.10. “It’s irrational for the fact that mentally at the moment, I’m absolutely screwed up, 
but I don’t want to take the medication.” 
Service User 4. Para 7, p.9. “Because having a manic episode is dreadful mental and physically 
dreadful, and, you know, I want to avoid that at all costs.” 
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The use of medicines was linked to an improved quality of life by Service User 4, who 
acknowledged the advances in drug treatment and the potential advantage this conferred on 
her compared with the previous generation suffering with similar illnesses. 
The impact of medication on wellbeing was also echoed by Service User 3. 
 
5.10 Patient centred care  
The theme of ‘patient centred care’ will be discussed in the context of the identified patient 
support mechanisms and the need for holistic care which transcends pharmacological 
interventions. 
 
5.10.1 Support system 
The underpinning support mechanisms for service users varied and were linked to a number 
of variables, including a family network that was encouraging and non-judgemental, links to 
voluntary and third sector organisations and finally, links with healthcare professionals.  
When service users described support services that worked for them in their recovery, they 
did not describe complex support systems of care, but personal, flexible, joined-up or 
coordinated responses that offered choices. Service users discussed the accessibility of 
treatment in terms of where it was delivered.  They saw clear benefits in being able to receive 
the treatment within the setting of their own home; this finding is consistent with that of a 
Scottish study which looked at recovery from long-term mental illness, in which a key 
determinant of successful outcomes for service users was linked to the support received from 
healthcare professionals, voluntary organisations and peers (Smith-Merry et al., 2010, p. 92).  
Service User 4 Para 2, p.16. “Well, I’m a bit of an optimist so I would hope that they have enabled 
me to live a fairly normal life, or, at least, make my life less problematic.” 
Para 2, p.16. “My life has been more...more...well, less challenging than it was for my 
grandmother, put it that way around.” 
Service User 3. Para 4, p.12. “Oh, absolutely enormous, I couldn’t…I think two generations ago, 
I’d probably be a long time patient in a psychiatric hospital, it’s set me free, It’s given me back a 
normal life.” 
Service User 4. Para 9, p.9. “I have in the past anyway, managed the depressive episodes while I’m 
at home with support from care coordinators, et cetera.” 
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Service User 3, detailed an account in which he had made numerous requests for 
administration of his depot injection via the deltoid muscle rather than gluteal; this would mean 
receiving an injection in the arm rather than the buttock.  
He was able to access support via the trust patient liaison service which led to concordance 
with his wishes.  This raises an important issue of service user awareness and the role of 
advocacy. If the wellbeing of service users is a primary concern, then healthcare professionals 
have to try and find a balance between their provision of, and advocacy for, immediate 
treatment needs on the one hand and their longer-term relationships with service users. Thus 
a simple enquiry might have mitigated a long-standing battle to enable the service user to 
receive his depot injection via the deltoid muscle.  
 
Service User 5 lived in isolation and had limited family support; she was therefore mindful of 
the impact of medicines on her ability to undertake her daily tasks.  
 
5.10.2 Holistic care 
Service users described how they wanted psychiatrists to take a more holistic view of them. 
Although they did want them to explore their symptoms, they required to be seen as more than 
a set of symptoms.  
Service User 5. Para 6, p.17. “So, I think, you’ve got to look at the person, not just the physical 
person, the, sort of, emotional person, look at their intellect, look at their whole being.” 
Service User 3. Para 1, p.7. “and I found a card from the patient care and liaison service, which 
deals with patient complaints and I got in touch with them and they got it sorted for me.” 
Service User 5. Para 6, p.4. “I can’t afford to have all these things going on, if there’s nobody 
there to support me and help me.” 
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Service users perceived a lack of empathy and understanding of their history and the 
circumstances related to their ill health and life situation. Psychiatrists were urged to listen to 
the needs of the service users and to respond holistically as typified by the following response 
from service user 1: 
This view was echoed in the Scottish review of mental health service users (Smith-Merry et 
al., 2010, p. 131); furthermore Ha & Longnecker (2010, p. 42) conclude in their review of doctor 
patient communication that doctors with better communication and interpersonal skills are able 
to detect problems earlier, prevent medical crises, and provide better support to their patients.  
 
Medication was viewed in the context of a more holistic spectrum of interventions aimed at 
improving wellbeing. 
Interviewees indicated that non-medical forms of treatment or therapy (religious practice, 
talking therapies, counselling, and support groups) had been important factors in supporting 
their recovery.  
These findings are consistent with that of Smith-Merry et al (2010, p. 130) who identified that 
service users were accepting of combining conventional and alternative therapies. In a more 
recent Scottish survey, respondents indicated that in addition to medication, family support 
and alternative therapies were considered as the most important factors supporting recovery 
(Reid, Hinchliffe, & Waterton, 2014, p. 3). 
 
Service User 1. Para 4, p. 13. “I think medicines play a part, but I think you’ve got to look at the 
bigger picture.” 
Para 8, p.13. “Things like exercise and things like that, I think, are important.  I think talking 
therapies are very important as well.” 
Service User 3. Para 2, p.8. “I’ve been through a lot of prayer counselling and deliverance.” 
Service User 1. Para 5, p.24. “I just think we need more information, we need more discussion, we 
need a more holistic approach to psychiatric medication.” 
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Service users found non-pharmacological interventions useful in providing strategies and 
techniques to limit stressful states, however some of these processes were quite demanding 
emotionally. 
5.11 Communication 
Service users discussed the impact of communication on their relationship with healthcare 
professionals, in particular nurses and psychiatrists. There was less focus on relationships 
with GPs and their interaction with them was based primarily on the management of physical 
healthcare. This finding is in keeping with the perspective of representatives from the 
pharmaceutical industry, who expressed opinions that mental health services are largely 
neglected by GPs (see Section 5.4.2).   
 
Service users also expressed the need for relevant and timely information about prescribed 
medicines. There was a desire for information to be provided in a variety of ways and at 
differing stages throughout the recovery period.  
 
It was clear from the interviews that service users thought that trusting relationships was an 
important aspect in their care and they spoke of the positive and negative experiences of the 
healthcare professionals they had worked with. The quality of the clinician–service user  
relationship has been demonstrated to be of great importance to service users and has been 
shown to influence attitudes and understanding of prescribed medicines (Coulter, 2002, p. 
669; Laugharne, Priebe, McCabe, Garland, & Clifford, 2012, p. 82; Bolster & Manias, 2010,  
p. 163). 
 
The discussion that follows will detail the key findings in relation to the communication with 
healthcare professionals and the information needs of the service users.  
 
 
 
 
 
 
Service User 1. Para 1, p.13. “I’m doing a mindfulness course at the moment, which I’ve actually 
just been asked if I want to come off it, because I’m finding that quite difficult.” 
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5.11.1 Healthcare professionals  
 
Service User 1 was distrustful of doctors and at the time of the interview had been given the 
option to change consultant by her existing psychiatrist. In her interview, she discussed her 
history of mistrust of doctors which was based on her professional experience of working with 
them.   
The issue of trust was one of the important elements in the relationship with health 
professionals and has been identified as a key aspect of the recovery process for service 
users (Bezreh, Laws, Taubin, Rifkin, & Wilson, 2012, p. 17; Borg & Kristiansen, 2004, p. 496; 
Ha & Longnecker, 2010, p. 42; Topor, Borg, Di Girolamo, & Davidson, 2011, p. 3). 
Service User 5 went on to discuss some aspects of her relationship with her doctors that 
characterised a good relationship; these were demonstrable acts of compassion and concern.  
The need for compassionate care was echoed in the findings of a review, Rethink (2006, p. 
10), in which service users identified the need for healthcare professionals to be more caring 
and empathetic. Similarly,  Borg & Kristiansen  (2004, p. 502) found that service users were 
open regarding the diversity in what helps, and were willing to stretch the boundaries of what 
was considered the ‘professional’ role of clinicians.  Thus compassionate care can be viewed 
as respectful and empathetic in nature and appreciating  the strengths and difficulties faced 
by the individual (Cleary, Horsfall, & Escott, 2015, p. 563). However, compassionate care 
should enable the service user to make sense of their dilemmas and harness their strength to 
engender hope and develop confidence and a sense of self-efficacy.  
Service User 5. Para 4, p.5. “My doctor, would come out of hours to me, if he was popping by he 
would just make sure, are you okay.” 
Para 4, p.5. “Everything I asked for, they really tried their best to sort it out.” 
Service User 1. Para 11, p.4. “Well, he thinks I think we’ve got conflict, and that’s why he’s 
offered me a change of consultant.” 
Service User 5. Para 2, p.3. “Some consultants and doctors you can trust, and some health people 
are very, very good.” 
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By contrast Service Users 3 and 4 considered empathy inappropriate under certain 
circumstances which were related to the presentation of their illness.  
This finding is contrasted by the findings of Ha & Longnecker  (2010, p. 40), who identified 
empathy as one of the most important ways of providing support to reduce service users’ 
feelings of isolation and validating their feelings or thoughts as normal and to be expected.  
 
The variability in the expectations of healthcare professionals would suggest the need to 
understand the individual service user’s beliefs about health and health care provision; 
furthermore, the clinician should understand that empathy can be misplaced under certain 
circumstances.  
 
The relationships with nursing staff were discussed in the context of an initial point of contact 
and support. Service User 4 described the characteristics of her relationship with her CPN 
with whom she was close.  
The role of the CPN was viewed as a service user advocate and supportive in a more 
immediate sense than that of psychiatrists.  CPNs  appear to be centrally involved in care and 
health education of any of the service users, which is consistent with the findings of Reilly et 
al (2012, p. 5) in which the primary contact for service users with enduring mental health 
illnesses was CPNs. 
Service User 3. Para 1, p.4. “I think if you’re psychotic, they have to be detached, because they 
can’t empathise completely, because they can’t agree with what you’re saying.” 
 
Service User 4. Para 7, p.3. “Too kind in a way as to be, like, very forgiving about some of my 
behaviours, if you like.” 
Para 7, p.3. “You know, some people are, sort of, too understanding about it whereas I’ve set 
myself up to behave as normally as possible.” 
Service User 3. Para 5, p.9. “I’d first of all have a word with my CPN and I’d go and see Dr 
xxxxxx.” 
Service User 4. Para 1, p.11. “Because...well, he’s just so down to earth, and he just says it how it 
is.” 
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The role of the GP in the care of service users was minimal and in one case, a service user 
was unable to be discharged from mental health services because of the refusal of the GP 
practice to accept him. This refusal occurred, despite the mental stability of the individual who 
was in full-time employment. The reason that the service user was not accepted by the 
practice was because the individual was receiving treatment with an antipsychotic depot 
injection and the practice claimed not to have the skills to manage the individual and the 
administration of his medication.  
 
Service User 5 highlighted the time-constraints in communication with her GP and the impact 
this this had in terms of holistic care.  
Service User 1 outlined her relationship with her GP in terms of her mental health status. It 
was clear from the interviews that service users did not view GPs as central to their care; this 
is consistent with the views expressed by representatives from the pharmaceutical industry 
(see Section 5.4.2).  
The role of GPs was viewed as limited to annual reviews and involvement with physical 
healthcare. Service User 4 outlined the role of her GP in her annual review of her physical 
healthcare medication. 
The care of service users with enduring mental illness is set against a review in the quality 
framework against which GPs are measured. In 2014/15, the national review saw the removal 
of the requirement of GPs to undertake annual monitoring of weight, cholesterol and glycaemic   
levels in patients with severe mental illness. This decision was fiercely criticised by GPs with 
a specialist interest in mental health and conflicted with the government attempt to redress the 
Service User 1. Para 2, p.14. “My GP has categorically said that he will not discuss my mental 
health issues with me, but he also doesn’t discuss any issues that could be possibly related to 
bariatric surgery.” 
Service User 4. Para 5, p.4. “And they go through all my medication, because I have to take some 
for blood pressure.” 
Service User 5. Para 8, p.6. “When you do actually go in, you feel a bit guilty that you’re going to 
be taking a bit more time and they’re going to be waiting even longer, so it’s, like, you know, you 
feel like you can’t take up all their time.” 
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disparity of physical healthcare in services users with enduring mental illness (Price, 2013, 
para 4).  
 
5.11.2 Information  
Service users discussed medicines information in the context of their needs and the sources 
from which information was obtained.  
 
Service User 5 used the internet to obtain written information on prescribed medicines but 
expressed concerns about the veracity of the published information on the various websites 
and the potential industry influence which was concerning for her.  
The observation by Service User 5 is consistent with the finding of Read & Cain (2013, p. 429) 
who concluded in their review that drug company–funded websites were  biased and could 
not be considered an objective source of mental health information, for the public or 
practitioner.  
 
Service User 5 went on to explain that she adopted an approach of double checking the 
information received from one psychiatrist with a second opinion from another as a means of 
verification.  
O’Neill (2002, p. 9) identified that in an age of consumerism, service users may choose to 
scrutinise their doctors more closely and call the traditional trust afforded them into question. 
This is balanced against an acknowledgement by doctors that deception can be employed as 
part of a communication strategy in the best interests of service users.  Explanation of adverse 
effects of medication, or specifying a diagnosis, presented particular difficulties, leading to 
delays in the disclosure of such information (Seale et al., 2006, p. 2867). 
Service User 5. Para 8, p.3. “I will ask the psychiatrist, but I do like to ask more than one 
psychiatrist.” 
Para 12, p.3. “Because you get completely different responses from different ones. Like, I have 
recently.” 
Service User 5. Para 4, p.3. “I read studies that have been done by people, probably like yourself, 
on the internet.” 
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The need for timely information was expressed by Service User 3 and was set in a historical 
context of his early diagnosis.  
The need for more information, especially on the side effects of medication, was expressed 
by all service users and is consistent with the results of the national survey by Rethink, in 
which 45% (total n=2222) of service users believed that they did not have any choice in the 
type of medications they were prescribed, with 54% claiming to have received no written 
information about the side-effects of their psychotropic medicines (Rethink, 2006, p. 9).  
 
The need for written and verbal information was expressed by all service users and it was 
acknowledged that there was a lack of consistency in this practice.  
This finding is consistent with the study by Olofinjana & Taylor (2005, p. 371) in which the 
majority of the participants felt that they were not given sufficient or, in some cases, any 
information about prescribed antipsychotic medication.  
 
  
Service User 3. Para 14, p.10. “I think I would have liked more information at an earlier stage I 
think.” 
Service User 4. Para 5, p.4. “My GP just said I think we need to change your medication, end of, 
there was no talking and I find that even with my consultant, they never explain to you the side 
effects that there could be so that you can make an informed choice.” 
Service User 1. Para 6, p.21. “I think you need the written that you can actually…you know, the 
one to…the face-to-face, but the written that you can actually go and read it in your own time.” 
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5.12 Summary 
Four main themes emerged from the interviews with service users; they were choice and 
medication, response to treatment, patient centred care and communication.  
 
The theme of choice and medication explored the extent to which service users felt involved 
in the decisions about the medication that they were prescribed. The findings from this study 
indicate that service users did not feel fully engaged in making decisions about their prescribed 
medicines and this is consistent with the findings from other studies (Gray, Rofail, Allen, & 
Newey, 2005, p. 36; Olofinjana & Taylor, 2005, p. 371; Duncan, Best, & Hagen, 2010, p. 12). 
   
The development of a helping and supportive relationship with professionals was often a 
pivotal turning point in service users’ journeys. Overall, service users regarded demonstrations 
of empathy, trust, collaboration, shared power, respect, personal investment and kind 
gestures as most helpful in their therapeutic relationship with mental health professionals. 
However, the findings of this study differ from that of Borg and Kristiansen (2004, p. 502), in 
that limitations to an empathic relationship with doctors were also identified. 
  
Service users obtained information from a variety of sources and were mindful of the need for 
continuous information on prescribed medication as part of their recovery process. There was 
a need for information to be provided in a variety of ways and a clear desire to understand the 
potential side effects of prescribed medicines. 
 
Perhaps most importantly, service users desired a more holistic approach to their treatment 
than was provided by healthcare professionals.  Which was echoed in the findings from other 
studies (Reid, Hinchliffe, & Waterton, 2014, p. 3; Smith-Merry et al., 2010, p. 130). 
 
 
 
 
 
 
  
  
141 
 
5.13 Pharmacists 
Interviews were conducted with pharmacists involved in formulary and/or guideline 
development across the local health economy during January and February 2014. All 
interviews were conducted at NHS locations and ranged from 40 to 67 minutes. The 
interviewees included specialist mental health and non-specialist pharmacists. The aim of the 
interviews was to develop an understanding of the perceived factors that influence the 
implementation of prescribing guidelines in a mental health setting and to explore the factors 
that impact on prescribing. Non-specialist pharmacists were included to give a comparative 
context from outside the field of psychiatry.  
 
The interviews with the pharmacists identified three key themes which are presented in Figure 
5.3.  
The themes identified from the study were: 
• Philosophy of care 
• Prescribing practice 
• Working practice 
 
The first theme, philosophy of care, explored the meaning of efficacy, from both the healthcare 
professional perspective, and what it might mean for a service user. The philosophy of care 
theme also explored the concept of patient centred care and shared decision-making and 
linked these ideals with the reality of the current service delivery model. 
 
The second theme to emerge from the interviews with pharmacists was prescribing practice. 
This theme explored the drivers for clinician behaviour and the influences on prescribing 
across the health economy. This theme also explored the role of prescribing guidelines in 
clinical practice, their implementation and factors that govern the use of guidelines.  
 
The final theme, working practice, explored prescribing across primary and secondary care 
and the communication issues that are inherent in current healthcare infrastructure. The theme 
also explored the potential or otherwise, of working with the pharmaceutical industry and the 
drivers influencing this.  
 
A discussion of the emergent themes and subthemes from the interview transcripts will be 
presented using Framework analysis and will include any interrelationships between themes.  
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Figure 5.3 Pharmacist Interviews: Main Themes and Subthemes 
 
5.14 Philosophy of care 
The philosophy of care theme took into consideration the meaning of efficacy from the 
healthcare professional perspective and what efficacy might mean to the individual as the 
recipient of care.  The theme also included the importance of patient centred care and the role 
of healthcare professionals in a patient-centric service. 
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5.14.1 Efficacy - Service user perception 
Efficacy was considered in the context of the healthcare professional perspective, the 
individual as the recipient of care and the organisational ideal by Pharmacist 1.  
Efficacy was deemed to relate to the impact on the quality of life if considered from the service 
user perspective.  This link between achieving normality without debilitating physical health 
related consequences is echoed in a number of studies (De Boer, et al., 2015, p. 681; Lester, 
Tait, England, & Tritter, 2006, p. 418; Olfson et al., 2000, p. 221).  
 
This notion of efficacy was contrasted with Pharmacist 2 who considered service users to be 
idealistic in their expectation of therapeutic outcomes. 
This finding is inconsistent with that of other studies which identified that service users 
expected some benefits from pharmacological treatment, but did not view it as curative (Lang, 
2005, p. 584).  
 
In the public campaign, Defeat Depression, many people were wary of taking antidepressants 
and in addition to the perceived limitation of pharmacological interventions, more than three-
quarters of those who were surveyed believed that the medications were addictive (Paykel et 
al, 1998, p. 520).  
 
Pharmacist 2 was employed by a neighbouring CCG and was not directly involved in patient 
care; whereas Pharmacist 3, was at the time of the interviews, an active non-medical 
prescriber and therefore engaged in direct patient care.  
Pharmacist 3. Para 3, p.8 “Can it allow me to return to as much a normal life as possible without 
having any other er physical or mental consequences for my health?” 
Pharmacist 2. Para 9, p.5. “Patients would just think about the effectiveness of it so they would 
like a consultation, a magic drug to end their problem.” 
Pharmacist 1. Para 4, p.69. “And efficacy to me also means that you know…from a patient, it’s 
got to be quality of life…you got…you’ve got to have quality of life measures in there…you 
know…and I think from an organisation point of view, efficacy is then much broader because then 
you’re looking at population level.” 
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The differences in response between Pharmacists 3 and 2 may reflect the health economic 
perspective of prescribing practice in which the individual needs are not foremost in the day 
to day activities of Pharmacist 2.   
 
Pharmacist 5 identified the balance between perceived efficacy and the burden of adverse 
effects.   
The impact of weight gain from psychotropic medication has been shown to be the most 
distressing adverse effect experienced by service users in the treatment of mental illness  
(Fakhouri, 1999, p. S285). Furthermore, the issue of weight gain with psychotropic medication 
was identified as a concern by service users in this study (see Section 5.9.1).  
 
5.14.2 Efficacy - Healthcare professional perspective 
Pharmacist 4 identified efficacy in terms of symptom control and stabilisation, but also made 
the distinction between symptom attenuation versus improved quality of life for the individual. 
Thus, the traditional healthcare professional perspective could be viewed in the context of 
service user control and the management of presenting symptomatology.  
This is contrasted with the service user perspective of efficacy, which was viewed in a wider 
context of wellbeing (see Section 5.9.2). Some service users have considered that the side 
effects associated with medication were so debilitating that they were not worth enduring and 
in addition, the only reason medications were used was to make individuals ’fit in’ to society 
(Smith-Merry et al., 2010, p. 145).  
 
 
 
Pharmacist 5. Para 1, p.2. “The big thing was that you won’t put on weight and you know we had 
some great patients, wonderfully controlled on clozapine erm but you know massive 20, 22 
stone…. 
So it’s in their view was the clozapine efficacious. Well yes on one hand but on the other hand it 
came with some pretty heavy baggage.” 
Pharmacist 4. Para 5, p.7. “but what was traditionally experienced of control…and stability of 
the patient verses quality for that individual patient concerned.” 
Para 9, p.7. “so there might be a perception by the outsider that’s become an efficacious 
treatment because it’s taken away the pressures of that patient.” 
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5.14.3 Patient centred care 
The theme patient centred care includes the role of patient choice and the impact that this has 
on the therapeutic alliance with healthcare professionals as well as the implications for the 
wider health economy. The theme of patient centred care also included patient understanding 
of the medication that they are prescribed and the implication this has on healthcare 
professional communication in both the timing and format of information given to the individual. 
Finally, the theme of patient centred care takes into consideration concordance with treatment 
and the factors that impact on this.   
 
5.14.4 Choice and medication 
At the time of the interviews Pharmacist 1 worked for a CCG and had minimal direct patient 
contact.  
As part of his role he was charged with ensuring that the prescribing budget for the health 
economy was managed.  This role facilitates a health economic view of healthcare linked with 
distributive justice, which is concerned with the allocation of resources. Thus, in response to 
a question relating to the importance of patient choice, his answer focused on the limitations 
of choice and the potential lack of understanding of the factors that govern the available 
options. This response does not consider the role of the service user as a consumer but can 
be viewed as a provider-centric response in which prescribing costs are seen in isolation. 
There is a potential concern for such a restricted view as it may pigeon-hole prescribing costs 
as a stand-alone measure of cost effectiveness; while cheaper treatments in some 
circumstances may enable delivery of an ‘in-year’ financial target, they may lead to longer 
term hidden costs associated with the management of adverse effects.  
Pharmacist 2, who was employed by a local CCG, describes the ideal scenario for a consumer 
based model of healthcare provision in which choice is fundamental.  
Pharmacist 1. Para 5, p.2. “And you know a patient might think, actually I’ve looked on the 
internet, I want that drug (laughs) what they may not understand is actually there is a lot of 
caveats before we can have that drug so I think.” 
Pharmacist 2. Para 5, p.6. “If there is a divergence of opinion, then the patient obviously has the 
opportunity to go and get a second opinion if they’re lucky.” 
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In practice, a consumer based model of care is not routinely achieved for several reasons 
which can include fear, especially during the early phase of mental illness.  
 
Often service users will link their ability to make choices based on the prior experience of their 
illness with the effectiveness or otherwise of past treatments. Interviews with service users in 
this study (see Section 5.9.3) have confirmed that service users grow in confidence as a result 
of their experience with mental health services which is consistent with the findings of other 
studies (Adams & Drake, 2006, p. 91; Deegan & Drake, 2006, p. 1636; Laugharne et al., 2012, 
p. 502).  
 
Service users considered a trusting relationship with clinicians a vital aspect of their care and 
the therapeutic alliance between clinician and service user is identified by Pharmacist 4.  
Service users in this study recognised that the nature of their illness itself could undermine the 
relationship with their clinician and identified that continuity of care was also an important 
factor in developing a therapeutic relationship. 
 
5.14.5 Patient understanding  
Service users’ understanding of their diagnosis and the need for treatment is related to 
concordance and in turn concordance, satisfaction and understanding are all related to the 
amount, type  and timing of information given (Mitchell & Selmes, 2007, p. 336).  
The relationship between understanding and concordance was highlighted by Pharmacist 1. 
Studies have shown that service users can typically leave a consultation with a limited 
understanding of the rationale for therapy (Weiden et al., 2004, p. 52). Poor  service user 
understanding of the rationale for prescribed medicines has been linked with non-compliance, 
and in particular, service users  with low literacy may have difficulty understanding instructions 
(Praska, Kripalani, Seright, & Jacobson, 2005, p. 1441; Kochevar & Yano, 2006, p. S27).  
Pharmacist 1. Para 7, p.6. “You see a lot of people who have been given medication who are not 
taking it for one reason or another, quite often they don’t quite understand what it was for in the 
first place.” 
Pharmacist 4. Para 6, p.3. “It becomes this relationship their prescriber and the patient … and 
how much scope that prescriber through their discussion gives them that opportunity to express 
their desires and wants.” 
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This is particularity concerning because Dudley and Walsall have literacy rates below the 
national average, with the number of adults between 16-64 without any formal qualifications 
ranging from 21.6% in Walsall North to a low of 16.0% in Dudley south compared with a 
national average of 11.1% (Sedghi, 2011, para. 2). 
 
Pharmacist 4 identified the need for patient understanding of the treatment they receive and 
the potential benefits of the intervention.  
 
5.15 Prescribing practice  
The theme of prescribing practice incorporated the role of guidelines and their limitation in a 
‘real world’ setting. The theme also explored the barriers and facilitators for guideline use. 
 
5.15.1 The role of prescribing guidelines  
The role of prescribing guidelines was viewed as a mechanism for facilitating consistency of 
prescribing across the local health economy. Thus, standardisation was deemed as an 
important mechanism for identifying individuals who were prescribing outside of evidence-
based standards; a view which was also echoed by GP 4 (see Section 5.21.2).  
In addition to acting as a governance framework for prescribing practice, guidelines were 
viewed in the context of facilitating cost-effective prescribing which is consistent with the 
findings of Grant (2006, p. 28) who identified the role of prescribing guidelines as promoting 
prescribing efficiencies.   
 
These observations are consistent with those of Weinmann et al.  (2007, p. 421) who 
articulated that guidelines should lead to improved quality of care by decreasing inappropriate 
variation in clinical practice, in addition to promoting a standardised approach to prescribing.  
 
Pharmacist 4. Para 7, p.5. “The idea is that the patient understands why it is they’re taking the 
medication…or the need to take the medication…or what it’s going to help and benefit to the…” 
Pharmacist 1. Para 10, p.1. “Having some sort of consistency with clinicians…it’s how you might 
show that you’ve erm incorporated national guidance as well as local sort of agreement.” 
Para 11, p.1 “but there is an educational element to it as well a sort of clinical practice hopefully 
across the broader group of erm clinicians across you know both primary secondary care sector” 
Para 12, p.1. “safety is within there; cost effectiveness has got to be part of that as well” 
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The educational role of prescribing guidelines was identified by Pharmacist 4.  
The finding is consistent with that of Rashidian, Eccles, & Russell  (2008, p. 232) in their study 
of the willingness of specialists and GPs to use joint treatment guidelines. Both groups agreed 
that these were useful as an educational tool, which could facilitate communication and 
improve harmonisation between primary and secondary care.  
 
The educational role of prescribing guidelines for junior doctors has also been established  
and is found to be of value to them as they often lack the knowledge in specific specialities 
(Pulcini et al., 2011, p. 84). Despite the lack of prescribing knowledge of junior doctors, they 
are often responsible for much of the prescribing in an in-patient setting.  The recognised need 
to support junior medical staff was identified across the West Midlands and this has led to the 
development of a regional e-learning programme to support them in prescribing more 
effectively and safely.  
 
5.15.2  Barriers to guideline implementation 
In the development of prescribing guidelines there are a number of factors that act as 
facilitators or barriers to implementation (Bauer, 2002, p. 149; Weinmann, Janssen, & Gaebel, 
2005, p. 22). Pharmacists detailed in their interviews an understanding of the potential 
facilitators and barriers to prescribing guideline implementation. Aspects of professional 
culture were identified that could facilitate or discourage compliance with evidence-based 
practice.  
 
5.15.2.1 Cultural barriers  
Pharmacist 1 highlighted the reluctance of mental health clinicians to engage in the process 
of formulary/guideline development.  
Pharmacist 4. Para 7, p.1. “It’s to guide consistency and delivery of medication and to support 
those who aren’t familiar with those areas as to what they should be prescribing or direct them to 
further reading to enable them to then go onto making a prescribing decision.” 
Pharmacist 1. Para 3, p. 26,…“but your probably always going to have certain barriers with 
clinicians as well…erm I can remember in my early days certainly round here if I mentioned the F 
word, the formulary word to psychiatrists it was sort of…” 
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This was set against a backdrop of the then, lack of trust employed pharmacists and hence a 
lack of strategic leadership in medicines management. The author was the first full-time trust 
employed pharmacist and within the first year in post, began the development of a series of 
prescribing guidelines which was supported by medical colleagues and subsequently 
disseminated across the local health economy.   
 
Pharmacist 1 identified the importance of the relationship with the originator of the guidance 
and the inclusion in the process of development. 
The observation by Pharmacist 1 is based on the engagement of end users and this is 
consistent with the study by Rashidian, Eccles, & Russell (2008, p. 149) in which high 
representation of secondary care clinicians was seen to undermine the credibility of the 
guidelines themselves, as they were perceived as seeing ‘filtered’ patients and were 
associated with a lack of appreciation of the patient–doctor communication in general practice. 
This creates a potential problem for mental health engagement with GPs as there are over 
120 practices across the Dudley and Walsall boroughs and engagement at an individual 
practice level would be difficult to achieve. Thus, the implementation process is dependent on 
the communication mechanisms in place across the local CCGs and the integration of 
pharmacy teams at the practice level to reinforce key messages.  
 
5.15.2.2 Availability of guidelines 
A further barrier to guideline implementation was the ready availability of prescribing 
guidelines. This finding has implications in the mental health setting as there is a limited 
technological infrastructure to support prescribing.  
The review by Cabana et al.  (1999, p. 1461),  identified that clinicians only used guidelines if 
they were readily accessible; furthermore, the study by Connelly et al (1990, p. 356) found 
that clinicians accessed guidelines if they felt they would achieve a beneficial outcome in a 
limited timeframe. 
Pharmacist 1. Para 2, p.14. “I think the key factor with any formulary has got to be your clinical 
engagement. I think if you don’t have your clinical engagement, you won’t have….it doesn’t really 
matter how good your formulary is…” 
 
Pharmacist 2. Para 6, p.10. “Right, availability you know- can you put your hand to the guidance 
at a glance, you know almost at a glance.” 
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5.15.2.3 Comprehension of guidelines  
Another barrier to guideline use was the time required to read and understand the prescribing 
guidelines. 
Pharmacist 4 in his response to the issue of implementation, alluded to the role of the area 
prescribing committees in disseminating information on prescribing guidelines which includes 
a variety of clinical forums.  
 
5.15.3  Facilitators for guideline implementation  
The broad categories that represent the facilitators for implementing prescribing guidelines 
from this study include: presentational considerations, promotional strategies, implementation 
strategies, resources, individual-level factors, organisational-level factors, and factors external 
to the organisation.  
 
5.15.3.1 Presentation  
Pharmacist 2, who was instrumental in the design and presentation of CCG prescribing 
guidelines identified the practicality of the guidelines which was linked to the ease of use.  
The prescribing guidelines across the Walsall CCG are based on a simple design which guides 
the prescriber via the use of icons and includes details such as diagnosis, drug treatment, 
monitoring requirements and when to refer to specialists.   
 
The need for readily readable and understandable guidelines is consistent with the findings of 
other studies (Cabana et al., 1999, p. 1463; Forsner et al., 2010, p. 7; Addington, Kyle, Desai, 
Pharmacist 4. Para 9, p.8. “There needs to be a forum for discussion circle so we have an area 
medicines management committee which has a prescribing sub-committee where these ideas, or 
idea.” 
Pharmacist 2. Para 2, p.3. “But they generally are practical so that helps with the implementation 
of driving them forward and is a key factor.” 
Pharmacist 2. Para 1, p.9. “I guess that is another one. You know, time to read the guidance and 
understand it erm.” 
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& Wang, 2010, p.1328). Despite the need for clear and available guidelines, over simplification 
has been shown to limit clinician uptake (Cabana et al.,1999, p. 1461).  
 
5.15.3.2 Shared care agreements 
One of the facilitators put forward by Pharmacist 1 was that shared care agreements 
encouraged generalists to prescribe a drug they may have been unfamiliar with.  
Despite the view expressed by Pharmacist 1,  there is evidence to suggest that the GP 
concerns are not primarily related to the familiarity of prescribing a given medicine, but rather 
the cost implication and potential impact on practice drug budgets (Horne, Mailey, Frost, & 
Lea, 2001, p. 192). The issue of cost containment is further compounded by the role of the 
practice based pharmacists who have a remit for delivering prescribing efficiencies.  
 
In a review of shared care arrangements, Smith, Allwright, & O’Dowd (2007, p. 15) indicated 
improvements in mental health outcomes; for example, the proportion of patients recovering 
from depression and improvements in prescribing practice because of their use. 
 
5.15.3.3 Clinical engagement  
Pharmacist 2 identified the importance of a key opinion leader as part of an implementation 
strategy across the health economy. This idea was also considered by pharmaceutical 
Industry Representative 4 (see Section 5.3.12).   
Pharmacist 4 also identified the potential role of psychiatric specialists in championing 
guideline promotion across the local health economy.  
Pharmacist 1. Para 12, p.15. “When you go at a point of prescribing, that’s an ideal 
opportunity…. Erm…plus also you have things like you know I would for new drugs, particularly 
in psychiatry you may be looking at a lot more shared care agreements…” 
Pharmacist 2. Para 2, p.3. “made the adoption of guidelines easier if they were signed off by a 
clinician erm a clinician in secondary care for instance that was well thought of in primary care.” 
Pharmacist 4. Para 13, p.2. “So if its medicine that was used in the older adults psychiatry, you’ll 
be then looking for an older aged psychiatrist to take a lead and evaluate that, and to really guide 
his peers or her peers, in adopting those guidelines.” 
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The use of peer-led championing of guidelines is reflected in the findings of the review by 
Flodgren et al. (2011, p. 14) in which the potential role of opinion leaders, alone or in 
combination with other interventions, was identified as potentially beneficial in promoting 
evidence-based practice. This conflicts with the findings of Rashidian, Eccles, & Russell (2008, 
p. 149) in which specialists were seen to undermine guideline credibility.  
 
At present, psychiatrists are not actively engaged in the education of GPs across the health 
economy and there is a clear role for their involvement in an education outreach programme 
to improve awareness in psychiatric therapeutics which could be used as a wider 
implementation strategy for improved prescribing practice.  
 
In addition to recommending the use of a key opinion leader, Pharmaceutical Industry 
Representative 4 also detailed a multidisciplinary ‘road-show’ approach to improving guideline 
awareness and implementation (see Section 5.3.1.2). This idea was also echoed by 
Pharmacist 3 who advocated the use of a similar approach.  
 
Forsner et al. (2010a, p. 6) in their study of facilitators and barriers to guideline implementation, 
identified the need for a baseline understanding of clinical practice.  Regular audits of patient 
care delivered by the clinicians were reported to be of help in identifying ongoing important 
gaps between current care and guideline recommendations.  
 
The role of mental health pharmacists in implementing and engaging clinicians was identified 
and outlined by Pharmacist 1. 
 
 
 
 
Pharmacist 3. Para 5, p.7. “So how you how you roll it out to the end users and its almost erm 
you need to put in some leg work to allay any fears address any concerns.” 
Pharmacist 1. Para 5, p.28. “Erm, getting them engaged and working through medicines 
committees or subgroups etcetera…I think is really important…and probably...having the advent 
of mental health pharmacists….” 
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5.15.3.4 Access  
One of the facilitators for guideline adoption was identified as access, which was dependent 
on the existing technological infrastructure. Pharmacist 1 identified the importance of 
technology as a means embedding evidence-based prescribing practice.  
 
5.16 Working practice 
Pharmacists discussed the working relationship between primary and secondary care and 
identified ways in which communication could be improved to deliver better patient care. The 
theme of working practice also considers the historical and potential future working 
relationship with the pharmaceutical industry and its relevance in the new NHS.   
 
A key issue that was identified from this study was the communication between primary and 
secondary care; there were two main issues that were identified; first the speed at which 
information was disseminated from mental health services to primary care and secondly the 
quality of the information that is communicated. Pharmacist 4 summarised the issues of 
communication below: 
While GPs are involved in the care of people with serious mental illness there is evidence to 
suggest that for service users  in contact with secondary mental health services, the relational  
and cross boundary continuity of care are poor (Reilly et al., 2012, p. 1).  
 
Pharmacist 1. Para 4, p.15. “but the whole point of formularies is that you’ve got to get that 
across to your person on the ground and this is where things like IT comes in.” 
Pharmacist 4. Para 3, p.13. “communication of the…the care plan…particularly around the 
prescribing.” 
Para 3, p.13. “they’re not always a connect between the two in terms of immediacy of the 
information…so you have situations where patients have been sent for lithium blood checks in the 
community, because they can’t find the latest result they had from the hospital.” 
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At present in the Walsall borough of the trust, prescribers have access to any blood monitoring 
results undertaken in primary care; but due to the limitations of the technological infrastructure, 
there is limited access in Dudley. The issue of transferring information between healthcare 
settings is identified in the following extract: 
With the current technological infrastructure, it is possible that service users will receive 
duplicate therapeutic drug monitoring, as well as biochemical monitoring, or potentially not 
receive appropriate monitoring. The problem of inappropriate monitoring has been identified 
by national audits such as the National Audit of Schizophrenia (NAS) and the Prescribing 
Observatory for Mental Health (POMH) audit findings (Patel et al., 2014, p. 507; Barnes & 
Paton, 2011, p. 330). 
 
As part of a national move to improve the continuity of care for patients, changes to the 
2015/16 NHS standard contract for NHS Trusts were introduced in October 2015. One of the 
changes required NHS providers to send discharge summaries within 24 hours of discharge 
to GP practices. These discharge summaries include information on prescribed medicines, 
which supports the timely supply of information to primary care colleagues, and the process 
of medicines reconciliation across the health economy.  
 
5.16.1 Engagement with the pharmaceutical industry  
All the interviewed pharmacists were suspicious of the pharmaceutical industry. They believed 
that the industry’s sole agenda was to increase its profit margins.  Despite these views there 
was an acknowledgement of the inevitability of joint working with them.  
Pharmacist 1 was particularly cynical of the pharmaceutical industry and at times had refused 
to engage with them. 
 
Pharmacist 2. Para 1, p.4. “So this transfer of information is still an issue and it has been for 
years, and you know we’re not going to solve it overnight erm obviously, the electronic transfer of 
information would be preferable in that situation to make sure that everyone has access to the full 
patient’s notes.” 
Pharmacist 1. Para 10, p.32. “Well my stock answer on this with industry is that I don’t think the 
industry understand (laughs) the NHS that well at the moment…erm…” 
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The approach of the industry in identifying and using key opinion leaders is highlighted below 
in the comment by Pharmacist 4 and links with the idea of engaging with a senior clinician. 
 
5.16.2 Joint Working with the pharmaceutical industry  
The inevitability of working with the pharmaceutical industry was expressed by Pharmacist 3, 
who linked the idea of trying to implement services with the resources available from the 
industry.  
One way in which the industry could support service users with enduring mental illness is to 
facilitate education to enable individuals to understand and manage their own health care,  
which has been demonstrated to be problematic for them (Mitchell et al., 2012, p. 437; Weiden 
et al., 2004, p. 55).  
 
The potential support in achieving improved physical health was identified by Pharmacist 3.  
In a broader context, Pharmacist 5 identified the need to collaborate with the pharmaceutical 
industry to enable the UK to continue to access new drugs.  
Pharmacist 3. “I think there are things that…they can support if you want…some of the physical 
health monitoring stuff they can give you some sort of steerage...you will have to use the pharm 
industry to pay for some of the initiatives that you want to do.” 
Pharmacist 5. Para 1, p.13. “If we don't collaborate and don't work with them and don't start to 
develop things such as value based pricing, the UK in terms of sales, doesn't matter. You know, it's 
smaller than Florida, much smaller. So you know, why do we matter in the global scale of things? 
So if we don't start to engage, I think there is a risk.” 
Pharmacist 4. Para 2, p.18. “What industry can be very good at, or maybe very bad at is picking 
off the people that they think are going to support them…the loudest voices, the biggest players 
who then put an extra pressure on committees to see things going through.” 
Pharmacist 3. Para 3, p.12. “I think in some way that we’ve got to go because... they’re the 
people who’ve got the money and can help you implement certain things so.” 
Para 3, p.13. “I do think that you wouldn’t progress if you didn’t have them working with you so 
you know sometimes.” 
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Despite these concerns there is an acknowledgment that new drug therapies are not 
particularly innovative (Barral, 1995, p. 21; La Revue Prescrire, 2005, p. 73), and that there is 
a paucity of mental health research (Dix, 2015, p. 210) coupled with significant publication 
bias in psychiatric clinical trials (Abraham, 2009, p. 105; Read & Cain, 2013, p. 432; Turner, 
2013b, p. 465).  
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5.17 Summary 
The main themes that emerged from interviews with pharmacists were philosophy of care, 
prescribing practice and working practice. The philosophy of care theme incorporated patient 
choice and understanding and explored the idea of efficacy from the perspective of the 
pharmacist and their interpretation of what efficacy means for a service user. While there was 
a general acceptance of the need for patient engagement, this was set in a context of 
containing prescribing costs; thus, choice was viewed within the context of NHS affordability.  
There was an acknowledgement that service users needed appropriate and timely information 
about their prescribed medication and that this should be tailored to the individual’s needs.  
 
Pharmacists had differing expectations of the role of guidelines in practice. The identified roles 
for prescribing guidelines were linked to, clinician support for decision-making, reducing 
variation in clinical practice and the promotion of cost-effective prescribing. Implementation of 
guidelines was also considered and barriers to implementation were linked to communication 
and underpinning technological infrastructures. Facilitators for use included the use of shared 
care protocols to support GP prescribing; ease of access to guidelines was considered an 
important aspect of implementation which was linked to the available technological 
infrastructure. The final theme of working practice explored working relationship between 
primary care and mental health services and considered the ways in which communication 
could be improved. This theme also explored the relationship with the pharmaceutical industry 
and the NHS and although pharmacists were somewhat cautious about engagement, there 
was some acknowledgement of the inevitability of a working relationship based on the financial 
constraints facing the NHS. 
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5.18 General practitioners 
The interviews with GPs were conducted over the period of December 2013 to November 
2014. Gaining access to interview GPs proved to be difficult and in one case the interview had 
to be scheduled six months in advance of the proposed interview date.  All interviewees were 
participants in area prescribing committees and of the five, two were involved in the 
commissioning of mental health services in Dudley and Walsall respectively and had a 
specialist interest in mental health.   
 
All interviews were conducted in the respective GP practices and interviews ranged from 33 
to 81 minutes in duration.  
 
Using Framework analysis three main themes and numerous sub-themes were identified 
which are presented in Figure 5.4.  
 
Figure 5.4 General Practitioner Interviews: Main themes and subthemes 
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A discussion on the main themes and subthemes which was generated from the data will be 
presented which will include: interrelationships between themes and relationships with the 
findings from previous stakeholder group interviews.  
The main themes to emerge from the interviews with GPs were: 
• Philosophy of Care 
• Prescribing practice  
• Working practice  
 
The first theme ‘Philosophy of Care’ incorporated the subthemes of efficacy and its relevance 
in clinical practice. This was related to the subtheme of patient centred prescribing practice 
which explored the patient related factors that impact on prescribing. Finally, the subtheme of 
shared-decision making was explored in relation to current prescribing practice.  
 
The second theme of prescribing practice explored the role of prescribing guidelines in clinical 
practice in relation to evidence-based practice and medicines optimisation.  The theme also 
explored the influences on prescribing practice.  
 
The third and final theme of working practice explored the working relationship between 
primary care and mental health services. This theme explored the potential ways in which 
communication could be improved to deliver improved patient care.  
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5.19 Philosophy of care 
The theme of philosophy of care explored the tension between the ideal and the reality of the 
impact of drug therapy on the individual and the intended outcomes of treatment from the 
perspective of the GP and patient; this was linked to patient-centred practice and treatments 
which reflected the individual as the recipient of care. The role of the patient in terms of the 
choice of treatment was explored in the context of current practice.  
 
5.19.1 Efficacy 
In this study efficacy, as defined by GP 3, was considered to be time-dependent and broader 
in context than symptom remission. The long-term efficacy of pharmacological interventions 
in chronic mental illness was called into question by GP 3 who had a specialist interest in 
mental health.  
Her statement implies a time dependence, which is consistent with the observations of 
Moncrieff (2009, p. 151) who has called into question the long-term efficacy of psychotropic 
medication. Furthermore, some studies of antidepressants have failed to demonstrate the 
long-term impact on suicide rates compared with controls (Khan et al., 2001, p. 113; Mann et 
al., 2005, p. 2071). In a study of relapse rates for patients with schizophrenia following 
discontinuation of antipsychotic medication, only 13% (n=6 out of 45) of participants required 
hospitalisation; which has led some to call into question the long-term efficacy of 
antipsychotics (Gitlin et al., 2004, p. 1839). Efficacy was considered in terms of specific, 
agreed outcomes by GP 4.  
GP 4. Para 3, p 7. “Well, any drug, efficacy for me, it comes down to what the problem is and 
what you're trying to get, and anything that brings you closer to your end point 
So when you're looking at antidepressants per se, if somebody's depressed, I'm looking if they're 
less depressed.” 
Para 4, p 7. “If they're bipolar I'm looking for them to have smaller swings and extremes of…well, 
it's mainly depression, their mood. And mostly it comes back from the patient's perspective in most 
drugs of what they feel.” 
Para 5, p.7. “With other things whereby three weeks down the line somebody comes back and they 
feel a bit happier, it's very difficult to know that is the antidepressant. We assume it is in many 
cases. But often I think there's much more to it than just the antidepressant, the things that have 
affected their mood.” 
GP 3. Para 5, p.5. “But really, for me I think efficacy would be to use everything effectively for the 
time being.” 
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Agreeing treatment strategies has been identified as an important aspect of creating a 
successful therapeutic relationship. Furthermore, on initiating treatment in primary care, 
treatment goals should be agreed and subject to periodic review (Ha & Longnecker, 2010, p. 
42).  Coulter, Roberts & Dixon  (2013, p. 14) in their report on long-term conditions recommend 
that patients receive copies of their care plans as part of the consultation process.  
 
A more recent onset of change in personal circumstances, employment, family support and 
education status have all been demonstrated as good prognostic indicators for remission of 
depression  (Smith-Merry et al., 2010, p. 147) hence pharmacological treatments  are part of 
a spectrum of interventions that can impact on the course of a depressive episode. Thus, the 
observation by GP 4, in not attributing the improvement in mood solely to an antidepressant 
is consistent with the evidence.  
 
Patient centred care has been promoted as a way of engaging with the individual to optimise 
outcomes with the use of medicines (Royal Pharmaceutical Society, 2013, p. 3). This coupled 
with the rise in consumerism and the expectation by service users that their needs will be met, 
(Gabe & Monaghan, 2013, p. 203), should be balanced against the limitations of 
pharmacological interventions. 
 
Thus, GP 3, who has a specialist interest in mental health, views the use of medicines as 
‘limited’ in the treatment of mental health disorders, and articulates efficacy in terms of the 
mitigation of unwanted symptoms as determined by the patient and not the prescriber.    
 
5.19.2 Patient centred prescribing  
The limitations of prescribing guidelines in the context of the individual is highlighted by GP 2 
and is related to the complexities of clinical practice; thus, the GP is required to individualise 
treatment based on the patient while at the same time being mindful of the implications for 
non-guideline based prescribing practice.  
GP 3. Para 8, p.5. “And, I think the balance in the efficacy of a tablet is to reduce unwanted, by 
the patient not by the psychiatrist, unwanted symptoms.” 
GP 2. Para 5, p.5. “and that when you’ve got a patient sitting in front of you there are all sorts of 
other things that may have to be taken into account.” 
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As previously identified in this discussion (see Section 5.4.1), in psychiatry the generalisation 
of research findings is often limited by poor supporting data and therefore harder to translate 
into clinical practice (Nierenberg, 2009, p.529).  
   
The issue of individualised versus guideline driven practice is also identified by the consultant 
psychiatrists and will be discussed later in the psychiatrist section of the results and discussion 
(see Section 5.24.1). 
 
The importance of information that is tailored to the individual and the quality of communication 
between the doctor and service user have been demonstrated to contribute to improved 
understanding  and adherence to treatment (Ha & Longnecker, 2010, p. 42;  Mitchell & 
Selmes, 2007, p. 339).  
 
GP 4 identifies the importance of communication with the patient to support their decision-
making process.  
The review by Sajatovic et al. (2004, p. 901), found that effective therapies in bipolar disorder 
occur in the context of long-term management, which incorporates a clear understanding of 
medications  their risks and benefits, as well as education about illness awareness and self-
management by the recipients of care. Thus, there is a need for GPs to understand the 
diagnoses and treatments so that there is continuity in the messages given to service users 
from specialist mental health services and primary care. This would also suggest the need for 
clear written communication from specialist services, which supports the role of the GP, in 
addition to shared-care arrangements.  
 
GP 4. Para 7, p.20. “You’ve got to always explain to a person what it's for, what the drug does 
and how it benefits them and it's got to be their choice to use it.” 
Para 2, p.21. “But the drugs aren't a punishment for you, the drugs are a gift.” 
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GP 3 posits a scenario in which a service user is intentionally non-adherent with medication 
and which incorporates the utility theory, in which the individual has made a conscious 
decision not to take medication. This then leads to an exploration with the individual to 
understand why they have decided not to take the medication.  
Distinguishing intentional non-adherence (missing or altering doses to suit one’s individual 
needs) from unintentional non-adherence (e.g. forgetting to take medication) is a critical step 
in determining pharmacological treatment success or otherwise (Mitchell & Selmes, 2007, p. 
338). Intentional non-adherence is predicted by the balance of an individual’s reasons for and 
against taking medication. The predictors of  non-adherence include: lack of efficacy, 
intolerable adverse effects, the desire to manage independently of medical intervention (self-
efficacy) and disagreement with or mistrust of healthcare professionals (Crowe, Wilson, & 
Inder, 2011, p. 900; Mitchell & Selmes, 2007, p. 339; NICE, 2009, p. 7).   
 
Seale et al. (2006, p. 2868), in their study of psychiatrists, reported that patients were, at times, 
dishonest about their medication taking behaviour; however, there was equally an 
acknowledgement by psychiatrists of strategic withholding of information about the side effects 
of medication, thus departing from the ideal of a therapeutic alliance.  
 
The communication and interpersonal skills of doctors are linked with early detection of 
potential problems which, in turn, can lead to the avoidance of a costly hospital admission and 
provide better support to service users.   
This may lead to higher-quality outcomes and better satisfaction, lower costs of care, greater 
patient understanding of health issues, and better adherence to the treatment process (Ha & 
Longnecker, 2010, p. 42). The provision of a patient centric consultation is also set in the 
context of a limited timeframe for engagement with the individual and this was a concern that 
GP 3. Para 1, p.8. “People do things for a reason, or they don’t do things for a reason.” 
Para 2, p.8. “I know you’re really not taking it, and there are many reasons for that, why you 
might not be taking it.” 
Para 2, p.8. “Normally if you’re forgetting to take it it’s because deep down you don’t want to be 
on this medication, and there are reasons for that.” 
GP 5. “but then having a consultation with a patient and another 20/30 percent of the people the 
problems have been resolved talking to the doctor.” 
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was expressed by service user 5, who acknowledged that she would feel guilty to ‘take up the 
doctors time’ (see Section 5.10.1).  
 
5.20 Prescribing practice 
The theme of prescribing practice explores the role of prescribing guidelines and their impact 
on clinical practice as well as the factors driving their use. The theme also explored the factors 
that influence prescribing practice in primary care. 
 
5.20.1 The Role of prescribing guidelines 
The role of prescribing guidelines as decision support tools for practitioners was identified by    
GPs and was viewed as a mechanism for promoting evidence-based practice.  They were 
viewed as part of a mechanism to improve the quality of care and identifying outlying 
prescribing practice.  
Field & Lohr (1990, p. 58) cite the role of guidelines in supporting patient decisions about 
appropriate health care; however, despite this notion, none of the GPs identified the role of 
prescribing guidelines in the context of patient support.  
 
There was an inherent expectation that specialists had reviewed the evidence and that the 
prescribing guidelines represented the distillation of that evidence.  
The theme of consistency in prescribing practice was also identified by GP 2.  
The use of prescribing guidelines was viewed as a mechanism for review of patients with 
enduring mental illness in a primary care setting. This is particularly important for primary care 
clinicians who are responsible for treating individuals with enduring mental illness.  
GP 1.  Para 4, p.2. “I think prescribing guidelines basically will help a GP to improve the quality 
of prescribing, based on up to date current medical knowledge, which has been tried and tested, in 
general, and the GP will adhere to good practice.” 
GP 2. Para 3, p.2. “I think it provides a consistency throughout the borough and the practice and 
obviously, the clusters of practices.” 
Para 3, p.2. Enables us to hopefully manage people just in primary care as well, often without 
perhaps needing to make secondary care referrals.” 
Para 3, p.2. “but I suppose in the remit of drugs and psychiatry in particular it’s useful to have a 
sort of framework of regular review.” 
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Despite the use of prescribing guidelines; continuity of care across health economies, remains 
poor for a substantial proportion of service users (Reilly et al., 2012, p. 5). Thus, guidelines 
were viewed as a mechanism to facilitate communication between mental health services and 
primary care. 
 
GP 3 detailed the tension between her own experiences and the guideline recommendations 
which was alluded to by GP 1, who also had a specialist interest in mental health.  
GPs viewed consultations with patients as more complicated than their portrayal in guidelines; 
which is consistent with the findings of Carlsen, Glenton, & Pope, (2007, p. 973), in which 
guidelines were viewed as lacking flexibility to take into account the complexity of individual 
circumstances, such as multiple diagnoses, adverse effects, and individual preferences. 
 
GP 4 identified prescribing guidelines as a governance framework for prescribing practice, 
which would imply that objectively, arrangements are in place to monitor prescribing practice; 
however, while this is important there is an inherent problem of trying to identify objective 
quality indicators to demonstrate clinical improvement in mental health.  
5.20.2 Prescribing influences 
Patient pressure 
GP 3 reflected in her comment that patients were overly optimistic about the benefits of 
pharmacological interventions. This statement is similar to that of Pharmacist 2 in which 
patients were considered to expect a ‘magic drug’ (see Section 5.14.1). 
GP 3. Para 2, p.2. “and I think really guidelines are there to assist specifically those who may not 
be experienced in the field.” 
GP 4. Para 4, p.2. “the chance of us going down and looking at the direct literature which tells us 
about the studies that promote these drugs in the first place are going to be really, really difficult 
for us to get access.” 
GP 3. Para 7, p.7. I think patients for them, you know, can place too much optimism in a 
medication.” 
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Despite these perspectives of the perceived overt optimism in pharmacological treatment, 
there is contrasting evidence to suggest that GPs can misinterpret  patients’ expectations with 
regard to prescribing, and where consultations are conducted in a paternalistic manner,  there 
can be a tendency to fail to elicit patients’ expectations or unvoiced agendas; which can 
subsequently  result in unnecessary prescribing and poor adherence  (Little et al., 2004, p. 3). 
The findings contrast with that of the study by  Lewis & Tully, (2011, p. 8) in which hospital 
doctors reported pressure to prescribe from patients, relatives, or carers and in some cases  
gave in to demands to maintain good relations with patients. The complexity of experiencing 
pressure to prescribe also stemmed from circumstances particularly relevant to secondary 
care, such as prescribing to avoid conflict in the multidisciplinary team.  
 
Key Opinion Leaders 
Adoption of guideline recommendations by specialists have been shown to be positively  
influenced by key opinion leaders (Tansella & Thornicroft, 2009, p. 284). Although Rashidian 
et al. (2008, p. 149) identified a limitation to this approach as specialists were viewed as seeing 
‘filtered patients’ from the GP perspective. The idea of specialist promotion of guidelines 
reflects the comments made by Pharmacist 4, who advocated a role for guideline champions 
in specialist clinical areas as a means of promoting good prescribing practice (see Section 
15.14.3.3). GP 2 identifies the role of peer to peer support for prescribing of a new drug.  
 
GP 3 identifies the practice of strategic industry influence on senior clinicians in the CCG with 
a view to facilitating increased market access for their products.  
 
 
 
GP 2. Para 9, p.2. Yes.  Yes, I think peer to peer is quite useful.  You sort of naturally talk to other 
doctors that might have more experience with a particular drug and, you know – oh, this has been 
quite good.” 
GP 3. Para 9, p. 16. “I wonder really if there’s a sneaky thing about it, because if you’ve formed a 
relationship with, say, the prescribing leads for the CCG, then when it comes to arguing about 
which antidepressant, whether subconsciously they’re all affected.” 
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A further influence on prescribing was identified via the role of the practice pharmacist by GP 
2.  
The pharmacist was viewed as having specialist knowledge and providing relevant medicines 
information. GP 4 identified the role of the pharmacist in reviewing the clinical trial data and 
distilling it for use in a care-pathway.   
It was clear that the advice received played a major part in influencing prescriber decision 
making; prescribers directly acted on the advice provided, and in many instances, complied 
explicitly with the advice given. 
  
The extract from GP 5 indicates the supporting role of the pharmacist and their potential to 
influence prescribing practice. 
This finding is consistent with other studies that have identified the role of pharmacists in 
influencing prescribing patterns in primary care (Rutter, Fitzpatrick, & Rutter, 2015, p. 311;  
Lowrie, Lloyd, Mcconnachie, & Morrison, 2014, p. 7).  
  
5.21 Working practice  
The theme of working practice explored the relationship between primary care and mental 
health services and the role of specialists in sharing information and education of primary 
care colleagues.  
 
5.21.1 Interface working  
GPs indicated that communication with mental health services was poor and that there was a 
lack of responsiveness to resolve emergency needs that might circumvent hospital 
GP 5. Para 2, p.9. “I am doing it jointly with the help of my pharmacist in the practice. If he 
wasn’t there I won’t be prescribing anything.” 
GP 2. Para 10, p.4. “And also possibly a number on that where, if we’re unsure about something 
we can go for advice, so the pharmacy advisers...” 
GP 4. Para 4, p.2. “Big pharmacy team in Walsall and they'll actually look at the research, they'll 
review it, they'll come up with a sensible pathway and that gives us a bit of security that if we're 
within that pathway we're safe.” 
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admissions. Furthermore, GPs described a ‘disconnect’ from mental health services and 
highlighted the need for meaningful engagement that would embrace numerous ways of 
communication.  
 
The comments from GP 1, who is responsible for commissioning mental health services, 
highlighted these concerns.  
In a study by Horne et al. (2001, p. 190), similar concerns were expressed by GPs regarding 
the communication of shared care arrangements and, in particular, the delay in receiving 
communication from specialised services which was perceived to have serious implications 
for patient care. 
 
Given the prevalence of mental illness, GPs are increasingly called upon to provide 
appropriate treatment that psychiatric services cannot provide alone. GP 2 highlighted the 
issue of trying to contact the mental health services for individual patient-related and wider 
system-related issues.  
This finding is particularly concerning as the GP has a role of liaison with multiple agencies on 
behalf of patients, and typically, patients find engagement with primary care less stigmatising 
than mental health services and more comprehensive, since it manages physical ailments 
along with mental health disorders (Fleury et al., 2012, p. 2). It is therefore important that 
mental health services support GPs to maintain the wellbeing of patients in primary care and 
this was identified as an area for development by Consultant 2 (See Section 5.26.1). 
 
 
 
GP 1. Para 2, p.9. “And I think the communication between secondary and primary care has to 
improve.” 
Para 2, p.9. “It has to be fast, it has to be relevant, it has to be evidence based, and it has to be 
more often, more frequent.” 
Para 2, p.9. “I personally think we should use all forms of communication, telephone, email, 
fax…personal face-to-face talk, with the secondary, primary care clinicians, like a consultant, GP 
forum for example.” 
GP 2. Para 9, p.7. “As a GP in Dudley I don’t feel at all connected to DWMH whatsoever.” 
Para 5, p.8. “When we’ve had issues and we’ve tried to meet with our local primary care mental 
health manager we’ve been stonewalled.” 
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5.21.2 Knowledge and skills transfer  
GPs expressed differing degrees of knowledge about mental health pharmacological 
interventions. GPs 1 and 3 had a remit for mental health service commissioning and therefore 
claimed to be more knowledgeable in this regard.  
 
A number of barriers have been identified in relation to diagnosis and treatment  of psychiatric 
disorders in general practice which includes a lack of knowledge, skills, and interest, and 
negative attitudes to mental health (Cook & Wang, 2010, p. 7; Fleury et al., 2009, p. 9; Jorm 
et al., 2012, p. 1036).  
 
GP 5 identified his lack of knowledge with respect to psychopharmacological treatments.  
This lack of understanding was echoed in a study by Fleury et al. (2009, p. 6) in which only a 
minority of patients were managed primarily by their GP; which was attributed to their lack of 
expertise in treating such patients. 
 
Siriwardena et al. (2010, p. 731) identified a lack of knowledge in hypnotic use and   GPs were 
found to believe incorrectly that z-hypnotics were safer to prescribe than their older 
benzodiazepine counterparts, despite the lack of evidence to the contrary. The study also 
identified that GPs had poor knowledge of psychological therapies for insomnia or their 
possible clinical benefits. 
 
GP 4 discussed the use of audit as a mechanism for measuring compliance with prescribing 
guidelines.  
This could be used as a mechanism for delivering education on prescribing practice.   
Grimshaw et al. (2004, p. 33) in their review of guideline implementation strategies, concluded 
that audit and educational input were shown to have modest effects on implementation on 
practice; however, there are two important factors that were not taken into consideration by 
GP 5. Para 8, p.13. “I am open to you; I don’t have too much knowledge about mental health 
medication.” 
GP 4. Para 1, p.15. “I'm not saying at a punishment level, but I'm saying at a level just for 
education to say you prescribe this all the time for this condition, wouldn't you be better trying this 
one.” 
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this review. The first is the omission of implementation studies in mental health and the second 
is the financial constraints on the NHS which can also act as a catalyst for changing prescribing 
practice.  
 
In a more recent study comparing interventions to enhance prescribing efficiencies,  Godman 
et al. (2010, p. 718) demonstrated that audit, in combination with other interventions, impacted 
on prescribing practice.  
 
GP 3 recommended that routine correspondence be adapted to include an education tool to 
empower GPs’ understanding of diagnosis and treatment. Such an approach is a variant of 
educational outreach. This links with the idea of GP 3 to retain more patients in primary care 
rather than referring into mental health services.  
This view was unique to her and reflects a new way of thinking amongst those interviewed; it 
is consistent with a tariff based model of payment for mental health providers in which it is 
likely to be more cost effective to treat patients closer to home.  
 
 
 
 
  
GP 3. Para 5, p.2. “And, that’s what’s needed, and when specialists take time out to actually write 
educationally within a patient’s notes.” 
Para 5, p.3. “In this practice, we are now going down the line quite heavily because of 
commissioning, is to actually seek advice rather than to refer.” 
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5.22 Summary 
One of the main themes that emerged from interviews with GPs was philosophy of care which 
explored efficacy from the perspective of the GP and the perceived patient expectations with 
respect to pharmacological interventions. Efficacy was considered in a broader context than 
pharmacological interventions and was considered as time dependent. Furthermore, the 
theme explored the tension between guideline-driven and personalised care. There were 
concerns for the individual patient’s needs coupled with the potential limitations of guideline-
driven care for complex patients.   
 
The second theme of prescribing practice incorporated the role of prescribing guidelines and 
influences on prescribing practice. Prescribing guidelines were viewed as a governance 
framework against which GPs could be assured that their prescribing practice was evidence-
based. In addition, prescribing guidelines were considered as an educational intervention in 
which clinical trial data were distilled into a usable format to guide practice. There was an 
acknowledgement that guidelines were limited in certain patient groups and of variable benefit, 
dependent on the GPs’ knowledge-base. Influences on prescribing practice were driven by 
pharmacists who were viewed as specialists and advisors; in addition, peer recommendation 
was also considered as a potential influence on prescribing practice.  
 
The final theme of working practice explored the relationship between GPs and the local 
mental health trust and the role of knowledge and skills transference between mental health 
services and primary care. There was a consensus that communication between primary care 
and mental health services was poor. The main factors contributing to this view were the lack 
of rapid access to mental health advice from within the trust and the perceived poor 
communication and integration with training and education.    
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5.23 Consultant psychiatrists  
Interviews with consultant psychiatrists were conducted over the period of December 2013 to 
April 2014 and included a Medical Director, an Associate Medical Director, a Clinical Director 
and two general Adult Psychiatrists.  All interviews were conducted on NHS sites at the 
request of participants. Interviews ranged from 46 minutes to 67 minutes.  
Using Framework analysis, three main themes and several sub-themes were identified see 
Figure 5.5.  
The emergent themes were as follows: 
• Philosophy of care 
• Prescribing practice  
• Working practice 
 
As with the GP group, the theme of ‘philosophy of care’ explored the tension between the ideal 
and the reality of the impact of drug therapy on the individual. The theme also incorporated 
the psychiatrist views on efficacy and their interpretation of the service user’s perspective in 
this regard. This theme also explored patient centred care and in particular, the role of shared 
decision-making as part of the consultation process.  
 
The second theme, ‘prescribing practice’, explored the role of prescribing guidelines in clinical 
practice in relation to evidence-based medicine and the tension between guideline driven care, 
clinical expertise and clinician freedom.  The theme also explored the influences on prescribing 
practice including the pharmaceutical industry, key opinion leaders and clinical experience.  
 
The third and final theme of ‘working practice’ explored the working relationship with primary 
care services. This theme also explored joint working with the pharmaceutical industry and 
the impact of drug development on patient care.  
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Figure 5.5 Consultant Psychiatrists Interviews: Main Themes and Subthemes  
 
5.24     Philosophy of care  
The philosophy of care theme took into consideration efficacy from the perspective of the 
psychiatrist and what they thought efficacy might mean to the individual as the recipient of 
care.  The theme also included the extent to which psychiatrists felt that shared decision-
making was relevant in clinical practice. 
 
5.24.1    Efficacy  
Efficacy was described in holistic and patient focused terms by Consultant 2 and all 
respondents associated efficacy with tolerability for the individual.  This is an important finding 
since the relationship between the clinician and the individual is one of the most important 
variables in the decision to take prescribed medication.  
Consultant 2. Para 5, p.18. “Feeling better and their lives being better, I guess. An awful lot of 
people, that’s what matters. It doesn’t matter how they rate on a scale, it matters what their 
relationships are with the family, at work, whether they’re able to do things that they enjoy doing, 
that they’re able to enjoy life, whether they’re able to go out on their own and this sort of…goals 
that are about how they’re functioning.” 
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Oehl et al. (2000, p. 84) identified the importance of the clinician’s understanding of the service 
user experience in terms of their needs, fears and experiences around medication taking.  
 
Consultant 4 identified the limitation of symptom remission in terms of the recipient of care. 
This observation is consistent with the findings from the service user interviews, in which 
symptom remission was considered only a part of personal wellbeing (see Section 5.9.4).   
An appreciation of the individual’s lifestyle is important in understanding the difference 
between poor symptom control due to lack of efficacy rather than non-compliance or a 
comorbid problem (e.g., substance misuse), which might deter the clinician from seeking a 
more effective treatment option. An understanding of the service user’s perspective on efficacy 
or well-being is part of a wider engagement which can lead to the implementation of support 
mechanisms to help a service user with limited understanding of the role of medication in 
wellbeing (Adams & Drake, 2006, p. 94).   
 
5.24.2    Patient-centred care  
The role of shared decision-making was discussed in the context of the relationship with 
service users. The response from Consultant 1, typifies a paternalistic approach to 
engagement in which the individual is dependent on the clinician or is reluctant to engage.  
The paternalistic view of the role of the clinician has been a dominant model in healthcare and 
one of the factors that has been identified as promoting patient involvement in decision-making 
is the ability to access information via the internet (Tambuyzer, Pieters, & Van Audenhove, 
2014, p. 139). The use of the internet was also alluded to by Consultant 1 (see Section 5.32.3). 
 
At the time of the interview, Consultant 1 was close to retirement and it is possible that this 
view reflects an historical approach to consultations with service users. This view of the 
historical, authoritarian approach of doctors was identified by Service Users 3 and 5, who in 
Consultant 4. Para 4, p.20. “Symptom remission is not necessarily the best thing for them.  Also it 
is their functioning, their lifestyle, impact on them, their families, risks, all these things should be 
taken into account, not only about the symptom removal or symptom change.” 
Consultant 1. Para 3, p.9. “I mean often patients don’t want to share decision making.  
They either want you to make it and they make that very clear or they’re not well enough to 
actually engage in a meaningful discussion about it.” 
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their interviews, identify the lack of treatment choice that were offered to them and the 
reluctance of doctors to engage in their treatment preferences (see Sections 5.8).  
 
Consultant 2, in her response, identifies the importance of goal-setting and varying the 
approach of the consultation to meet the needs of the individual.  
This approach is consistent with that of Adams & Drake (2006, p. 90) who note that in shared 
decision-making, “the practitioner becomes a consultant to the client, helping to provide 
information, to discuss options, to clarify values and preferences, and to support the client's 
autonomy.”  
 
Consultant 5 identifies the importance of trust as part of the therapeutic relationship. In this 
context, Hall, Dugan, Zheng, & Mishra (2001, p. 615) define trust as “the optimistic acceptance 
of a vulnerable situation in which the individual believes the clinician will care for their best 
interests.” 
Bezreh, Laws, Taubin, Rifkin & Wilson  (2012, p. 17) in their review concluded that, distrust of 
doctors’ recommendations about medications may be more widespread than doctors 
perceive, but that this distrust is not always expressed. This is consistent with the findings 
from this study in which service users have chosen for a variety of reasons not to express their 
concerns regarding prescribed medication to their psychiatrist (see Section 5.8).  
The review recommends that doctors encourage their patients to express dissent and even 
mistrust about medications and medical practice. This is an important recommendation and 
one that challenges the paternal model of the doctor-patient consultation.  
 
Consultant 5. Para 9, p.11. “Yes, definitely.  It’s all about trust, it’s all about people will take 
medication from people that they like, that they trust, and that they share the decision with.” 
Para 9, p.11. “… nearly all mental health problems are associated with fear, so the more 
information you give somebody, the more you empower them to be in the driving seat of their own 
recovery, the better the outcome generally.” 
Consultant 2. Para 9, p.7. “I do think that it’s quite worthwhile exploring with the patient 
expectations they have from medication and almost in some way it mirrors, I think, some old 
interpersonal relationship in their life.” 
Para 2, p.8. “I don’t think that one size fits all and that it’s quite individual thing how people…it’s 
important for them to be allowed to engage in a way they want to engage, but really, it varies.” 
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5.25     Prescribing practice   
The theme of prescribing practice considers the role of prescribing guidelines on clinical 
practice for psychiatrists and the influences on prescribing practice. 
 
5.25.1   Role of prescribing guidelines  
While the pharmaceutical industry representatives, pharmacists and GPs considered 
prescribing guidelines primarily in the context of promoting evidenced-based prescribing (see 
Sections 5.31, 5.14.1 and 5.20.1), this view was not reflected by the consultant psychiatrists 
who acknowledged the role of prescribing guidelines in terms of promoting evidenced-based 
practice but considered guidelines primarily as an educational tool. In addition, guidelines were 
also considered to be a support mechanism to assist the prescriber in specialist patient 
groups.  
The idea of prescribing guidelines as an educational tool is consistent with the findings in this 
study in which both pharmacists and GPs identify the importance of adherence to evidence-
based practice and the role of guidelines in its promotion (see Sections 6.14.1 and 6.21.2).  
This has also been demonstrated by other studies (Bauer, 2002, p. 139; Pulcini et al., 2011, 
p. 85; Rashidian et al., 2008, p. 232).    
 
The role of prescribing guidelines in reducing irrational prescribing practice was articulated by 
Consultant 2 and  is consistent with existing  recommendations (Bauer, 2002, p. 139). 
 
 
 
Consultant 1.  Para 3, p.7. “I think most people will use it as an aid memoir for themselves and 
for helping and training people who don’t have the knowledge so forth new doctors who are new 
to psychiatry…” 
 Para 3, p.7. “The guidance I think is particularly useful for people who have got no previous 
experience of medication prescribing practices.” 
Para 3, p.7. “I think it is also useful to have because some of the things change like prescribing 
guidance for pregnancy are always those are always useful to have because they keep changing 
and it’s something commonly GPs ring up and ask you.” 
Consultant 2. Para 7, p.7. “The risk of not having any guidance is people prescribing based on 
their idiosyncratic clinical experience that sometimes can be quite harmful, so I do think that in 
terms of risk and benefits guidelines, they’re good.” 
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5.25.2   Influences on prescribing  
Evidence was cited as the most important driving factor for influencing prescribing practice 
and, in addition, the pharmaceutical industry was cited as a determinant of prescribing practice 
which is consistent with the findings of Spurling et al, (2010, p. 22) and (Jelinek & Neate, 2009, 
p. 220). Unlike GPs, there was no reference to patient pressure or pharmacists as influencing 
prescribing (see Section 5.20.2).    
As previously acknowledged, the evidence-base for pharmacological interventions in 
psychiatry is often limited; which has led to the recommendation that clinicians lobby their drug 
regulatory agencies to be more transparent (Turner, 2013b, p. 465). Despite this 
recommendation, it is difficult to envisage this happening as there is often a mutually beneficial 
relationship that exists between psychiatrists and the pharmaceutical industry. Psychiatrists 
often benefit from industry sponsored education events and payments for acting as advisors. 
The industry values relationships with psychiatrists, especially those in a strategic role to help 
promote their products as was identified by GP 3 (see Section 5.20.2).  
 
Consultant 1 identified the role of peer support as a potential driver for influencing prescribing 
practice; this was consistent with the findings from the GP 2 who identified the role of peer-to- 
peer support for prescribing of a new drug (see Section 5.20.2).  
 
 
 
 
 
Consultant 4. Para 4, p.2. “Personally think that the greatest influence is my own views about the 
medication and the research behind and evidence behind, and also the papers or any other sort of 
work which is done by other people.” 
Para 4, p.2. “Drug companies or the pharmaceutical industry’s influence is there as well.  But I 
consider that what information and support they provide I consider it helpful rather than 
influencing me to prescribe.” 
Consultant 1. Para 5, p.3. “We have one of issues about people having  been tried on a variety of 
treatment and then there is a discussion about what colleagues would think be a good thing, what 
have colleagues found to be useful.” 
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5.26     Working practice  
The theme of working practice incorporated the role of psychiatrists in communication across 
the interface between specialist services and primary care and their role in supporting GPs. 
The theme of working practice also included the innovation in mental health therapeutics. 
Finally, this theme of working practice included the role of the pharmaceutical industry and the 
potential for joint working. 
 
5.26.1     Interface  
Consultant 2 identified the role of psychiatrists in providing specialist advice to GPs and the 
potential for prevention of referrals to specialist care. This reflects the perspective of GP 3, 
who is responsible for the commissioning of mental health services and is consistent with the 
idea of providing ‘care closer to home’ which has now become enshrined in the new model of 
healthcare delivery (vanguard sites), which is intended to help single organisations to provide 
GP, hospital, community and mental health services (See Section 5.21.2).  
 
The tension between the need for support and its provision was also identified by GP 2 who 
explained the difficulties he had encountered in obtaining advice from mental health services 
(see Section 5.21.1).  
The empowerment of GPs to manage patients with enduring mental illness is in part 
dependent on support from specialists. In the study by Horne et al. (2001, p. 192) GPs 
expressed their concerns about their lack of knowledge in relation to prescribing in specialist 
groups which was reflected in this study  by GP 5 who identified his lack of knowledge of 
prescribing in mental health (see Section 5.21.2).  
Consultant 2. Para 3, p.15. “I think maybe we can work on that and really…them and us 
getting…yeah, having some framework where we can…both of us can comfortably feel that we can 
give some prescribing advice even without referring a patient. 
I think prevent referrals to secondary care. It can also, I guess, make people, make GPs more 
empowered that they are able to manage…” 
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Consultant 5 identified prescribing costs as a concern for primary care clinicians.  
All GPs in this study reported compliance with prescribing guidelines which they claimed was 
based on promoting rational and cost-effective prescribing; this is consistent with the findings 
of a GP study of attitudes to joint treatment guidelines (Kasje et al., 2004, p. 232).  
 
5.26.2     Innovation 
The lack of innovation in pharmacological treatments is widely acknowledged in mental health 
(Light & Lexchin 2012, p. 2; Dix, 2015, para 2; Barral, 1995, p. 21; La Revue Prescrire, 2005, 
p. 73). Consultant 1 identifies the lack of therapeutic advances in psychiatry.  
Despite the acknowledgement that there is a lack of innovative drugs in development for the 
treatment of mental illness, there was also an acknowledgement that prescribing guidelines 
could impact of freedom to prescribe.  
 
The lack of innovative medicines in psychiatry was identified by Consultant 5 in the following 
statement:  
 
Consultant 5. Para 1, p.17. I was going to say prescribing costs, but the worry for primary care 
colleagues is why are you asking me to prescribe this really expensive drug for a condition where 
you can prescribe something cheaper, So, there’s the costs, prescribing the right drugs, the 
monitoring around certain medications, discharging people into primary care and how often they 
need to be reviewed, where the responsibility lies, shared care protocols.” 
Consultant 1. Para 2, p.11. “Because you know innovations in psychiatric drugs are very few and 
far between really, it’s not really as if we have a wonder drug even every 10 years really and I 
think there is a possibility you could just stagnate any pharmaceutical development if you are too 
fancy on the price.” 
Consultant 5. Para 3, p.5. “But, I think the last ten years have been notable by the fact that 
nothing’s really…apart from aripiprazole, no really ground breaking stuff.” 
Consultant 4. Para 3, p.4. “Yeah, prescribing guidelines can interfere with innovation.  People 
can be quite restrictive with regard to really trying something out, if they blindly adhere to 
prescribing guidelines.” 
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5.26.3     Joint working 
There were mixed feelings about working with the pharmaceutical industry and an 
acknowledgement that the financial pressure facing the NHS would catalyse the need for joint- 
working. Despite this view there was deep distrust of the industry and its motives, which were 
closely related to the findings from the pharmacist interviews (see Section 5.16.1). The distrust 
of the pharmaceutical industry was echoed in a recent survey of doctors (n=300) in which 75% 
viewed the industry as looking to increase their profits, with 84% of respondents calling for 
greater transparency (Megget, 2015, p. 29).   
The extract from Consultant 1 implied the notion of being used as a key opinion leader by the 
pharmaceutical industry to promote its product.  
 
Consultant 2 has an interest in clinical trials and therefore has a working relationship with the 
pharmaceutical industry in this regard.  
Her comments reflect the tension between the perceived inevitability of the working 
relationship and the distrust of the motives of the pharmaceutical industry.  
 
Despite widespread mistrust of the pharmaceutical industry and paucity of clinical trial 
evidence,  there are those that suggest that the NHS can learn from the quality assurance 
experience of the pharmaceutical industry (Nelson, 2007, p. 117).  
 
Consultant 1. 
Para 5, p.13. “I stopped seeing them because the reps would tend to say to people I have spoken 
to Dr xxxxxx about this and either he uses this drug or that.” 
Para 3, p.14. “Probably no.  I mean the finance of the NHS is going to shrink and the feeling 
currently is that outside partnerships with various voluntary, public sector, private organisations 
is the way to go.” 
Consultant 2. Para 12, p.11.  “I think we have to work with them but I’m on the other hand a bit 
suspicious, because they do have clear rein of wanting to promote their product.” 
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The idea of learning from the pharmaceutical industry in terms of research and the potential 
for joint working in this regard was identified by Consultant 4. 
  
Consultant 4.  
Para 12, p.13. “I don’t see any reason why we can’t work with the pharmaceutical industry, as 
long as you’re not going to be completely influenced by what they tell you…So I think it’s about 
utilising them appropriately and keeping them at arm’s length ….” 
Para 14, p.13. “Their research facilities, that they utilise and these days anyway, you can’t do any 
research unless it’s a large-scale research, because of the absolute nightmare about ethics 
approval and things.” 
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5.27   Summary 
The findings of the study with psychiatrists indicated that patient treatment was considered in 
terms of tolerability for the recipient of care; however, there seemed to be limited engagement 
with service users regarding the choice of medication that they are prescribed. The 
paternalistic approach to consultations was evident from one interview and the need to set 
treatment goals, coupled with the importance of trust in the psychiatrist was identified as 
factors for improved service user outcomes.  
 
Prescribing guidelines were considered an important tool in the standardisation of treatment 
and of educational importance for less experienced prescribers. This view was echoed by GP 
3 (see Section 5.20.1). Despite the merits of prescribing guidelines, psychiatrists were mindful 
that their use did not impinge on clinician freedom.  
 
All psychiatrists acknowledged the role of the pharmaceutical industry in disseminating 
information regarding clinical trials but were reluctant to acknowledge any influence on 
prescribing practice. Key factors governing prescribing practice were identified as the 
robustness of the available clinical trial data and peer-to-peer recommendations.  
 
The psychiatrists did not highlight the range of communication issues that were identified by 
their GP colleagues (see Section 5.21.1); however, there was an acknowledgement that they 
could provide specialist knowledge and support for GPs. This finding is similar to that of the 
study by Kasje et al. (2004, p. 235) in which GPs expressed the need for improved 
communication which was not reflected by specialists.   
 
There was an acknowledgement by psychiatrists, of limited developments in pharmacological 
treatments for mental health conditions. Furthermore, psychiatrists expressed concerns that 
the use of guidelines could adversely impact on innovative prescribing practice.  
 
Psychiatrists expressed similar reservations to other healthcare professionals about 
engagement with the pharmaceutical industry, however, there was an acknowledgement of 
the need for collaborative working which included support for NHS-based research.  
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5.28 Discussion 
The findings from this study reveal several factors that impact on prescribing practice and the 
potential to optimise patient care. These involve service delivery models, healthcare 
professional attitudes, the influences on their practice and patient related factors.  
The research aimed to explore the extent to which service users perceive they are involved in 
making treatment decisions about the medication that they are prescribed. The research also 
explored the factors that influence prescribing in mental health from a range of stakeholders.  
The discussion will consider those themes that directly relate to the study objectives and will 
set them in the context of the wider body of knowledge. The research objectives are listed 
below: 
1. To explore the extent to which service users perceive they were involved in making 
treatment decisions about their prescribed medication. The research also explores the factors 
that influence the service user’s involvement in treatment decision making. 
2. To explore the perceived factors that influence prescribing from the perspective of 
healthcare professionals; consultant psychiatrists, pharmacists involved in formulary/guideline 
development across the local health economy and GP/GP commissioners and representatives 
from the pharmaceutical industry with a national or international remit.  
3.  To develop an understanding of the perceived factors that influence the implementation of 
prescribing guidelines in a mental health setting from the perspective of consultant 
psychiatrists, pharmacists involved in formulary/ guideline development across the local health 
economy, GP/GP commissioners and senior representatives from the pharmaceutical 
industry.  
4. To provide a framework of recommendations for optimising the use of medicines across the 
health economy. 
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5.28.1 Communication 
The study explored how service users obtained information about prescribed medicines and 
the extent of their engagement in the decision-making process. The findings of the study 
indicated that information was identified as a mechanism for individual empowerment and was 
viewed as underpinning person-centred care. This finding is consistent with that of Deegan & 
Drake, (2006, p. 87) who articulated a model in which the recipient of care was considered the 
expert of their own wellbeing.  
 
The service users identified various challenges in their journey towards recovery and 
highlighted growing confidence in terms of decision making and navigating their way around 
the complexities of the compartmentalised healthcare system. 
 
The need for more information, especially on the side effects of medication, was expressed 
by all service users and is consistent with the results of the national survey by Rethink, in 
which 45% of n=2222 service users believed that they did not have any choice in the type of 
medications they were prescribed, with 54% claiming to have received no written information 
about the side-effects of their psychotropic medicines (Rethink, 2006, p. 9). 
 
Service users identified non-adherence with treatments which was based on their analysis of 
risks versus benefits; thus, the service users regarded their own judgement as pivotal in the 
decision to take prescribed medication.  Furthermore, all service users acknowledged that 
they had experienced disagreements with their psychiatrist and that this was linked to their 
level of adherence with treatment. This finding is consistent with the review by Jimmy & Jose, 
(2011, p. 156) who concluded that poor clinician-patient communication and inadequate 
knowledge about medication and its use were factors that negatively impacted on adherence 
to treatment.  
 
The findings from this study indicate that the decision by service users not to take medicines 
is often withheld from clinicians for a variety of reasons; including, not wanting to be perceived 
as non-adherent and conflict avoidance. The implications of non-disclosure would suggest the 
need for healthcare professionals to engage meaningfully and openly with service users about 
their medication taking behaviour.  Such an approach to engagement would challenge the 
legitimacy of a paternalistic model of healthcare, in which the agenda for medication taking is 
set by the healthcare professional. Furthermore, such an approach would encourage  patients 
to express disagreement and mistrust about medications and medical practice (Bezreh et al, 
2012, p. 17).   
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Thus, it may be necessary to invite shared decision-making overtly into the consultation with 
individuals and to encourage disclosure of opinions that may be perceived as taboo or 
threatening to the healthcare professional.  
 
The findings from this study suggested that individuals welcomed a collaborative 
communication style by the clinician which facilitates enhanced service user knowledge of the 
medication. Such an approach has been demonstrated to improved satisfaction with 
medication and improved reliability of medication use (Mitchell & Selmes, 2007, p. 340).  
 
Service users identified psychiatrists as their primary point of contact for information on 
prescribed psychotropic medicines, however information was sought from alternative sources 
such as the internet or peers. The findings from the study suggest that psychiatrists were 
considered a more reliable source of information than either the internet or other service users; 
however, there was an acknowledgement of triangulating information obtained from 
psychiatrists which is reflective of consumeristic behaviour, rather than the trusting behaviour 
that often assumed by clinicians (Mather, Baker, & Laugharne, 2012, p. 166). This finding has 
important implications for service delivery as healthcare providers need to ensure that 
communication about medication is open, honest, informative, bidirectional and that there is 
consistency in messages between healthcare professionals and organisations providing 
healthcare (Bezreh et al., 2012, p. 17). 
 
The limitations of the timeframe for engagement during a consultation was identified by service 
users and healthcare professionals alike and were viewed as negatively impacting on the 
delivery of key messages promoting the optimisation of medicines. 
 
5.28.2 Choice and medication 
Service users expressed dissatisfaction with the lack of choice that they were offered,  which 
is consistent with the findings from other studies indicating that there is a substantial gap 
between service users’ preferences for information and their actual involvement in decision-
making (Ford, Schofield, & Hope, 2003, p. 77; Read, 2009, p. 31; Fotaki et al., 2008, p. 182).  
The review by Entwistle, Sheldon, & Watt (1998, p. 220) identified that a substantial proportion 
of service users were insufficiently informed to be able to exercise treatment choice effectively. 
The implications of the findings from this study are that the service delivery model is not 
meeting the expectation of the service users. In an era of technological development where 
information is readily available, service users are well  placed to obtain information on 
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prescribed medicines, despite concerns about the questionable quality of that information (De 
Freitas, Falls, Haque, & Bursztajn, 2014, p. 222; Read & Cain, 2013, p. 424).  
 
Service users articulated their autonomy in a variety of ways including: silent dissent, lack of 
engagement and vocally challenging treatment recommendations proposed by healthcare 
professionals; thus suggesting the need for greater healthcare professional understanding of 
the complexities of medication taking behaviour associated with service users as suggested 
by the results of other studies (Ha & Longnecker, 2010, p. 38 ; Mitchell & Selmes, 2007, p. 
337). 
 
The autonomy of the service user as the final arbiter of the decision to take medicines is 
consistent with the study by  Woltmann & Whitley (2010, p. 33) who found that service users 
regarded their own autonomy as central to any decision-making process and therefore central 
to any shared decision-making. Their study also highlighted that when service users believed 
a clinician was making decisions for them in a paternalistic fashion, they verbally acceded to 
the clinician and did not voice their own preferences, which is consistent with the findings from 
this study. 
 
At present, there is minimal incentivisation for mental healthcare providers to offer service 
users treatment choice and while the NHS constitution affirms the individual’s right to 
treatment choice, the options are based on two caveats: NICE approval and confirmation by 
the doctor that these are appropriate for the individual. This is particularly concerning in a 
mental health context as most drugs do not have NICE approval and in effect, the NHS 
constitution affirms the role of the healthcare professional as the  final arbiter of the decision 
making process, which is in conflict with the concept of shared decision-making (Deegan & 
Drake, 2006, p. 87). A further factor which is impacting on patient choice is the increasing 
financial pressure on NHS providers to minimise prescribing costs which, is further likely to 
impede patient choice as healthcare providers focus on providing the cheapest treatment 
options.  
 
There was an acknowledgement by some psychiatrists of the need to have a dynamic flexibility 
in their engagement with service users, taking into account their mental state and experience. 
Despite this acknowledgement there was no explicit recognition of the importance of 
engagement of service users in shared decision-making.  The autonomy for shared decision 
making thus remains the domain of the clinician and the status quo of a lack of meaningful 
engagement continues. This is consistent with the findings of Hamann et al. (2009, p. 1111) 
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where psychiatrists expressed reservations  about shared decision-making with 
pharmacological treatment.  
 
5.28.3 Patient-centred care  
Service users identified the importance of supportive networks which they relied on at times 
of need. Primarily family and healthcare professionals were identified as supporting the 
wellbeing of the indiviual. The importance of supportive networks for individuals with enduring 
mental illness has been well documented. Braunholtz et al. (2006, p. 6) found that mental 
wellbeing was associated with positive family and friend relationships. The findings from the 
study by Fisher (2003, p. 3) suggest that individuals should be supported to increase family 
members’ understanding of their mental health problem. At present, the trust pharmacy team 
is actively engaged in the delivery of education sessions for service users and their carers to 
reinforce understanding about medication and the wider services available to support 
medication use, such as medication reviews by community pharmacists and medicines 
information services provided by the clinical pharmacy team. As carers often act as advocates, 
lay therapists, and confidants,  in addition to early detectors of relapse signs,  it is logical to 
support their understanding of medicines and the available support networks (Smith-Merry et 
al., 2010, p. 112).  
  
In keeping with other studies, service users expressed the desire to be offered  alternatives to 
pharmacological interventions (Smith-Merry, Sturdy, & Freeman, 2010, p. 130; Gray, Rofail, 
Allen, & Newey, 2005, p. 36).  The identification of alternative interventions to support 
wellbeing reinforces the need for healthcare professionals to be able to signpost service users 
to a range of services offering support. The findings from this study indicate that service users 
view their wellbeing in the context of a wider spectrum of interventions than is currently 
delivered by mainstream mental health services. 
 
5.28.4 Response to medication 
Several issues were identified from the study in terms of how service users identified 
medication and wellbeing. Individuals identified troubling side effects as challenging in terms 
of the impact on their quality of life. Weight gain was identified as problematic with all service 
users and was linked with discontinuation of treatment by some. This is consistent with 
findings from the literature (Oehl, Hummer, & Fleischhacker, 2000, p. 84; Weiden, Mackell, & 
McDonnell, 2004, p. 56). This is particularly concerning as the associated physical healthcare 
of service users with mental or intellectual disabilities has been shown to be inferior to that of 
patients with purely physical health diagnoses  (BMA, 2014, p. 33). The psychiatrists who were 
interviewed in this study expressed concerns about the potential impact of adverse effects on 
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service users and in turn, the therapeutic relationship with themselves. Thus, the therapeutic 
alliance was in part attributed to minimising the potential harm associated with 
pharmacological treatment. This has important implications as there is evidence to suggest 
that there are discrepancies between psychiatrists and service users in estimating the degree 
to which psychotropic medicines exert their adverse effects (Rettenbacher, Burns, Kemmler 
& Fleischhacker, 2004, p. 2871). Furthermore, explaining a medication’s full side effect profile 
can prove difficult to achieve in clinical practice and may be regarded by  doctors  as 
impractical (Seale et al., 2006, p. 2866).  Despite the challenge of disclosure, service users 
need to be supported and healthcare professionals should facilitate  an environment in which  
empowerment is more likely to occur, thus enabling individuals to optimise the use of 
medicines and recognising their expertise in “their own lives”(Williamson, 2014, p. 5). 
A complication of mental health pharmacological treatment is that there is a substantial gap  
between the efficacy of known treatments and treatment effectiveness in real-world settings 
(Sajatovic et al., 2004, p. 264; Turner, 2013b, p. 458). Thus, as was  highlighted in the CATIE 
study which compared atypical antipsychotics; many participants discontinued treatment 
because of lack of efficacy (Lieberman & Stroup, 2011, p. 770). 
 
5.28.5 Prescribing practice  
The findings from this study identified that prescribing practice was influenced by the 
complexities of the individuals that were encountered in clinical practice. It was argued by GPs 
and psychiatrists that guidelines often posed difficulties when the individual nature of patients’ 
problems did not fit with guidelines and that these standardised approaches conflict with the 
idea of patient-centred care. These findings are consistent with the meta-synthesis by Carlsen, 
Glenton, & Pope, (2007, p. 973) in which GPs described the  tension between their own 
experiences and the guideline recommendations. This finding has implications for guideline 
adoption as it is unlikely that clinicians will engage with treatment protocols that are not 
contextualised for use in a real-world setting. Thus, prescribing guidelines will require a review 
to incorporate commonly encountered comorbid disease states to support prescribing practice 
in more complex individuals.  
 
In primary care, pharmacists were identified has having a role in Influencing prescribing 
practice. This can be understood in the context of practice based pharmacists who are 
responsible for monitoring prescribing practice, which can include formulary adherence and 
expenditure as well as providing a medicines information service for GPs. This finding is 
consistent with other studies that have identified the role of pharmacists in influencing 
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prescribing patterns in primary care (Rutter, Fitzpatrick, & Rutter, 2015, p. 311;  Lowrie, Lloyd, 
Mcconnachie, & Morrison, 2014, p. 7).  
 
With the implementation of vanguard models of care, it is possible that there will be a move 
towards treating more patients with enduring mental illness in primary care; therefore, there 
will be a greater need for expertise in mental health therapeutics across health economies.   
 
Psychiatrists identified evidence as the most important factor influencing prescribing practice; 
however, when this was explored in greater detail, the source of the evidence was linked to 
information imparted by the pharmaceutical industry from whom most psychiatrists obtained 
their updates on drug developments. Thus, the influence of pharmaceutical industry is 
experienced through the dissemination of largely industry sponsored research findings, which 
in turn impacts on prescribing practice  (Jelinek & Neate, 2009, p. 220; Spurling et al., 2010, 
p. 22). 
 
5.28.6 Guideline implementation 
Several barriers were identified in implementing prescribing guidelines based on historical 
practice. The cultural barriers were linked to the process of clinical engagement during the 
development of the prescribing guideline. The findings from this study suggest the need for a 
balance between specialist and primary care input into guideline development. The need for 
wider health economy engagement in guideline development is consistent with the findings of 
the study by Rashidian, Eccles, & Russell (2008, p. 149) in which high representation of 
secondary care clinicians was seen to undermine the credibility of the guidelines themselves, 
as they were perceived as seeing ‘filtered’ patients and were associated with a lack of 
appreciation for  the patient–doctor communication in general practice. In the author’s practice, 
this creates a potential problem for mental health engagement with GPs as there are over 120 
practices across the Dudley and Walsall boroughs and engagement at an individual practice 
level would be difficult to achieve. Thus, the implementation process is dependent on the 
communication mechanisms in place across the local CCGs and the integration of pharmacy 
teams at the practice level to reinforce key messages.  
 
Another factor that was identified as a potential barrier to guideline implementation was the 
accessibility of guidelines; this is of particular concern for mental health prescribers as there 
is no electronic prescribing support to promote safe and effective practice.  The use of 
electronic prescribing reminders has been demonstrated to improved adherence to protocol 
driven algorithms for a range of mental health conditions (Milner et al., 2009, p. 1011; Forsner 
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et al., 2010a p. 5). This has important implications for service users as the physical monitoring 
associated with psychotropic use remains poorly managed in mental health and the use of 
electronic reminders could be used to support the care of patients in this regard (Patel et al., 
2014, p. 507; Barnes & Paton, 2011, p. 330).  
 
The findings from this study reinforce the need for guideline development  to strike a balance 
between being readily understood and accessible on the one hand and comprehensive 
enough to support clinical practice on the other,  as oversimplification has been demonstrated 
to impede implementation (Addington, Kyle, Desai, & Wang, 2010, p. 1328; Milner et al., 2009, 
p. 1012; Cabana et al., 1999, p. 1461; Kasje, Denig, & Haaijer-Ruskamp, 2002, p. 514). 
 
The findings from this study suggests that GPs are more inclined to adopt prescribing 
guidelines than their specialist counterparts  (Kasje et al., 2004, p. 235). It is possible that it 
will become increasing difficult in the current economic climate for mental health services to 
adopt the use of new medicines with negligible benefits over cheaper existing ones.   
 
Clinical engagement was identified as a way of promoting improved prescribing practice. This 
approach has been adopted across DWMHT and as part of a wider strategy to improve 
prescribing practice. The mental health pharmacy team is engaged in prescribing audits which 
are fed back to prescribers at various clinical forums. In addition to audits, a six-monthly review 
of prescribing practice is undertaken with each consultant team across the trust. This feedback 
includes a breakdown of findings with recommendations for change as well as feedback on 
compliance with guideline standards such as generic prescribing. Action plans are agreed with 
the consultants and progress is determined at follow-up meetings. Thus, the pharmacy team 
is actively engaged in the implementation of recommended prescribing standards across the 
trust; however, despite the educational interventions employed by the trust pharmacy team, 
in isolation there is evidence to suggest that the effectiveness of such approaches is limited 
(Bauer, 2002, p. 149).   
 
The use of key opinion leaders was identified by pharmacists and GPs’ as a potential way of 
promoting evidence-based prescribing practice across the local health economy. While such 
an approach may have merits as highlighted in the editorial by Tansella & Thornicroft, (2009, 
p. 283),  there are others that consider the use of key opinion leaders of variable effectiveness 
(Grimshaw et al., 2004, p. 64; Rashidian, Eccles, & Russell, 2008, p.149).  
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5.28.7 Medicines optimisation 
A pharmaceutical company has been approached to engage in a risk share scheme that would 
promote payment for patient outcomes.  The company was asked to agree on outcome 
measures that would be used to determine a payment tariff. If service users were maintained 
in line with the agreed outcomes, then the trust would continue to pay for the medicine; 
however, if the service user failed to respond to, or was intolerant of the medicine, then the 
trust would receive a refund from the company. Unfortunately, an agreement could not be met 
with the company in question as it stipulated that the drug should be used as a first-line agent, 
despite a lack of evidence to suggest that it was superior to existing cheaper alternatives.  
 
The findings from the interviews with GPs indicated that there was scope for improved 
communication with the trust. This led the author to develop a  joint medicines management 
CQUIN in conjunction with commissioners. The CQUIN is designed to improve communication 
between the trust, CCG and community pharmacies for service users who are treated under 
the care of the trust Crisis Resolution and Home Treatment Team. The CQUIN has led to an 
increased focus on identifying service users who are experiencing difficulties with their 
prescribed medication and relaying these issues across the health economy so that 
appropriate, supportive interventions can be made.  
 
Service user engagement in prescribing guideline development and review has become a 
routine part of policy review. In addition to this, an education programme has been developed 
with service user groups to help them understand the medicines optimisation support that is 
available across the trust and the wider health economy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
192 
 
5.28.8 Summary 
In summary, a gap was identified between the service user expectation of shared decision-
making and its delivery in clinical practice. In trying to overcome some of the difficulties 
encountered as part of the recovery process, service users adopted a range of strategies to 
manage the relationship with their psychiatrist, including: negotiation, verbal acquiescence, 
and triangulation of information received.  Service users obtained information about prescribed 
medicines from a variety of sources including other service users, the internet and healthcare 
professionals.  
 
Central to the concerns faced by healthcare professionals was the quality of the supporting 
infrastructure to deliver patient-centred care. Protocol driven care was perceived to be at 
variance with patient-centred care in more complex patients. All healthcare professionals 
acknowledged the importance of contextualising prescribing guidelines to facilitate their use 
in patients with comorbid disease states.   
 
There was a general recognition that prescribing guidelines had more of an influence on 
prescribing practice in primary care which is attributable to two factors: the non-specialist 
nature of general practice and the technological infrastructure to support prescribing practice. 
The lack of an electronic prescribing system in the mental health trust limits the integration of 
guidelines across the organisation. 
 
The current prescribing practice across the local health economy could be improved by the 
sharing of timely information between healthcare settings and by psychiatrists sharing their 
expertise with GPs to help support the care of service users in primary care. It is possible that 
this might be achieved by the implementation of new models of care in which there is greater 
integration between healthcare providers. 
 
If the full realisation of the benefits of medicines in mental health is to be realised, there is a 
need for a step change in which service users are empowered to make informed decisions 
about their treatment, taking into consideration their lifestyle and the impact of medicines. This 
will require a focus on providing relevant information on medicines to service users coupled 
with ongoing engagement with them to address any concerns they might have. Furthermore, 
to fully optimise the use of medicines, healthcare professionals will need to consider the 
evaluation of adherence to treatment as part of routine care.  
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5.29 Thematic map  
The research themes have been incorporated in Figure 5.28 which identifies the main themes 
for each stakeholder group based on Framework analysis. The diagram also identifies 
convergent and divergent themes across the stakeholder groups. 
 
 Figure 5.6 Thematic Map of the Research Themes 
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5.30 Synthesis of findings  
This research sought to explore different perspectives on prescribing practice and the potential 
for optimising care. The study therefore explored the views of: 
• Service users 
• Healthcare professionals  
• Representatives from the pharmaceutical industry 
This final sub-section of Chapter 5, presents the synthesis of the key findings, and is structured 
as follows: 
• Summary of the findings 
• Synthesis of the key findings 
• Strengths and weaknesses of the study 
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5.31 Summary of findings  
This section summarises the findings from the stakeholder groups.  
 
5.31.1 Pharmaceutical industry    
Engagement with the changing NHS landscape was a key theme that emerged from the 
interviews with representatives from the pharmaceutical industry. There was also an 
acknowledgement of a need for a paradigm shift in the current relationship, which would place 
greater emphasis on the value proposition of new products. This sentiment was expressed by 
Pharmaceutical Industry representative 3. 
 
5.31.2 Service users 
Service users expressed concerns regarding the lack of treatment choice, and low levels of 
satisfaction with timely information on prescribed medication. Furthermore, divergence 
between their treatment aspirations and those of the service providers were apparent. The 
statement from Service User 5 reveals a perspective of healthcare that is at odds with patient-
centred care. 
 
5.31.3 General practitioners  
GPs described the tensions between resource limitations and the delivery of patient-centred 
care, which was described as complex, and existing outside of guideline-driven care. GPs also 
expressed concerns over poor communication with the local mental health provider. GPs 
considered the mental health provider to be a repository of information and support.  GP 4 
identified the need for close working with the local mental health trust.  
Industry Representative 3. Para 9, p.8. “There should be less room for me too’s and that less 
drugs should get funding but that the good drugs should get funding.” 
Service User 5. Para 12, p.10. “That basically the services are not services for people, it’s a 
business.  So, it’s mainly run on a business level.” 
GP 4.  Para 4, p.30. “But when it comes to specialist drugs I think specialist should remain 
involved and I think at least we should have more community CPNs that patients have direct 
access to if they need help, quick access.”  
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5.31.4 Pharmacists 
Pharmacists considered guidelines as a means of promoting medicines optimisation. 
Guidelines were considered to have a role in supporting clinicians with decision-making, and 
reducing variation in clinical practice. Facilitators for the use of guidelines included, perceived 
benefit for the clinician and ease of access. Shared decision-making was thought to improve 
the patient-clinician relationship and increase medicine adherence.  Pharmacist 4 identified a 
link between the acceptance of a diagnosis and the subsequent need for treatment.  
 
5.31.5 Consultant psychiatrists 
Consultant psychiatrists acknowledged the importance of guidelines, however there were 
concerns raised about their potential impact on freedom to prescribe. Choice was considered 
primarily in terms of clinicians’ access to newer medicines; however, there was very little 
discussion about patient-centred choice.  Consultant Psychiatrist 1 outlined the following 
approach to shared-decision making: 
Overall, psychiatrists did not perceive a problem in communication with primary care, unlike 
GPs. In keeping with other healthcare professional groups, psychiatrists acknowledged the 
inevitably of joint working with the pharmaceutical industry, despite their reservations about 
the industries motives for collaboration (see Sections 5.16.1, 5.20.2 and 5.26.3). 
 
  
Pharmacist 4. Para 3, p.4. “it’s about they have condition X, and it’s about them and how do they 
feel about that…and these are some of the options that they can take with the pros and cons of 
doing that and they are within…sit within a prescribing guideline.” 
Consultant Psychiatrist 1.  Para 3, p.9. “if you are very worried I would say go away and think 
about it.  99% of people told to go away and think about it come back and say actually yeah, I’ll 
give it a go.” 
  
197 
 
5.32 Emergent themes from the study 
A total of 9 themes emerged from the analysis of the interviews across the stakeholder groups. 
As the emergent themes from pharmacists, GPs and consultants were the same: working 
practice, prescribing practice and philosophy of care; these professional groups have been 
amalgamated for diagrammatical representation. The colour coding denotes the stakeholder 
group from which the theme emerged. Where spheres within the diagram have more than one 
colour this denotes an emergent theme which occurred across more than one of the identified 
groups, however this does not imply convergence or divergence. The relationships between 
the emergent themes from the stakeholder groups are shown in Figure 5.7. 
 
Figure 5.7 Emergent themes from the study 
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5.33 Synthesis of findings  
The author considered an evaluation of convergent and divergent themes to explore the 
tensions and concord between the stakeholder groups, and where possible, to identify 
potential recommendations to optimise the use of medicines in keeping with the research aims 
and objectives. 
 
From the synthesis of the study four core tensions and three areas of concord arose (see 
Figures 5.8 & 5.9).  
The areas of tension were: 
• Joint working between the pharmaceutical industry and the NHS 
• Guideline versus individual driven care 
• Patient-centred care versus the realities of its delivery in a resource limited system 
• Rhetoric of service user choice versus the realities of shared decision-making in 
practice 
The areas of concord were: 
• Communication and its importance in medicines optimisation 
• The role of guidelines  
• Wellbeing and its meaning for service users 
 
The following section of this chapter will discuss the divergent and convergent findings from 
this study which will be supported with verbatim quotes from participants.  
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Figure 5.8 The Core tensions identified from the study 
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5.33.1 Joint working  
Joint working between the pharmaceutical industry and the NHS is set against a context in 
which the NHS faces unprecedented pressure to achieve improved quality and productivity 
under severe economic pressure (Ousey & Bielby, 2011, p. 153). 
 
A key tension that emerged from the study was collaborative working between the NHS and 
the pharmaceutical industry. Representatives from the pharmaceutical industry were keen to 
explore joint working and more specifically, new ways of working, especially the development 
of care-pathways, which they considered a strategic way of identifying unmet clinical needs 
within the NHS (see Section 5.5.2).  
The obvious implications of this proposed way of working is that the industry could be seen to 
be driving clinical needs based on their pharmacological portfolio. 
 
Healthcare-professionals, while acknowledging the inevitability of joint working, were cautious 
about working with the pharmaceutical industry, whom they perceived to have differing 
motives for engagement (see Sections 5.16.1, 5.20.2 and 5.26.3). 
 
Suspicions about joint working with the pharmaceutical industry have been identified based 
on conflicting priorities with the NHS (Moynihan, 2011, p. 1). While the pharmaceutical industry 
aims to maximise profits based on increasing sales of their products; the NHS aims to 
maximise population health. Furthermore, the NHS has a remit to deliver cost-effective 
prescribing which includes the use of cheaper treatments to achieve desired patient outcomes.  
 
Pharmacist 2 expressed strong reservations about joint working with the pharmaceutical 
industry and considered the agendas of both organisations to be in conflict; a view which is 
shared by Moynihan (2011, p. 1). 
Industry 1. Para 1, p.29. “Have a focus group, get people from primary care, the commissioners, 
maybe chief pharmacists, people like that, bring them all together and just try and brainstorm 
what are the opportunities for joint working in mental health?” 
 
Pharmacist 2. “I gonna put it up front...and I don’t trust them at all.  Erm their agenda is not the 
NHS agenda, it’s not the patient agenda. It is separate thing, the shareholder agenda. The sooner 
the NHS realises that and works away from them the better.” 
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Consultant 5 also expressed reservations about engagement with the pharmaceutical industry 
which was reflected in his comment below. 
Despite the acknowledgement of the industry agenda, consultant psychiatrists and GPs 
identified the potential for training and educational support from the industry (see Sections 
5.26.3 and 5.32.1). 
 
Nationally, concerns have been raised about the role of the pharmaceutical industry in medical 
education, which have been linked to the potential bias in doctors’ professional development 
(Spurgeon, 2008, p. 743). 
 
GP 3 outlined a pragmatic approach in which the NHS would engage with the pharmaceutical 
industry to their advantage.  
The observation by GP 3 is particularly relevant for GPs, who as generalists, are perhaps, 
more open to influence from the pharmaceutical industry as was demonstrated in the study by 
Muijrers, Grol, Sijbrandij, Janknegt, & Knottnerus (2005, p. 627) who identified a negative 
correlation between evidence-based prescribing and frequency of visits by pharmaceutical 
industry representatives. 
 
Pharmacists, differed from their medical colleagues, in that they did not see a key role for the 
pharmaceutical industry to support healthcare professional education. However, despite their 
deep suspicions of the industry, they did see a potential role for joint working, in which the 
industry would commit to risk-sharing schemes based on joint agreements of clinical outcomes 
with commissioners and healthcare providers (see Section 5.16).  
Consultant 5. Para 5, p.14. “I mean, obviously, the bottom line is these companies are there to 
make money, and in many cases to make lots of money, so there’s a slightly uncomfortable feel 
about getting too close, getting into bed with companies.” 
GP 3. Para 8, p.16. “and I’ve seen their shift and focus change from trying to get lead and 
champions, to prescribing their drugs into more of working with organisation.” 
Para 1, p.17. “But, we should actually play the game too, so if they’re offering loads of support, 
loads of money, loads of other things to help the organisation, our organisation, develop better 
protocols, do workshops, offer training, well don’t knock it, use it.” 
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Furthermore, pharmacists identified the potential for schemes that would lead to 
improvements in cost-effective prescribing. Thus, the pharmacists considered the contribution 
of the pharmaceutical industry to joint working in terms of direct financial benefit to the NHS 
(see Section 5.16.1). The statement from Pharmacist 1 summarised the potential financial 
gain from collaboration with the pharmaceutical industry.  
 
5.33.2 Guideline versus individual driven care 
A key finding from the study was the tension between individualisation and standardisation of 
care based on prescribing guidance. Healthcare professionals identified the difficulties 
associated with meeting the needs of individuals, whilst trying to adhere to guideline-driven 
care. Some psychiatrists acknowledged the limitations of using outcome measures that did 
not necessarily reflect important aspects of the patient experience. This point was reinforced 
by service users during their interviews (see Section 5.9.2).  
 
There was also an acknowledgement by psychiatrists in particular, that prescribing guidelines 
were of limited clinical value in difficult-to-treat patient groups which is consistent with the 
findings of Forsner et al. (2010b, p. 7). 
In the absence of evidence, a psychiatrist is likely to rely on clinical experience and guidelines 
may be of limited clinical relevance. In the study by Rashidian et al. (2008, p. 153), a lack of 
contextualisation of prescribing guidelines led some clinicians to conclude that their use was 
of minimal value.  
 
The delivery of patient-centred care is further complicated by several factors including; 
postgraduate medical education as it is estimated that the pharmaceutical industry sponsors 
about 60% of training (Spurgeon, 2008, p. 743). Thus, in addition to the paucity of robust 
evidence in psychiatry and industry influenced postgraduate medical education, the ability to 
Pharmacist 1. Para 9, p.36 “…a kickback back to the commissioners in terms of rebates…yeah it 
would be interesting to see if mental health companies are looking at rebates…” 
Consultant 1. Para 3, p.4. “I think I take it as guidance not as you have to do it and I think if you 
speak to most of my colleagues they would do the same…” 
“They would be aware of the guidance but they would also know that isn’t going to be for 100% of 
the patients.” 
Para 3, p.4. “You’ve done the first four things and actually nothing’s happened and then you are 
into stuff where there is not a lot an awful lot of evidence.” 
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deliver patient-centred care in a mental health setting is impaired. Furthermore, existing 
guidelines that do not take account of all evidence can result in suboptimal, ineffective, or 
harmful practices for service users (Woolf et al., 1999, p. 529). 
 
Pharmacist 5 identified the limitations of prescribing guidelines and acknowledged the 
importance of clinical decision making for the individual. 
The limitations of prescribing guidelines were further highlighted by Pharmacist 2 who 
identified the importance of considering the individual’s co-morbid disease state.  
The observation by Pharmacist 2 is consistent with the findings of Davis & Taylor-Vaisey 
(1997, p. 412) who identified co-morbid diseases as a contributory factor for non-compliance 
with clinical guidelines.  
 
GP 4 highlighted the limitation of prescribing guidelines, in a context of personal-goal setting 
between the GP and patient. The case identified a long-term benzodiazepine user in which an 
agreement was made with the patient to reduce rather than discontinue treatment.   
The scenario highlights the importance of adopting a patient-centred approach to prescribing 
which can be at variance with protocol-driven care. Furthermore, under certain circumstances, 
there is evidence to suggest that clinicians do not consider clinical guidance as relevant to the 
individual recipients of care (Cabana et al., 1999, p.1463).  
Pharmacist 5. Para 2, p.1. “I think we take ourselves into very dangerous territory if we say it 
mandates what they will do because obviously, we’re dealing with a patient at the end of this and 
so for me, what human beings are very good at is (particularly healthcare professionals) is making 
decisions.” 
Pharmacist 2. Para 4, p.1. “They’re not really there to be followed to a letter, because patients 
come with more than one problem and you have to account for the comorbidities.” 
GP 4. Para 1, p.9. “To me that's success for him, it's success for me. From a guidance point of 
view we failed because we're still prescribing something that we shouldn't be.” 
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Despite the reluctance to acknowledge the impact of the pharmaceutical industry influence on 
prescribing by psychiatrists; Service User 3, a former counsellor, identified prescribing trends 
in her previous professional capacity. 
The influence of the pharmaceutical industry on prescribing practice is well documented and 
is not limited to marketing alone but also includes the reporting of favourable clinical trial data 
(De Freitas, Falls, Haque, & Bursztajn, 2014, p. 219; Moynihan, 2011, p. 2; Muijrers et al., 
2005, p. 627 Turner, 2013b, p. 465; Fischer et al. 2009, p. 795). As the pharmaceutical industry 
are forbidden from direct marketing of prescription only medicines to patients in the UK, it is 
hard to correlate prescribing trends with patient preferences.  
 
5.33.3 Patient centred care   
In this study, service users have expressed a desire to be involved in treatment decision-
making and to be considered holistically in terms of the care that they receive. This is similar 
to findings of the study by Smith-Merry et al. (2010, p. 130) in which patients considered 
holistic care a key factor in their recovery from acute mental illness.  Service users identified 
the importance of treatment which met their needs and which was characterised as being non-
judgmental, empowering and pragmatic which is similar to the model of care as outlined by 
Cleary et al. (2015, p. 564).  
In this study, psychiatrists, GPs and pharmacists discussed the importance of identifying and 
recognising individual patient needs (see Sections 5.14.5 and 5.19.2). In particular, 
psychiatrists focused their attention on individualised treatments, drawing on their clinical 
expertise and experience. Pharmacists and GPs also recognised the importance of the 
individual needs, but also considered the wider health-economics of prescribing practice (see 
Sections 5.19.2 and 5.20.1).  
 
Service User 3.  Para 7, p.11. “Oh we’ve got a new drug now, because then you would see the 
referrals with this new drug.” 
Para 7, p.11. “And everybody would be on it.  Everybody would be on it.  Then, later down the 
line we’d have another new drug, and everybody would be on that.”   
Service User 4. Para 6, p.17. “So, I think, you’ve got to look at the person, not just the physical 
person, the, sort of, emotional person, look at their intellect, look at their.” 
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Representatives from the pharmaceutical industry recognised the limitations of protocol-driven 
care, and all healthcare professionals consistently discussed the limitations of guidelines in 
clinical practice (see Sections 5.3.1.1, 5.19.2 and 5.25.1). In the case of psychiatrists, whilst 
their treatment decisions were reported as individualised, in the sense that decisions were 
bespoke for each patient, it did not necessarily reflect patient preferences. It is possible that 
healthcare professionals do not view patient preferences as a fundamental issue, either 
because they do not think it is relevant, or possibly, because it may be perceived as impossible 
to engage patients who have a variety of treatment preferences.  
 
The observation from Consultant 1 would seem to suggest that most service users are ill-
equipped to make informed decisions about prescribed medication. 
A further finding from this study was that healthcare professionals discussed patient-centred 
care in the context of the time allocation for a consultation, communication and the relationship 
with the healthcare provider. However, despite the acknowledgement of the limitations of the 
existing system, it was not clear that this necessarily led to explicit attempts to understand the 
preferences and/or needs of individuals. 
 
Service User 2 describes an impersonal consultation in which she feels that she is not the 
focus of attention.  
Service User 2 identified the importance of establishing a relationship with her doctor. This 
implies the notion of a relationship which is built over time, and in which there is a shared 
knowledge that transcends the clinical presentation of the individual.  The constraints of time 
on engagement with healthcare professionals was also identified by Service User 5 (see 
Section 5.10.1).  
 
Service User 2. Para 7, p.4. “Talking to me for a start, you know, because sometimes they sit there 
and they’re typing away on their laptops as if you’re the second.” 
Para 7, p.4. “for them to get to know me, a bit about my life, so they can…if they’ve got a better 
picture of me.” 
Consultant 1. Para 3. p.9. “There are a minority at the moment although that may change, that 
are very interested and have done a lot of looking on the internet and stuff but mostly people are 
very badly informed and are worried they are going to zombies and that they are going to be 
completely changed and medication is going to do terrible things to them.” 
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Furthermore, the issue of the consultation timeframe was identified by Consultant 2 and 
Pharmacist 4. 
Pharmacist 4 identifies a connection between the consultation time and the impact on 
meaningful engagement with the individual.  
As mental illness is often associated with stigma, there is a need to consider the potential 
impact on the individual and the importance of achieving a concordant relationship between 
the service user and healthcare professional. The potential stigma associated with a mental 
illness is perhaps one causal factor in the caution of healthcare professionals to formally 
diagnosing individuals. (Lampe et al., 2012, p. 377). 
 
GP 3 alludes to a provider-centric model of care in which the effectiveness of treatments is 
based on standardised outcome metrics, which differs from the views of the individuals as the 
recipients of care.  
 
  
GP 3. Para 10, p.4. “So really, it’s like what is wellbeing for the psychiatrist, it’s that there’re not 
actively psychotic, they’re nicely sedate, they’re not jumping off the bridge.” 
Para 10, p.4. “But actually, the fact that they may be not doing anything, not going out, not happy, 
for them is not a sign of poor wellbeing.” 
Consultant 2. Para 5, p.9. “I wonder whether we don’t allow enough time to discuss which things 
are serious but which are happen really rarely, and I do think it helps people a lot.” 
Pharmacist 4.  Para 3, p.5. “I think sometimes there’s a pressure within prescribing; I mean with 
contact time that you have with the patient that you’ve got to do it all there and then because they 
might not come back.” 
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5.33.4 Choice and medication 
Health professionals recognised the role of choice in the treatment of the individual but differed 
in the extent to which they believed that treatment choice should be a routine part of care (see 
Sections 5.14.4, 5.19.2 and 5.24.2). Pharmacists considered treatment choice as secondary 
to the financial capacity of the NHS to offer such options, and as such, choice was set in the 
context of distributive justice rather than patient-centred care. This view of healthcare provision 
was linked to the roles of the pharmacists, who were involved in budgetary analysis and or 
management of drug expenditure.  
Psychiatrists identified the importance of involving patients in decision-making but 
acknowledged that the extent to which individuals can be involved, was impacted upon by 
their desire to and capacity for engagement (see Section 5.24.2).   
GPs did not consider treatment choice a primary consideration in the treatment of individuals 
with enduring mental illness.  
There are several reasons for this; it is possible that GPs are not routinely responsible for 
initiation of treatment and therefore are not able to have an initial discussion about treatment 
options. It is also possible that financial concerns are a contributory factor in limiting   treatment 
choice, as GPs are expected to manage prescribing costs. A further factor impacting on the 
GPs consideration of choice may be linked to the knowledge of the GP with respect to the 
potential treatment options and their suitability for the individual. 
Pharmacist 1. Para 14, p. 64. “I think there has to be a balance between freedom of choice and 
the needs of…well obviously, you got to balance the needs of the patient against the needs of the 
NHS, even the needs of perhaps the commissioner…” 
Consultant 3. Para 8, p.11. “When they become acutely unwell and psychotic, and particularly 
when they are detained under the Mental Health Act, that is the more difficult and tricky time for 
people to understand about their treatment plan and care plan and consent - give informed 
consent about any treatment options or interventions.”  
GP 4. Para 3, p.17. “When you're looking at it from a commissioning point of view or a practical 
point of view, from the other side, you can't give the best straight off. You've got to give what is the 
most cost effective, sensible…” 
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Service users stressed that they were dissatisfied with the extent to which healthcare 
professionals involved them in decisions about their prescribed medication (see Section 5.8). 
In particular,  service users felt that they were provided with insufficient treatment options.  
Unlike the findings from the study by Laugharne et al.  (2012, p. 500) in which service users 
described a loss of confidence in their own judgement, which negated the potential for 
treatment choice during the acute phase of their illness, the findings of this study suggest that 
service users considered choice and information as integral to their recovery (see Section 
5.8.2).  
 
Patient choice and empowerment are interlinked and complex concepts that need to be 
considered carefully, and individuals require different approaches to their involvement in care. 
The response from Service User 1, identifies the shortcomings in the existing system in which 
the recipient of care is ill-informed about her prescribed treatment. 
The findings from this study indicate that a universal approach to engagement with service 
users in terms of treatment choice is unlikely to be satisfactory. Treatment choice should 
therefore be explored with service users and consultations should be adopted to meet the 
needs of the individual.  
 
  
Service User 4. Para 16, p.7. “I would have been happier if I’d been given a few options,” 
Para 16, p.7. “Say somebody had said, well, you could take that, but the side effects might be 
that.” 
Para 5, p.8. “it wouldn’t take long just to give, say, four options to a service user.” 
Service User 1. Para 3, p.20. “But when you’re prescribed something as an inpatient, you don’t 
get the list to read, so you don’t know what the side effects are.” 
Para 3, p.20. You don’t know how they’re supposed to work, you know, so you’re just prescribed, 
this is what you’ve to take, and, you know, end of story.” 
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5.33.5 Summary of the core tensions  
This study identified a tension between guideline driven, and patient centred care. These 
tensions exist in the context of delivering pharmaceutical care across a health economy which 
contrasts with a focus on a patient-centred agenda in which patients are engaged in decision-
making and choice. 
 
5.33.6 Patient versus guideline centred care 
Healthcare professionals, in attempting to adopt a patient-centred approach by developing an 
understanding of a patient’s problem, from their own and the patient’s perspective, is 
contrasted by the health economy focus of prescribing guidelines which, standardises 
decision-making, rather than individualising it. This presents a large challenge to health 
professionals who are responsible for balancing these competing tensions between adopting 
an individualised patient-centred care whilst adhering to the culture of evidence-based 
prescribing. 
 
Prescribing guidelines are currently designed to take into consideration the pharmacological 
management of  a single disease state (Coulter, 2013, p. 21). The findings from this study 
suggests that this does not always facilitate patient-centred prescribing practice. This occurs 
for a number of reasons which include: 
 
• The complexity of presenting disease states that are often encountered in clinical 
practice which are not reflected in guidelines.  
• The service user desire for consideration of alternative therapies which are often 
excluded from protocol driven care because of the lack of supporting evidence.  
• The need for achieving distributive justice which focuses on a health economy based 
prescribing practice. 
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Comorbidities  
The complexities of prescribing in individuals with physical health conditions have been 
identified in this study (see Sections 5.9.1 & 5.19.2).  
 
The need to treat individuals with comorbid diseases is common, and will become more so as 
the population ages and survival from acute disease improves. Therefore, the management 
of people with comorbid diseases is a key challenge for healthcare providers.  Prescribing 
guidelines have an important role to play in meeting this challenge, but are constrained by the 
evidence on which recommendations are based and by their current design. 
 
The use of polypharmacy is not intrinsically inappropriate, but where patients have strong 
preferences about limiting their pharmacological treatment burden, or the impact of treatment 
on wellbeing, then prescribing guidelines should be part of a support mechanism help to 
facilitate shared decision-making.  
 
The use of prescribing guidelines may be inappropriate for individuals, and blanket 
recommendations, rather than a menu of options or recommendations for shared decision- 
making can lead to treatment that excludes patients’ preferences. Thus, consistent practice 
patterns and reduced variation may come at the expense of reducing individualised care for 
patients with specific needs (Woolf et al., 1999, p. 529).  
 
Patient education and empowerment have important implications for medication optimisation 
and the very nature of engagement with healthcare professionals (RPS, 2013, p. 35). 
Furthermore, if service users are encouraged to be more open and ‘active’, this will have 
implications for the nature of engagement with healthcare professionals who not only have to 
be able to listen but also have to be able to deal constructively with challenges. A collaborative 
approach is outlined by Consultant 5 below. 
The attitudes and skills that relate to one person ‘acting upon’ another are different from the 
attitudes and skills that are appropriate when two people are properly ‘inter-acting’ 
 
Consultant 5. Para 4, p.11. “I think once you’ve connected with patient, once you’ve earned that 
trust, and that’s tricky because the thing to do when somebody is vulnerable is don’t hurt them by 
prescribing decisions or behaviour.” 
Para 4, p.11. “It is a journey, that sounds like a cliché, but the most effective prescribing is 
prescribing that’s signed up to on both sides of the relationship.” 
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Complementary therapies  
All service users expressed the desire to be treated holistically and the use of medication was 
considered as part of a spectrum of interventions that impacted on wellbeing (see Section 
5.9.4).  The comments from Service User 1 identifies the role of supporting therapies. 
Service users have developed alternative approaches to mental health that can complement 
existing services such as self-help groups (Tait & Lester, 2005, p. 171). Complementary and 
alternative therapies and approaches have been an element of people’s recovery (Smith-
Merry et al. 2010, p. 130). One way in which prescribing guidelines could support access to 
wider services is by inclusion of references to available support services.  
  
5.33.7 Distributive justice versus individual choice  
This study identified a tension between individual choice and distributive justice. Healthcare 
providers with a responsibility for managing prescribing budgets or formulary adherence were 
more focused on optimising the use of medicines across a health economy or healthcare 
setting within the context of an allocated prescribing budget (see Sections 5.14.4 and 5.19.2).  
Service users on the other hand, highlighted the importance of choice and consideration of 
personal factors (see Section 5.8).  
 
Pharmacists are often charged with responsibility for deciding whether pharmacological 
interventions are clinically appropriate and cost-effective. Across the local health economy, 
the accountability for the management of the CCG prescribing budget is the responsibility of 
the Head of Medicines Management. At a provider level, responsibility for management of the 
prescribing budget is entrusted to the Chief Pharmacist. Thus, patient choice is set against a 
context in which those charged with managing the prescribing budgets are facing increasing 
pressure to curb prescribing costs.  
 
 
 
 
 
 
 
 
 
 
 
Service User 1. Para 2, p.13. “But normally I find talking therapies are really  quite beneficial, 
and I think just to have somebody to talk to actually helps a lot.” 
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5.33.8 Joint working vs professional independence 
A key tension that was identified from this study was the drive for collaborative working 
between the NHS and the pharmaceutical industry. Representatives from the pharmaceutical 
industry were keen to explore new ways of working with the NHS (see Section 5.5.2), however, 
pharmacists expressed concerns about engagement with the pharmaceutical industry, who 
they felt did not appreciate the financial constraints on prescribing budgets (see Section 5.16).  
 
The role of the pharmaceutical industry in education was acknowledged by all psychiatrists 
despite their acceptance of the financial motives behind the industry’s desire for collaboration 
(see Section 5.26.3). This view contrasted with that expressed by pharmacists who identified 
the potential for Joint working with the industry in terms of facilitating stakeholder engagement 
for guideline implementation and improving cost-effective prescribing.  
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5.33.9 Concordant findings  
 
The analysis of the findings from the study identified the following areas of concord: 
 
• Communication and its importance in medicines optimisation. 
• The role of guidelines in clinical practice. 
• Wellbeing and what it means for service users. 
 
Figure 5.9 outlines the key findings in which there was broad agreement across the relevant 
stakeholder groups. 
 
 
 
 
 
Figure 5.9 Convergent themes 
 
  
Convergent 
Themes 
Communication
Role of 
Guidelines
Wellbeing
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5.33.10    Communication 
There was an acknowledgement by healthcare professionals and the pharmaceutical industry 
of the need to communicate effectively with service users as the recipients of care. 
Furthermore, there was an acceptance of the need to engage with the individual and to 
promote their understanding of the role of medication in their wellbeing (see Sections 5.3.2, 
5.14.5, 5.19.2 and 5.24.2). The extract from the interview with Pharmacist 3 emphasises the 
need for patient engagement and understanding.  
The response from Pharmacist 3 implies a patient led assessment of the risks and benefits 
associated with treatment, as suggested by utility theory (Mitchell & Selmes, 2007, p. 338). 
The need for patient engagement was articulated by Service User 3 in the following extract:  
Service User 3 exercised her right to reflect on her treatment options and assumed control 
over the decision-making process which is consistent with the findings from Woltmann & 
Whitley (2010, p. 33).  
 
The findings from this study indicated that service users viewed communication with 
healthcare professionals and psychiatrists as fundamental to their care. Effective 
communication was viewed in the context of understanding the particular needs and historical 
context of the individual.  
 
 
 
 
Pharmacist 3. Para 5, p.5. “I mean why would I start all this new stuff that I don’t really 
understand.”  
Para 7, p.5. the idea is that the patient understands why it is they’re taking the medication…or the 
need to take the medication…or what it’s going to help and benefit to the…”  
Service User 3. Para 16, p.12. “I sit there and I go, can we go through it and make sure, what are 
my options, how is this going to benefit me? And sometimes I will go and see them three or four 
times before I literally take a medication.”  
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In response to a question in which service users were asked to identify key recommendations 
for healthcare professionals, Service Users 1 & 3 gave the following response: 
The responses identified the importance of being understood. Hence personalisation was 
considered an essential component of patient-centred care.  
 
The need for consistency in conveying information to service users was highlighted in the 
following extract from Consultant Psychiatrist 3 who also identified the importance of continuity 
for the recipient of care.  
This finding is consistent with the findings from other studies in which continuity of care was 
deemed an important aspect of patient care (Laugharne, Priebe, McCabe, Garland, & 
Clifford, 2012, p. 499; NICE, 2014, p. 6).  
 
GP 3 further emphasised the importance of service user engagement as part of a process 
for facilitating an understanding of the rationale for treatment, thus empowering the individual 
to review their treatment options.  
  
Consultant 3. Para 7, p.11. “We have got a continuity model here, possibly only a few places in 
the country that the same team manages them in the community or as an inpatient as well…… “ 
Para 8, p.11. “When they become acutely unwell and psychotic, and particularly when they are 
detained under the Mental Health Act, that is the more difficult and tricky time for people to 
understand about their treatment plan and care plan and consent - give informed consent about 
any treatment options or interventions.” 
Para 4, p.12. But we still, we need to continue to pursue that sort of practice to say continue to 
inform them, continue to repeatedly give them some information.” 
GP 3. Para 5, p.15. “And at the centre of it all, we're talking about…but the guidance, the patient 
should be able to follow it and understand it and understand why you've done something.” 
Service User 1.  
Para 15, p.22. “Listen to your patient.” 
Para 1, p.23. “Don’t dismiss what they’re saying offhand because it’s not toeing the party line.” 
 
Service User 3. 
Para 15, p.16. “Listening.  Listening to service users.” 
Para 1, p.17. “So I do honestly think, listening, working together with service users.” 
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5.33.11    The role of guidelines  
Despite the acknowledged limited role of prescribing guidelines in certain patient groups, there 
was broad agreement from industry representatives, GPs and pharmacists that prescribing 
guidelines acted as governance framework for practice (see Sections 5.3.1, 5.14.1, 5.20.1 and 
5.25.1). Furthermore, all professional stakeholder groups and industry representatives 
acknowledged the role of prescribing guidelines in promoting evidence-based practice and 
minimising risks to service users. Psychiatrists identified the need for prescribing guidance in 
specialist patient groups such as pregnancy (see Section 5.25.1). 
Pharmacist 4 outlines his perspective on the applicability of prescribing guidelines in the 
following comment: 
The comment by Pharmacist 4 reflects the limitations of prescribing guidelines under certain 
circumstances, e.g. in patients with comorbid disease states. This was reflected in the findings 
by Industry Representatives (see Section 5.3.3.1). 
 
Industry Representative 2 identifies the role of guidelines in the context of an aide-mémoire 
for GPs. 
The response from Industry Representative 2 identifies the role of guidelines in the education 
of the practitioner which is consistent with the findings from the pharmacist interviews (see 
Section 5.14.1) and consultant interviews in which prescribing guideline were considered as 
an educational support mechanism for less experienced doctors (see Section 5.25.1). 
Furthermore, GPs identified a role for guidelines as an educational tool and reinforcing 
expected standards of prescribing (see Section 5.21.2).  
 
Industry Representative 2. Para 4, p 11: “and you’re making a diagnosis, how can I hold every 
clinical guideline in my head.” 
 
Para 6, p 11: “How can I even hold the questioning I need to ask to get me to the right 
diagnosis?” 
Pharmacist 4. Para 4, p.1. “It’s a set of rules that would apply to the majority of patients, not 
necessarily every single one.” 
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The notion of measuring the impact of prescribing guidelines was alluded to by Industry 
Representative 4 who was a former prescribing advisor for a PCT.  
 
It is possible that this view reflects his prior experience in which practice based pharmacists 
were measured by achievement of prescribing efficiencies which directly relate to prescribing 
guideline adherence. Measuring the impact of prescribing guidelines in clinical practice is 
linked by Pharmacist 3 to corporate expectations of prescribing practice. 
Corporate expectations of prescribing in a mental health setting is often linked to cost 
containment, as the costs associated with prescribing are easily determined and are often 
measured in isolation of clinical outcomes and associated secondary costs.  
 
GP 2 outlines the role of a borough formulary, a platform against which prescribing can be 
measured which gives an assurance to the practitioner. This is consistent with the perspective 
from the pharmaceutical industry representatives (see Section 5.3.1.1) in which the role of 
guidelines are articulated in terms of a governance structure and assurance for GPs. 
 
 
 
 
 
 
Industry Representative 4. Para 4, p. I0. “I think it does have an impact, I think it should have an 
impact and it does have an impact.” 
GP 2. Para 9, p.3. “but I think sometimes having a locality formulary can be helpful because it 
can give you an idea and you’ve got the backing of that in a way.” 
Pharmacist 3. Para 2, p.1. “Lays a parameter for the organisation as to what the organisation 
expects a prescriber or their prescribing patterns to be.” 
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The role of guidelines in assurance to the individual GP was further outlined by GP 5 who had 
expressed his lack of knowledge of mental health therapeutics (see Section 5.21.2) with the 
following statement: 
Consultant 2 outlined the rationale for the use of prescribing guidelines in clinical practice in 
supporting clinical decision making. 
Constant 2 went on to rationalise the role of guidelines in mitigating poor prescribing practice 
with the following statement: 
This observation by Consultant 2 regarding idiosyncratic prescribing is consistent with the 
findings of serval national audits in which prescribing practice has not reflected national 
guidance across a range of measures, including associated physical health checks and 
inappropriate polypharmacy (Patel et al., 2014, p. 507; Barnes & Paton, 2011, p. 330). 
 
Consultant 3 summarises in the following statement the role of prescribing guidelines in the 
context of a governance framework and best practice model of care. 
 
GP 5. Para 4, p.2. “there's various things that will progress, but being in general practice you 
might not be the forefront of new introductions to things and new drugs coming out, et cetera.” 
 
Para 4, p.2. “So we also are quite dependent on guidance, so usually guidelines as to what we can 
prescribe, how we follow things and what we do.” 
Consultant 2.  Para 2, p.2. “that they’re a helpful tool to guide clinical decisions on starting 
treatment, and particularly in the situations where there is no specific reason or preference for 
only one then, just to summarise the best available evidence and, yeah, helping the decision 
making process.” 
Consultant 2. Para 7, p.7. “The risk of not having any guidance is people prescribing based on 
their idiosyncratic clinical experience that sometimes can be quite harmful, so I do think that in 
terms of risk and benefits guidance they’re good……” 
 
“…it’s good to actually have to refer to guidance so that we are not allowed to prescribe anything 
out of our clinical experience.” 
Consultant 3. Para 8, p.2. “I do think they’re relevant, yes, because I think the consistency, and 
the fact that the evidence base on which they’re generated is useful to all prescribers.” 
  
219 
 
Consultant 3 later outlines the inherent risk of prescribing outside of a governance framework. 
He also alludes to the role of prescribing guidelines in governing the physical wellbeing of the 
patient by outlining the appropriate physical healthcare of the recipient of care. 
Consultant 3. Para 3, p.9. “There’s no doubt about it, sometimes if there’s no guidance, there’s 
no reference point, there’s a risk….” 
 
“And, at least it provides certain standards, not just standards of what you prescribe, but 
standards of how you manage the response, how you treat people physically, and what monitoring 
needs are required.”  
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5.33.12   Wellbeing 
Service users expressed varying ideas about wellbeing and the potential impact of medication 
(see Section 5.9.2). There was an acknowledgement of the positive impact of medicines on 
quality of life but this was balanced against the potentially debilitating adverse effects and the 
problem of weight gain (see Section 5.9.1). These views were also reflected in the interviews 
with healthcare professionals and representatives from the pharmaceutical industry who were 
asked to consider what efficacy might mean to the recipient of care (see Sections 5.3.2, 5.14.1, 
5.19.1 and 5.24.1).  
The following is an extract from Service User 2 with regards to medication and wellbeing. The 
extract captures both the quality of life for the individual and identifies the importance of 
tolerability. 
The findings from the interviews with the consultant’s mirrors that of the service users 
themselves and is typified by the following quote from Consultant 5, in which he responds to 
a question probing him about what efficacy might mean to a service user. 
In section 5.19.1, GP 3 identifies efficacy in terms of desirable symptom remission for the 
recipient of care and makes a distinction between their desires and that of the clinician. This 
observation has important implications for patient care and medicines optimisation because it 
focuses attention on treatment goals as defined by the recipient of care. Thus, the individual 
and the practitioner share their respective information and determine collaboratively the 
optimal treatment, which is consistent with the model of shared decision making as outlined 
by Deegan & Drake (2006, p. 1637).  
 
 
Consultant 5. Para 4, p.17. “more concerned about the harm, how little this drug is going to have 
a negative impact on me, is it going to make me a zombie, over sedate.  Is it going to cause me any 
other side effects, sexual dysfunction, agitation, is it going to cause me long term damage, is it 
going to cause my physical health” 
Service User 2. Para 3, p.5. so, this medication was working for me, you know, I was quite getting 
on with my life, it didn’t make me feel doped up.” 
  
221 
 
The following extract from the interview with GP 2 outlines his perception of the patient 
perspective on wellbeing and reinforces the notion of quality of life which is linked to tolerability 
and stability for the individual. 
 
Section 5.14.1 details the findings from the pharmacist interviews in terms of what efficacy 
might mean to a service user. Pharmacists 3 and 5 considered that the service user would 
balance wellbeing with tolerability which is in keeping with the findings from the interviews 
with the service users (see Section 5.9.2). 
 
  
GP 2. Para 7, p.5. “Some form of stabilisation, good improvement, it would be tolerable, enable 
them to enjoy a better quality of life compared to when they were premorbid.” 
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5.33.13    Summary of concordant findings 
The findings from this study suggest that communication with service users was fundamental 
to a concordant relationship which facilitates the optimal use of medicines. Service users 
expressed the need to be understood holistically reflecting their value systems and required 
healthcare professionals to provide reassurance, practical advice and support (see Sections 
5.9.3 and 5.9.4).  
 
Healthcare professionals expressed the importance of continuity in conveying information to 
individuals with enduring mental illness about their medication. Furthermore, there was an 
acknowledgement of the need to empower service users to optimise the outcomes from the 
medicines they are prescribed (see Sections 5.14.5, 5.19.2 and 5.24.2). 
 
The use of prescribing guidelines was viewed in the context of promoting evidenced-based 
practice and education, especially with primary care clinicians and junior medical staff (see 
Sections 5.3.1, 5.14.1, 5.20.1 and 5.25.1). Consultants while affirming the need for prescribing 
autonomy, acknowledged the importance of guidelines in minimising poor prescribing practice. 
In particular, prescribing guidelines were considered to be of significant value in special patient 
groups where there is minimal evidence to support evidence-based prescribing (see Section 
5.25.1).  
 
The findings from this study indicated that healthcare professionals acknowledged the impact 
of adverse effects on patient perceptions of wellbeing associated with medication use (see 
Sections 5.14.1, 5.20.2 and 5.24.1). This is an interesting finding since both healthcare 
professionals and service users were aligned in the understanding that principally, recipients 
of treatment were primarily concerned with the side effect burden of the intervention and that 
the impact on symptom remission, while important, was not a primary concern.  The finding is 
typified by the following quote from GP 4. 
 
 
 
 
 
GP 4. Para 3, p.3. “the patient will want to know what we expect in terms of side effects, which 
will inform whether they are prepared to take a chance with side effects versus the efficacies of the 
treatment.” 
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5.34 Strengths and limitations of the study 
The strength of this study is that it explored prescribing in mental health from a range of 
stakeholders; which has not been undertaken previously in a single study. The relatively small 
stakeholder sample size may be considered as a limitation of this study. However, the 
emergent data were rich enough to cover a wide range of views and there was a recurrence 
of several themes which provided sufficient data for analysis. 
 
5.34.1 Healthcare professionals  
The health professionals who took part in this study agreed to do so following a request from 
the researcher; therefore, those with a clear interest in medicines optimisation, who were 
willing to take the time to participate in this study may not have been representative of the 
wider workforce. It is not known if participants who declined the invitation to take part would 
have similar experiences to those who agreed to participate. In this sense, the participants are 
unlikely to be representative of the stakeholder groups as a whole.  
 
5.34.2 Service users 
Not all participants were satisfied with their pharmacological treatment; but they had engaged 
with treatment and may have been more positive than those who did not engage. Conversely, 
those who participated may represent a more negative cohort wishing to express their 
dissatisfaction with treatment.  
 
The age of the expert by experience service user group involved in the study may also limit 
the findings. This is because all individuals in this group were below the age of 65. As mental 
health problems are present in individuals of all ages, it is possible that older participants might 
have added to the rich, descriptive data obtained from the study. It is also possible that expert 
by experience service users might not be representative of service users that are not 
strategically engaged with healthcare provision and might represent another limitation of this 
study. 
 
The heterogeneity of mental health diagnoses across the service user group may have had 
an impact on the study findings with needs and expectations varying according to diagnosis. 
 
5.34.3 Pharmaceutical industry  
Representatives from the pharmaceutical industry were chosen because of their seniority and 
strategic remit within the organisation. All industry interviewees discussed the need for joint 
working, and the exploration of new ways of collaboration with the NHS. However, despite 
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these aspirations, industry representatives at a local level are primarily driven by sales-targets. 
Thus, the views expressed by interviewees contrast with the factors driving the activity of local 
sales representatives.  
 
5.34.4 Researcher Characteristics/Identity 
As a Chief Pharmacist, the author was directly involved in guideline development and strategic 
leadership for medicines management across the trust. It is therefore possible that this may 
have had some influence on the responses received from interviewees.  
 
It is acknowledged that although the author may have held some preconceived ideas, these 
were not necessarily the same as those with direct experiences of prescribing, commissioning 
of mental health services or representation of the pharmaceutical industry. The author 
attempted to be as objective as possible throughout the data collection.  It has been argued 
that only individuals that are directly engaged as members of a group can fully understand the 
experiences of those within that group and therefore the interpretations of an ‘outsider’ in this 
case the author, may diverge from those shared experiences (Hockey, 1999, p. 220). 
 
5.34.5 Generalisability 
The findings from this study cannot be generalised to all mental health services. This is 
consistent with the research methodology which aimed to explore participant’s views and 
experiences in detail. The author has provided a rich, transparent and contextualised account 
of participant’s views to enable the reader to determine the transferability of the findings to 
their healthcare setting.   
 
5.34.6 Reflexivity  
It is possible that the researcher in the role of a Chief Pharmacist could, unintentionally, exert 
pressure on healthcare professionals and service users to participate. To minimise the 
potential influence to participate, individuals were approached on a single occasion to 
participate and were informed that their involvement was optional.  
 
It was also possible that participants felt obliged to answer in a particular manner. To try to 
elicit genuine responses, the researcher followed the interview in conversational manner 
which often meant that the interview questions were not asked in the order as outlined in the 
interview schedule. Iterative questioning, in which the participant was asked similar questions, 
enabled the interviewer to cross check prior responses and probe for detailed answers which 
would highlight potential falsehoods.    
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The author made every effort to ensure objectivity and was aware of the potential biases as 
articulated by Miles and Huberman (1994, p. 263): 
• holistic fallacy: interpreting events as more patterned and congruent than they really 
are, lopping off the many loose ends of which life is made; 
• elite bias: overweighting data from articulate, well-informed, usually high status 
informants and underrepresenting data from less articulate, lower-status ones; 
• going native: losing your perspective or your “bracketing” ability, being co-opted into 
the perceptions and explanations of local informants. 
 
In this study, the researcher repeatedly referred to the dataset when developing the themes 
during data analysis; this was subject to external scrutiny by project supervisors.   
 
Elite bias was minimised by analysing each stakeholder group separately, thus giving a voice 
to each interviewed group. Furthermore, the focus of the analysis of the interviews was based 
in part on meeting the study aims and objectives which was not dependent on the seniority of 
the individual respondent.  
 
The researcher remained aware of his perspective as a pharmacist and it is possible that the 
he exercised attributional bias.  
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Chapter 6: Conclusions 
The aim of this study was to explore prescribing practice in a mental health setting from a 
range of stakeholders using qualitative research methodology and in particular, the use of 
semi structured face-to-face interviews. Framework analysis was used to analyse the 
interview transcripts which facilitated a rich understanding of the comparisons between 
various stakeholder groups.  
 
Despite the primary objectives of the study, the analysis of the findings led to rich descriptive 
data that, in addition to addressing the initial research aims and objectives identified key 
tensions and concord between stakeholder groups.  The conclusion will detail the findings 
from the study in relation to the study aims and objectives and will summarise the core 
emergent tensions and concord based on the Framework analysis of the interviews; following 
this the conclusion will summarise the recommendations for future research and detail the 
actions for practice in relation to the research findings.  
 
6.1 Authenticity of data 
Lincoln and Denzin (2011, p. 366) cautioned that the involvement of the inquirer can influence 
the ability to speak authentically for the experience of others, which requires conscious 
attention to the influence of the inquirer. The author was mindful of the concerns as articulated 
by Lincoln and Denzin and this influenced the decision to use Framework analysis for the 
study data. The use of a variety of stakeholders is representative of the complexity of real life 
health care systems and the existence of multiple perspectives on health care. The use of the 
Framework analysis was chosen in an attempt to produce findings that were transparent and 
that could be directly linked to the study data set, in addition to meeting the research aims and 
objectives. 
 
The study incorporated a variety of differing stakeholders to ensure that the research reflected 
not only the concerns of the providers but also the recipients of care. The research was 
designed to reflect the meaning, lived experiences and perceptions of the participants. This   
was reflected in the design of the questions. Participants were asked to respond to open 
descriptions of the subject under consideration which is supportive of establishing the 
trustworthiness and authenticity of the data (Streubert and Carpenter, 2011, p. 93).  
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For example, in this study service users were asked the following:  
This question gave an opportunity to compare and contrast data with healthcare professionals 
in terms of their role in communicating to service users.  
 
The audit trail of how data were collected and analysed has been detailed in Chapter 4 of this 
thesis. The use of verbatim extracts from the data set also enable transparency from the raw 
data to interpreted meanings. The potential influence of the inquirer in authentically 
representing the views of others has been identified and addressed through the use of data 
extracts, thus highlighting the views of the various stakeholders.  
 
6.2 Meeting the study objectives  
The four key objectives from this study were as follows:  
1. To explore with service users the extent of their involvement in treatment decisions about 
prescribed medication and the factors that influence this.   
2. To explore the factors that influence the implementation of prescribing guidelines in a mental 
health setting from a range of stakeholders.  
3. To explore the perceived factors that influence prescribing in a mental health setting.   
4. To provide a framework of recommendations for optimising the use of medicines across the 
health economy. 
 
Objective 1: Exploration of involvement in decision making and factors that influence 
this 
The findings of the study suggest that service users did not consider their involvement central 
to the decision-making process and this was set within a historical context of engagement with 
their psychiatrist. The lack of engagement occurred for several reasons including; paternalism 
by the clinician, service user fear of the consequences of challenging clinician autonomy and 
a lack of awareness of their treatment options. 
 
The paternalistic role of clinicians was reinforced by one consultant who was near retirement 
at the time of the interviews. His statements were linked to an historical approach to 
consultations in which the clinicians were regarded as experts and the recipients of care were 
not regarded as experts of their own wellbeing.  
“Based on your experience, what is the most important thing that mental health professionals 
should know in order to be helpful to people using medications?” 
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This finding is consistent with that of  other reviews in which patients were regarded as passive 
recipients of care (Tambuyzer, Pieters, & Van Audenhove, 2014, p. 143; Ha & Longnecker, 
2010, p.  38). There was an acceptance by other psychiatrists that patients have embraced a 
more active role in their care, however, despite this acknowledgement, treatment choice was 
discussed in the context of available options for the psychiatrist and not the service user. This 
has important implications for service users who expressed the need to have meaningful 
engagement in their treatment options. Thus, the findings from this study would suggest that 
the needs of service users are not currently being met within the context of treatment choices.  
 
This study identified that service users were fearful of the consequences of being perceived 
as non-compliant with treatment and this was linked to reputational concerns for the individual 
as well as the potential for compulsory detention and treatment under the Mental Health Act.  
In contrast to the findings by Eliacin, Salyers, Kukla, & Matthias, (2014, p. 26), where service 
users expressed fear about their own competency to make an informed decision about their 
pharmaceutical care, participants in this study expressed a degree of confidence about making 
treatment decisions. In part, the confidence of participants in the study is related to two factors, 
the first is the length of their experience with mental health services and the second is their 
professional backgrounds as three of the service users were involved in healthcare delivery.  
 
Objective 2: Factors that influence the implementation of prescribing guidelines 
The study identified several factors that impacted on the implementation of prescribing 
guidelines in clinical practice, which included the technological infrastructure to facilitate timely 
reminders, which was present in primary care, but not in the mental health trust. Furthermore, 
GPs identified that prescribing guidelines could be used as part of a wider educational 
outreach programme which could incorporate clinical audit as part of a drive to improve 
prescribing standards.  Comprehension of clinical guidelines was identified as a potential 
barrier to successful implementation by pharmacists who suggested that this could be 
addressed by an educational outreach programme as well as focusing on a practical design 
for prescribing guidelines. Shared care agreements were also regarded as a further 
mechanism to encourage GPs to prescribe psychotropic medicines with which they were 
unfamiliar.  
 
GPs and pharmacists considered the use of peer support a suitable mechanism to facilitate 
the process of implementation as well as an educational programme detailing the rationale 
and background to the guideline development.  
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Objective 3: Factors that influence prescribing in a mental health setting 
The complexity of individuals seen in clinical practice was identified as a key factor governing 
prescribing practice by all healthcare professional groups. Individuals with comorbid disease 
states were identified as a limiting factor in implementing protocol driven care by healthcare 
professionals. GPs viewed the role of guidelines as educational and instructive in prescribing 
practice, by contrast psychiatrists acknowledged the limited influence of guidelines on their 
prescribing practice, however there was an acknowledgement that prescribing guidelines 
would influence prescribing for more junior medical staff. Psychiatrists cited evidence as the 
most important factor driving their prescribing decisions and there was minimal 
acknowledgement of the role of the pharmaceutical industry on influencing practice.  
GPs unlike their specialist counterparts, cited patient pressure as a potential influence on 
prescribing practice, this view was linked to expectations by patients that GPs would use 
pharmacological interventions to manage their presenting symptoms. 
 
Objective 4: A framework of recommendations for guideline development and practice 
  
Service Users 
The findings from the service user interviews indicated that they wanted to be engaged in 
decisions about the pharmacological treatments they receive; they felt that they were provided 
with inadequate information about prescribed medicines. As a result of these findings a 
number of steps have been taken or are in development to optimise the use of medicines for 
service users. These steps include: the use of service user groups in the revision of prescribing 
guidelines, the development of summary guidelines for service users, a continuous 
programme of educational meetings with service user/carer and voluntary sector 
organisations and the provision of counselling on medication for all inpatients prior to 
discharge from in-patient care.  
 
GPs 
During the interviews with GPs several concerns were raised which related to poor 
communication with mental health services and in particular, a lack of clarity regarding the 
monitoring associated with the prescribing of psychotropic medicines. In response to these 
findings, the pharmacy team is working with medical colleagues to develop an education 
programme for GPs in terms of physical healthcare of patients with enduring mental illness. 
Furthermore, internal newsletters that have been developed to inform, and educate healthcare 
professionals within the trust will now be made available to healthcare professionals across 
the local health economy.  
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Psychiatrists 
The author will present the findings of the study to the Associate Medical Directors of the trust. 
Emphasis will be placed on the need for rapid access of information and support by GP 
colleagues in mental health therapeutics. The author has developed a Medicines Management 
CQUIN for 2016/17 which includes a measure of the evidence detailing the provision of 
information on prescribed medication to service users. The CQUIN has also led to improved 
identification and communication with primary care for individuals who experience difficulties 
with prescribed medication.   
 
Pharmaceutical Industry 
The desire for a closer working relationship with the NHS was expressed by all representatives 
from the pharmaceutical industry. There was also an acknowledgement of the importance of 
demonstrating the ‘value-proposition’ of new medicines to the NHS and risk sharing scheme 
has been adopted with a pharmaceutical company. The author is currently working with a 
pharmaceutical company to enable service users to have their depot injections administered 
in a non-psychiatric setting, via a community pharmacy.  
 
As a result of discussions with the pharmaceutical representatives, all newly approved 
psychotropic medicines are subject to trust-wide evaluation to determine the impact on patient-
care. This information will be fed-back to all prescribers across the trust and will also be 
conveyed to commissioners for wider discussions.   
 
Pharmacists  
Pharmacists have identified the importance of prescribing guidelines as an educational tool 
and as a means of supporting evidence-based prescribing. The author will support trust-
employed pharmacists, to deliver education support and training for CCG and community 
pharmacists.  
 
The pharmacy team have been actively involved in redesigning the discharge summary to 
make more explicit the rationale for prescribed medication and any changes in prescribing 
following admission to mental health services.  
 
Trust-employed pharmacists will continue to support the evaluation of psychotropic medicines 
and will continue to work in conjunction with regional mental-health clinical pharmacists to 
support the regional work-streams aimed at improving prescribing practice.  The work-streams 
will also incorporate undergraduates from regional schools of pharmacy to support practice 
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research, but equally important, to promote and generate interest in mental health 
therapeutics. 
 
6.3 Key conclusions 
The findings from the study highlighted the complexity of decision making in prescribing 
practice. The success of patient centred care is dependent on several factors including; 
healthcare professional attitudes, healthcare provider models, patient empowerment, and 
resources such as electronic prescribing to support evidenced-based prescribing practice. The 
scarcity of timely prescribing reminders impacts heavily upon the decisions that are made 
which can have a substantial impact upon variability in treatment decisions and the ability to 
facilitate patient choice in a meaningful way.   
 
6.4 Areas of tensions 
The study identified a range of tensions between the differing stakeholder groups. These 
core tensions were: 
• Joint working between the pharmaceutical industry and the NHS. 
• Guideline versus individual driven care. 
• Patient-centred care versus the realities of its delivery in a resource limited system. 
• Rhetoric of service user choice versus the realities of shared-decision making in 
practice. 
 
Joint working between the pharmaceutical industry and the NHS 
This study identified the complexity of the relationship between the pharmaceutical industry 
and the NHS. Representatives from the pharmaceutical industry expressed the desire for more 
meaningful collaboration with the NHS. Furthermore, there was a focus on demonstrating the 
value proposition for pharmaceutical products and a need to be more closely aligned with the 
NHS infrastructure.  It was acknowledged by healthcare professionals that there was a need 
for engagement with the industry but the nature and extent of the engagement was variable 
between the differing healthcare professional groups. All healthcare professionals considered 
the industry agenda to be linked directly to increasing sales, whilst that of the NHS focuses on 
maximising health outcomes by promoting cost-effective prescribing, in this sense healthcare 
professionals felt at odds with the industry agenda. These views are reflected in the critique 
of the pharmaceutical industry by Moynihan (2011, p. 1). Pharmacists were particularly 
distrustful of the pharmaceutical industry and viewed joint working in the context of efficiency 
gains for the NHS and the potential for facilitating stakeholder engagement. This view differed 
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from those of the GPs and psychiatrists who considered the industry to be a facilitator for 
continual professional development. 
 
Guideline versus individual driven care 
The findings from this study indicate that GPs and pharmacists recognised and accepted the 
primary role of prescribing guidelines in the context of promoting cost-effective prescribing. 
This view differed from that of psychiatrists who considered prescribing guidelines as primarily 
an educational tool for more junior medical staff. Psychiatrists noted that prescribing guidelines 
were restrictive and that they should retain autonomy to prescribe outside of the governance 
framework of guideline-driven care. These finding are consistent with that of other studies in 
which specialists were more reluctant than GPs to implement guidelines in clinical practice 
(Kasje et al., 2004, p. 235; Kasje et al., 2002, p. 514). A further finding from this study was 
that there was an acknowledgement of the importance of focusing on treating the individual 
rather than adhering to guideline driven care. A key consideration from this study is that 
prescribing guidelines should be explicit about the promotion of shared-decision making with 
service users which is consistent with the recommendations of (van der Weijden et al., 2013, 
p. 855).  
 
Patient-centred care versus the realities of its delivery in a resource limited system 
The delivery of patient-centred care was set against a context of delivering prescribing within 
a governance framework. The limitations of guideline driven care was acknowledged by all 
healthcare professionals who viewed guidelines as limited in the treatment of more complex 
individuals.  
 
The nature of the healthcare professional’s interaction with the individual was a key issue for 
service users who expressed concerns that their views were not often accounted for as part 
of the consultation process. This finding is consistent with that of other studies in which 
individuals expressed concerns about not being engaged in the decision making process 
(Olofinjana, 2005, p. 370; Smith-Merry et al., 2010, p. 145).  Furthermore, service users 
expressed concerns that consultants were focused on pharmacological interventions and that 
their care was not reviewed holistically. This was in part attributed to the limited consultation 
time and the lack of continuity in engagement with individual medical staff. Thus in essence, 
the three factors impacting on the delivery of patient centred care are: 
• The style of communication by the healthcare professional, paternalistic versus a 
patient centred approach. 
• The individual as the recipient of care incorporating their needs and expectation. 
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• The service delivery model which may conflict with the healthcare professionals’ 
ideology and which can include the prescribing infrastructure, continuity of staff and 
the time allocation for engagement with patients.  
 
By addressing these tensions, the potential of pharmacological interventions to improve 
mental health well-being can be better realised.  
 
The rhetoric of service user choice versus the realities in practice 
The notion of a ‘patient’s best interest’ has often been provider led in mental health services, 
and the views of service users as experts in the understanding of their needs has often been 
overlooked. This is consistent with that of Curtis et al. (2010, p. 15), who identified in their 
review,  that knowledge is seen as the domain of healthcare professionals who determine 
what treatments are in the best interest of recipients of care.  
 
There was minimal acknowledgement from healthcare professionals about the importance of 
patient choice; there are potentially a number of reasons for this, first healthcare professionals 
have traditionally adopted a paternalistic role in treating individuals and the notion of the 
patient in the role of “consumer” is not culturally embedded in professional thinking.  
A further limitation to offering individual choice is linked to distributive justice in which the 
primary focus of healthcare professionals is based on optimising the use of medicines across 
a given population. Another potential factor that impacts on choice is the limited timeframe 
during a consultation to engage with individuals to offer sufficient choice.  
 
6.5 Areas of concord  
In addition to identifying tensions the study also identified areas of concord, these were: 
 
• Communication and its importance in medicines optimisation 
• The role of guidelines  
• Efficacy and its meaning for service users 
 
Communication 
The need for consistent and individualised communication was acknowledged by all 
healthcare professionals, representatives from the pharmaceutical industry and service users 
themselves. Service users expressed a desire for individualised care in which their concerns 
were addressed during consultation with healthcare professionals, they also noted that there 
were issues of continuity in inter-professional communication that impacted on their wellbeing.  
This is consistent with the findings of the review by Reilly et al. (2012, p. 5) in which information 
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and health economy continuity was poor for individuals with severe mental illness.  The 
findings from this study have important implications for medicines optimisation, as it is likely 
that if there is no clear agreement between the recipient of care and the healthcare 
professional then concordance will be less than ideal. Thus, the impact of medicines on 
wellbeing cannot be fully realised unless there is optimal communication with the recipients of 
care, furthermore information needs to be tailored to the individual, timely and consistent 
across healthcare settings. 
 
The role of prescribing guidelines 
All healthcare professionals considered prescribing guidelines a useful source of evidence for 
clinical practice. Furthermore, GPs considered prescribing guidelines essential to their 
educational development in mental health therapeutics. In addition to a role in educating 
doctors, pharmacist also linked the use of prescribing guidelines with the promotion of cost-
effective prescribing; a view which was shared by GPs. Conversely, psychiatrists considered 
the use of prescribing guidelines more applicable to junior member of staff, however, they 
acknowledged the importance of guidelines in supporting the treatment of more complex 
individuals. Psychiatrists also noted a role of prescribing guidelines as a benchmarking tool 
which could be used to measure practice against defined standards, thus facilitating patient 
safety. 
  
Wellbeing and its meaning for the recipient of care 
Healthcare professionals and representatives from the pharmaceutical industry were asked to 
consider the service user perspective on the association between medication and wellbeing. 
The findings from the study indicated that service users, healthcare professionals and the 
pharmaceutical industry were in broad agreement that tolerability was a key issue for 
individuals and this had to be balanced against any perceived benefits of treatment. Service 
users assessed the impact of pharmacological treatment in terms of tolerability and quality of 
life improvements which enabled them to undertake their activities of daily living. The concord 
between healthcare professionals’ appreciation of the service user perspective on the impact 
of medication and well-being has important implications for agreeing outcomes and for shared 
decision-making. Understanding the individual’s perspective is important in facilitating a 
consultation that is more in keeping with the desires as expressed by service users. The 
empathy of healthcare professionals with the service user experience is important in promoting 
shared decision making and a sense of partnership working.  
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6.6 Recommendations for future research 
The study has identified a number of tensions between stakeholder groups which warrant 
further investigation.   
 
The identification of a tension between the pharmaceutical industries desire for greater 
collaborative working with the NHS and the deep held suspicion by healthcare professionals 
of the pharmaceutical industries motives could serve as a basis for future research. This study 
focused on the attitudes of senior GPs and psychiatrists, however, future research could 
explore the views of more junior medical staff and non-medical prescribers on joint working 
with the pharmaceutical industry, the study could focus on the role of the pharmaceutical 
industry in education and training.  
 
Further research could be undertaken to evaluate the impact on patient outcomes of existing 
joint working between the pharmaceutical industry and mental health services. 
 
Considering the planned move by the pharmaceutical industry to publish details of 
sponsorship, gifts and hospitality offered to healthcare providers and commissioning bodies, 
a future study could explore the impact of publication, on the frequency and nature of the 
activity between mental health services and the pharmaceutical industry.  
 
This study identified a tension between the rhetoric of service user choice and shared decision 
making. There are two areas that need to be addressed in future research exploring shared 
decision-making and patient choice: 
• identifying different methods that can be used to explore shared decision-making and; 
• exploring the effectiveness of different ways of making decisions. 
 
Identifying patient preferences and priorities, alongside measures capturing clinical outcomes 
such as illness severity, may reveal more about the factors that patients identify as important. 
 
Identifying individuals’ needs and understanding better their perception of a ‘good’ treatment 
outcome may enhance patient satisfaction and modify healthcare professional expectations 
regarding patient outcomes.  
 
Patient-centred care versus the existing service delivery was identified as a tension in this 
study which is consistent with the findings of other studies (Seale et al., 2006, p. 2870; Smith-
Merry et al., 2010, p. 130). An ethnographic approach could be adopted in a future study to   
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explore through observing actual consultations. This approach would allow for the exploration 
of decision-making and holistic care in a more natural context than the method used within 
this study. It may also have the potential to evaluate the indirect ways that patient preferences 
may or may not influence decision making during the consultation. While such an approach 
might yield useful insights, it would not be without limitations and the incorporation of more 
‘intrusive’ measures may reduce the likelihood that professionals and service users will 
participate in such a study. 
 
In addition to the identified tensions from this study, further research could incorporate the 
findings from this study, where applicable, and determine quantitatively if implementation has 
any impact on service user care.  Furthermore, this study did not include non-medical 
prescribers as a stakeholder group because of the limited numbers in practice across the trust. 
A future study could incorporate their views and explore ways of improving prescribing practice 
across a health-economy. 
 
6.7 Practice and organisation development 
At the request of the author, the trust service user groups across the local health economy 
have been approached and an on-going programme has been developed. Pharmacists 
provide updates to these groups to promote the resources that are available to empower 
individuals to optimise the use of medicines. The pharmacy team is also actively engaged in 
communicating medicines related issues to colleagues in primary care. This is intended to 
support the individual with the transition from one healthcare setting to another and to mitigate 
the risks of future admissions to hospital due to medication. 
 
A Medicines Management Competency Framework has been developed to support nursing 
and medical staff across the trust to understand in greater detail medicines management 
standards and the role of medication in the treatment of both psychiatric and physical health 
conditions. The framework promotes an understanding of the benefits and limitations of 
prescribed medicines and empowers nurses and doctors to better engage with individuals 
about their medication.  
 
The pharmacy team is working in conjunction with colleagues from the psychology department 
to develop joint guidelines and to promote patient engagement and empowerment with 
medication taking. All service users on admission to hospital wards are offered the opportunity 
to discuss prescribed medicines with a member of the pharmacy team.  In addition to 
engagement with healthcare professionals across the trust, the pharmacy team also supports 
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Social Care staff in medicines optimisation by delivering training and education. This initiative 
supports staff who may have engagement with service users regarding medication.  
 
Pharmacy  
All members of the pharmacy team are expected to be actively involved in continual 
professional development (CPD) as required by the General Pharmaceutical Council and are 
expected to be active in delivering training and education to service users/carers, Social Care 
staff and healthcare professionals.   
 
All pharmacists are expected to undertake the Postgraduate Certificate in Psychiatric 
Therapeutics run by Aston University which is designed to support pharmacists who wish to 
specialise in mental health. The training supports the role of the clinical pharmacist in engaging 
with healthcare professionals and services users alike to promote the optimal use of 
medicines. 
 
Pharmacy technicians have become increasingly engaged in providing clinical information to 
healthcare professionals and service users. As part of a development programme, pharmacy 
technicians are actively encouraged to undertake training to support their emerging role. All 
technicians are expected to undertake the Centre for Pharmacy Postgraduate Education 
(CPPE) training on consultation skills prior to completion of the module in mental health. 
Following successful completion of this, pharmacy technicians will be supported to undertake 
clinical modules from the Aston University Postgraduate Certificate in Psychiatric 
Therapeutics.  
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Chapter 7: Reflective account  
Personal reflections  
As a pharmacist with a special interest in mental health and a responsibility for developing 
localised prescribing guidance, I was often curious about the extent to which clinicians valued 
prescribing guidance, if at all, and the perceived needs of GPs, when compared with specialist 
prescribers in a mental health setting.  Furthermore, I was intrigued at the possibility of 
considering the potential barriers and facilitators to guideline implementation across the local 
health economy. As a Chief Pharmacist, I was mindful that my own profession was often 
responsible for developing and monitoring compliance with prescribing guidance and therefore 
it was logical to include its views on how to best optimise evidence-based prescribing across 
the local health economy.  
 
Following conversations with expert by experience service users, I was intrigued at the extent 
to which they felt that their experience was central to their therapeutic journey. Several 
discussions with service users had led to the expression of dissatisfaction with the 
pharmacological treatments they had received; in particular, a lack of information on 
medication. These conversations broadened my initial research idea to incorporate the views 
and perspectives of the service users as the recipients of care, and to explore the extent to 
which they perceived involvement in making treatment decisions, and the factors that influence 
this.  
 
The inclusion of the pharmaceutical industry as part of the research, occurred after several 
conversations with representatives from various companies who expressed the need for more 
collaborative working between the industry and the NHS. The research project explored with 
representatives from the pharmaceutical industry the perceived factors that influence 
prescribing and implementation of guidelines in mental health. Also, the research explored the 
ways in which the pharmaceutical industry and the NHS can collaborate to deliver better 
patient-care. 
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Part 1- Reflections on taught component of the Doctorate 
7.1 Statistical methods (SPSS) 
The statistical module was challenging and very relevant to my practice as a pharmacist 
involved in reviewing clinical trial data. There are numerous statistical approaches that are 
adopted to demonstrate the efficacy of medicines in clinical trials and the statistical module 
was a useful revision for information that I had learned from various post-graduate studies. I 
discovered the use of YouTube as a means of supplementing information gained from 
lectures. The use of a visual means of learning was linked to the feedback on my learning 
style, which was never assessed prior to my doctoral studies. As a visual learner I was able 
to supplement formal lectures with online visual resources. 
 
7.2 Qualitative research 
As a novice researcher, I was unfamiliar with qualitative research and its underpinning 
philosophical beliefs, about values, concepts, and the nature of knowledge itself. In order to 
understand these philosophical perspectives, I read several texts, but found that definitions, 
were at times confusing. Following a discussion with a colleague, I read Patton’s Qualitative 
Research and Evaluation Methods. This text was a useful, practical, comprehensive and 
reader-friendly guide for a novice researcher and supported my learning. 
 
7.3 Publication and dissemination 
The publication and dissemination unit enabled me to think about the importance and 
relevance of publication. This was particularly important as I was involved in a regional work-
stream which was aimed at promoting and disseminating good practice amongst NHS 
employed pharmacy staff in the West Midlands.  
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7.4 Part 2 – The research project 
In some ways, the progression to Part 2 of the professional doctorate felt like a new beginning. 
In essence, I was able to focus on the goal of undertaking the research project, which was the 
primary reason for enrolling on the course.  
 
The aim of the research project was to gain an understanding of the views of a variety of 
stakeholders on prescribing practice in mental setting. It was anticipated that the findings from 
the study would lead to recommendations for improving prescribing practice.  
 
One of the challenges that had to be overcome was the engagement with the pharmaceutical 
industry and GPs in particular. The pharmaceutical industry representatives were initially 
cautious about taking part in the study. However, I decided that I would adopt the principle of 
peer pressure to encourage participation in this group. Following the first interview with the 
pharmaceutical industry representative, subsequent representatives were informed that a 
competitor had already participated, although the identity of the competitor was never 
revealed. This seemed to catalyse involvement in the study and near completion of the data 
collection, the Chief Executive of a pharmaceutical company approached me in person to 
participate.  
 
In one instance, an appointment with a GP was made 6 months in advance of the planned 
interview, due to his busy schedule. I was mindful that personal relationships which had been 
developed over a number of years were a contributory factor in agreeing to participate for 
healthcare professional and service users.  
 
This study was the first occasion in which I had undertaken qualitative research and a key 
concern was the lack of experience in interviewing subjects; despite reading several text-
books and watching numerous videos. The pilot interviews were the best way to prepare for 
data collection and they informed my approach on questioning subjects which led me to adopt 
more of a ‘conversational’ rather than ‘question and answer’ style of interviewing.  
 
7.5 Impact of the doctorate in the workplace 
The professional doctorate was the first multidisciplinary post-graduate study that I had 
undertaken. This enabled me to consider the target audience more carefully as I am often 
responsible for conveying key messages both verbal and written to a variety of healthcare 
professionals. This was also reflected in my work environment in which I would be required to 
write a variety of papers for submission at board-level that would detail the role, achievements 
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and strategic intent of the pharmacy service. The recipients of these papers would often 
include non-clinical staff and therefore prior understanding of the role of pharmacy could not 
be assumed. 
 
7.6 Professional development 
  
Throughout my career, I have enjoyed and valued the role of education and training which 
have been a key aspect of my professional development. As a resident pharmacist, I was 
faced with the challenge of providing medicines information and framing answers in a context 
based on the knowledge and experience of the recipient. The provision of information outside 
of the core working hours for pharmacy would involve information retrieval and dissemination 
swiftly, depending on the nature of the enquiry. The importance of remaining up-to-date with 
clinical knowledge was further reinforced by studying for the Clinical Diploma at Keele 
University.  
 
Following my decision to specialise in mental health, I recognised that my knowledge was 
limited in this specialism and this motivated me to study a Post-Graduate Certificate and 
Diploma in Psychiatric Therapeutics. My first role in psychiatry proved very challenging as I 
was working in a general hospital that provided a pharmacy service to the local mental health 
trust. There was both limited understanding of, and importance given for developing the role. 
In some ways, this galvanised my working relationships with colleagues from the mental health 
trust and I sought help and support for my learning from both medical and nursing colleagues 
with whom I would later meet in my role as a Chief Pharmacist.  
 
Following a period in mental health I decided that I needed to gain a differing perspective on 
healthcare provision and worked as a prescribing advisor for a PCT. This was a period of great 
professional development as I started to conceptualise the delivery of pharmaceutical care in 
terms of the health economy perspective and not the individual recipient of care. Furthermore, 
I was responsible for managing prescribing across a locality which involved close working with 
key GPs. This proved to be advantageous in future discussions with commissioners as I could 
understand the pressures they faced in managing prescribing costs.  
 
My interest in mental health was not diminished in any way and so I decided to undertake a 
Master’s degree which evaluated the impact of interventions to minimise the use of 
benzodiazepines and z-hypnotics in primary care.  During this period, I also undertook training 
to become a non-medical prescriber specialising in the management of depression and 
anxiety related disorders in primary care.  
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After three years in primary care I decided to return to my area of interest and was employed 
as the Deputy Director of Pharmacy at Birmingham and Solihull Mental Health Trust. It was 
during this period that I reviewed my ideas about research in mental health. I shared my initial 
thoughts with a colleague who helped to refine my thinking which ultimately contributed to the 
current study.  
 
My career progression has been aligned with the drive for continual learning and professional 
development. Each career move and postgraduate study has helped to shape my thinking and 
refine my ideas in terms of communication, leadership and gaps in knowledge and awareness.    
 
My professional development has been characterised by the need to challenge my own 
boundaries. Perhaps one of the most significant insights that I have gained in recent years is 
my passion for delivering education and training, which I suspect, will play an important role 
in my future career progression as well as contributing to practice-based research.  
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Appendix 1: Literature search strategy 
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Literature search strategy 
A review of the literature was undertaken using the NHS Healthcare databases advanced 
search (HDAS) to identify studies or relevant publications that would address the aims and 
objectives of the study or that would help to set a context to the New NHS following the 2012 
Health and Social Care reforms.  
The principles of a systematic review (i.e. comprehensive searches, transparency and 
consideration of study quality) were adhered to using the approach as outlined by the Critical 
Appraisal Skills Programme (CASP).   
 
The search was kept purposefully extensive to encompass the complexities of the literature 
relevant to the following aspects of the study. Any study investigating these issues was 
considered relevant: 
 
• The impact of the Health and Social Care Act and subsequent NHS reforms 
• The role of the Pharmaceutical industry and its relationship with the NHS  
• The history and role of mental health service user engagement within the NHS 
• Prescribing guidance in mental health  
 
The following databases were systematically searched in February 2014 and auto-alert 
searches were set-up to ensure new literature was identified throughout the study’s duration.  
A hand search of retrieved articles was undertaken to obtain publications of interest for 
inclusion in the review.  
 
A final search was conducted in February 2016 of the following databases: 
• MEDLINE 
• PsycINFO 
• EMBASE 
• The Cochrane Library 
• Department of Health Database 
• Health Management Information Consortium 
• Health Business Elite 
 
The search was conducted using a mix of subject headings (see examples below) and freetext 
terms. Relevant terms were combined for the differing subject headings.  
 
Individual searches were conducted on each database because of the varied subject 
coverage, indexed content, date coverage and other features such as the facility to ‘map to a 
thesaurus.’  
 
The literature searches were based on the main headings and subheadings as identified in 
the tables below, e.g. NHS Transformation, economic imperative for change, Clinical 
Commissioning Groups and payment by results.  
 
Examples are given of specific searches within each subsection of the literature review.  The 
examples highlight the use of a range of databases.  
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NHS Transformation - Database and search terms used 
Main heading & 
subheadings 
Database/ sources  Key search terms  
NHS transformation 
 
• The economic 
imperative  
 
• Clinical 
Commissioning 
Groups
 
• Payment by 
results
 
 
 
• EMBASE 
• Contacts at the DoH 
• Health Management 
Information Consortium 
• Health Business Elite 
• Medline 
 
• 5 Year forward 
view  
• Care closer to 
home 
• Care clusters 
• Clinical 
• Commissioning 
Groups 
• CQUIN 
• Devolution 
• Economics  
• General practice  
• Health and Social 
Care Act  
• Healthcare budget 
• Healthcare 
expenditure  
• Healthcare reforms 
• Healthcare quality 
• Interface 
• Mental health  
• Models of Care 
• New NHS 
• Commissioning 
• NHS reformation 
• NHS structure 
• NHS 
transformation 
• NHS vanguards 
• NHS White Paper 
• Payment by 
Results (PbR) 
• Primary care 
• Quality outcomes 
framework 
• Regulation 
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Below is an example of a search of the EMBASE database for literature relating to the 
implementation of Payment by Results in English NHS mental health providers. Similar 
searches were conducted using the Health Business Elite, Health Management Information 
Consortium and Medline.  
Payment by results (PbR) search using EMBASE 
1. EMBASE; exp REIMBURSEMENT/ OR exp 
PROSPECTIVE PAYMENT/ OR exp NATIONAL HEALTH 
SERVICE/ OR exp HEALTH CARE COST/ OR exp 
ECONOMICS/ OR exp HEALTH ECONOMICS/ OR exp 
HEALTH CARE QUALITY/ OR exp FINANCIAL 
MANAGEMENT/; 3095687 results. 
Payment by Results identified the following 
(EMTREE) index headers: 
• reimbursement        
• prospective payment         
• national health service       
• health care cost   
• economics       
• health economics       
• health care quality       
• financial management 
2. EMBASE; "payment by results".ti,ab; 268 results.  
3. EMBASE; exp COST EFFECTIVENESS ANALYSIS/ OR 
exp ECONOMICS/; 351168 results. 
Cost effectiveness identified the following 
(EMTREE) index headers: 
• Cost effectiveness analysis 
• Economics 
  
4. EMBASE; "price tarif*".ti,ab; 54 results.  
5. EMBASE; "pbr".ti,ab; 1799 results. 
6. EMBASE; exp MENTAL HEALTH/; 103789 results. 
7. EMBASE; "mental health".ti,ab; 118621 results. 
8. EMBASE; exp MENTAL DISORDERS/ OR exp 
MENTAL DISEASE/ OR exp ORGANIZATION AND 
MANAGEMENT/; 3034984 results. 
9. EMBASE; "mental disorder*".ti,ab; 35743 results. 
10. EMBASE; exp MENTAL DISEASE/ OR exp MENTAL 
HEALTH/ OR exp DEPRESSION/ OR exp HEALTH/; 
2487814 results. 
Mental Health identified the following (EMTREE) 
index headers: 
• mental disease        
• schizophrenia   
• depression   
• mental health 
11. EMBASE; "mental ill*".ti,ab; 28353 results.  
12. EMBASE; exp MENTAL DISEASE/ OR exp 
SCHIZOPHRENIA/ OR exp MEDICAL PRACTICE/; 
1812855 results. 
13. EMBASE; "mental disease*".ti,ab; 3290 results. 
14. EMBASE; exp FORENSIC PSYCHIATRY/ OR exp 
LIAISON PSYCHIATRY/ OR exp PSYCHIATRY/; 123613 
results. 
Psychiatry identified the following (EMTREE) 
index headers: 
• forensic psychiatry [Scope]        
• liaison psychiatry [Scope]        
 
15. EMBASE; "psychiatry".ti,ab; 64115 results. 
16. EMBASE; exp ORGANIZATION AND 
MANAGEMENT/ OR exp ORGANIZATION, HEALTH 
CARE/ OR exp ORGANIZATION,HOSPITAL/ OR exp 
HEALTH CARE QUALITY/ OR exp HEALTH CARE 
Commission identified the following (EMTREE) 
index headers: 
• health care organization  
• organization and management        
• health care quality     
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POLICY/ OR exp EUROPEAN UNION/; 4093691 
results. 
• health care policy       
• European Union 
17. EMBASE; "commission*".ti,ab; 38879 results.  
18. EMBASE; exp UNITED KINGDOM/; 374030 
results. 
19. EMBASE; "england".ti,ab; 46954 results. 
20. EMBASE; exp FINANCIAL MANAGEMENT/ OR exp 
ORGANIZATION AND MANAGEMENT/ OR exp 
HEALTH CARE COST/ OR exp GOVERNMENT/ OR exp 
FINANCE/ OR exp HEALTH CARE POLICY/ OR exp 
HEALTH CARE DELIVERY/; 5134775 results. 
The term “Financ” identified the following 
(EMTREE) index headers: 
• financial management         
• cost benefit analysis      
• cost of illness 
• health care cost  
• health care policy    
• finance 
• health care delivery 
21. EMBASE; "financ*".ti,ab; 99695 results.  
22. EMBASE; "incentiv*".ti,ab; 26523 results. 
23. EMBASE; "prospective payment".ti,ab; 2527 
results. 
24. EMBASE "payment system*".ti,ab; 3519 
25. EMBASE; 1 OR 2 OR 3 OR 4 OR 5; 3097391 
results. 
26. EMBASE; 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 
OR 13 OR 14 OR 15; 3774132 results. 
27. EMBASE; 16 OR 17 OR 18 OR 19 OR 20 OR  
21 OR 22 OR 23 OR 24; 6938662 results. 
28. EMBASE; 25 AND 26 AND 27;   
1012266 results. 
29. EMBASE; 60 [Limit to: Priority Journals and 
Human and (Languages English) and (Publication 
Types Article or Journal) and (Human Age Groups 
Adult 18 to 64 years or Aged 65+ years) and (Year 
Published Last 4 Years or Last 5 Years)]; 3050 results. 
All titles and abstracts were read to determine 
their suitability for inclusion to the literature 
review. Articles of interest that were referenced 
to in the identified literature were also obtained 
for use in the literature review.  
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Main heading & 
subheadings 
Database/ Sources  Key Search terms  
Service user 
engagement within the 
NHS 
 
• The background 
and the history 
 
• Consumerism and 
service user 
participation 
 
• Involvement in 
mental health 
services  
 
• The rationale for 
involvement  
 
• Optimising the use 
of medicines 
 
• Choice and 
medication 
 
• Adherence  
• Intentional non-
adherence  
• Specific side 
effects 
• Illness beliefs and 
knowledge 
 
• Non-adherence
  
• Shared decision 
making  
 
• Service user 
perspective  
•  
• Service user in 
policy 
development  
• Service user in 
medicines priority 
setting 
  
• CINAHL 
• Cochrane Library 
• EMBASE 
• Health Management 
Information 
Consortium 
• MEDLINE 
• PsycINFO 
• The Cochrane Library 
• Adherence  
• Adverse effects 
• Choice  
• Collaboration 
• Compulsion 
• Compliance  
• Concordance 
• Contribution   
• Consent 
• Consult 
• Consumer 
• Customer  
• Engagement 
• Francis report  
• NHS Constitution 
• Illness beliefs 
• Inclusion  
• Information 
• Involvement  
• Knowledge 
• Mental Health Act 
• Mental health 
• Mental Illness  
• NHS & Community 
Care Act 
• National Service 
Framework 
• Negotiation 
• Participation 
• Partnership 
• Patient  
• Provider 
• Psychiatrist 
• Psychiatry 
• Service user  
• Shared decision 
making 
• Wellbeing 
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Below is an example of a search for compliance with treatment in mental health. This search 
demonstrates the number of references identified following use of the CINAHL database. 
Similar independent searches were conducted using the Cochrane Library, EMBASE, Health 
Management Information Consortium, MEDLINE and PsycINFO.  
1. CINAHL; exp MEDICATION COMPLIANCE/ OR exp 
PATIENT COMPLIANCE/; 25650 results. 
Medication compliance identified the following 
headings:  
• Patient compliance 
• Medication compliance  
2. CINAHL; "adhere*".ti,ab; 19752 results.  
3. CINAHL; exp "COMPLIANCE WITH THERAPEUTIC 
REGIMEN (SABA CCC)"/ OR exp "COMPLIANCE WITH 
MEDICATION REGIMEN (SABA CCC)"/; 2 results. 
Compliance identified the following headings: 
• Compliance with Therapeutic Regimen       
• Compliance with Medication Regimen  
 
4. CINAHL; "complia*".ti,ab; 18059 results.  
5. CINAHL; exp TREATMENT REFUSAL/; 3437 results. 
6. CINAHL; "treatment refusal".ti,ab; 43 results. 
7. CINAHL; exp PROFESSIONAL-PATIENT RELATIONS/; 
57134 results. 
8. CINAHL; (doctor ADJ patient*).ti,ab; 1298 results. 
9. CINAHL; (professional ADJ patient*).ti,ab; 439 
results. 
10. CINAHL; "concordan*".ti,ab; 4074 results. 
11. CINAHL; exp TREATMENT REFUSAL/; 3437 results. 
12. CINAHL; exp CONSUMER PARTICIPATION/; 10925 
results. 
13. CINAHL; (patient ADJ partici*).ti,ab; 3956 results. 
14. CINAHL; (patient ADJ engag*).ti,ab; 773 results. 
15. CINAHL; "patient participation".ti,ab; 696 results. 
16. CINAHL; exp CONSUMER ATTITUDES/; 3722 results. 
17. CINAHL; "consumer*".ti,ab; 15124 results. 
18. CINAHL; "medication compliance".ti,ab; 384 results. 
19. CINAHL; (medication ADJ adher*).ti,ab; 2242 
results. 
20. CINAHL; exp "NONCOMPLIANCE (NANDA)"/; 14 
results. 
21. CINAHL; "noncompliance".ti,ab; 1163 results. 
22. CINAHL; nonadherence.ti,ab; 1188 results. 
23. CINAHL; exp SELF MEDICATION/; 868 results. 
24. CINAHL; exp PSYCHIATRY/; 7962 results. 
25. CINAHL; "psychiatry".ti,ab; 6160 results. 
26. CINAHL; exp MENTAL HEALTH/; 13776 results. 
27. CINAHL; (mental ADJ health).ti,ab; 45496 results. 
28. CINAHL; "service user".ti,ab; 959 results. 
29. CINAHL; "patient*".ti,ab; 645663 results. 
30. CINAHL; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 10 OR 11 
OR 12 OR 15 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23; 
69609 results. 
31. CINAHL; 7 OR 8 OR 9 OR 13 OR 14 OR 16 OR 17 OR 
24 OR 25 OR 26 OR 27; 137602 results. 
32. CINAHL; 28 OR 29; 646466 results. 
33. CINAHL; 30 AND 31 AND 32; 5247 results. 
34. CINAHL; 33 [Limit to: References Available and 
Publication Year 2006-2016 and Peer Reviewed and 
(Journal Subset Australia &amp; New Zealand or Blind 
All titles and abstracts were read to determine their 
suitability for inclusion to the literature review. 
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Peer Reviewed or Europe or Nursing or Online/Print or 
Peer Reviewed or UK &amp; Ireland or USA) and 
(Publication Type Drugs or Journal Article or Review or 
Systematic Review)]; 815  
Articles of interest that were referenced to in the 
identified literature were also obtained for use in 
the literature review. 
 
Main heading & 
subheadings 
Database/ Sources  Key search terms  
Pharmaceutical 
industry 
• The industry 
and the NHS 
  
• The 
economic 
imperative  
 
• Research 
and 
development 
costs 
 
• A crisis in 
innovation
  
• The 
influence on 
research 
findings
  
• The 
influence on 
service users 
  
• Joint 
working with 
the NHS
  
• Risk sharing 
with the NHS 
 
 
 
 
 
 
 
• Department of Health 
Database 
• EMBASE 
• MEDLINE 
• PsycINFO 
• The Cochrane Library 
• ABPI website 
 
• Bias  
• Code of practice  
• Company 
• Conflict of interest 
• Development 
• Drug Industry  
• Drugs 
• Finance 
• Funding 
• Impact 
• Industry  
• Influence 
• Joint working 
• Manufacturer 
• Mental Health 
• Organisation 
• Pharmaceutical 
Industry  
• Prescribing 
• Psychiatry 
• Publication bias 
• Relationship 
• Representative 
• Research  
• Risk sharing 
• Sponsor 
• Support 
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Below is outlined a search strategy using the PsycINFO database. The search was undertaken 
to identify publications which explore the relationship between the pharmaceutical industry 
and prescribing practice. The literature search was run independently on several databases 
and websites as listed above.   
The pharmaceutical industry influence on prescribing -  Search results using the PsychInfo 
database. 
1 PsycInfo exp PHARMACEUTICAL INDUSTRY/ 1555 
results  
 
2 PsycInfo "drug industry".ti,ab  88 results 
3 PsycInfo "pharmaceutical industry".ti,ab 1267 
results 
4 PsycInfo exp ANTIDEPRESSANT DRUGS/ OR exp 
CNS AFFECTING DRUGS/ OR exp CNS DEPRESSANT 
DRUGS/ OR exp CNS STIMULATING DRUGS/ OR exp 
DRUG THERAPY/ OR exp DRUGS/ OR exp HYPNOTIC 
DRUGS/ 317757 results 
A search for drugs identified the following headings:  
• Antidepressant drugs 
• CNS affecting drugs 
• CNS depressant drugs 
• CNS stimulating drugs 
• Drug therapy 
• Drugs 
• Hypnotic drugs 
5 PsycInfo "drug marketing".ti,ab 32 results  
6 PsycInfo exp INTERPERSONAL INFLUENCES/ 6196 
results 
7 PsycInfo "influen*".ti,ab 412835 results  
8 PsycInfo "bias*".ti,ab 71476 results 
9 PsycInfo exp "PRESCRIBING (DRUGS)"/ OR exp 
PRESCRIPTION DRUGS/ OR exp PRESCRIPTION 
PRIVILEGES/ 6115 results    
A truncated search prescri* identified the following 
relevant headings: 
• Prescribing drugs        
• Prescription drugs        
• Prescription privileges 
10 PsycInfo "prescri*".ti,ab 36275 results   
11 PsycInfo "impact*".ti,ab 268030 results 
12 PsycInfo exp COMMUNITY MENTAL HEALTH/ OR 
exp COMMUNITY MENTAL HEALTH SERVICES/ OR 
exp MENTAL HEALTH SERVICES/ 38171 results 
A search for mental health identified the following 
relevant headings: 
• Community mental health    
• Community Mental Health Services          
• Mental Health Services    
 
13 PsycInfo "mental health".ti,ab 136423 results  
14 PsycInfo exp COMMUNITY PSYCHIATRY/ OR exp 
NEUROPSYCHIATRY/ OR exp PSYCHIATRIC 
EVALUATION/ OR exp PSYCHIATRIC HOSPITALS/ OR 
exp PSYCHIATRISTS/ OR exp PSYCHIATRY/ 61562 
results 
A search for mental health identified the following 
relevant headings: 
• Community Psychiatry  
• Neuropsychiatry   
• Psychiatric evaluation 
• Psychiatric hospitals 
• Psychiatrists 
• Psychiatry 
15 PsycInfo "psychia*".ti,ab 206604 results  
16 PsycInfo 1 OR 2 OR 3 2216 results 
17 PsycInfo 4 OR 5 OR 6 OR 7 OR 8 OR 11 963366 
results 
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18 PsycInfo 9 OR 10 37017 results  
19 PsycInfo 12 OR 13 OR 14 OR 15 334895 results 
20 PsycInfo 16 AND 17 AND 18 AND 19 103 results 
21 PsycInfo 20 [Limit to: Publication Year 2006-2016 
and Peer reviewed and (Language English) and (Age 
group Adulthood 18 Yrs & Older) and (Population 
Human)] 11 results 
All titles and abstracts were read to determine their 
suitability for inclusion to the literature review.  
Articles of interest that were referenced to in the 
identified literature were also obtained for use in 
the literature review. 
  
  
Main heading & 
subheadings 
Database/ Sources  Key search terms  
Prescribing guidance 
in mental health 
• Department of Health Database 
• EMBASE 
• MEDLINE 
• PsycINFO 
• The Cochrane Library 
• ABPI  
 
• Adherence  
• Anxiety 
• Bipolar 
• Clinical   
• Compliance 
• Depression 
• Dissemination 
• Formulary 
• General Practice 
• Guide 
• Implementation 
• Influence 
• Mental Health 
• Organisation 
• Practice 
• Prescribing 
• Protocol 
• Primary care 
• Psychiatry 
• Schizophrenia 
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Below is an example of a search of a Medline search for publications relating to the 
implementation of prescribing guidelines in mental health settings. Searches were also 
undertaken using the following databases/sources: EMBASE, Department of Health website, 
PsychINFO, the Cochrane library and the ABPI website. 
1. Medline; exp PRACTICE GUIDELINE/ OR exp 
PRACTICE GUIDELINES AS TOPIC/; 92486 results. 
 
2. Medline; (practice ADJ guid*).ti,ab; 4492 results. 
3. Medline; (prescribing ADJ guid*).ti,ab; 131 results. 
4. Medline; exp GUIDELINE/ OR exp GUIDELINE 
ADHERENCE/; 24714 results. 
5. Medline; (guid* ADJ adher*).ti,ab; 1026 results. 
6. Medline; exp CLINICAL PROTOCOLS/; 139240 
results. 
7. Medline; protocol*.ti,ab; 306638 results. 
8. Medline; implement*.ti,ab; 307344 results. 
9. Medline; (guid* ADJ implement*).ti,ab; 1216 
results. 
10. Medline; (protocol ADJ implement*).ti,ab; 504 
results. 
11. Medline; exp INFORMATION DISSEMINATION/ 
OR exp COMMUNICATION/ OR exp DIFFUSION OF 
INNOVATION/; 426036 results. 
A truncated search disss* identified the following 
relevant headings: 
• Communication  
• Diffusion of innovation  
12. Medline; disseminat*.ti,ab; 93956 results.  
13. Medline; (dissem* ADJ of ADJ information).ti,ab; 
1 results. 
14. Medline; (clinical AND guid*).ti,ab; 78126 
results. 
15. Medline; (imple* ADJ strat*).ti,ab; 550 results. 
16. Medline; implement*.ti,ab; 307344 results. 
17. Medline; (educ* ADJ out*).ti,ab; 721 results. 
18. Medline; exp FORMULARIES/ OR exp 
FORMULARIES AS TOPIC/; 2812 results. 
19. Medline; formu*.ti,ab; 119151 results. 
20. Medline; exp MENTAL HEALTH/; 26266 results. 
21. Medline; (mental ADJ health).ti,ab; 94355 
results. 
22. Medline; exp PSYCHIATRY/; 120148 results. 
23. Medline; psychia*.ti,ab; 191754 results. 
24. Medline; exp CLINICAL DECISION-MAKING,  exp 
DECISION SUPPORT SYSTEMS, CLINICAL/ OR exp 
DECISION SUPPORT SYSTEMS, 
MANAGEMENT/; 6605 results. 
A truncated search decisio* identified the following 
relevant headings: 
• Decision support systems, clinical 
• Decision support systems, management  
• Clinical decision making  
25. Medline; (decision ADJ support ADJ 
system).ti,ab; 2218 results. 
 
26. Medline; 1 OR 2 OR 3 OR 4 OR 6 OR 7 OR 14 OR 
18 OR 19; 711596 results. 
27. Medline; 5 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 
OR 15 OR 16 OR 17 OR 24 OR 25; 809155 results. 
28. Medline; 20 OR 21 OR 22 OR 23; 359247 results. 
29. Medline; 26 AND 27 AND 28; 3127 results. 
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30. Medline; 29 [Limit to: Publication Year 2006-
2016 and Peer reviewed and (Document type 
Comparative Study or Editorial or Evaluation Studies 
or Guideline or Journal Article or Meta-analysis or 
Multicenter Study or Observational Study or Review) 
and (Language English)]; 1686 results. 
All titles and abstracts were read to determine their 
suitability for inclusion to the literature review.  
Articles of interest that were referenced to in the 
identified literature were also obtained for use in 
the literature review. 
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Appendix 2: Interview schedules 
 
 
  
  
284 
 
Interview Guide: Pharmaceutical representative  
 
Category Questions  
General 
 
1. What do you see as the role of   
prescribing guidelines in clinical 
practice?  
 
Prompts  
• Reduction in variation of 
patient care 
• Addressing the issue of rising 
prescribing costs 
• Keeping clinicians abreast of 
new evidence  
 
 
What are the main influences driving the 
prescribing of a new drug?  
   
explore 
Pharmaceutical 
industry 
Pharmaceutical 
representatives 
Adverts/ mailing   
 
Professional 
colleagues  
Hospital colleague 
endorsement 
Hospital colleague 
prescribing 
 
Patient request 
 
2. How might prescribing guidelines 
impact on new drug prescribing and 
innovation in mental health? 
 
Explore the issues 
in the context of 
the changing NHS 
landscape.  
 
Implementation 
3. How difficult is it to implement 
evidence based prescribing guidance 
in a mental health setting? 
 
Explore  
personal beliefs 
Evidence in the 
context of 
patients in a 
clinical setting 
 
4. What do you consider the practical 
barriers to guideline 
implementation? 
Explore issues such as  
Time 
Number of guidelines 
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Resources, 
presentation 
 
5. What factors are most important in 
enabling the implementation of 
prescribing guidelines in: 
 
Primary care:  
 
 
 
Secondary care:  
 
 
 
 
6. I want you to take some time to 
think about prescribing guidelines. In 
addition to recommended list of 
drugs what else should be 
incorporated into prescribing 
guidelines? 
 
Explore 
Cost 
Physical health 
monitoring 
requirements  
Agreed endpoints for 
prescribing 
Incorporation in GP 
systems  
 
Choice 
7. How do you view the impact of 
prescribing guidelines on clinician 
freedom? 
 
 
8. What are your views on shared 
decision-making? 
Prompts  
How might shared decision-making 
impact on: 
• The therapeutic relationship 
between clinician and 
patient? 
• Concordance with medication 
 
 
 
In your opinion what are the barriers to 
shared decision-making during the recovery 
phase of mental illness?  
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Cost 
effectiveness 
By 2014 a new system of value-based 
pricing (VBP) will replace the existing 
pharmaceutical price regulation scheme 
(PPRS).  
Unlike NICE where rulings where 
mandatory for PCTs the new national 
body will make recommendations which 
will not be compulsory for a GP 
consortium,  leading to variable  
prescribing of new drugs across differing 
GP consortia.   
 
9. How might value-based pricing 
impact the prescribing of new 
medicines for mental health 
conditions? 
 
What impact do you think this will have on 
your relationship with the NHS?  
 
 
10. How might payment by results 
impact on choice medicines in 
psychiatry? 
 
 
11. How can the demands for increased 
sales of newer medicines by 
pharmaceutical companies be 
balanced with the need for cost 
containment of prescribing budgets? 
 
 
Joint Working 
12. How important is the future working  
relationship with the NHS? 
 
 
 
 
13. Thinking about the changing NHS 
landscape. How might the 
pharmaceutical industry work with 
the NHS to promote cost effective 
prescribing? 
 
 
 
Interface issues 
14. Thinking about the  interface 
between mental health and primary 
care services, what are the key 
prescribing issues  from the 
perspective of: 
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GPs/ commissioners 
 
 
  
Psychiatrists  
 
 
 
Effectiveness 
15. When you think about treatment 
with medicines in a mental health 
setting, what does efficacy mean to 
you? 
 
 
16. What do you think efficacy means to 
a service user?  
 
 
 
 
Healthcare professional?  
 
 
General Based on our discussion are there any other 
issues or comments that you wish to raise?   
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Interview Guide: Service users  
Questions  Notes 
• Summarising statement about the 
research project and the purpose of the 
interview.  
• Clarify that the interview will be 
recorded.  
 
• Questions to be used as a guide only 
 
1. Tell me how you feel about your 
condition and the treatment you receive? 
2.  How do you get on with your 
doctor? 
 
3. Are you able to talk openly to your 
doctor about your medication? 
Please give an example? 
  
Focus on overall feelings of medication, 
and relationship with psychiatrist. 
Note cues for later questions / overall 
attitude and experience of medication 
and prescribing. 
 
 
 
Prompts:  Side effects, effectiveness, long 
term impact, staying well or other.  
 
 
 
Explore whether the service user is able 
to disclose complete and accurate 
information e.g. lack of compliance with 
treatment. If not why not?   
Explore concordance vs compliance                
 
4. How useful is the information you 
are given about the side effects of treatment?  
 
Focus on side effects and how far these 
are taken seriously and imparted by 
psychiatrist. 
Explore relationship between side effects 
and concordance. 
Probe about personal experience and 
how this might impact on their 
concordance. 
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5. When you visit your doctor how 
involved are you in the decision about the 
treatment you receive? 
Can you give an example? 
 
6. How important is it to you that you 
have a choice in the medication you are treated 
with? 
 
 
7. What are your thoughts about 
alternative treatments for your condition? 
 
 
  
Focus on how far treatment by the 
psychiatrist covers a range of available 
options, and how far this leads to choice. 
How far does the interviewee feel an 
active agent in their treatment? 
Possible issues arising – relationship with 
mental health services, negative and 
positive. Remain sensitive to bad 
experiences – allow critical accounts to 
be expressed by the interviewee within 
this section if necessary, before moving 
on to other sections. 
Probe  
Hypnotherapy? 
Acupuncture   
Talking therapies etc 
 
8. How much do medicines contribute 
to you feeling better?  
Probe for the rationale 
How might they identify 
improvement in symptoms or is the 
perception related to side effects or 
something completely different?  
9. What would you do if you felt that 
your medication was not working?  
Does the service user have a clear 
understanding of the options 
available? 
Was the possibility of treatment 
failure discussed?  
 
Focus on how service user registers the 
impact and effectiveness of medication, 
and any improvements in health.  
Possible issues arising – a picture of how 
far the service user feels medication is 
part of managing their condition, and 
staying well. 
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10. What are the most important factors 
in influencing your decision to take medication?  
 
 
 
 
 
11. Where do you get information about 
your medication? 
 
Prompts 
Personal experience  
Impact on others 
Professional input 
Other 
 
 
Probe  
Internet  
Professionals 
Other service users  
Other 
Focus on how service users become 
informed about medication, the sources 
they use and trust 
Possible issues arising – (for later 
analysis?) - links between service users' 
sources of information, and their overall 
attitude to relationship with MH services, 
medication and side effects.  
12. If a new drug became available to 
treat your condition, what would affect your 
decision to try it? 
 
 
 
 
 
 
 
A focus on new treatments, and how 
open the service user would be to these. 
Explore why they have answered this 
way. 
 Probe for their rationale.  
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13. What impact has psychiatric 
medicines had on your everyday life? 
 
 
14. Can you think of any additional 
support that might benefit your understanding 
of the medicines you are prescribed? 
 
Focus on how medication has impacted 
on everyday life, and the consequences 
to the service user of being treated with 
medication. 
15. Based on your experience, what is 
the most important thing that mental health 
professionals should know in order to be helpful 
to people using medications? 
 
 
16. Based on our discussion is there 
anything that you wish to add?  
Probe for a rationale 
 
 
 
Focus on anything else which the service 
user feels is important, that hasn't been 
covered. 
Chance to ask any further questions 
about overall issues arising, clarify any 
matters, and pick up on links between 
answers 
Finally: Describe what will happen to the 
research and the availability of the 
findings. 
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Interview Guide: Pharmacists  
 
Questions  
1. What do you see as the role of     
prescribing guidelines in clinical 
practice?  
             
 
Probe 
Reduction in variation of patient care 
Addressing the issue of rising 
prescribing costs 
Keeping clinicians abreast of new 
evidence  
 
2. To what extent do we (pharmacists) take 
into account patient related factors 
when producing prescribing guidelines in 
mental health?  
 
  
Probe 
Are guidelines contextual, taking into 
account difficult to treat 
 
 
 
3. What are the main influences driving the 
prescribing of a new drug? 
Probe 
Industry influence 
Professional colleagues  
Hospital colleague endorsement 
Hospital colleague prescribing 
Patient request 
 
4. How might prescribing guidelines impact 
on new drug prescribing and innovation 
in mental health? 
 
Explore the issues in the context of the 
changing NHS landscape.  
 
5. What do you consider the practical 
barriers to guideline implementation? 
 
 
Explore issues such as  
Time 
Number of guidelines 
Resources, presentation 
 
6. What factors are most important in 
enabling the implementation of 
prescribing guidelines. in: 
 
Primary care: PCT pharmacists 
  
Secondary care: hospital based 
pharmacists  
 
 
 
 
 
It is important to explore if there is an a 
understanding of the issues across NHS 
organisations  
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7. I want you to take some time to think 
about prescribing guidelines. In addition 
to recommended list of drugs what else 
should be incorporated into prescribing 
guidelines? 
 
Explore 
Cost 
Physical health monitoring 
requirements  
Agreed endpoints for prescribing 
Incorporation in GP systems  
 
8. How do you view the impact of 
prescribing guidelines on freedom of 
choice for patients? 
 
 
9. How might shared decision-making 
impact on: 
• The therapeutic relationship 
between clinician and 
patient? 
 
• Concordance with medication 
Seek a clear rationale for their thought 
process.  
10. In your opinion what are the barriers to 
shared decision-making during the 
recovery phase of mental illness?  
 
 
By 2014 a new system of value-based 
pricing (VBP) will replace the existing 
pharmaceutical price regulation scheme 
(PPRS).  
Unlike NICE where rulings where 
mandatory for PCTs the new national 
body will make recommendations which 
will not be compulsory for a GP 
consortium,  leading to variable  
prescribing of new drugs across differing 
GP consortia.   
 
 
 
 
 
11. How might value-based pricing impact 
the prescribing of new medicines for 
mental health conditions? 
 
 
12. How might payment by results impact 
on choice medicines in psychiatry? 
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13. What are your views on working with 
the pharmaceutical industry? 
 
If a context is needed, focus on the 
promotion of cost effective 
prescribing.  
 
 
14. Thinking about the changing NHS 
landscape. How might the 
pharmaceutical industry work with the 
NHS to promote cost effective 
prescribing? 
 
 
15. Thinking about the interface between 
mental health and primary care services, 
what do you see as the key prescribing 
issues?  
 
 
16. When you think about treatment with 
medicines in a mental health setting, 
what does efficacy mean to you? 
 
 
17. What do you think efficacy means to a 
service user?  
 
 
18. Based on our discussion are there any 
other issues or comments that you wish 
to raise?   
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Interview Guide: General practitioners   
 
Questions  
1. What is the role of prescribing 
guidelines in your clinical practice?  
 
Explore the relevance to the 
clinician 
 
 
 
2. What would influence your decision 
to prescribe a new drug to a patient 
with a mental health condition?  
      GPs  
 
  
explore 
Pharmaceutical industry 
Pharmaceutical representatives 
Adverts/ mailing   
 
 
Patient request 
 
3. How might prescribing guidelines 
impact on new drug prescribing and 
innovation in mental health? 
 
Explore the issues in the context of 
the changing NHS landscape.  
 
4. What do you consider the practical 
barriers to guideline 
implementation? 
 
 
Explore issues such as  
Time 
Number of guidelines 
Resources, presentation 
 
5. What factors are most important in 
enabling the implementation of 
prescribing guidelines in: 
 
 
 
6.  I want you to take some time to  
think about prescribing guidelines. In 
addition to recommended list of 
drugs what else would inform your 
clinical practice? 
 
Explore 
Cost 
Physical health monitoring 
requirements  
Agreed endpoints for prescribing 
Incorporation in GP systems  
 
7. Is there anything that would make 
you more likely to refer to 
prescribing guidelines?  
      
Explore 
Accessibility  
Simplicity  
Presentation 
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8. How do you view the impact of 
prescribing guidelines on clinician 
freedom? 
 
 
9. What are your views on shared 
decision-making? 
Prompts  
How might shared decision-making 
impact on: 
• The therapeutic relationship 
between clinician and 
patient? 
• Concordance with medication 
 
10. In your opinion what are the barriers 
to shared decision-making during the 
recovery phase of mental illness?  
 
 
11. What are your views on working with 
the pharmaceutical industry? 
 
 
 
 
12. Thinking about the changing NHS 
landscape. How might the 
pharmaceutical industry work with 
the NHS to promote cost effective 
prescribing? 
 
 
13. Do you think that the Pharmaceutical 
representatives could have a role in 
facilitating guideline 
implementation? 
 
 
Please explain your response 
 
 
Thinking about the interface 
between mental health and primary 
care services, what are the key 
prescribing issues?  
 
Care pathways access 
14. When you think about treatment 
with medicines in a mental health 
setting, what does efficacy mean to 
you? 
 
 
15. What do you think efficacy means to 
a patient?  
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16. Based on our discussion are there 
any other issues or comments that 
you wish to raise?   
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Interview Guide: Consultant psychiatrists   
 
Questions  
1. What is the role of prescribing 
guidelines in your clinical practice?  
 
Explore the relevance to the 
clinician 
 
  
 
Probe 
 
Reduction in variation of patient care 
Addressing the issue of rising 
prescribing costs 
Keeping clinicians abreast of new 
evidence  
 
2. What would influence your decision 
to prescribe a new drug to a patient 
with a mental health condition?  
       
 
  
Probe 
industry influence 
 
Professional colleagues  
Hospital colleague endorsement 
Hospital colleague prescribing 
 
Patient request 
 
3. How might prescribing guidelines 
impact on new drug prescribing and 
innovation in mental health? 
 
Explore the issues in the context of 
the changing NHS landscape.  
 
4. How difficult is it to implement 
evidence based prescribing guidance 
in a mental health setting? 
 
Explore  
personal beliefs 
Evidence in the context of patients in a 
clinical setting 
5. What do you consider the practical 
barriers to guideline 
implementation? 
 
 
Explore issues such as  
Time 
Number of guidelines 
Resources, presentation 
 
6. What factors are most important in 
enabling the implementation of 
prescribing guidelines in your 
practice? 
 
 
7.  I want you to take some time to 
think about prescribing guidelines. In 
addition to recommended list of 
drugs what else should be 
incorporated into prescribing 
guidelines? 
 
Explore 
Cost 
Physical health monitoring 
requirements  
Agreed endpoints for prescribing 
Incorporation in GP systems  
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8. Is there anything that would make 
you more likely to refer to 
prescribing guidelines?  
      
 
9. How do you view the impact of 
prescribing guidelines on clinician 
freedom? 
 
 
10. What are your views on shared 
decision-making? 
Prompts  
How might shared decision-making 
impact on: 
• The therapeutic relationship 
between clinician and 
patient? 
• Concordance with medication 
 
11. In your opinion what are the barriers 
to shared decision-making during the 
recovery phase of mental illness?  
 
 
By 2014 a new system of value-based 
pricing (VBP) will replace the existing 
pharmaceutical price regulation scheme 
(PPRS).  
Unlike NICE where rulings where 
mandatory for PCTs the new national 
body will make recommendations which 
will not be compulsory for a GP 
consortium,  leading to variable  
prescribing of new drugs across differing 
GP consortia.   
 
 
 
 
 
12. How might value-based pricing 
impact the prescribing of new 
medicines for mental health 
conditions? 
 
 
13. How might payment by results 
impact on choice medicines in 
psychiatry? 
 
 
14. What are your views on working with 
the pharmaceutical industry? 
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15. Thinking about the changing NHS 
landscape. How might the 
pharmaceutical industry work with 
the NHS to promote cost effective 
prescribing? 
 
 
16. Do you think that the Pharmaceutical 
representatives could have a role in 
facilitating guideline 
implementation? 
 
 
Please explain your response 
 
 
17. Thinking about the interface 
between mental health and primary 
care services, what are the key 
prescribing issues?    
 
 
18. When you think about treatment 
with medicines in a mental health 
setting, what does efficacy mean to 
you? 
 
 
19. What do you think efficacy means to 
a service user?  
 
 
20. Based on our discussion are there 
any other issues or comments that 
you wish to raise?   
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Appendix 3: Information for participants 
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Information for research participants 
 
Prescribing guidance and practice: Exploring the factors that have an impact 
on prescribing in a mental health environment. 
 
Professional Doctorate Research Project  
University of Portsmouth 
 
My name is Andrew Campbell and I am a doctoral student at the University of Portsmouth; I 
would like to invite you to participate in my research study. Before you decide whether or not 
to take part, it is important that you understand why this research is being done and what it 
will involve. Please take the time to read the following information carefully which should take 
about 10 minutes and ask me if there is anything that is not clear or if you would like more 
information.  
 
What is the purpose of the study? 
The purpose of the research is to understand from the perspective of a service user the extent 
to which you feel involved in making decisions about the medicines you take to treat your 
illness and the factors that influence your involvement. 
 
 
Why have you been asked to join in?  
This study will focus on a range of people linked directly or indirectly linked to the prescribing 
of medicines for the treatment of mental health conditions. The study will include a total of 5 
service users.  
 
Do I have to take part? 
It is up to you to decide whether you wish to join the study. I will describe the study and go 
through this information sheet. If you agree to take part, you will then be asked to complete a 
pre-screening questionnaire to determine if you are suitable to participate in the study. If you 
are eligible to participate in the study you will be asked to sign a consent form. If you are not 
eligible to participate you will be given a full explanation why you have not been considered 
for inclusion into the study. Please note that potential participants are free to withdraw at any 
time, without giving a reason. 
 
What will happen to me if I take part?  
The research involves participation in a single interview, which will be audio taped.  
Your participation is voluntary, and you may withdraw from the process at any time.  
 
If you decide to participate in the research and become uncomfortable during the interview at 
any time, please let the interviewer know. You may stop the interview at any time.   
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Reimbursement of expenses 
Participants will be reimbursed travel expenses up to a maximum of £5 for taking part in the 
research. This will be to cover public transport fares or mileage at the rate of 25 pence per 
mile.   
 
Will my taking part in the study be kept confidential?  
If the results of the research are published, quotes from the audio-tapes may be published to 
illustrate the views of participants. Under no circumstances will the identity of individuals be 
made public and individuals will not be able to be identified from quotes or descriptions of 
participants. 
 
Records identifying you will be kept confidential and, to the extent permitted by the laws and/or 
regulations, will not be made publicly available. 
 
You have the right to see a summary of the final study results.  
 
Audiotapes and transcripts will be archived and kept up to three years after consent has been 
obtained for participation in the study.  
 
What are the possible benefits of taking part? 
There are unlikely to be any benefits for you personally. It is hoped that as a result of the study 
future prescribing guidelines will take into account the views of service users which might lead 
to improved prescribing practice.  
 
Contact details  
For more information regarding the research and your rights please contact: 
 
 
Thank you for reading so far – if you are still interested, please go to Part 2: 
 
Andrew Campbell     
Chief Pharmacist  
Dudley and Walsall  
Mental Health Partnership Trust 
Clee Ward 
01384 365713 
andrew.campbell@dwmh.nhs.uk 
Prof David Brown 
Professor in Pharmacy Practice 
Pharmacy and Biomedical Sciences 
Division of Pharmacy Practice  
School of Pharmacy and Biomedical 
Sciences  
University of Portsmouth  
St Michael's Building  
White Swan Road  
Portsmouth  
david.brown@port.ac.uk 
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 Part 2 
 
What if there is a problem or something goes wrong? 
If you are unhappy with any aspect of the research you should establish contact with Andrew 
Campbell, Professor David Brown or the Patient Advice and Liaison Service on 0800 0730510. 
 
Will anyone else know I'm doing this?  
All information collected will be kept confidential. This means we will only tell those who have 
a need or right to know. 
 
Who is organising and funding the research? 
This study is being conducted as part of a professional doctorate and is funded by the mental 
health trust and the researcher.  
 
Who has reviewed the study? 
Before any research goes ahead it has to be checked by a Research Ethics Committee. They 
make sure that the research is fair. Your project has been checked by the Research Ethics 
Committee.  
 
Thank you for reading this – please ask any questions if you need to. 
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Information for research participants 
 
Prescribing guidance and practice: Exploring the factors that have an impact 
on prescribing in a mental health environment 
 
Professional Doctorate Research Project  
University of Portsmouth 
 
My name is Andrew Campbell and I am a doctoral student at the University of Portsmouth; I 
would like to invite you to participate in my research study. Before you decide whether or not 
to take part, it is important that you understand why this research is being done and what it 
will involve. Please take the time to read the following information carefully which should take 
about 10 minutes and ask me if there is anything that is not clear or if you would like more 
information.  
 
 
Aim of the research  
The purpose of the research is to understand from the perspective of a consultant psychiatrist 
what are the important issues in prescribing and the development of guidance for prescribing 
in a mental health setting?  
 
How are decisions made now?  
Decisions about which drugs are recommended for use across Dudley and Walsall Mental 
Health Trust are made by the Medicines Management Committee.  
 
Why is this research important?  
There is little work determining the views on how best to implement prescribing guidelines in 
a mental health setting.  
 
There will be a need for clearer guidance on prescribing responsibility between mental health 
services and General Practitioners in light of the transition of patients from specialist to primary 
care. 
 
This research aims to  
 
• Develop an understanding of the perceived factors that influence the implementation 
of prescribing guidelines in a mental health setting. 
• To explore the perceived factors that influences prescribing from healthcare 
professionals and representatives from the pharmaceutical industry.   
• Explore the patient perception of their involvement in decisions regarding drug 
therapy.     
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Why have you been asked to join in?  
This study will focus on a range of people linked directly or indirectly linked to the prescribing 
of medicines for the treatment of mental health conditions.   
 
What will the research involve?  
The research involves participation in a single interview, which will be audio taped?   
 
Your participation is voluntary, and you may withdraw from the process at any time.  
 
I would like you to consent to participate in this study as we believe that you can make an 
important contribution to the research.  
 
If you do not wish to participate you do not have to do anything in response to this request. 
 
If you become uncomfortable with the discussion at any time, please let the interviewer know. 
You may stop the interview at any time.   
 
Will my taking part in the study be kept confidential?  
If the results of the research are published, quotes from the audio-tapes may be published to 
illustrate the views of participants. Under no circumstances will the identity of individuals be 
made public and individuals will not be able to be identified from quotes or descriptions of 
participants. 
 
Records identifying you will be kept confidential and, to the extent permitted by the laws and/or 
regulations, will not be made publicly available. 
 
You have the right to see a summary of the final study results.  
 
Audiotapes and transcripts will be archived and kept up to three years after consent has been 
obtained for participation in the study.  
 
Reimbursement of expenses 
Participants will be reimbursed travel expenses up to a maximum of £5 for taking part in the 
research. This will be to cover public transport fares or mileage at the rate of 25 pence per 
mile.   
 
For more information regarding the research and your rights please contact: 
 
 
 
Andrew Campbell     
Chief Pharmacist  
Dudley and Walsall  
Mental Health Partnership Trust 
Clee Ward 
01384 365713 
 
Prof David Brown 
Professor in Pharmacy Practice 
Pharmacy and Biomedical Sciences 
Division of Pharmacy Practice  
School of Pharmacy and Biomedical 
Sciences  
University of Portsmouth  
St Michael's Building  
White Swan Road  
Portsmouth  
 
  
307 
 
 
Information for research participants 
 
Prescribing guidance and practice: Exploring the factors that have an impact 
on prescribing in a mental health environment. 
 
Professional Doctorate Research Project  
University of Portsmouth 
 
My name is Andrew Campbell and I am a doctoral student at the University of Portsmouth; I 
would like to invite you to participate in my research study. Before you decide whether or not 
to take part, it is important that you understand why this research is being done and what it 
will involve. Please take the time to read the following information carefully which should take 
about 10 minutes and ask me if there is anything that is not clear or if you would like more 
information.  
 
Aim of the research  
The purpose of the research is to understand from the perspective of pharmacists 
what are the important issues in prescribing and the development of guidance for prescribing 
in a mental health setting?  
 
How are decisions made now?  
Decisions about which drugs are recommended for use across Dudley and Walsall Mental 
Health Trust are made by the Medicines Management Committee.  
 
Why is this research important?  
There is little work determining the views on how best to implement prescribing guidelines in 
a mental health setting.  
 
NHS organisations are being encouraged to involve patients in the local decision making.  
 
This research aims to  
 
• Develop an understanding of the perceived factors that influence the implementation 
of prescribing guidelines in a mental health setting.  
• Explore the patient perception of their involvement in decisions regarding drug 
therapy.     
• To explore the perceived factors that influences prescribing from healthcare 
professionals and representatives from the pharmaceutical industry.   
 
Why have you been asked to join in?  
This study will focus on a range of people linked directly or indirectly linked to the prescribing 
of medicines for the treatment of mental health conditions.  
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What will the research involve?  
The research involves participation in a single interview, which will be audio taped?   
 
Your participation is voluntary, and you may withdraw from the process at anytime.  
 
I would like you to consent to participate in this study as we believe that you can make an 
important contribution to the research.  
 
If you do not wish to participate you do not have to do anything in response to this request. 
 
If you become uncomfortable with the discussion at any time, please let the interviewer know. 
You may stop the interview at any time.   
 
Will my taking part in the study be kept confidential?  
If the results of the research are published, quotes from the audio-tapes may be published to 
illustrate the views of participants. Under no circumstances will the identity of individuals be 
made public and individuals will not be able to be identified from quotes or descriptions of 
participants. 
 
Records identifying you will be kept confidential and, to the extent permitted by the laws and/or 
regulations, will not be made publicly available. 
 
You have the right to see a summary of the final study results.  
 
Audiotapes and transcripts will be archived and kept up to three years after consent has been 
obtained for participation in the study.  
 
Reimbursement of expenses 
Participants will be reimbursed travel expenses up to a maximum of £5 for taking part in the 
research. This will be to cover public transport fares or mileage at the rate of 25 pence per 
mile.   
 
For more information regarding the research and your rights please contact: 
 
  
Andrew Campbell     
Chief Pharmacist  
Dudley and Walsall  
Mental Health Partnership Trust 
Clee Ward 
01384 365713 
 
Prof David Brown 
Professor in Pharmacy Practice 
Pharmacy and Biomedical Sciences 
Division of Pharmacy Practice  
School of Pharmacy and Biomedical 
Sciences  
University of Portsmouth  
St Michael's Building  
White Swan Road  
Portsmouth  
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Information for research participants 
 
Prescribing guidance and practice: Exploring the factors that have an impact 
on prescribing in a mental health environment. 
 
Professional Doctorate Research Project  
University of Portsmouth 
 
My name is Andrew Campbell and I am a doctoral student at the University of Portsmouth; I 
would like to invite you to participate in my research study. Before you decide whether or not 
to take part, it is important that you understand why this research is being done and what it 
will involve. Please take the time to read the following information carefully which should take 
about 10 minutes and ask me if there is anything that is not clear or if you would like more 
information.  
 
Aim of the research  
The purpose of the research is to understand from the pharmaceutical industry 
what are the important issues in prescribing and the development of guidance for prescribing 
in a mental health setting?  
 
How are decisions made now?  
Decisions about which drugs are recommended for use across Dudley and Walsall Mental 
Health Trust are made by the Medicines Management Committee.  
 
Why is this research important?  
There is little work determining the views on how best to implement prescribing guidelines in 
a mental health setting.  
 
NHS organisations are being encouraged to work collaboratively with the pharmaceutical 
industry to improve patient outcomes.    
 
This research aims to  
 
• To explore the perceived factors that influences prescribing from healthcare 
professionals and representatives from the pharmaceutical industry.   
• Explore the patient perception of their involvement in decisions regarding drug 
therapy.     
• Develop an understanding of the perceived factors that influence the implementation 
of prescribing guidelines in a mental health setting. 
 
Why have you been asked to join in?  
This study will focus on a range of people linked directly or indirectly linked to the prescribing 
of medicines for the treatment of mental health conditions.   
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What will the research involve?  
The research involves participation in a single interview, which will be audio taped?   
 
Your participation is voluntary, and you may withdraw from the process at any time.   
 
I would like you to consent to participate in this study as we believe that you can make an 
important contribution to the research.  
 
If you do not wish to participate you do not have to do anything in response to this request. 
 
If you become uncomfortable with the discussion at any time, please let the interviewer know. 
You may stop the interview at any time.   
 
Will my taking part in the study be kept confidential?  
If the results of the research are published, quotes from the audio-tapes may be published to 
illustrate the views of participants. Under no circumstances will the identity of individuals be 
made public and individuals will not be able to be identified from quotes or descriptions of 
participants. 
 
Records identifying you will be kept confidential and, to the extent permitted by the laws and/or 
regulations, will not be made publicly available. 
 
You have the right to see a summary of the final study results.  
 
Audiotapes and transcripts will be archived and kept up to three years after consent has been 
obtained for participation in the study.  
 
 
For more information regarding the research and your rights please contact: 
 
  
Andrew Campbell     
Chief Pharmacist  
Dudley and Walsall  
Mental Health Partnership Trust 
Clee Ward 
01384 365713 
 
Prof David Brown 
Professor in Pharmacy Practice 
Pharmacy and Biomedical Sciences 
Division of Pharmacy Practice  
School of Pharmacy and Biomedical 
Sciences  
University of Portsmouth  
St Michael's Building  
White Swan Road  
Portsmouth  
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Information for research participants 
 
Prescribing guidance and practice: Exploring the factors that have an impact 
on prescribing in a mental health environment. 
 
Professional Doctorate Research Project  
University of Portsmouth 
 
My name is Andrew Campbell and I am a doctoral student at the University of Portsmouth; I 
would like to invite you to participate in my research study. Before you decide whether or not 
to take part, it is important that you understand why this research is being done and what it 
will involve. Please take the time to read the following information carefully which should take 
about 10 minutes and ask me if there is anything that is not clear or if you would like more 
information.  
 
Aim of the research  
The purpose of the research is to understand from the perspective of General Practitioners 
the important issues in prescribing and the development of guidance for prescribing in a 
mental health setting?  
 
How are decisions made now?  
Decisions about which drugs are recommended for use across Dudley and Walsall Mental 
Health Trust are made by the Medicines Management Committee in conjunction with the 
locality area prescribing committees.   
 
Why is this research important?  
There is little work determining the views on how best to implement prescribing guidelines in 
a mental health setting.  
 
There will be a need for clearer guidance on prescribing responsibility between mental health 
services and General Practitioners in light of the transition of patients from specialist to primary 
care. 
 
NHS organisations are being encouraged to involve patients in the local decision making.  
 
 
This research aims to  
 
• Explore the patient perception of their involvement in decisions regarding drug 
therapy.     
• Develop an understanding of the perceived factors that influence the implementation 
of prescribing guidelines in a mental health setting. 
• To explore the perceived factors that influences prescribing from healthcare 
professionals and representatives from the pharmaceutical industry.   
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Why have you been asked to join in?  
This study will focus on a range of people linked directly or indirectly linked to the prescribing 
of medicines for the treatment of mental health conditions.   
 
What will the research involve?  
The research involves participation in a single interview, which will be audio taped?   
 
Your participation is voluntary, and you may withdraw from the process at any time.  
 
I would like you to consent to participate in this study as we believe that you can make an 
important contribution to the research.  
 
If you do not wish to participate you do not have to do anything in response to this request. 
 
If you become uncomfortable with the discussion at any time, please let the interviewer know. 
You may stop the interview at any time.   
 
Will my taking part in the study be kept confidential?  
If the results of the research are published, quotes from the audio-tapes may be published to 
illustrate the views of participants. Under no circumstances will the identity of individuals be 
made public and individuals will not be able to be identified from quotes or descriptions of 
participants. 
 
Records identifying you will be kept confidential and, to the extent permitted by the laws and/or 
regulations, will not be made publicly available. 
 
You have the right to see a summary of the final study results.  
 
Audiotapes and transcripts will be archived and kept up to three years after consent has been 
obtained for participation in the study.  
 
Reimbursement of expenses 
Participants will be reimbursed travel expenses up to a maximum of £5 for taking part in the 
research. This will be to cover public transport fares or mileage at the rate of 25 pence per 
mile.   
 
For more information regarding the research and your rights please contact: 
 
  
Andrew Campbell     
Chief Pharmacist  
Dudley and Walsall  
Mental Health Partnership Trust 
Clee Ward 
01384 365713 
 
Prof David Brown 
Professor in Pharmacy Practice 
Pharmacy and Biomedical Sciences 
Division of Pharmacy Practice  
School of Pharmacy and Biomedical 
Sciences  
University of Portsmouth  
St Michael's Building  
White Swan Road  
Portsmouth  
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Appendix 4: Screening questions for service 
users 
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Prescribing guidance and practice: Exploring the factors that have an impact 
on prescribing in a mental health environment. 
 
Screening Questions for Service User involvement in research 
 
1. Are you diagnosed with psychotic illness? 
E.g.  Hearing voices or experiencing delusions 
  
Yes  No   
  
2. Are you diagnosed with an anxiety related disorder?  
E.g.  
Generalised anxiety disorder  
Panic attacks 
Phobias (irrational fear) 
Obsessive Compulsive Disorder 
 
Yes  No   
 
3. Are you diagnosed with a mood related disorder?  
E.g.  
Depression 
Seasonal affective disorder 
Bipolar disorder (manic depression) 
 
Yes  No   
 
4. Is your mental illness caused by a head injury?  
 
Yes  No   
 
5. Do you suffer with a dementia type illness?  
 
Yes  No   
 
6. Are you currently attending outpatients or being cared for by a community mental 
health team? 
 
Yes  No   
 
7. Have you been admitted to hospital in the previous 12 months? 
 
Yes  No   
 
8. Have you taken any recreational drugs in the previous 12 months?  
 
Yes  No   
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Prescribing guidance and practice: Exploring the factors that have an impact 
on prescribing in a mental health environment. 
 
Participant Personal Information 
 
To enable effective analysis of your contribution to the research project, please answer the 
following questions by ticking the appropriate box. 
 
Name:  
 
Please tick the correct box 
 
Gender  
 
I am               Male                Female 
 
 
Age  
I am aged between                 18 – 24 years                      25 – 60 years 
 
 
 
       61 – 74 years                       75 – 84 years                      85 years and over 
 
 
 
Education                                    O level/GCSE                      Vocational qualification 
I have been formally                    or equivalent 
Educated up to the  
Following level                             A level or equivalent           Degree  
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Appendix 5: Flowchart for service user 
participation 
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Appendix 6: Interview consent form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
319 
 
 
 
Consent form 
 
Title of project: Prescribing guidance and practice: Exploring the factors that have an 
impact on prescribing in a mental health environment.  
 
Name of Researcher: Andrew Campbell 
 
 
 Please initial box 
1. I confirm that I have read and understood the information sheet for 
the above study.  I have had the opportunity to consider the 
information, ask questions and had these answered to my 
satisfaction.  
 
 
2. I understand that my participation is voluntary and that I am  
      free to withdraw at any time without giving any reason without  
      my medical or legal rights being affected. 
 
 
 
 
 
3.  I understand that the interview will be audio-taped and that  
     verbatim quotes of what I say may be published. I understand  
     that I will not be identifiable from any quotes published. 
 
 
 
 
4. I voluntarily agree to take part in the above study.  
 
 
 
 
 
 
_____________________  ________  _____________________ 
 
Name of Participant     Date   Signature 
 
 
_____________________  ________  _____________________  
 
Name of person   Date   Signature 
taking consent         
 
 When completed, 1 copy must be given to the participant and one copy retained by 
the researchers site file.     
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Appendix 7: Ethics approval letter 
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Appendix 8: Demographics of service users  
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Table 7.1 Service user demographics   
Identifier 
 
Gender Age Education Diagnosis 
Service User 1 Female 
 
25-60 Vocational Bipolar 
Service User 2 Male 
 
25-60 Degree Schizophrenia 
Service User 3 Female 
 
25-60 O levels Bipolar 
Service User 4 Female 
 
61-74 Degree Bipolar 
Service User 5 Female 
 
25-60 O levels Bipolar 
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Appendix 9: Thematic map of the research 
themes 
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Thematic map of the research themes 
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Appendix 10: Form UPR16 - Research ethics 
review checklist  
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